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1. Introduction 
1.1 History of antibiotic discovery 
One of the greatest revolutions in the history of medication is considered 
to be the introduction of antibiotics, a class of compounds that still play 
an essential and crucial role in the control of diseases. Mankind 
benefitted from and misused this form of chemotherapy, leading to the 
development of antibiotic resistance that has surpassed our knowledge 
and turned into a tremendously serious issue on a global scale.   
Our ancient cultures have been observed to utilize distinct antimicrobial 
remedies in aspects of curing diseases. In the investigation of 
fluorescence distribution in human skeletal from ancient Sudanese Nubia 
(350-550 CE),
[1],[2]
 tetracycline (1) in Figure 1 could be traced, as it 
behaved as an active ion chelator and produced intense yellow-green 
fluorophors by forming complex calcium and protein compounds.
[3],[4]
 The 
only explanation for this discovery, is that the deposited food from their 
daily nutrient was contaminated with the tetracycline-producing 
Streptomycetes.
[1]
 This phenomenon was also found in the samples 
taken from the femoral midshafts of the late Roman period skeletons 
from the Dakhlen Oasis, Egypt.
[5]
 An assumption arising from these 
findings is, that the population infected by transmissible disease in 
Sudanese Nubian was recorded to be low, whilst no bone infection was 
revealed in the samples from the Dakhlen Oasis due to the protective 
effect from oral administration of tetracycline.
[5],[6]
 The incorporation of 
tetracycline and the hydroxyapatite mineral composition in bones and 
tooth enamel leaves the obvious evidence for scientific research to tackle 
the exposure of tetracycline.
[7]
   
 
 
 
2 
 
 
Figure 1 A variety of antibiotics.  
However, similar successful examples of tracing other antibiotics in the 
ancient times are not available when it lacks of evidence. Red soils in the 
Hashemite Kingdom of Jordan have been used historically for treating 
 
 
3 
 
skin infections and diaper rash.
[8]
 They can be purchased in the current 
pharmaceutical market as a cheap alternative solution.
[8]
 Quite a few 
antibiotic-producing bacteria and antibiotic remedies were isolated from 
these soils.
[8]
 For instance, the Actinomyces bacteria, Lysobacter spp. 
and Bacillus spp., which produce actinomycin C2 and actinomycin C3,
[8] 
polypeptide antibiotics that bind to a pre-melted DNA conformation 
present within the transcriptional complex, preventing the elongation of 
growing RNA chains.
[9] 
However, these compounds are impossible to be 
preserved over the centuries. 
The traditional or alternative medicine offered a second chance for 
mining out possible natural antimicrobials with historical relevance, 
particularly herbal medicine used frequently in traditional Chinese 
medicine and passed on from generation to generation. Qinghaosu 
(artemisinin, 2) is perhaps the most famous anti-malarial drug used by 
Chinese herbalists for millennia and extracted by Tu Youyou in the 
1970s from Artemisia plants.
[10],[11]
 An increasing number of 
antimicrobially active components in the traditional Chinese medicine 
has been discovered and contributed to the existing arsenal of worldwide 
medicine. For example, the antimicrobial activity of 20 traditional Chinese 
medicines against four common oral bacteria, Streptococcus mitis, 
Streptococcus sanguis, Streptococcus mutans and Porphyromonas 
gingivalis, was validated by Wong’s team.[12] Among them, the extracts of 
Fructus armeniaca mume were active against all four bacteria, while 
other 13 remedies were effective against Porphyromonas gingivalis.
[12]
 
Another interesting example is the plant of Pericarpium trichosanthis, its 
extracts having a very broad antibacterial spectrum, including 78 
nosocomial drug resistant strains like Acinetobacter baumannii.
[13]
 This 
Chinese herbal medicine, the pericarp of Trichosanthes kirilowii Maxim 
or Trichosanthes rosthornii Harms (Fam. Cucurbitaceae), is traditionally 
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used for coughs or difficulties in expectorating sputum, dyspnea, chest 
congestion and other respiratory tract symptoms.
[14]
 Its clinical 
application is to cure asthmatic tracheitis, cor pulmonale asthma and 
coronary heart disease.
[14]
 In the analysis of its chemical components by 
GC-MS, 4-hydroxybenzoic and isovanillic acids were identified and 
correlated with the distinct antibacterial and antioxidant activity.
[13]
 
Further research indicated that the mechanism of action involved the 
inhibition of the microorganisms’ outer membrane functionality and 
indeed potential in development of new natural antibiotics.
[13]
   
 
Figure 2 Time scale of the Golden Age of antibiotic discovery (1940-1960) and the Golden 
Age of antibiotic medicinal chemistry (from 1960 to present). An innovation gap existed 
between 1962 and 2000, in which no noval classes of antibiotics were explored.[15]  
In fact, the modern antibiotic era started with Paul Ehrlich’s Salvarsan 
(3). Holding his own invented staining bacteria technique, he performed 
a large-scale and systematic screening program in 1904 to search a drug 
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against the sexual transmitted disease syphilis, caused by the spirochete 
Treponema pallidum.
[7]
 Before that, this lethal disease was often handled 
with inorganic mercury salts, a therapy with a high mortality and poor 
effectiveness.
[7]
 After testing hundreds of self-synthesized organoarsenic 
derivatives from a dangerously toxic drug Atoxyl, a compound labeled 
“606” revealed an extraordinary ability to cure syphilis-infected rabbits 
and positive clinical results with the restricted trials on patients led to the 
introduction of Salvaran on the market in 1910.
[16]
 Later, another more 
soluble and less toxic modified drug Neosalvarsan (4) was also marketed 
and both had success in terms of revenues.
[7]
 However, the mode of 
action of this drug is still one of the unsolved mysteries though its 
chemical structure has been already elucidated.
[17]
   
The following discovery of synthetic sulfa drugs, sulfonamidochrysoidine 
(KI-730, Prontosil, 5) was also relied on the systematic screening 
approach invented by Paul Ehrlich.
[7]
 This method has tremendous 
impact on drug search strategies in the pharmaceutical industry and 
gave rise to massive production of new drugs, including antibiotics as 
well.
[7]
 Prontosil was first made by Bayer chemists Josef Klarer and Fritz 
Mietzsch and later, in 1935, Gerhard Domagk found them active against 
streptococcal infection in mice in vivo but not in vitro.
[18]
 Further work 
indicated that the active part of this drug was in fact its metabolic 
product, namely sulfanilamide.
[19]
 It might inhibit bacterial growth by 
interfering with substances, which are essential for the growth of the 
organism.
[20] 
 
The serendipitous discovery of penicillin (6) from the mold Penicillium 
notatum by Sir Alexander Fleming in 1929
[21]
 set up an unprecedented 
gold era for antibiotic research. A Petri dish with growing Staphylococcus 
aureus was accidently contaminated by blue-green mold (a fungus from 
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the Penicillium genus).
[21]
 In addition, the contaminated area was 
observed to constrain the growth of original microorganism due to the 
production of specific substances.
[21]
 Fleming obtained these compounds 
and named them as Penicillin. However, the purification of this antibiotic 
was done by Howard Florey and Ernest Chain from Oxford after several 
decades.
[22]
 The clinical usage of penicillin can vigorously lessen the 
infections caused by Gram-positive pathogens such as Staphylococcus 
and Streptococcus species.
[23]
 
In 1944 Albert Schatz isolated another powerful natural product, 
streptomycin (7), obtained from the soil bacterium Streptomyces griseus 
and was the first antibiotic cure for the tuberculosis agent Mycobacterium 
tuberculosis.
[24]
 Together with chloramphenicol (8), tetracycline, 
macrolides (erythromycin, 9), glycopeptides (e.g. vancomycin 10 and 
teicoplanin) and other antibiotics, mined out from the rich natural pool, 
they were so successful to cure and prevent the infections during World 
War II and considered as miracle drugs for the ultimate medical 
treatment.
[25] 
In fact, the first antibiotic drug used in hospital was pyocyanase obtained 
by Rudolph Emmerich and Oscar Löw from Bacillus pyocyaneus (now 
called Pseudomonas aeruginosa) in the 1890s.
[26]
 Owing to its 
inconsistent performance and toxic preparation procedure, it was 
eliminated from the market in the end.
[26] 
The following results indicated 
that the substances with antibiotic property from Pseudomonas 
aeruginosa
[27]
 were two quorum sensing molecules, 2-alkyl-4-
quinolone
[28]
 and N-(3-oxododecanoyl)homoserine lactone,
[29]
 and one 
non-enzymatically formed product from the latter molecule, 3-(1-
hydroxydecyclidene)-5-(2-hydroxyethyl)pyrrolidine-2,4-dione,
[29]
 
respectively.  
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Figure 3 Synthetic tailoring of antibiotic core structures resulted in continuous generations of 
antibiotic classes in the past 50 years.[15]  
Apart from most of natural original antimicrobial agents, man-made 
‘magic bullets’ obtained by distinct synthetic approaches were also 
introduced in clinical therapies. Nalidixic acid (16), the first synthesized 
quinolone antibiotic, was found in 1962 by George Lesher and his 
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colleagues during the production of chloroquine.
[30]
 It was widely used to 
treat urinary tract infections in humans.
[30]
   
Till the next new scaffold of antibiotic was developed, in the following 
four decades the research was only confined to structurally manipulate 
and optimize the existing antibiotics by synthetic methodologies (Figure 
3). Nalidixic acid (16) as the first generation of quinolone antibiotics 
exhibits bactericidal against many different Gram-negative bacteria (e.g. 
Escherichia coli)
[31]
 and some Gram-positive bacteria, including Bacillus 
subtilis.
[32]
 Interestingly, investigation to the mode of action of this agent 
at different concentrations demonstrated completely opposite results. At 
reasonable bactericidal concentration, inhibition of deoxyribonucleic acid 
(DNA) synthesis was observed, instead of ribonucleic acid (RNA) or 
protein synthesis, whereas at higher concentration, this drugs extends its 
bactericidal activity and inhibits both RNA and protein synthesis.
[31]
 This 
agent has been abandoned for its toxicity, low potency and serious 
adverse effects, specially to infants and young children.
[33],[34]
  
The improvement of this class was continued by the introduction of the 
second generation. Inspired from the discovery of norfloxacin, with a 
boarder spectrum of antibacterial activity against both Gram-positive and 
Gram-negative bacteria exemplified by Pseudomonas aeruginosa and 
Serratia marcescens,
[35]
 for which a fluorine atom was installed to the 
quinolone ring gaining in antibacterial potency,
[36]
 ciprofloxacin (17) was 
developed in 1987 by attaching a different carbon chain on the nitrogen 
atom compared to norfloxacin.
[37]
 This small change has led it to be the 
most regularly prescribed second-generation quinolone.
[38]
 Ciprofloxacin 
has an expanded spectrum of in vitro antibacterial activity, particular 
against Gram-negative bacteria Pseudomonas aeruginosa strains,
[39],[40]
 
which led to excellent results in many respiratory infection
[41]
 and other 
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types of infection.
[42]-[45]
 Gram-positive activity however, is poorly 
represented,
[46]
 for instance, pneumococcal infection
[47]
 which limits 
ciprofloxacin applications.  
Shortly afterwards, third-generation quinolones were synthesized, with 
the typical Gram-negative activity and atypical intracellular activity but 
with improved Gram-positive coverage.
[46]
 Levofloxacin (18) and 
ofloxacin were the isomers of quinolone antimicrobial agents obtained by 
the Japanese pharmaceutical tycoon Daiichi Sankyo.
[48],[49]
 The former 
compound is a good example for this class, for it is active against a 
range of Gram-positive and -negative bacteria and atypical organisms
[50]
 
and found great acceptance in the treatment of various infections caused 
by both penicillin-susceptible and -resistant strains of Streptococcus 
pneumoniae.
[50]
 It also shows good tolerability without phototoxicity, 
hepatic and cardiac adverse events which are quite often seen in some 
other fluoroquinolones.
[51]
  
The coming fourth-generation agents try to maintain Gram-negative 
coverage, ameliorate Gram-positive coverage and gain anaerobic 
coverage.
[38],[46]
 A saturated piperidino pyrrolidine appendage was 
chemically introduced into the aromatic ring of ciprofloxacin instead of 
piperazine and one methoxy group was also attached to generate 
moxifloxacin (19) as one of fourth-generation synthetic fluoroquinolone 
antibiotics.
[52]
 It displays excellent activity against Gram-negative bacilli 
(Enterobacteriaceae, Haemonphilus influenzae, Moraxella catarrhalis), 
enhanced Gram-positive activity against Staphylococcus pneumoniae 
(both penicillin-susceptible and penicillin-resistant strains) and S. aureus 
and ameliorated activity against anaerobes in comparison to 
ciprofloxacin.
[53],[54]
 It also exhibits better activity against atypical 
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pathogens and more superior antibacterial ability against Legionella 
pneumophila than erythromycin.
[55]
  
Moreover, the story of development of new antimicrobial agents through 
the chemical tailoring of main antibiotic core structures has never been 
completely finished in the past 50 years. Meanwhile, the engine of 
searching new antibiotic scaffolds is continuously running. An entirely 
novel synthetically antibiotic, linezolid, was designed in early ‘90s and 
approved for usage by FDA in the US in 2000.
[56],[57]
 As first-generation 
oxazolidinone, it possesses potent activity against most Gram-positive 
bacteria and highly effectively against multi-drug bacteria, including 
streptococci, vancomycin-resistant enterococci (VRE) and methicillin-
resistant Staphylococcus aureus (MRSA).
[58]
 It is often used to treat 
complicated skin soft structure infections and hospital-acquired 
pneumonia through oral and intravenous administration.
[59],[60]
 However, 
after its commercialization, linezolid-resistant strains of Staphylococcus 
aureus
[61]
 and Enterococcus faecium
[62]-[64]
 were discovered clinically. So 
the possibilities of design and synthesis of novel compounds with 
improved potency of antimicrobial activities as well as activity against 
linezolid-resistant strains were explored according to the structural 
conformation of linezolid. Tedizolid (also named torezolid) is a second-
generation oxazolidinone antibiotic and its phosphate derivative was 
developed in U.S. in 2014 for treatment of acute bacterial skin and skin 
structure infections (ABSSSI).
[65]
 It exerts 4- to 16-fold greater 
effectiveness than linezolid against most Gram-positive 
microorganisms
[66],[67]
 and activity against the atypical Chlamydia 
spp.
[68],[69]
 and certain linezolid-resistant strains of S. aureus including 
chloramphenicol-florfenicol resistant cfr-bearing strains.
[70],[67]
 Recently, a 
novel oxazolidinone resistance gene (optrA) was isolated from 
Enterococcus faecium and Enterococcus faecalis in China.
[71] 
This gene 
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can confer transferable resistance or elevated MICs to oxazolidonones 
(linezolid and tedizolid) and phenicols (chloramphenicol and florfenicol) 
when no clinical breakpoints were available.
[71] 
 
The research for developing new antibiotics originated from either natural 
products or synthetic chemicals is still interest triggering. Before 
investing billions of dollars and time-consuming efforts in drug 
development, it is practical and highly demanding to fully understand 
drug-target interactions and the development of the antibiotic resistances 
in order to manufacture more new approaches to expanding this 
antimicrobial arsenal.  
1.2 Antibiotic modes of action 
The majority of antibiotics display their antimicrobial activity at specific 
sites of microbes or certain metabolic processes, due to their structure 
feature and affinities to distinct targets within bacterial cells.
[72]
 Two main 
groups of antimicrobial agents (bactericidal and bacteriostatic antibiotics) 
can be distinguished from each other according to their different 
interactions with the bacterial cellular components or system resulting in 
either induction of cell death or inhibition of cell growth.
[73]
 The 
mechanism of antibiotic actions can be summarized as follows: inhibition 
of cell wall synthesis, inhibition of cell membrane function, inhibition of 
nucleic acid synthesis, inhibition of protein synthesis and blockage of key 
metabolic pathways.
[74],[75]
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Figure 4 Antibiotic target sites.[75] 
1.2.1 Inhibition of cell wall synthesis 
Most bacterial cells are encased by firm layers of peptidoglycan (PG, 
also called murein) which can protect the cells from suffering prevailing 
osmotic pressures in unfavorable environment.
[76]
 This covalently cross-
linked polymer matrix is made up of peptide-linked -(1-4)-N-acetyl 
hexosamine and its degree is responsible for the structural integrity of 
the cells.
[76],[77]
 To survive, bacteria have to produce peptidoglycan 
continuously by transglycosylase and transpeptidase enzymes, which 
add disaccharide pentapeptides to the glycan strands of existing 
peptidoglycan molecules and cross-link strands of immature 
peptidoglycan units.
[78]
 This process is shown in Scheme 1, that the D-Ala 
terminus of the pentapeptide-functionalized N-acetylglucosamine is 
dismissed in the final cell wall assembly step of Gram-negative and 
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many Gram-positive bacteria. Subsequently, the acyl part is cross-linked 
to an amino group in another chain in order to generate the 
peptidoglycan sacculus as a single polymeric macromolecule.
[79]
  
 
Scheme 1 Production of Peptidoglycan.[79] 
Two classes of antibiotics, -lactams and glycopeptides, are getting 
involved in interference with the cell wall biosynthesis in different 
procedures. A successful cell wall synthesis inhibitor can reshape the 
cell, induce cellular stress responses and eventually lead to the cell 
lysis.
[80]
 -Lactams (penicillins, carbapenems and cephalosporins) can 
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block the cross-linking of peptidoglycan units through the inhibition of 
peptide bond formation reaction under the catalysis of  transpeptidases 
(also named as penicillin-binding proteins (PBP)).
[78],[81],[82]
 This takes 
place in the penicilloylation of a PBP’s transpeptidase active site.[73] The 
group of -lactam drugs owns the similar structure as the terminal D-
alanyl-D-alanine dipeptide of peptidoglycan, therefore it can emulate the 
action with enzyme in the acylation phase of cross-link formation. In 
consequence, the enzyme is disabled and lost its ability to hydrolyze the 
new bond established by -lactams.
[83],[84]
 On the contrary, 
actinobacteria-derived glycopeptide antimicrobial agents (exemplified by 
vancomycin and teicoplanin) act differently, as to interfere with 
peptidoglycan synthesis in the aspect of binding with peptidoglycan units 
at the D-alanyl-D-alanine dipeptide as well as blocking transglycosylase 
and transpeptidase activity.
[85]
 In general, glycopeptides behave as steric 
inhibitors of peptidoglycan maturation and reduce the mechanical 
strength of the cells, apart from some that have direct impact on the 
transglycosylase enzyme.
[86]
 Currently, other antibiotics are introduced in 
usage, for they are able to restrain the bacterial growth by inhibiting the 
synthesis (fosfomycin) and transport (bacitracin) of individual 
peptidoglycan units or affecting cellular structural integrity from 
penetrating into the cell membrane and prevailing depolarization.
[73]
  
1.2.2 Inhibition of cell membrane function 
Bacterial cytoplasmic membranes are generally made up of lipids, 
proteins and lipoproteins.
[87]
 It serves as a diffusion barrier for water, 
ions, nutrients and transport systems.
[87]
 In fact, it is considered as a lipid 
matrix with globular proteins randomly distributed to permeate through 
the lipid bilayer.
[87]
 Most of antibiotics are working on the mechanism of 
disorganization of the membranes leading to cell damage.
[87]
 Polymyxin 
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B and colistimethate (polymyxin E) are two well-known compounds, 
which bind to lipopolysaccharide (LPS) in the outer membrane of gram-
negative bacteria to disrupt both the outer and inner membranes.
[88]
 
Principally, it causes disorder of membrane permeability resulting in the 
leakage of nucleic acids and cations, leading to cell death.
[87]
 
Daptomycin, however, depolarizes calcium-dependent membranes that 
lead to macromolecular synthesis inhibition and disruption of the 
bacterial membranes.
[89]
     
1.2.3 Inhibition of nucleic acid synthesis 
1.2.3.1 Inhibition of DNA synthesis 
DNA topoisomerase enzymes are responsible for modulation of 
chromosomal supercoiling via  strand breakage and rejoining reactions 
and further influence DNA synthesis, mRNA transcription and cell 
division.
[73]
 These enzymes are divided into two types (I & II) only 
depending on the number of strands of DNA broken in one round of 
action.
[90]
 They are in charge of the topological state of DNA with cells 
and indispensable for protein translation and cell replication.
[91] 
In 
particular, two type II topoisomerases, gyrase and topoisomerase IV, 
display essential performance in most nucleic acid processes, i.e. 
controlling levels of DNA under- and overwinding and removing knots 
and tangles from the bacterial chromosome.
[92]
 Gyrase is the only type II 
topoisomerase that introduces negative supercoils into DNA in the 
presence of ATP and also responsible for removing the accumulated 
torsional stress in front of replication forks and transcription 
complexes.
[93]-[96]
 Whereas, topoisomerase IV is mainly to remove knots 
that accumulate in the bacterial chromosome arising from fundamental 
cellular processes and decatenate daughter chromosomes upcoming 
replication.
[93]-[95],[97],[98]
 It is noted that two type II enzymes, 
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topoisomerase II and topoisomerase II,[94]-[96],[99],[100] are also encoded 
in human cells. Despite the similarity in amino acid sequence between 
them and the bacterial enzymes, the human enzymes unified two 
individual subunits into a single polypeptide chain after evolution and act 
as homodimers.
[94],[95],[100]
 The specific amino acid differences between 
human and bacterial type II topoisomerases make them ideal and 
attractive targets for antimicrobial agents.
[101]
  
Quinolones are the most successful antimicrobial agents that interfere 
with the bacterial chromosome by targeting DNA gyrase and 
topoisomerase IV and disrupting them at the DNA cleavage stage in 
order to prevent strand rejoining.
[102]-[104]
 The initial study of quinolone 
targeting revealed that gyrase is the primary drug target and 
topoisomerase IV is the secondary goal depending on analyzing in which 
enzyme Escherichia coli strains carry the drug resistance mutations.
[105]
 
As a consequence, E. coli gyrase is more predominantly affected by 
quinolones than topoisomerase IV
[104]
 and higher levels of gyrase-DNA 
cleavage complexes in cells are prompted.
[106]
 Strangely, genetic studies 
in streptococcus pneumoniae gave the opposite result that instead of 
gyrase, topoisomerase IV was actually the primary target for 
ciprofloxacin.
[107]
 It could be roughly concluded that gyrase is the primary 
target in Gram-negative organisms, whereas topoisomerase IV is 
preferentially inhibited by most quinolones in Gram-positive bacteria.
[108]
 
Nevertheless, this hypothesis is also not always true. In some cases, 
gyrase can be the primary target for quinolones in Gram-positive bacteria 
and distinct quinolones can have different primary targets in given 
bacteria.
[109]-[111] 
The issue of the targets of quinolone antibiotics is still in 
dispute and comprehensive evaluation must be done in terms of species 
by species and drug by drug.
[108]
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Scheme 2 Quinolone binds to topoisomerase through a water-metal ion bridge.[112] The top 
sheet demonstrates the crystal structure of a moxifloxacin-stabilized Acinetobacter 
baumannii topoisomerase IV-DNA cleavage complex. The black molecule is moxifloxacin 
and the noncatalytic Mg2+ ion is drawn in green. The four water molecules are colored blue. 
The yellow backbone is the protein amino acid chain. The side chains of the serine and 
acidic residues which generate hydrogen bonds with the water molecules in the water-metal 
ion bridge are painted red.[113] The down panel shows the water-metal ion bridge, displaying 
the interaction only with protein and not with DNA. Ciprofloxacin is painted in black and the 
noncatalytic Mg2+, water molecules, and serine and acidic residues are colored as above.[114]  
The reaction mechanism depicts as follows: Initially, a pair of staggered 
single strands break (nicks) under the action of gyrase, topoisomerase IV 
is covalently bound to the 5’ ends of the cleaved DNA.[115],[116] 
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Simultaneously, quinolones bind to enzyme-DNA complexes,
[117]
 which 
can also happen before cleavage of DNA. This binding with mutant 
gyrase or topoisomerase results in the failure to cleave DNA.
[118],[119]
 
Afterwards, another DNA cleavage-associated procedure takes place 
instead,
[117]
 that replication of the DNA ends in topoisomerases is 
inhibited by drug,
[112]
 and a variety of drug-mediated new cleaved 
complexes are created.
[120]-[123]
 Further studies indicated that Ser83 
according to E. coli GyrA numbering and an acidic residue, four amino 
acids downstream play an important role in mediation of drug-protein 
interactions thereby influence stabilization of cleaved complex.
[111],[124]-[129]
 
Crystallographic research suggested that a noncatalytic Mg
2+ 
ion was 
chelated by the C3/C4 keto acid of quinolones and coordinated to four 
water molecules, two of which were bonded to the serine and acidic 
residues through hydrogen bonds.
[112]
 This existence of water-metal ion 
bridge was later proven and confirmed that the serine and acidic 
residues are the anchor points that supply the connection to the 
enzymes.
[113],[130]
 Thus, the water-metal ion bridge acts as the primary 
interaction between quinolones and bacterial type II enzymes and 
provides the most important evidence that quinolones and their enzyme 
targets are mediated through C3/C4 keto acid of the drug scaffold.
[108]
 In 
terms of human type II topoisomerases, they lack serine and acidic 
residues and are unable to interact with quinolones.
[131]
 Therefore, this 
unique distinction gives the platform for developing new generation of 
quinolone drugs by discriminating between the bacterial and human 
enzymes.
[108]
  
After the quinolone-topoisomerase-DNA complex is formed, DNA 
replication is restrained at the blocked replication forks and result in 
inhibition of DNA synthesis, thereby leading to bacteriostasis and 
ultimately death of cells.
[103]
 This reversible outcome can be influenced 
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by the bacteriostatic concentrations of quinolones.
[103],[132]
 To be noticed, 
formation of this complexes with DNA by binding topoisomerases with 
quinolone drugs can cause serious DNA damage to the cells, due to the 
high distribution of gyrase in the chromosome.
[120],[133]
 Another 
consequence of the inhibition of DNA synthesis is to cause the DNA 
stress response (SOS response), where RecA is triggered by DNA 
damage and auto-cleavage of the LexA repressor protein is promoted to 
express the SOS-response genes so as to have DNA repair 
enzymes.
[134]
 To strengthen the potency of the quinolones, preventing 
induction of the SOS response can be one of the options.
[135]
  
1.2.3.2 Inhibition of RNA synthesis 
Rifamycins are a family of semi-synthetic bactericidal antibiotics that 
interfere with RNA synthesis, similar to the inhibition of DNA synthesis by 
quinolones, which cause damage on prokaryotic nucleic acid metabolism 
and bacterial cell death.
[136]
 This class of drugs blocks DNA-dependent 
transcription by strongly binding to the subunit of a DNA-bound and 
actively-transcribing RNA polymerase enzyme.
[137]-[139]
 The subunit can 
be found within the channel generated by the polymerase-DNA complex, 
where the fresh formed RNA strand arises from.
[140] 
RNA synthesis could 
not be performed beyond the addition of two ribonucleotides, because 
rifamycins inhibit nascent RNA strand initialization sterically.
[141]
 
However, it functions not by blocking the elongation step of RNA 
synthesis, but perhaps by interfering with elongation by allosteric 
modification of the enzyme.
[142]
  
1.2.4 Inhibition of protein synthesis 
Protein biosynthesis takes place on large macromolecular 
ribonucleoprotein complexes (ribosomes) that uses cytoplasmic 
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accessory factors in an iterative process termed translation.
[143],[144]
 The 
ribosomes catalyze peptide bond formation and synthesize the 
polypeptide according to the genetic code of the mRNA.
[143] 
In principle, 
this process can be summarized in three sequential steps: initiation, 
peptide elongation and termination.
[143] 
As main field, the ribosome 
provides optimal condition and conformational structure for performing 
the translation. It has two unequal subunits (30S and 50S) which 
establish translation initiation phase and three tRNA binding sites that 
span both subunits: the aminoacyl tRNA binding/decoding A site, the 
peptidyl-tRNA binding P site and the uncharged tRNA exiting “E” site.[145] 
As the active site of the ribosome, the peptidyl transferase complex 
(PTC) stays at the interface of the A and P sites on the 50S subunit, 
afterwards the newly synthesized peptides emerge the ribosome through 
a 100 Ǻ hydrophobic tunnel at the backside of the PTC.[146]  
 
Figure 5 Formation of peptide bond on ribosome. As illustrated in the graphic, the carbonyl 
carbon of the pept-tRNA in the P site (blue) is attacked by the a-amino group of aminoacyl-
tRNA in the A site (red) resulting in a new peptid bond in the A site and a deacylated tRNA in 
the P site. The 50S subunit is painted in light gray, while the 30S subunit is colored in dark 
gray.[147]  
Initiation of translation is carried out at the first place, where a ternary 
complex composed of initiation factors (IF-1, IF-2 and IF-3), mRNA, the 
30S RNA and initiating N-formyl-methionyl-tRNA is formed, and 
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subsequently binds to the 50S ribosomal subunit to build up a more 
intact complex.
[145]
 The following step is elongation. The elongation factor 
Ef-Tu binds with GTP as so to deliver the amino acyl-tRNA (aa-tRNA) 
into the A site.
[148]
 Incidentally, the ribosome applies decoding process for 
verifying the accuracy of the incoming aa-tRNA into the A site so that the 
incorporated amino acids could be proper onto the nascent chain.
[148]-[150]
 
Decoding associates with the reversible binding of the anticodon of an 
EF-Tu-aa-tRNA complex to the codon at the A site of the ribosome.
[145]
 
After the accommodation step, conformational modify in EF-Tu and the 
ribosome results in GTP hydrolysis and the cleavage of EF-Tu.
[151],[152]
 In 
that case, peptidyl transferase reaction between the peptidyl-tRNA and 
aa-RNA can occur fluently.
[145]
 Supported by the ratchet-like movement 
of the ribosome, translocation takes place along the mRNA by one codon 
leading to the tRNA shifting from the A site to the P site to the E site.
[145]
 
Recent studies illustrated the process with idea that 3’ end of the aa-
tRNA in the A site rotates 180° round a local 2-fold rotation axis in the 
PTC and migrates the rest of the tRNA molecule into the P sites while 
peptidyl transfer displays in the PTC at the same time.
[145],[153]
 Finally, a 
stop codon in the mRNA at the A site terminates the ribosome activity. A 
variety of cytoplasmic factors including release factor, emancipate the 
polypeptide and alter the ribosome for recycling.
[145]
   
The drugs that inhibit protein synthesis can be mainly classified into two 
species: the 50S inhibitors and 30S inhibitors. A variety of antimicrobial 
agents serve as 50S ribosome inhibitors including the macrolides (e.g., 
erythromycin), lincosamide (e.g., clindamycin), streptogramin (e.g., 
dalfopristin/quinupristin), amphenicol (e.g., chloramphenicol) and 
oxazolidinone (e.g., linezolid).
[145],[154]
 Streptogramins bind to the P site of 
the 50S ribosome as well as other structurally diverse antibiotics, for 
instance, macrolides, lincosamides and thiopeptides.
[145]
 Streptogramins 
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A and B are separately bacteriostatic yet show the bactericidal property if 
both are used in combination.
[155] 
On one hand, streptogramin A binds to 
the peptidyl transferase complex in the absence of aminoacyl-tRNAs so 
that the substance attachment to the donor and acceptor sites are 
blocked, thereby the early phase in elongation is restrained.
[145]
 On the 
other hand, mode of action from streptogramin B relies on blockage of 
protein chains extension to release incomplete peptides, eventually bind 
to the ribosome at any step of protein synthesis.
[145],[155],[156]
 
Oxazolidinones act through a different mode of action. This class also 
binds to the P site of 50S unit, particularly located near to the 23S 
rRNA.
[145]
 It interferes with the initiator fMet-rRNA during the formation of 
the initiating complex, thus influences the formation of the first peptide 
bond for the mRNA translation.
[145],[157],[158]
  
30S ribosome inhibitors are comprised of tetracycline and aminocyclitol 
class of antibiotics. Tetracyclines function by inhibition of aminoacyl-
tRNAs binding to the ribosome.
[159]
 Spectinomycin and the 
aminoglycoside family of antibiotics (e.g., streptomycin, kanamycin and 
gentamicin) belong to the aminocyclitol class and bind the 16S rRNA 
assembly of the 30S ribosome subunit.
[73] 
Spectinomycin works by 
disrupting the stability of peptidyl-tRNA binding to the ribosome and 
blocking elongation factor-catalyzed translocation, yet no influence on 
protein translation.
[160]-[163]
 However, the interaction between 
aminoglycosides and the 16S rRNA can cause protein mistranslation 
instead. The conformational changes in the complex between an mRNA 
codon and its cognate charged aminoacyl-tRNA at the ribosome were 
constructed, thereby tRNA mismatching was promoted and leading to 
protein mistranslation.
[164]-[166]
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1.2.5 Blockage of key metabolic pathways 
Other antibiotics act as essential substrates in the cellular metabolism for 
the survival of the bacterial pathogens.
[72]
 Bacterial enzymes attach 
themselves to the antibiotic instead of the regular components.
[72]
 
Sulphonamides and trimethoprim stand as typical antimicrobial agents 
from this group. Both interfere with the folic acid pathway, which plays a 
significant role in the metabolism of nucleic acid and amino acids.
[74]
 
Sulfonamides bind to dihydropteroate synthase, whilst trimethoprim 
inhibits dihydrofolate reductase. Both enzymes are necessitated for the 
production of folic acid.
[74]
 With regards to this, the production of nucleic 
acids (DNA and RNA) and amino acids in bacteria are switched off by 
sulphonamides and trimethoprim.
[74]
 
1.3 Antibiotic resistance 
As an alternative medical treatment instead of normal drugs, the 
invention of antibiotics transfused new blood into the modern medicine, 
even once viewed as magic bullets. In 2009, the entire consumption of 
antibiotics represented 5% of the global drug market and accounted for 
$42 billion in sales.
[167]
 The upcoming emergence of antibiotic resistance 
destroyed this elusive utopia and increased the morbidity and mortality 
rates of infections caused by multidrug-resistant bacteria. Each year, 
approximately 25,000 patients in Europe suffer from multidrug-resistant 
bacterial infections and lose their lives,
[168]
 whilst in the United States 
more than 2 million people obtain infectious diseases arising from 
antibiotic-resistant bacteria, among which 23,000 could not be cured and 
died as a result.
[169],[170] 
It has been determined by the World Health 
Organization as one the three most important public health treats of the 
21
th
 century.
[169] 
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As a matter of fact, the coevolution of bacterial resistance and natural 
antibiotic compounds has been present for billions of years.
[171]
 The 
recent studies towards the evolution of -lactamases provided the 
evidence.
[172],[173]
 However, this has never been an issue blackmailing the 
human health like nowadays. Because the resistant strains are often less 
virulent, thus less competitive than the sensitive strains and thereby the 
selective pressure is minimized.
[171]
 Along with entering the antibiotic era, 
the evolution was impressively accelerated and production of bacterial 
resistance was enlarged as well. Penicillin-resistant strains of 
Staphylococcus aureus were detected only 2 years after this antibiotic 
was introduced clinically.
[174]
 Gradually the situation worsened, as multi-
resistance was already observed in enterobacteria during the late 1950s 
and disseminating since then.
[175]
  
In principle, antibiotic resistance can be divided into three classes, 
namely, intrinsic, acquired and adaptive.
[171]
 Intrinsic resistance utilizes 
the inherent structural and functional characteristics from a specific 
bacterial to resist the activity of antibiotics (Figure 6).
[171]
 For instance, 
the organisms lack a susceptible target for a specific antibiotic. The 
biocide triclosan has a broad-spectrum against Gram-positive and many 
Gram-negative pathogens,
[176]
 but it cannot interfere with membrane 
growth of the Gram-negative genus Pseudomonas. The reason is that an 
insensitive allele of fabI encoded an additional enoyl-ACP reductase, so 
that the target for triclosan is different as for sensitive species.
[177]
 
Another factor for this type of resistance is the composition of the cell 
envelope, in which the Gram-negative pathogens, like Pseudomonas 
aeruginosa and Acinetobacter baumannii hold a semipermeable outer 
membrane with low permeability.
[171] 
So some agents cannot cross the 
outer layer and function properly. Vancomycin is such an example as it 
works well in the Gram-positive bacteria but it is unable to penetrate the 
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outer layer of Gram-negative species and loses its antibiotic activity.
[178]
 
Additionally, the constitutive efflux pumps are present in many bacteria 
and delivery antimicrobial agents out of the cell.
[171]
 
 
 
Figure 6 Mechanisms of Intrinsic Resistance. The intrinsic resistance mechanisms are 
illustrated by the interaction between -lactam antibiotics and the penicillin-binding protein 
(PBP). For instance, antibiotic A is succeeded in restraining the peptidoglycan synthesis by 
penetrating the cell through a membrane-spanning porin protein, thereby binding to PBP. 
Antibiotic B can perfom the same action, yet it is readily eliminated by efflux pumps. 
However, antibiotic C cannot transverse the outer membrane to seek the PBP.[176]  
Acquired resistance can arise from the susceptible microbes either 
merged with new genetic material, plasmids (conjugation or 
transformation), transposons (conjugation), integrons and 
bacteriophages (transduction) or merely chromosomal mutation leads to 
cross-resistance.
[171],[179] 
Little changes in mutations can lead to a large 
improvement in the minimum inhibitory concentration (MIC) and convert 
low-level resistance into high-level resistance.
[171] 
For example, an 
additive effect of mutations in the genes galU, neuG, mexZ, and rplY on 
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the resistance of P. aeruginosa to the aminoglycoside tobramycin was 
observed and the individual mutations resulted in merely 2-fold 
resistance whilst the quadruple mutation created 16-fold more.
[171], [180] 
In addition, environmental factors, such as stress, nutrient conditions, 
growth state, or even subinhibitory levels of the antibiotics themselves, 
lead bacteria to react and alter genes and/or protein expression which 
produce adaptive resistance.
[171]
 Intrinsic and acquired resistances are 
stable and can be launched to descendants, whereas adaptive ones are 
often reversible after removal of the inducing condition.
[171]
   
1.3.1 Genetics of antibiotic resistance 
To survive confronting a variety of environmental difficulties, like 
antimicrobial agents, bacteria can embrace an incredible genetic 
plasticity.
[181]
 Two major genetic weapons from bacteria can dilute the 
effect of antibiotic functions, mutational resistance and acquisition of 
foreign DNA through horizontal gene transfer.
[181]
  
1.3.1.1 Mutational resistance 
Mutations in genes are developed among susceptible bacterial cells in 
order to prevent the cell death from the antimicrobial agents.
[181]
 After a 
resistant mutant is introduced, the antibiotic takes action and excludes 
the susceptible population, thereby the resistant bacteria are 
overloaded.
[181]
 Mechanisms of this sort of resistance is assumed to be 
the followings: modification of the antibiotic target; the lower uptake of 
the drugs; activation of efflux pumps against the responsible substances; 
or global cell adaptions.
[181]
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1.3.1.2 Horizontal gene transfer 
Another common source to manufacture antimicrobial resistance relies 
on acquisition of external DNA via horizontal gene transfer.
[181]
 The 
mechanisms of resistance gene transfer between bacteria are comprised 
of plasmid transfer, transfer by viral delivery, and transfer of free 
DNA.
[179]
 In general, three main approaches can achieve the gene 
transformation, including transduction by the way of bacteriophages and 
integrons, conjugation through plasmids and conjugative transposons, 
and transformation via incorporation of chromosomal DNA, plasmids into 
a chromosome.
[179]
 Afterwards, manipulated genes merge with the 
recipient chromosome by recombination or transposition and result in the 
changes in the terminal gene sequence.
[182]-[184] 
          
1.3.2 Molecular mechanisms of antibiotic resistance 
Antibiotic resistance can take place through modifications of the 
antimicrobial molecule, molecular bypass, active efflux (or decreased 
permeability) and target modification.
[181]
 The consequences can be 
diverse and complicated in subjecting different targets. In most cases, 
bacteria are in possession of distinct resistant mechanisms which 
interrupt certain class of antimicrobial agents.
[185]
 For instance, the 
genomic study of a strain of Acinetobacter baumannii demonstrated that 
an 86 kb resistance ‘island’ in chromosome owns 45 resistance genes, 
among that multiple -lactamases, aminoglycoside modifying enzymes 
and efflux systems are contained.
[186]
 Additionally, some mechanisms are 
spread worldwide, like molecular bypass mechanisms of the global 
disseminated vancomycin resistance Enterococcus.
[187]
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1.3.2.1 Modifications of the antibiotic molecule  
Bacteria apply two strategies for defending themselves against the lethal 
attack from antibiotics. Bacteria release the enzymes either to inactivate 
the drug by attaching specific chemical moieties to the complex, or to 
destroy the compound directly in order to inhibit the antibiotic 
properties.
[181]
   
Chemical alteration of the antimicrobial molecule performed by 
appropriate enzymes is a typical acquired antibiotic resistance occurring 
in Gram-negative and Gram-positive microorganisms.
[181]
 Mainly, it 
consists of catalyzing acylation (aminoglycosides, chloramphenicol, 
streptogramins), phosphorylation (aminoglycosides, chloramphenicol), 
and adenylation (aminoglycosides, lincosamides).
[181]
 The frequent 
outcome is to enhance the steric hindrance of the molecules so as to 
decrease the affinity of the drugs to its target, alternately with higher 
bacterial MIC values.
[181]
    
Aminoglycosides modifying enzymes (AMEs) are one of the typical 
examples, in which the hydroxyl or amino groups of the aminoglycoside 
molecule can be covalently changed.
[181]
 According to their different 
biochemical activities, they can be expressed as aminoglycoside 
acetyltransferase (AAC), aminoglycoside nucleotidyltransferase (ANT) or 
aminoglycoside phosphotransferase (APH).
[181]
 The number from 1 to 6 
stands for the modification site on the particular carbon of the sugar ring, 
while the single or double apostrophe depicts the reaction taken place in 
the first or in the second sugar moiety, separately.
[181] 
Multiple AMEs 
have been detected and considered as the main mechanism of 
aminoglycoside resistance nowadays.
[181]
 The distribution of these 
enzymes are quite different, even from the same family. APH family can 
be found in Gram-positive and Gram-negative bacteria and changes 
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kanamycin and streptomycin rather than gentamicin and tobramycin.
[181]
 
But then, AAC(6’)-I is widely distributed in Gram-negative pathogens 
including Enterobacteriaceae, Pseudomonas and Acinetobacter and 
influences many aminoglycosides, for instance, amikacin and 
gentamicin.
[188]
 Adenyltransferases are enabled to impact gentamicin and 
tobramycin. The genes encoding ANT(4’), ANT(6’) and ANT(9’) are 
mostly detectable in Gram-positive bacteria, whereas ANT(2’’) and 
ANT(3’’) show up more frequently in Gram-negative microorganisms.[188]  
Alteration of chloramphenicol by enzymatic inactivation assumes another 
representative model, which is conducted by the expression of 
acetyltransferase termed as CATs (chloramphenicol 
acetyltransferases).
[181]
 Multiple cat genes are mainly located in both 
Gram-positive and Gram-negative species and cataloged in two major 
classes. Group A can produce high-level resistance whilst type B only 
assesses to low-level chloramphenicol resistance.
[189]
   
1.3.2.2 Molecular destruction 
-Lactamases termed as -lactam resistances are in charge of 
destroying the antibiotic molecules via breaking the amide bond of the -
lactam ring, hence jeopardizing the effectiveness of the antimicrobial 
agents.
[181]
 These enzymes were noticed since the 1940s, even one year 
earlier than the clinical introduction of penicillin and believed to be 
existed for million years.
[190],[191] 
After penicillin was utilized worldwide, 
infections caused by penicillin-resistant S. aureus became a serious 
issue in clinic and its resistant mechanism arises from convenient 
transmission of the plasmid-encoded penicillinase between S. aureus 
strains.
[192]
 Therefore, the manufacture of new -lactam drugs has 
considered this as major factor, for instance, ampicillin with wider 
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spectrum of activity and less susceptibility to penicillinases was 
developed and produced afterwards.
[181]
 Along with the extensive 
application of -lactam antibiotics in medical treatment (penicillins, 
cephalosporins, carbapenems and monobactams), -lactamases have 
become one of the most widespread and clinically notable resistance 
enzymes.
[193]
  
The mechanisms of -lactamases can be described in two different 
ways: a covalent enzyme intermediate is formed or hydrolysis occurs 
through a nucleophilic water molecule that is metal-promoted (Scheme 
3).
[194]
 The former pathway is performed by catalytic Ser, which is 
functionally analogous to Ser proteinases.
[185]
 Its hydroxyl group attacks 
the electrophilic carbonyl carbon on the -lactam ring.[185] As a result, a 
covalent enzyme intermediate is afforded followed by a rapid hydrolysis 
leading to the opened lactam ring and inactivation of the antibiotics.
[185]
 
The second hypothesis depicts that the metallo--lactamases manipulate 
a water molecule activated by 1-2 active site Zn
2+
 atoms to attack the -
lactam ring directly.
[185]
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Scheme 3 Two distinct mechanisms of Ser and metallo--lactamases.[185] 
1.3.2.3 Molecular bypass  
Bacteria are able to evolve new working sites which share very similar 
biochemical functions as the original targets meanwhile are not 
prohibited by antimicrobial agents.
[181]
 This replacement or bypass 
mechanism can acquire the effective resistance to the drugs.
[181]
 
Vancomycin resistance in enterococci stands for a classic instance from 
this group. In principle, vancomycin forms a complex by binding the acyl-
D-Alanyl-D-Alanine terminus of the developing peptidoglycan which 
assembly of the bacterial cell wall.
[181]
 A series of five hydrogen bonds is 
observed in this complex.
[195]
 However, in the resistance mechanism, the 
isosteric depsipeptide acyl-D-Alanyl-D-Lactate replaces the acyl-D-Alanyl-
D-Alanine binding to the antibiotic instead.
[181]
 The new ester linkage 
abolishes a key H-bond donor and brings in electronic repulsion that 
weakens the antimicrobial binding.
[181]
 Nine enterococcal van gene 
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clusters (vanA-vanN) have been found in soil organisms including 
Paenibacillus thiaminolyticus and P. apiares.
[196]
 The vanADLM clusters 
generate precursors ending in D-Lac while D-Ser-ending peptidoglycan is 
afforded by the vanCEGN.
[181]
    
 
Scheme 4 Vancomycin and other glycopeptide antibiotics bind to the acyl-D-Ala-D-Ala 
terminus of growing peptidoglycan chains and their precursors with five hydrogen bonds. 
Resistance occurs with an isosteric replacement of the acyl-D-Ala-D-Ala with acyl-D-Ala-D-
Lactate and leads to the loss of one hydrogen bond instead of original solid five hydrogen 
bonds.[181],[185]   
Another well-described strategy is to enlarge the production of antibiotic 
targets in order to overwhelm the antibiotics.
[181]
 Development of 
resistance to trimethoprim/sulfamethoxazole (TMP-SMX) is a typical 
example of this mechanism. Bacteria overproduce the dihydropteroic 
acid synthase (DHPS) and dihydrofolate reductase (DHFR) via mutations 
in the promoter region of the DNA.
[181]
 The former synthesizes 
dihydrofolate from para-aminobenzoic acid.
[181]
 This procedure is 
inhibited by sulfamethoxazole. Another enzyme catalyzes the production 
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of tetrahydrofolate from dihydrofolate, which is constrained by 
trimethoprim.
[181]
 These massively manufactured enzymes causes 
overwhelmed difficulties for the antibiotics, preventing inhibition of folate 
production.
[197],[198]
  
1.3.2.4 Efflux 
1.3.2.4.1 Reduced permeability 
Many antibiotics have to penetrate the outer and/or inner membrane to 
reach intracellular or periplasmic bacterial targets, particularly Gram-
negative bacteria, possessing a less permeable outer membrane 
compared to Gram-positive bacteria.
[181],[199],[200]
 By using water-filled 
diffusion channels termed as porin proteins, these hydrophilic antibiotics 
can enter the membranes, such as -lactams, tetracyclines and 
fluoroquinolones.
[201]
 Meanwhile, vancomycin has no activity against 
Gram-negative pathogens due to its inability of penetrating the outer 
membrane. Decreasing the permeability of the outer membrane can be a 
strategy for bacteria to cope with the antibiotics.
[181],[202] 
The key step is to 
alter the porins or replace the porins with more-selective channels.
[176]
 
Porins can be divided into different types based on their structures 
(trimetric or monomeric), selectivity and the expression regulation.
[181]
 
Modification of porins takes place in three distinct steps, including 
changing the type of porins expressed, varying the expression of porins 
and jeopardizing the porin function.
[181]
 However, all these procedures 
can lead to low-level resistance and often incorporate with other 
resistance mechanisms, like activating efflux pumps.
[203]
 To date, 
reductions in porin expression of Enterobacteriaceae, Pseudomonas 
spp. and Actinetobacter spp., play an essential role in resistance to 
carbapenems and cephalosporins. Both resistances were often 
considered being mediated by enzymatic degradation.
[204]-[208] 
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1.3.2.4.2 Increased efflux 
Bacteria are able to transport the toxic compounds out of the cell via 
efflux pumps and this action is associated with the intrinsic resistance of 
Gram-negative bacteria to the drugs which are used to cure the Gram-
positive bacterial infections.
[176],[181]
 The earliest observation can be 
traced back to 1980s when tetracycline was pumped out of the 
cytoplasm of E. coli by an efflux system.
[209]
 Afterwards, intensive 
research was focused on the characterization of distinct classes of efflux 
pumps in both Gram-negative and Gram-positive microorganisms.
[181]
 
These efflux pumps could be either narrowly substrate-specific (for 
instance, the tet pumps for tetracycline and mef genes encoding pumps 
for macrolides in pneumococci) or ship a wide variety of substrates out of 
the cells, termed as multidrug resistance (MDR) efflux pumps.
[210]
 
Substantial antibiotics are suffering from this sort of resistance, in 
particular, protein synthesis inhibitors, such as fluoroquinolones, -
lactams, carbapenems and polymyxins.
[181]
 There are five main types of 
efflux pumps that fulfill the assignment, including the major facilitator 
superfamily (MFS), the small multidrug resistance class (SMR), the 
resistance-nodulation-cell-division class (RND), the ATP-binding 
cassette class (ABC), and the multidrug and toxic compound extrusion 
class (MATE).
[181]
 They differentiate each other according to their 
structural conformation, energy source, extruded compounds and 
bacterial organisms that they locate.
[211]
  
Among them, the RND family of MDR efflux pumps is considered the 
most important and clinically relevant MDR efflux transporters in Gram-
negative pathogens.
[176]
 When overexpressed, RND pumps would start to 
remove massive substrates out of the bacterial cell, including antibiotics 
(tetracyclines, chloramphenicol some -lactams, novobiocin, fusidic acid 
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and fluoroquinolones) and toxic compounds (bile salts, cationic dyes and 
disinfectants).
[181],[211]
 The most well-studied RND pumps are AcrAB-TolC 
from E. coli and MexAB-OprM from P. aeruginosa.
[185] 
Crystal structures 
suggest that the RND systems embrace a cell membrane spanning 
pump (AcrB, MexB), an outer membrane pore (TolC, OprM) and a 
periplasmic adapter protein (AcrA, MexA) that links the former two.
[185]
 
Further understanding showed that AcrB has two distinct binding pockets 
(distal and proximal) which can transport dissimilar compounds with 
different sizes and properties, which results in broad-spectrum 
antimicrobial resistance,
[181],[212]-[216]
 subsequently a trimer rotation 
mechanism supports the exit of molecules through the outer membrane 
pores.
[185]
   
1.3.3 Protection of targets 
Several drugs are disrupted by this mechanism including tetracycline 
(Tet[M] and Tet[O]), fluoroquinolones (Qnr) and fusidic acid (FusB and 
FusC).
[181]
 For the tetracycline resistances, Tet(M) was found initially in 
Streptococcus spp. and Tet(O) in Campylobacter jejuni, later both are 
observed in different bacteria as well as in several plasmids and broad-
range conjugative transposons.
[217]
 They are associated with the 
translation factor superfamily of GTPases and serve as homologues of 
elongation factors (EF-G and EF-Tu) in protein synthesis.
[181]
 They 
incorporate within the ribosome and prevent tetracycline from binding to 
its target in a GTP-dependent manner.
[181]
 The whole process can be 
depicted as following: Tet(M) straightly extrudes and liberates 
tetracycline from the ribosome via a synergy between the domain IV of 
the 16S rRNA and the tetracycline binding site.
[218]
 As a consequence, 
the ribosomal conformation is changed and rebinding to the antibiotics is 
thereby avioded.
[218]
 Tet(O) performs a similar mechanism and its 
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substitution of tetracycline in the same ribosomal space revises the 
geometry of the antibiotic binding site so as to replace the antibiotic and 
restart protein synthesis .
[219]
 
1.3.4 Target modification 
Modification of the molecular target is one of the most common 
mechanisms of antimicrobial resistance. It can be achieved from point 
mutations in selected genes leading to small resistances, which are 
harmless to microbes.
[185]
 For instance, single mutations in target genes 
gyrA can result in high level resistance to fluoroquinolone antibiotics 
such as ciprofloxacin.
[185]
 Mutation of Ser to an amino acid with a heavy 
side chain (Leu, Trp, Ile) at position 83 or Asp87 to Asn, Tyr, or Gly takes 
place in fluoroquinolone resistant GyrA giving rise to higher level of 
resistance.
[185],[220]
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Scheme 5 Erm methyltransferases alter A2058 chemically so as to interrupt the interation 
with antibiotics sterically and electronically, thereby resistance occurs. The methyl donor 
SAM is turned into SAH (S-adenosylhomoserine).[185]
 
On the other hand, enzymatic transformation of the binding sites can 
also promote antibiotic resistance. Ribosome methyltransferase is one of 
the best characterized examples of this resistance. The Erm 
(erythromycin ribosomal methylation) enzymes are able to modify the 
23S rRNA of the 50S ribosomal subunit at position A2058 in E. 
coli.
[181],[185] 
Usually, it affects the function of three structurally dissimilar 
types of antimicrobial agents, the macrolides (e.g. erythromycin), 
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lincosamides (clindamycin) and type B streptogramins (e.g. 
quinupristin).
[185]
 Despite the vast diversity in structure, they are all 
binding to the peptide exit tunnel region of 50S ribosomal subunit.
[185]
 
A2058 builds the direct or indirect connections with the drugs via the 
exocyclic amine of the purine ring, N6. Mono- or dimethylation of N6 is 
carried out under catalyzed S-adenosylmethionine (SAM) by Erm 
methyltransferases.
[185]
 The outcome is to lose H-bond properties and 
impair the antibiotic binding sterically.
[185]
 Sharing the similar strategy, 
methyltransferases can also modify A1408 or G1405 of the 16S rRNA of 
the small ribosomal subunit and turn out to be the strongest obstacle for 
aminoglycoside antibiotics over the decades.
[221]
   
1.4 Approaches to development of novel antibiotics  
For quite a long period, plants were considered as the most generous 
and abundant sources of natural medical products.
[222]
 Indeed, a vast 
amount of active substances has been continuously isolated from 
them.
[222]
 Most of antimicrobial compounds extracted from plants are 
phenols or oxygen-substituted derivatives, which are often used by 
plants to defense the predation from microoganisms, insects, and 
herbivores.
[223],[224]
 For instance, the terpenoid capsaicin from chili 
peppers contributes to the plant flavor and similar herbs and spices from 
mankind’s season food are also able to isolate useful medicinal 
compounds.
[224]
 Later, the first synthetic antimicrobial agents were 
invented by screening libraries of chemicals in specific dyes.
[23]
 
Afterwards, the concept that bacteria and fungi can release the 
secondary metabolites with high potency and minimal toxicity towards 
treating bacterial infections in humans was fully accepted and changed 
the previous perspective.
[23]
 Selman Waksman applied this platform for 
screening soil-dwelling bacteria and particularly the spore-forming 
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actinomycetes in order to produce the active compounds that perturb the 
growth of microbes.
[225]
 This empirical method was referred to Waksman 
platform.
[225]
 Approximately, tens of millions of soil microbes have been 
screened by this effective and simply platform in the golden era.
[226]
 As a 
result, most of the existing natural antibiotic scaffolds were discovered 
during that period.
[23]
 It also contributed to understanding the minimal 
inhibitory concentration (MIC) of a compound that is capable of 
preventing the cell growth in vitro.
[23]
 The restriction of this platform was 
showed up slowly by the mid-1960s, for microbial evolution in designed 
circumstance propelled the production of unplanned metabolites with 
unfavorable medicinal properties.
[23]
 The resistance issue stemmed from 
the horizontal transfer of resistance genes between bacteria or 
chromosomal mutation became critical as well.
[23]
 The ensuing 
generation of new antimicrobial agents was mostly innovated from the 
existing natural scaffolds via chemical modification.
[23]
 The whole 
strategy can be summarized as bioactivity-guided screening, classical 
pharmacology, forward pharmacology
[227]
 or phenotypic drug 
discovery.
[228]
 Potential substances were screened for their bioactivity in 
whole cell-assays in the absence of the drug target.
[225]
 The research to 
the target and the mode of action of the compound was accomplished 
after its biological activity was proved.
[222]
   
The second approach is termed as chemical screening in the purpose of 
identification of novel structurally dissimilar compounds in the absence of 
considering the bioactivity.
[222]
 These compounds can be launched from 
either biological source (e.g. bacterial secondary metabolites) or from 
chemical libraries.
[222]
 Sophisticated analytical methodologies are 
involved into the structure elucidation, including high-performance liquid 
chromatography (HPLC), mass spectrometry (MS) and nuclear magnetic 
resonance spectroscopy (NMR).
[222]
 With the effort of large data-bases of 
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mass spectra for known substances, the replication can be avioded, 
thereby the bioactivity of the evaluated compounds can be tested 
directly.
[222] 
The last screening program is target-oriented screening with the intention 
to determine the compounds that attack an established molecular 
target.
[222]
 The cellular or molecular model of this target provides the 
significant platform for the drug development.
[222]
 The attributes of target 
also play an essential role in this strategy, such as, without human 
homologue, wild distribution in bacteria, the location of the target in 
microbes and a low frequency of resistance.
[222]
  
The biggest disadvantage of these traditional screening strategies is that 
thousands of compounds have been repeatedly detected.
[229]
 It can be 
estimated that most of microbial metabolites have been harvested unless 
high-throughput screenings with larger screening libraries are 
implemented.
[230]-[232]
  
Beside the traditional methods to discover the new antimicrobial agents, 
modern culture techniques and strategies are also accounting their own 
efforts for this field. Actinobacteria serve as the largest pool yielding 
enormous natural compounds, however only less than 1% of 
actinobacterial species have been successfully cultivated in laboratory so 
far whilst 99% of them still remain unculturable.
[233]
 The main problem 
eager in need of solving is how the novel bacterial strains can be 
cultivated under conventional laboratory conditions.
[222]
 Several new and 
revolutionary cultivation techniques have been pumped out so that a vast 
amount of initially uncultivable pathogens can be fostered.
[222]
   
Microfluidic bioreactor cultivation belongs to one of these new methods. 
In this high-throughput cultivation system, up to 600000 pure soil-derived 
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Actinobacteria can be raised in microfluidic droplets per hour.
[234] 
It can 
promote the slow growers under normal conditions yet inferior to fast-
growing microbes and seed the possibility of new antibiotic 
compounds.
[222]
 This idea aims to establish so far uncultured or 
unclassified actinomycetes and filamentous fungi in order to isolate new 
metabolites, has been used to found the company Naicons in 2006.
[222]
 
Owing to this, several new natural products have been found, for 
example, the protein synthesis inhibitor orthoformimycin, which owns a 
novel structure and possess a thoroughly rare mechanism of action, or 
an effective anti-inflammatory agent, the class III lanthipeptide NAI-
112.
[232]
  
On the other hand, in situ cultivation grows the microorganisms in a 
simulated environment. Kaeberlein et al. invented this technique via 
using diffusion chambers to imitate the marine environment in the case 
that two unknown microbes were isolated and termed as MSC1 and 
MSC2.
[235]
 It was proved that MSC1 share 93% sequence similarity with 
its relative Lewinella persica by 16S rRNA gene sequencing.
[235] 
Meanwhile, MSC2 is perhaps the relative of the species Acrobacter 
nitrofigilis, a common marine sediment microorganism related to nitrogen 
fixation.
[235]
 It was further developed into a multichannel device 
assembled with hundreds of miniature diffusion chambers, each 
inoculated with a single environmental cell.
[236]
 This device is termed as 
iChip (isolation chip), in which target bacterial strains rely on natural 
nutrients and are cultivated as single colonies in isolated microchambers 
so that the novel species can be fostered and easily transferred into pure 
culture.
[236]
 Lassomycin and teixobactin are two novel antimicrobial 
agents obtained by this strategy.
[237],[238]
 Lassomycin is isolated from 
Lentzea kentuckyensis and has excellent potency against 
Mycobacterium tuberculosis.
[239] 
Teixobactin is obtained by previously 
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unculturable Gram-negative bacteria Eleftheria terrae and shows 
bioactivity against Gram-positive species, methicillin-resistant 
Staphylococcus aureus, vancomycin-resistant enterococci and 
Chlostridium difficile while no resistant mutants of S. aureus and M. 
tuberculosis were detected.
[240]
  
Co-culture technique provides another opportunity to access the 
potential drugs, in which bioactive compounds released from assistant 
bacteria impact the growth of other microorganisms so as to activate 
biosynthetic pathways as signals.
[240]
 Aspergillus/Streptomyces co-
cultivation has been done for exploration of new bioactive molecules.
[241]
  
Aspergicin and neoaspegicillic acid are the natural products produced by 
mixed-fermentation mycelia of marine-derived mangrove fungi.
[242] 
Among them, Aspergicin reveals the antibacterial effects against many 
clinical pathogens and both Gram-positive and Gram-negative 
bacteria.
[242]
   
Apart from sophisticated cultivation methodologies, Next-Generation 
Sequencing techniques are also able to detect novel complexes with 
potential therapeutic applications. A new bacterial taxon Entotheonella 
that co-inhabits the Red sea marine sponge Theonella swinhoei was 
identified by this single-cell and metagenomics-based method.
[243] 
According to metagenomics analysis, more than 40 bioactive polyketides 
and altered peptides from seven structurally dissimilar genres were 
observed and released from the endosymbiont in the sponge.
[243]
 This 
inspired example also enriched the novel reservoirs of microorganisms 
and their relative bioactive secondary metabolites.
[240]
 Unexplored 
habitats, including desert, marine environment and endosymbiotic 
environment, are full of interesting molecules.
[222] 
In the marine 
environment, salinity is perhaps the only parameter to be concerned in 
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association with microbial community composition and diversity, 
compared to temperature, pH value or other physical and chemical 
factors.
[244]
 Marine actinomycetes are physiologically and 
phylogenetically distinguished from terrestrial species yet produce a vast  
amount of chemically diverse bioactive compounds as well.
[245]
 Another 
abundant reservoir is the endophytes. The botanical diversity contributes 
to endophytic diversity in term of diverse plant life, tropic regions or 
temperate rainforests.
[246]
 The species estimation of endophytic 
organisms could be up to 300000 due to the large number of unexplored 
plant species.
[247]
 A review describing the natural products released from 
endophytic bacteria was stated, including ecomycins, pseudomycins, 
munumbicins and kakadumycins.
[248]
 All of them possess antibiotic 
impact on different clinical pathogens. Therefore, it was affirmed again 
that bacterial endophytes own the ability of novel antimicrobials 
production.
[248]
   
In addition, genome mining strategies have widespreaded in the last two 
decades,
[249]
 where the biosynthetic gene clusters of natural products are 
initially investigated and determine whether these gene clusters are 
associated with the production of new antimicrobials.
[250]
 For instance, 
the Streptomyces nodosus genome has 24 biosynthetic gene clusters for 
developing natural products, 18 of which are able to generate particular 
chemicals and their structurally relative compounds.
[251]
 This convenient 
method brings a plentiful of beneficial advantages. The low cost or even 
no expend can be reached when the existing bioinformatics tools screen 
encoded genomes of potential molecules.
[220]
 Adequate available DNA 
data nowadays are dedicated to this process as well.
[220]
 Accessible 
sophisticated web-based tools, including anti-SMASH,
[252]-[254]
  PRISM
[255]
 
or NaPDoS,
[249]
 simplify the genome mining procedure, which can be 
propelled easily and reliably in natural product biosynthesis or 
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bioinformatics.
[222]
 An intriguing outcome is that with more genetic 
discovery of bacteria, more diverse chemical compounds could be found 
than it was expected.
[222]
 Moreover, the information of the biosynthetic 
gene clusters gives the chance to predict the chemical classes and 
structures of the encoded molecules.
[222]
 This can direct a more targeted 
drug discovery technique (e.g. reactivity-guide isolation)
[256]
 and peptide 
and glycogenomic approaches
[257],[258]
 as well as the heterologous 
expression in an optimized expression host (also termed as activation of 
the silent gene cluster).
[222]
 The comprehensive biosynthetic gene cluster 
databases, for instance, MiBIG (Minimum Information about a 
Biosynthetic Gene cluster) make the suggestion in elucidating the novel 
encoded compounds more conveniently.
[259]
 To overcome the complexity 
between the gene clusters and bioactivity, a more cautious model named 
as target-directed genome mining was built, which detects potential 
resistance genes to yield more specific antibiotic compounds.
[260]
 There 
are also some other methods strengthening in silico research, such as 
peptide and glycogenomics, which combine computational estimation 
with mass spectrometry
[257],[258]
 or pattern-based genome mining, in 
which the vast amount of DNA sequence data is available to exploit.
[261]
 
The limitation of these computational genome mining processes is that 
they can only identify the biosynthetic gene clusters related to known 
biosynthetic mechanisms thereby the corresponding products are 
perhaps highly similar.
[222]
 For the unknown biosynthetic pathway 
species, Identification of Natural compound Biosynthesis pathways by 
Exploiting Knowledge of Transcriptional regulation (INBEKT) approach 
was developed.
[262]
 The signal-sensing regulators which promote or 
repress gene transcription by attaching to certain DNA motifs upstream 
of their target genes in response to environment factors, including 
nutrient starvation, oxidative stress and existence of competitive 
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microbial, were identified, therefore specific DNA-binding motifs and 
genome sequences were determined.
[222],[262]
 The successful example of 
INBEKT is to identify the biosynthetic gene cluster of the zincophore 
ethylene diamine disuccinic acid ([S,S]-EDDS).
[262]
 The zinc regulator Zur 
controls the production of (S,S)-EDDS in bacterial strain Amycolatopsis 
japonicum severely.
[262]
 The determination of the Zur-binding motifs in the 
A. japonicum genome results in the finding of the (S,S)-EDDS 
biosynthetic genes eventually.
[262]
   
The demand of new and fresh leads for antibiotic drugs is extremely 
high, since the antibiotic resistance has arisen immediately after the 
agents were introduced into the market. The barriers and some new 
perspectives for uncovering novel natural products can be summarized 
as four points. First of all, in present, there are very few antibiotic targets 
with a limited range of mechanisms.
[23]
 Meanwhile, the outcomes of 
genomic tools have not reached the ideal expectation.
[23] 
Unconventional 
targets and discovery platforms could be an alternative solution since 
great efforts have been invested in conventional ones however 
replication seems to be a powerful disadvantage.
[23]
 Secondly, the 
mechanisms of action of existing antimicrobial agents are too 
complicated to apply in modern drug discovery.
[23] 
A comprehensive 
understanding of these mechanisms should be done in the first place. 
Besides, the physical and chemical properties of current antibiotics bring 
the burden to the conventional collections of compounds and medicinal-
chemistry methods.
[23]
 In particular, physical characteristics of chemicals 
which can overcome the problem in permeability of the Gram-negative 
species deserve great efforts.
[23]
 The last point is to reconsider the 
determinants for identification of novel compounds.
[23]
 Waksman platform 
has been employed in this field since invented and reached a superior 
result meanwhile restricted the protocol where numerous targets, for 
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instance virulence factors and in terms of metabolism, are not seized in 
this traditional MIC approach.
[23]
 Besides, further ideas can be taken in 
consideration as well. Some compounds that only inhibit the pathogenic 
action instead of slaughtering the bacteria could avoid acquisition of 
mutations.
[222]
 Another strategy is to combine different sorts 
antimicrobials based on clinical experiments and patient records.
[23]
 It 
displays compelling impact on medical treatments nowadays, such as 
the combined usage of trimethoprim and sulfamethoxazole can result in 
the synergistic influence in folate metabolism or cooperation between 
amoxicillin and clavulanic acid, former is a -lactam antibiotic and later is 
an inhibitor of-lactamase drug resistance enzymes, can accomplish 
synergy and restrain a broad spectrum of microbes.
[23]
   
On the other hand, millions of synthetic chemicals have been produced 
for various purposes. To some extent, this can also enlarge the 
possibility for seeking new medicines. The synthetic fluoroquinolones 
can be exemplified as one of the most successful antibacterial agents for 
several decades.
[23]
 However, criteria like the Lipinski rule of five 
restricted the imagination firmly. In this rule, a potential orally active drug 
should have less than 5 hydrogen bond donors and less than 10 
hydrogon bond acceptors, while its molecular mass cannot beyond 500 
daltons.
[263],[264]
 Besides, the octanol-water partition coefficient log P 
should be controlled under 5.
[265]
 Yet, obeying to this rule couldnot simply 
guarantee the pharmacological activity of the candidate drugs. 
Therefore, for the discovery of novel oral medications, synthetic 
strategies focus mainly on the compounds optimized for human biology. 
As natural products and their derivatives, most of existing antibiotics 
cannot adapt those parameters.
[266]
 Meanwhile, the synthetic molecules 
could not accomplish the biological functions as the natural antimicrobial 
agents, such as penetration of the cell membranes.
[23]
 Thus, the situation 
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is placed in a dilemma that the compounds from screening natural-
product libraries are bioactive yet formerly known, whilst the outcome of 
synthetic libraries could yield potent ligands of biochemical targets with 
impoverished bioactivity.
[23]
   
Despite the necessity for new generations of antibiotics, the development 
of fresh leads particularly in those that capture deadly multidrug-resistant 
Gram-negative bacteria, is however pulled back due to high risk and low 
profit to the pharmaceutical and biotechnology firms.
[267]
 The reasons for 
antibiotics transforming from magic bullets into an financially unattractive 
object in less than one century can be depicted as below. First, 
compared to other drug classes, antimicrobials show less profit due to 
national conservation, an established generics market and short-term 
treatment.
[268],[269]
 Second, the uncertainty of the regulatory requirement 
for market approval in US and European Union adds more barriers to be 
overcome.
[270]
 Third, the investment in production of new drugs is shifted 
to other more profitable areas by many pharmaceutical 
companies.
[267],[271]
 Therefore, the academic and basic research should 
contribute more effort in propelling the development of novel antibiotics 
than previously.   
1.5 Fungal volatile organic compounds  
A variety of volatile organic compounds (VOCs) with low molecular 
weight are produced by individual fungal species via primary and 
secondary metabolism pathways.
[272]
 These compounds are easily 
evaporated into the gas phase at normal atmospheric temperature and 
pressure.
[273]
 In general, they have a special donor and are low to 
medium soluble in water.
[274]
 For example, 1-octen-3-ol (also termed as 
muchroom alchol) was identified as main aroma compound from 
distinctive mushromm species, including Agaricus bisporus,
[275],[276]
 and 
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mold genera like Aspergillus and Penicillium.
[277]
 Due to their certain 
properties, fungal VOCs are frequently considered as very practical and 
useful chemicals for agriculture, food and flavor industry.
[273]
 Along with 
the development of the modern analytical techonology, more and more 
chemically different and biologically active fungal VOCs have been 
found, including alcohols, acids, aldehydes, esters, ketones, thiols, 
aromatics, terpenes, and so on.
[273]
 Besides, they are also a rich natural 
source for the investigation of their biotechnological potential as 
mediators between fungi and plants, arthropods, bacteria, and other 
fungi.
[278]
 However, in comparison to the study about the VOCs with 
bacterial,
[279]
 plant, or synthetic origin, far less attention was paid to the 
VOCs of fungal origin.
[273]
 Therefore, my research interest in the topic of 
the investigation of the secondary metabolites from fungi was raised and 
fulfilled by studying the fungal representatives of Geniculosporium and 
Xylariacea, in terms of VOCs collection, detection, characterization and 
bioactivity evaluation.  
1.5.1 Geniculosporium 
Endophytic fungi can be found in almost all plants, including trees, 
grasses, algae, mosses and herbaceous plants.
[280]
 Most of them arise 
from Ascomycetes and Fungi imperfecti.
[281]
  In ordinary circumstances, 
they rely on the host plant for living in the absence of apparent 
diseases.
[281]
 When the host feels the threat from environmental stress, 
endophytes might turn into pathogens, thereby the delicate equilibrium 
between host and endophytes might be broken and chemical factors 
impact a lot in this balance.
[282]
 For instance, herbicidal natural products 
are released by the fungi and antifungal compounds are biosynthesized 
by the host plant.
[282]
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Endophytic fungus Geniculosporium sp. (strain number 2121) with callus 
of its host Teucrium scorodonia is able to produce the bioactive 
diterpene geniculol (29) and the acknowledged fungal metabolite 
cytochalasin F (30), both of which exhibit algacidal properties (Figure 
7).
[280]
 In addition, cytochalasin F displays inhibition of photosynthesis 
and has an ecological function in the plant-symbiont interaction.
[280]
 In 
previous study, several volatile lactones (31-33) have been detected 
from Geniculosporium sp. 9910 , which was isolated from the rockrose 
Cistus monspeliensis, also termed as Montpelier cistus.
[283]
 These 
lactons were collected from agar-plate cultures by usage of a closed-loop 
stripping apparatus.
[283]
 Unambiguous compound characterisation was 
done by GC-MS and verified by synthesis of reference compounds.
[283]
 
Pogostol (34), a sesquiterpene was found in the same fungal strain and 
its putative biosynthesis was investigated by feeding experiments with 
six 
13
C-labelled isotopomers of mevalonolactone in cooperation with 
13
C-
NMR analysis.
[284]
 It is noted that marine microorganisms can obtain 
different natural products compared to their terrestrial relatives. For 
example, fourteen new tricyclic sesquiterpenes (35-48) with the botryane 
skeleton and four known cytochalasins (49-52) were isolated from 
Geniculosporium sp. (internal strain number 6580) associated with the 
red alga Polysiphonia sp. from the Baltic Sea at Ahrenshoop, 
Germany.
[285]
 The novel botryane compounds (35-48) have some 
inhibitory impact in microbes Chlorella fusca, Bacillus megaterium and 
Microbotryum violaceum.
[285]
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Figure 7 Secondary metabolites from Endophytic fungus Geniculosporium sp. 
1.5.2 Xylariaceae 
Xylariaceae is one of the largest families of the Xylariales (Ascomycota) 
comprising over 85 genera and far more than 1340 species.
[286]
 It is 
assorted into two main groups (Hypoxyloideae and Xylarioideae) 
essentially based on an abundance of distinguishing features, including 
anamorphic type, form of stroma, extractable stromatal pigment and 
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other secondary metabolites.
[287]-[290] 
Xylarioideae constitutes the largest 
diverse type genus of Xylariaceae.
[290]
 Xylaria and its allies share mostly 
Geniculosporium-like anamorphs.
[290] 
It owns characteristic stromata as a 
clavate to stipitate or conspicuously constricted habit.
[290]
 In some wood-
inhabiting Xylaria spp. (X. polymorpha, X. hypoxylon), it can be easily 
identified due to its extremely large size in every mushroom field.
[290]
 
Some other Xylaria spp. can only generate inconspicuous stromata in 
tropical fruits, insect nests and so on.
[290]
 Initially, the hydroxyphthalide 
derivative xylaral (53) was the only compound isolated from X. 
polymorpha, which can obtain violet colour in aqueous ammonia (Figure 
8).
[291]
 Later, phlegmacin (54) and other emodin type stromatal pigments 
have been investigated from Xylaria euglossa.
[292]
 The established 
metabolites exist also in the Basidiomycetes of the genus Dermocybe, 
while the emodin pigments can be found in many ascomycetes.
[293]
 
Hypoxyloideae as the second major subgroup of Xylariaceae is 
comprised of the genus Hypoxylon and its immediate allies, such as 
Biscogniauxia, Camillea, Daldinia, Entonaeme and small tropical taxa.
[290]
 
They all show up a Nodulisporium-like anamorph and can be further 
separated into the Biscogniausxia/Camillea complex and Hypoxylon 
together with its immediate allies according to appearance of stromatal 
pigments.
[290]
 Dihydroisocoumarins, like formylmellein (55) was described 
in culture of Biscogniauxia marginata and also later found in other 
species of Biscogniauxia.
[294]-[297]
 Characteristic pigments deposited in 
granules directly between the perithecia and under the stromatal surface, 
exist in most of Hypoxylon species.
[290] 
Mitorubrins (56-58) were the first 
chemical compounds of these pigments detected from H. fragiforme.
[298]
 
Besides, they might also release chemically related azaphilones, like 
hypomiltin (59), the rubiginosins and entonaemins (60-63), and the fatty 
acids, rubiginosic acid (64).
[299]-[301]
 Endophytic Xylariaceae same as 
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other endophytic fungi, have been explored for mass production of 
volatile organic compounds. Up to date, there are only a few studies on 
the analysis of the produced volatiles from this family. For instance, 1,8-
cineole was discovered from a series of VOCs emitted from Hypoxylon 
sp. and related anamorph Nodulisporim sp.,
[302]-[304]
 the comparison of 
emitted volatiles between Daldinia concentria and Daldinia 
hawksworthii,
[305]
 and identification of 27 VOCs from D. cf. concentrica by 
gas chromatography-mass spectrometry analysis.
[306]
  
 
Figure 8 Secondary metabolites from Endophytic fungus Xylariacea. 
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1.6 Linezolid  
Except obtaining the immense inspiration from nature, modification of 
chemical skeletons of existing antibiotics could be another approach to  
develop novel potential candidates. Therefore, a completely different 
project regarding to alternation of linezolid, the first synthetic 
oxazolidininone antibacterial agent, was present in this thesis. 
Production of modified linezolid derivatives was made and biological 
activity was reported in correlation with their chemical structure.   
In general, the discovery of linezolid can be divided into several phases. 
The DuPont pharmaceutical initially reported two new antimicrobial 
compounds in 1987, DuP-105 and DuP721.
[307]
 These compounds were 
the first representatives of oxazolidininone antibiotic family and stemmed 
from a series of racemic 5-halomethyl-3-phenyl-2-oxazolidinones with 
properties for treatment of various plant diseases, for instance compound 
65 and its chemically modified  molecule 66.
[308]
 Compound 66 displays 
in vitro activity and in vivo efficacy against several Gram-positive and 
Gram-negative pathogens.
[309]
 The exploration to 66 elucidated the 
absolute configuration of the oxazolidinones, particularly at C-5, which 
exhibits the essential antibacterial activity (Figure 9) and eventually 
inspired the production of its descendants DuP-721 and DuP-105.
[310]
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Figure 9 Early structure-activity relationships of oxazolidinones examined at DuPont.[311] 
 
Figure 10 Development of oxazolidinone antibacterial agents.[311]  
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Later the assigment was passed to Pharmacia company, in which two 
analogues PNU-82965 and PNU-85055 containing bicyclic ring system 
(indanone and tetralone) instead of the common 4-substituted phenyl 
ring were accomplished and tested.
[312],[313]
 To be noted, only the S 
enantiomer was found to be antibacterial active, since the racemic 
material demonstrated exclusively half the potency of the pure 
enantiomer.
[310]
 The safety evaluation of racemic DuP-721 and PNU-
82965 was conducted to declaim that PNU-82965 indicated less 
aggressive lethal effect than racemic DuP-721 in the clinical evidences of 
the treated rats.
[314]
 This also proved that a structure-toxicity relationship 
remains in this family.
[311]
 Another racemic indoline congener PNU-85112 
was subsequently generated and showed an excellent safety profile in 
the toxicity study while impacted in vitro activity and in vivo efficacy 
similar as racemic DuP-721.
[315]
 Afterwards, even a tricycle fused 
racemate PNU-86093 was designated and synthesized to enhance the 
oxazolidinone pharmacophore.
[316]
 Unfortunately, it displayed in vitro 
antibacterial activity merely lower than racemic DuP-721.
[311]
 
By the end of 1992, three major types of oxazolidinone analogues were 
discovered, including piperazinylphenyloxazolidinones (e.g. PNU-
97665),
[317]
 indolinyloxazolidinones (e.g. PNU-97456)
[318] 
and the 
trophonylphenyloxazolidinones (e.g. PNU-96686).
[315]
 The indolines 
displayed a superior safety profile yet poor antibacterial activity.
[311]
 
However, the troponyl compounds with excellent antibacterial activity 
revealed impoverished water solubility and poor pharmacokinetic 
characteristics.
[311]
 Unlike the others, piperazine series retained not only 
outstanding in vitro and in vivo activity but also in possession of an 
acceptable safety profile, acceptable water solubility and remarkable 
pharmacokinetic parameters.
[311]
 Besides, these analogues were also the 
easiest obtainable compounds via synthesis.
[311]
 After screening several 
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candidates in this group, it was observed that one or two fluorine atoms 
flanking the para piperazine group indicated considerable potentiating 
impact on the antibacterial activity and hydroxyacetyl moiety was 
deemed to be the optimal nitrogen substituent.
[311]
 In consistence with 
this perspective, the monofluorophenyl molecule PNU-100594 with the 
optimal level in antibacterial activity, pharmacokinetics, water solubility 
and other pertinent properties was eventually generated.
[319]
 An early 
synthesis report is depicted in Scheme 6. It starts with 3,4-
difluoronitrobenzene (67) being treated with excess piperazine via 
nucleophilic aromatic displacement to afford the p-substituted 
nitrobenzene 68, selectively. Reduction of 68 and subsequent 
attachment with a carbobenzoxy (CBZ) activating group reached 
compound 69. Deprotonation with n-BuLi and later stirring together with 
(R)-glycidyl butyrate obtained compound 70 with a good yield (83%). 
Mesylation of 70 and reaction with potassium phthalimide give an 
intermediate. After that, cleavage of the phthalimide group and 
replacement with aqueous MeNH2 was followed by the treatment of Ac2O 
and pyridine to have 71. It was deproteted into amine and acylated with 
(benzyloxy)acetyl chloride. The last step was the benzylic hydrogenolytic 
cleavage to yield PNU-100692 (eperezoild) as final product.
[319]
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Scheme 6 Total synthesis of eperezolid (PNU-100592). Cbz = benzyloxycarbonyl, Ms = 
methanesulfonyl.[319]  
Replacement of the piperazine ring led to the discovery of 
antimycobacterial thiomorpholine derivative PUN-100480
[320]
 and 
morpholine analogue PNU-100766,
[319]
 termed as linezolid afterwards. 
The adjusted structure-activity relationships of oxazolidinone based on 
earlier DuPont work were exposed by Pharmacia and summarized in 
Figure 11.
[311]
 Two interesting points could be conducted in this 
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investigation. An appropriate electron-donating amino substituent on the 
phenyl ring can contribute to brilliant antibacterial activity and a good 
safety profile.
[305]
  One or two fluorine atoms flanking the morpholine or 
piperazine ring could enhance antibacterial activity as well.
[311]
 A brief 
large-scale production of linezolid was demonstrated in Scheme 7.
[321]
 A 
nucleophilic aromatic displacement of 3,4-difluoronitrobenzene (67) with 
excess morphine was followed by reduction to yield amine 72. Then, the 
attachment with a carbobenzoxy (CBZ) activating group was 
accomphlished and obtained 73. N-alkylation of amide was done by 
treatment of (S)-(+)-3-chloro-1,2-propanediol in order to introduce 5-S 
stereochemical center, subsequently deprotonated and oxazolidinone 
ring closure by potassium tert-butoxide and LDA to reach compound 74. 
Afterwards, hydroxyl group was protected by 4-nitrobenzensulfonyl 
chloride to afford 75.  Later, it was converted by ammonia into the 
corresponding amine 76. Finally, acetylation gave linezolide (PNU-
100766).
 [321]
   
 
Figure 11 Revised structure-activity relationships evaluated at Pharmacia.[311] 
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Scheme 7 Total synthesis of linezolid (PNU-100766). LDA = lithium diisopropylamide, Ns = 
meta-nitrophenylsulphonyl.[321]    
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Figure 12 Mechanism of antibacterial action of the linezolid.[322] 
Oxazolidinones share a unique characteristic mechanism of action which 
avoids them being targeted by existing resistance mechanism in bacteria 
(Figure 12). Oxazolidinones bind to the 50S ribosomal subunit, 
preventing it from complexing with the 30S subunit, mRNA, initiation 
factors and formylmethionyl-tRNA.
[323],[324] 
More specifically, Linezolid 
binds to the A site pocket at the peptidyltransferase center of the 
ribosome overlapping the aminoacyl moiety of an A-site bound tRNA.
[325]
 
This induces a newly distinct conformation of the universally conserved 
23S rRNA nucleotides and consequently results in a nonproductive state 
for peptide bond formation, blocks assembly of a functional initiation 
complex for protein synthesis and impairs translation of the 
mRNA.
[322],[325] 
It differs from other protein synthesis inhibitors, 
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exemplified as chloramphenicol, macrolides, lincosamides and 
tetracyclines, which tolerate mRNA translation afterwards, constraining 
peptide elongation.
[322] 
 
Figure 13 Overview of linezolid (cyan) and CCA-PHE (gold) binding to Haloarcula 
marismortui 50S ribosomal subunit. The acetamide arm hydrogen bonding to G2540 is 
indicated.[326]  
Two crystal structures of the oxazolidinone antibiotic linezolid bounding 
to the Deinococcus radiodurans and Haloarcula marismortui 50S 
ribosomal subunits were determined respectively and offer a definitive 
visualization to understanding the mechanism of action.
[325],[326]
 For 
instance, Figure 13 demonstrates the complex of linezolid and CCA-N 
acetylphenylalanine (CCA-Phe) binding to Haloarcula marismortui 50S 
ribosomal subunit. In it, hydrogen bonding and hydrophobic packing 
interactions are frequently utilized by linezolid in terms of connecting an 
all-RNA pocket.
[326]
 The oxazolidinone ring representing the 
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pharmacokinetic property is stacked against base moiety of U2539 and 
results in van der Waals interactions.
[326]
 A hydrogen bond between the 
acetamide NH and the phosphate group of G2540 could be observed as 
well.
[326]
 The fluorophenyl moiety of linezolid is located in a 
heteroaromatic crevice comprised of residues A2486 and C2487 in the 
peptidyltransferase center, named also as A-site cleft.
[326]
 This 
conformation has shown hydrophobic functionality in other antibiotic 
inhibitors.
[327]
 However, the morpholine ring does not exhibit any 
significant interactions with the ribosome, so that distinct functional 
groups can replace it in the absence of significant loss in activity.
[311]
 The 
elucidated crystal structures of linezolid bound to the 50S subunits of  
prokaryotic ribosomes  provide a structural basis for the discovery of 
next-generation oxazolidinones active against emerging drug-resistant 
clinical strains, including linezolid-resistant strains.
[328]
 
In accordance with the crystal structure of linezolid targeting Haloarcula 
marismortui 50S ribosomal subunit, in silico prediction for new and 
promising lead compounds has been conducted and several novel 
distinct oxazolidinone antibacterial agents were given from it.
[329]
 Reliable 
force field simulations (the AMBER and the OPLS-AA force fields), first 
principle calculations and accessible experimental data have all 
contributed to rebuilding the conformational space of linezolid in 
association with the isolated and the ribosomal bound state.
[329]
 Initially, 
an all-atom bacterial ribosomal model with nearly 1600 atoms was 
constructed and examined.
[329]
 Stochastic Monte Carlo (MC) method was 
employed to scan the conformational space with 30 different 
ribosomal/oxazolidinone complexes.
[329]
 Afterwards, their enthaplic 
penalties were calculated respectively according to Equation 1, where 
ΔΔEb represents the binding enthalpy relative to linezolid and the rest 
stand for the enthalpies of the complex between the ribosome and 
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specific linezolid analog (Eribo-guest), the complex between the ribosome 
and linezolid (Eribo-Izd), the solvated linezolid analog (Eguest) and the 
solvated linezolid (EIzd).
[329]
   
ΔΔEb = (Eribo-guest – Eribo-Izd) – (Eguest – EIzd)     (1) 
Also, the mechanical strengths of the relevant hydrogen bonds were 
evaluated, including relaxed force constants and compliance 
constants.
[329]
 Eight linezolid analogues with the experimentally known 
MIC (Minimal Inhibition Concentration) values were applied for 
crosschecking the robustness of the fresh-made model, by comparison 
to their calculated relative enthalpic binding energies, partially 
demonstrated in Table 1.
[329]
 Based on this protocol, 22 new linezolid 
derivatives (80-101) in Figure 14 were chosen merely by chemical 
intuition and their ribosome affinities were valued by the enthalpic 
penalties.
[329]
 These potential antibiotic compounds enrich the arsenal 
and give valuable inspirations toward the rational development of the 
next generation of oxazolidinone antibiotics.   
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Guest ΔΔEb [kJ/mol] MIC valuea 
 
-15.6 2 
 
-5.2 8 
 
-27.9 0.5 
Linezolid 0.0 1-2 
Table 1 Comparison between computed relative enthalpic binding energies and the 
experimentally known MIC (Minimal Inhibition Concentration). aMinimal Ihibition 
Concentration values detailed in mg/L for seletcted methicillin-resistant Staphylococcus 
aureus bacterial strains (MRSA).[329]  
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Figure 14 Predicted new linezolid derivatives.[329] 
Among these new compounds, molecule 92 owns the lowest relative 
enthalpic energy in binding affinity resulted from the theoretical 
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calculation. According to the computer simulation (Figure 15), two 
hydrogen bonds between oxazolidinone 92 and ribosomal 50S subunit 
emerged. One occurs between the NH in oxazolidinone and A2538, 
whilst another binding indicates between the oxazolidinone-ester-type 
oxygen and the G2012 guanine NH group.
[329]
 This assumed that 
compound 92 could be an outstanding candidate with excellent 
antibacterial properties. Therefore, a chemical synthetic approach was 
planned to reach this target. Its biological evaluation should be done for 
searching the antimicrobial properties.   
 
Figure 15 Illustration of the conformation and interaction between oxazolidinone 92 and 
ribosomal 50S subunit (blue area). Red colour balls stand for amino acid residues binding to 
compound 92 via the hydrogen bonds depicted as black dashed arrow lines, while green 
colour balls represent amino acid residues surrounding the compound.[329]  
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Figure 16 Tedizolid and its derivatives (102-104). 
In the study of oxazolidinone antibacterials, tedizolid is considered as 
another interesting relative topic. Its phosphorylated compounds service 
as an inactive prodrug and would be turned into tedizolid rapidly and 
extensively after oral or intravenous administration to treat acute 
bacterial skin and skin structure infections (ABSSSI).
[330]
 It also exhibits 
excellent activity against Gram-positive bacteria, including methicillin-
resistant Staphylococcus aureus (MRSA) and has been approved for 
usage by FDA in 2014.
[331]
 Tedizolid shares similar structures as linezolid 
or other oxazolidinone compounds, yet small modifications in the 
molecule resulted in four- to eightfold more potency in vivo than linezolid 
against a variety of bacterial pathogens.
[331]
 For example, a 
hydroxymethyl group at the C-5 position instead of the acetamide group 
in linezolid can display potency against linezolid-resistant bacterial 
strains with the cfr gene, which decreases oxazolidinone susceptibility in 
terms of shortage of certain ribosomal mutations.
[331]
 The optimization of 
pyridine and tetrazole rings reinforces the additional binding interactions 
with upper region of peptidyltransferase center (PTC) of the 50S 
ribosomal subunit.
[332]
 Its derivatives 102-104 (Figure 16) with similar 
novel two oxazolidinone rings as in compound 92 were considered as 
synthetic targets for this thesis as well.  
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2. Results and Discussion  
2.1 Analysis of volatiles emitted by fungus 
Geniculosporium 
The agar plate cultures of the endophytic fungal genus Geniculosporium 
sp. 9910 released the volatile compounds, which were collected on a 
charcoal filter through the closed-loop stripping apparatus (CLSA) 
headspace technique.
[333]
 After a collection time of 24 hours, the 
adsorbed filter was extracted with analytically pure dichloromethane and 
the extracts were analyzed by GC-MS. The analytical results were 
obtained three times to prove its reproducibility, and a representative 
chromatogram is demonstrated in Figure 17. The headspace extracts 
were composed of major compounds cis- and trans-lactones (32 and 
33), and 2-butyl-methylbut-2-enolide (31). They were reported previously 
from the same fungal species,
[283]
 along with minor metabolites 105 and 
106.  
 
Figure 17 Total ion chromatogram of a representative headspace extract from 
Geniculosporium sp. 9910.[283]  
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Figure 18 Mass spectra of volatile compounds 105 and 106.[334]   
The mass spectra of two unknown natural products (105 and 106) are 
shown in Figure 18. Due to their characteristic isotope patterns of the 
molecular ions, both compounds were assumed to contain one or two 
chlorine atoms. In comparison to mass spectra in electronic libraries, 
compound 105 was assigned as chlorodimethoxybenzenes while 
dichlorodimethoxybenzenes constituted substance 106. Yet, this 
couldnot be the evidence for the unambiguous compound structure, 
since the differences of distinct constitutional isomers were comparably 
small. Therefore, it is necessary to concern other complementary criteria, 
43
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such as the comparison of GC retention indices of those two 
components to all possible structural isomers.  
For this reason, six constitutional isomers of a chlorodimethoxybenzene 
(105a-105f) and eleven constitutional isomers (106a-106k) of a 
dichloromethoxybenzene were all obtained either via synthesis or 
purchased from commercial suppliers (Figure 19).  
 
Figure 19 Constitutional isomers of chlorodimethoxybenzene 105 and 
dichlorodimethoxybenzene 106.[334]   
Among the candidates for determining the structure of 
chlorodimethoxybenzene, compounds 105d and 105e were 
commercially available, while the other regioisomers were afforded 
individually by synthesis representing in Scheme 8. ortho-Lithiation of 
veratrole (107) followed by chlorination with trifluoromethanesulfonyl 
chloride and triethylamine afforded compound 105a with an acceptable 
yield (47%). 4-Aminoveratrole (108) was primarily converted into 
diazonium salt 109, subsequently via a Sandmeyer reaction generated 
105b (60% over two steps). Double methylations of 2-chlororesorcinol 
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(110) with potassium carbonate and methyl iodide in acetone was able to 
produce isomer 105c in a good yield (88%). The last isomer 105f was 
achieved by chlorination of 1,4-dimethoxybenzene (111) with 
benzyltrimethylammonium tetrachloroiodate in moderate yield (34%).
[335]
  
 
Scheme 8 Synthesis of chlorodimethoxybenzenes as reference compounds.[334]   
For dichlorodimethoxybenzene 106, all possible constitutional isomers 
were synthesized and summarized in Scheme 9. Compounds 106a, 
106c, and 106e were side products arising from the reaction of 1,2,3,4-
tetrachlorobenzene (112) with sodium methoxide in hot HMPA, which is 
described to manufacture 1,2,3-trichloro-4-methoxybenzene and 1,2,3-
trichloro-3-methoxybenzene by monosubstitution.
[336]
 Yet, disubstitution 
also took place and afforded a series of mixture, which were later 
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rigorously purified by repeated column chromatography. The same 
reaction condition could also bring the molecules 106f and 106g in better 
yields (29% and 17%). Methylation of the precursors, 3,5-
dichloroactechol (114) and 4,6-dichlororesorcinol (115) by treatment with 
potassium carbonate and methyl iodide resulted in the isomers 106b and 
106h in efficient yield (80%). Derivative 106i was prepared in two steps, 
initially benzoquinone (116) was treated with sulfuryl chloride under 
acidic condition to yield 2,3-dichlorohydroquinone (117), then methylation 
to reach the target with 13% overall yield. Reduction of 2,6-
dichorobenzoquinone (118) with ascorbic acid to the corresponding 
hydroquinone 119 further methylation developed 106k in acceptable 
yield (48%). Isomers 106d and 106j can be obtained by chlorination of 
veratrole (107) and 1,4-dimethoybenzene (111) with two equivalents of 
benzyltrimethylammonium tetrachloroiodate respectively. Both reactions 
were done in moderate yields (45% and 38%).  
All these constitutional isomers were examined by GC-MS analysis in 
application with the same GC column as for the headspace extract from 
Geniculosporium (HP5-MS). By comparison of mass spectra and 
retention indices (listed in Table 2), the structure of 105b and 106b were 
unambiguously assigned to the natural products 105 and 106 separately.  
Neither of them was discovered as natural products previously. On the 
contrary, compounds 105f and 106k have been investigated from the 
fungus Bjerkandera adusta.
[337]
 In fact, the dichloromethoxybenzene 
(106b or 106k) could be possibly derived from the 
monochloromethoxybenzene (105b or 105f) via a second chlorination 
and hypothesized that the chlorinated compounds in both metabolites 
share one and the same biosynthetic pathway.
[334] 
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Scheme 9 Synthesis of dichlorodimethoxybenzenes as reference compounds.[334]   
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Compound number Structure Compound name  I (HP5-MS) 
105a 
 
1-Chloro-2,3-dimethoxybenzene 1278 
105f 
 
2-Chloro-1,4-dimethoxybenzene 1292 
105b 
 
4-Chloro-1,2-dimethoxybenzene 1322 
105e 
 
1-Chloro-3,5-dimethoxybenzene 1340 
105d 
 
1-Chloro-2,4-dimethoxybenzene 1374 
105c 
 
2-Chloro-1,3-dimethoxybenzene 1404 
Natural Product 105   1322 
106c 
 
1,4-Dichloro-2,3-dimethoxybenzene 1339 
106b 
 
1,5-Dichloro-2,3-dimethoxybenzene 1426 
106k 
 
1,3-Dichloro-2,5-dimethoxybenzene 1443 
106j 
 
1,4-Dichloro-2,5-dimethoxybenzene 1448 
106a 
 
1,2-Dichloro-3,4-dimethoxybenzene 1466 
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106e 
 
1,3-Dichloro-2,4-dimethoxybenzene 1487 
106d 
 
1,2-Dichloro-4,5-dimethoxybenzene 1505 
106h 
 
1,5-Dichloro-2,4-dimethoxybenzene 1545 
106f 
 
2,5-Dichloro-1,3-dimethoxybenzene 1556 
106g 
 
1,2-Dichloro-3,5-dimethoxybenzene 1565 
106i 
 
2,3-Dichloro-1,4-dimethoxybenzene 1574 
Natural Product 106   1426 
Table 2 GC retention indices of all constitutional isomers of chloromethoxybenzene, 
dichloromethoxybenzene and natural products 105 and 106.[334]   
In conclusion, 4-chloro-1,2-dimethoxybenzene (105b) and 1,5-dichloro-
2,3-dimethoxybenzene (106b) were identified as volatile natural products 
(105 and 106) emitted by the fungus Geniculosporium. Their biological 
evaluation will be discussed in the following chapter.  
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2.2 Analysis of volatiles emitted by the fungal Xylariaceae 
In this study, 14 fungal strains from the Xylariaceae family were analysed 
for their volatiles emitted by agar plate cultures grown on YMG medium 
(Yeast and Malt Extract with Glucose). The volatiles were also trapped 
on charcoal filters through the closed-loop stripping apparatus (CLSA) 
headspace technique.
[333]
 After one day of collection, a solvent extract of 
the adsorbed filter was analyzed by GC-MS. The analytical results were 
acquired three times to prove its reproducibility. The compounds were 
identified based on their mass spectra and retention indices in 
comparison to literature data and commercially available or synthetic 
reference compounds. After all, a total of 88 volatile compounds from 
various classes were identified. A representative chromatogram of a 
headspace extract from Daldinia clavata STMA 06094 is shown in Figure 
20. The chromatograoms for the other species are demonstrated in 
chapter 4.4.1, while the occurrence of volatile organic compounds is 
tabulated in chapter 4.4.2.  
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Figure 20 Total ion chromatogram of a representative headspace extract from Daldinia 
clavata STMA 06094. The peak labelled with an asterisk represents an unidentified natural 
product from D. clavata.  
2.2.1 Fatty acid derivatives 
2.2.1.1 Alcohols 
 
Figure 21 Alcohols. 
Among the fatty acid derivatives, several different alcohols were 
detected, including one primary alcohol (122) , one secondary alcohol 
(123), two unsaturated alcohols (120 and 121), one cycloalkanol (124) 
and one diol (125) (Figure 21). 1-Octen-3-ol (120) was present in the 
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following fungi, Daldinia clavata, D. childiae, D. australis, D. eschscholzii, 
D. novae-zelandiae and D. concentrica. But only two strains D. australis 
and D. eschscholzii emitted 2-octen-1-ol (121). Both volatiles are 
produced as microbial volatile organic compounds (MVOC’s) during the 
primary fungal metabolism.
[338]
 In particular, 1-octen-3-ol (120) is 
considered as the major product arising from enzymatic break-down of 
linoleic acid
[339]
 and possesses the flavour of the mushrooms Agaricus 
bisporus and Pleurotus species.
[275],[340] 
The other metabolites can be 
also found in these organisms. 1-Tetradecanol (122) occurred in D. 
australis. 2-Hexanol (123) was detected in D. clavata, well known as 
typical fungal smell.
[277]
 Cyclohexanol (124) was only generated in strain 
D. childiae. This cycloalkanol plays an important role in inhibition of 
Sclerotinia sclerotiorum spore germination and mycelium growth.
[341]
 In 
addition, one diol, 2,3-butanediol (125) was emitted by D. hawksworthii. 
This volatile compound is able to promote the growth and induce 
systemic resistance in Arabidopsis thaliana.
[342],[343]
 It is also revealed that 
this diol can induce the plant production of nitric oxide (NO) and 
hydrogen peroxide either under normal circumstance or under drought 
stress.
[344],[345]
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2.2.1.2 Aldehydes and ketones 
 
Figure 22 Aldehyde and ketones.  
One aldehyde (126) and several ketones (127-131) were identified, in 
addition to unsaturated ketones (132-134), hydroxyketones (135-137), 
cyclic ketone (138) and diketone (139) (Figure 22). Tiglic aldehyde (126) 
occurred only in the fungal strain D. clavata. The methyl branched 
ketones, 2-methyl-3-pentanone (127) and 4-methyl-3-hexanone (128) 
were widespread in the Daldinia species, along with other typical fungal 
metabolites,
[346]
 3-octanone (129), 2-octanone (130) and 2-undecanone 
(131). Among the unsaturated ketones, (E)-4-methylhex-4-en-3-one 
(132) was identified in the strains D. clavata, D. novae-zelandiae and D. 
concentrica. Ketone 133 was dominated in D. clavata and D. childiae. It 
can be also named as manicone, which exists as an ant alarm 
pheromone from two north American species of ants Manica mutica and 
M. bradleyi (Hymenoptera, Formicidae).
[347]
 D. novae-zelandiae released 
6-methyl-5-hepten-2-one (134) derived from fatty acid biosynthesis.
[348]
  
Besides, 2-hydroxyhexan-3-one (135) and 2-hydroxy-4-methylhexan-3-
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one (136) accompanied with acetyl valeryl (139), appeared frequently in 
D. clavata, D. novae-zelandiae and D. concentrica. They were 
investigated previously as volatile compounds from Gram-positive 
bacteria, Corynebacterium glutamicum.
[349] 
(4R,5R,6S)-5-Hydroxy-4,6-
dimethyloctan-3-one (137) was first time discovered as natural  product 
in fungi family and participates in total synthesis of (-)-ebelactone A and 
B
[350]
 and Auripyrone A.
[351]
 It was distributed in almost every investigated 
Xylariaceae species. In addition, cyclohexanone (138) was found in trace 
amount in D. childiae and Biscogniauxia cylinderispora respectively.  
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2.2.1.3 Identification of volatiles 133 and 137 via synthesis 
 
Figure 23 Mass spectra of natural products 133 and 137.[352]  
The absolute structural configuration of volatile organic compounds 
cannot only rely on the proposals based on GC-MS analysis data. In 
some cases, it is necessary to pursue reference compounds via 
chemical synthesis. The mass spectrum of compound 133 revealed 
characteristic fragment ions at m/z = 154 (molecular ion M
+
), m/z = 139 
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(loss of methyl group), m/z =125 as base peak indicating an ethyl 
branching and m/z = 97 (cleavage of sec-butyl group). The chemical 
formula can be concluded as C10H8O and shares a similar data base 
spectrum of manicone, (E)-4,6-dimethyloct-4-en-3-one. However, no 
available retention index for this substance was found in literature. 
Therefore, a total synthesis of compound 133 was planned from 2-
methylbutanal (140) and triethyl 2-phosphonopropionate (141) by the 
treatment with lithium chloride and DBU in acetonitrile through a Horner-
Wadsworth-Emmons reaction,
[353]
 having ethyl (E)-2,4-dimethylhex-2-
enoate (142) as a separable mixture of E and Z stereoisomers (E/Z = 
10:1), subsequently reduced by diisobutylaluminium hydride into 
corresponding alcohol (143) with an acceptable yield (55%),
[354]
 oxidised 
by pyridinium chlorochromate
[355]
 and introduced the alkyl side chain via 
Grignard reaction yielding 56% of compound 144, ultimately treated with 
another pyridinium chlorochromate oxidation in moderate yield (37%) 
(Scheme 10). The overall yield of 5 steps synthesis to reach the target 
molecule is only 1%. One explanation is that all the intermediates 
involved have sincerely low molecular weight leading to strong volatility 
in air, thereby the loss of products obviously existed during the 
operations.  
 
Scheme 10 Synthesis of compound 133.[352] 
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Figure 24 Mass spectra of natural product 133 and its authentic synthetic sample.  
The mass spectra between natural product and authentic sample are 
shown in Figure 24 and share small differences, for instance, fragment 
ions at m/z = 41 and m/z = 55 indicate higher intensity in natural product 
than synthetic sample. This could be the background interference from 
the machine. Their retention indices are very close to each other, 1136 
from natural product and 1140 from synthetic substrate, respectively. 
Based on these observations, compound 133 was assigned as 
manicone.   
On the other hand, the mass spectrum of ketone 137 indicated some 
fragment ions which were also detected in 133 (Figure 23). This might 
suggest that both metabolites are structurally related. The fragments ions 
at m/z = 57 as a base peak and m/z = 86 result from -cleavage and 
McLafferty rearrangement of 4-methyl-3-ketone. The fragment ion at m/z 
= 115 that may result from an -cleavage next to the alcohol function 
supported the molecular structure as a hydroxy-ketone. The fragment ion 
at m/z = 154 results from the dehydration of hydroxyl group and the 
fragment ion at m/z = 143 arises from the cleavage of alkyl group from 
the molecular ion. The higher retention time of compound 137 in 
comparison of 133 offers the hint that via a dehydrolation of hydroxyl-
ketone 137, the C=C double bond in 133 can be installed as 
expected.
[352]
 Therefore, the molecular formula for hydroxyl-ketone 137 
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can be assigned as C10H20O2. To verify the structural proposal, an aldol 
addition between racemic 2-methylbutanal (140) and pentan-3-one (145) 
was carried out and generated a racemic mixture of all four 
diastereomers 137a-d (Scheme 11).
[356]
 All eight stereoisomers were 
successfully separated by GC on a homochiral stationary phase 
performed with a CP-ChiraSil-Dex CB capillary column, one of which 
was identified as natural product 137 in comparison of retention time and 
mass spectra (Figure 25).  
 
Scheme 11 Synthesis of a racemic mixture of all four diasteromers of 137.[352]   
In order to understand the relative and absolute configuration of the 
natural product 137, an enantioselective synthesis was initially 
conducted (Scheme 12). It began with (S)-(-)-2-methylbutanol (146) via 
Swern oxidation with oxalyl chloride and DMSO at low temperature and 
was converted into the corresponding aldehyde, followed by one-pot 
Wittig reaction with ethyl 2-(triphenylphosphoranylidene)propionate (147) 
under reflux yielded the esters (2E,4S)- and (2Z,4S)-148 as a mixture of 
diastereomers (approximately 15:1) which were separated by repeated 
column chromatography.
[357]
 Reduction of E-ester with 
diisobutylaluminium hydride afforded the corresponding alcohol (149) 
with an acceptable yield (72%).
[354]
 Sharpless epoxidation introduced the 
epoxides (150a and 150b) enantioselectively by (+)-diethyl L-tartrate and 
(-)-diethyl D-tartrate, (80% and 88%, respectively).
[358]
 Afterwards, treated 
with tert-butyldimethylsilyl trifluoromethanesulfonate and Hünig’s base, 
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epoxide rings were opened, followed by hydride migration to reach 
aldehydes (151a and 151b).
[359]
 These aldehydes were extremely 
unstable in air and can be further oxidized into carboxylic acids. 
Therefore, direct addition of ethyl group at C-2 position with Grignard 
reagent achieved compounds 152a and 152b with moderate yields over 
two steps (48% and 26%, separately). Subsequently, oxidation by 
pyridinium chlorochromate gave the access to 153a and 153b in high 
yields (88% and 75%). At last, deprotection with hydrogen fluoride in 
pyridine at 0 °C formed 50% of (4R,5S,6S)-137a and 72% of (4S,5R,6S)-
137b.
[360]
 The overall yields of 7 synthetic steps to reach both isomers 
(4R,5S,6S)-137a and (4S,5R,6S)-137b were 6% and 7% respectively.  
 
Scheme 12 Enantioselective synthesis of (4R,5S,6S)-137a and (4S,5R,6S)-137b.[352]   
The same approach starting from (2Z,4S)-148 could also give access to 
two more stereoisomers, (4S,5S,6S)-137c and (4R,5R,6S)-137d. 
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However, the Z-ester couldnot be reached in sufficient quantity for 
completing the further synthetic sequence. Therefore, (4S,5S,6S)-137c 
and (4R,5R,6S)-137d were afforded by epimerisations at the -carbon 
(C-4) of (4R,5S,6S)-137a and (4S,5R,6S)-137b under mildly basic 
condition, respectively (Scheme 13).  
 
Scheme 13 Epimerisations of (4R,5S,6S)-137a and (4S,5R,6S)-137b under basic 
conditions.[352] 
Four newly synthesized compounds ((4R,5S,6S)-137a, (4S,5R,6S)-
137b, (4S,5S,6S)-137c and (4R,5R,6S)-137d) were added to the 
synthetic mixture of all eight stereoisomers separately and  the analysis 
of enantioselective GC demonstrated that the natural product was 
assigned to (4R,5R,6S)-137d in terms of retention time and mass 
spectra (Figure 25).  
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Figure 25 Gas chromatographic analysis of 137 on a homochiral stationary phase performed 
with a  CP-ChiraSil-Dex CB capillary column. a) the synthetic mixture of all eight 
stereoisomers (Scheme 11), b) natural product form D. clavata, c) enantioselectively 
synthesized (4R,5S,6S)-137a (Scheme 12), d) enantioselectively synthesized  (4S,5R,6S)-
137b (Scheme 12), e) coinjection of a) and epimersation product (4S,5S,6S)-137c (Scheme 
13) and f) coinjection of a) and epimersation product (4R,5R,6S)-137d (Scheme 13). The 
asterisk labelled peak represents the second main volatile organic compound in the 
headspace extracts from D. clavata, also showed in Figure 20.[352]   
Additionally, the chemical characterisation of all eight stereoisomers of 
137 obtained by aldol addition (Scheme 11) could be accomplished by 
extensive chromatographic purification. First and foremost, via column 
chromatography on silica gel, one pair enantiomer 137a were excluded 
from the racemic mixture. Preparative reversed phase HPLC succeeded 
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in separating other three compounds 137b, 137c and 137d. 
Furthermore, preparative HPLC on a homochiral stationary phase refined 
the pure enantiomers of these compounds, expect 137a. Fortunately, 
enantiomerocally pure (4R,5S,6S)-137a was produced by 
enantioselective synthesis as described above, and the peaks of the 
enantiomers of 137a in the GC chromatogram on a homochiral stationary 
phase could be distributed individually by comparsion to synthetic 
authenic sample (4R,5S,6S)-137a. At last, the structures of all eight 
peaks in chiral GC analysis could be determined and proved again the 
structure of (4R,5R,6S)-137d as the volatile organic compound released 
from D. clavata (Figure 26).  A table of the 
13
C NMR data of all four 
stereoisomers 137a-d are summarised below.  
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Figure 26 Gas chromatographic analysis of 137 on a homochiral stationary phase performed 
with a CP-ChiraSil-Dex CB capillary column. a) the synthetic mixture of all eight 
stereoisomers (Scheme 11), b) natural product from D. clavata, and c)- m) pure racemates 
and enantiomers of 137a-d. Compound (4R,5S,6S)-137a was afforded by enantionselective 
synthesis (Scheme 12), the pure racemates of 137a-d and the pure enantiomers of 137a, 
137b and 137d were obtained by chromatographic separation from the synthetic mixture of 
all eight stereoisomers. The asterisk labelled peak stands for the second main volatile 
organic compound in the headspace extracts from D. clavata, also showed in Figure 20.[352] 
 
 
13C NMR (ppm) 137a 137b 137c 137d 
a 9.3 11.2 11.8 12.0 
b 25.4 26.2 23.6 27.1 
c 37.3 37.5 38.1 37.0 
d 15.0 14.5 16.3 13.9 
e 74.6 74.7 78.5 75.8 
f 47.3 48.2 47.7 48.8 
g 11.3 11.4 14.8 12.5 
h 215.4 214.5 215.7 215.0 
i 34.6 34.9 36.2 36.1 
j 7.8 7.8 7.7 7.8 
Table 3 Carbon NMR spectroscopic data (chemical shifts in ppm) for 137a-d (125 MHz, 
C6D6). 
The biosynthetic pathway to (4R,5R,6S)-137d can be assumed as a 
typical fungal iterative polyketide synthase (PKS). As represented in 
Scheme 14, acryl-carrier-protein (ACP) bounding to acetate as a starter, 
first elongation occurs with malonyl-SCoA (Mal-SCoA) under the 
catalysis of of an acyl transferase (AT) and a ketosynthase (KS) domain 
and affords acetoacetyl-SACP. Later, SAM-dependent C-methylation by 
a methyl transferase domain (MT) might be performed to introduce  the 
stereochemical course in the 4R-configuration for 156. The same 
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stereochemical course should continuously proceed in the coming chain 
extension steps as an iterative PKS takes place. A hydroxyl group is 
added at C-3 position by a keto-reductase (KR), followed by elimination 
of water by a dehydratase domain (DH) and reduction of the C=C double 
bond by an enoyl reductase (ER) to install the stereocenter in 159. 
Subsequently, another chain extension with malonyl-SCoA and 
methylation introduces a second stereocenter in 161. The final 
stereochemical course for target molecule is completed by reduction of 
161 with KR into corresponding alcohol 162. The last extension is also 
carried out by malonyl-SCoA and methylation to reach intermediate 164. 
Afterwards, a thioesterase (TE) converts 164 into the -keto acid 165, 
which is spontaneously decarboxylated into (4R,5R,6S)-137d.
[352]
 Further 
investigations are necessarily demanded to confirm this hypothetical 
PKS biosynthesis.  
 
Scheme 14 Proposed biosynthetic pathway to (4R,5R,6S)-137d.[352] 
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2.2.1.4 Esters 
 
Figure 27 Esters (166-168). 
The production of volatile fatty acids and fatty acid esters in the 
fermentation of the yeast Saccharomyces cerevisiae has been studied 
and several hypotheses about the mechanism of the ester synthesis 
have been published.
[361]
 Two main flavour active esters, the acetate 
esters and the medium-chain fatty acid (MCFA) ethyl esters, remain in 
the fermented beverages.
[361]
 In our case, butyl acetate (166) as a typical 
apple aroma and flavour volatile,
[362]
 was found in D. clavata in trace 
amount. It can reduce the conidial adhesion and germination from fungus 
Botrytis cinerea which leads to apple fruit rot.
[362]
 Another flavour volatile 
fraction hexyl propionate (167) can be observed in D. australis. The -
hydroxy ester 168 likely arising from leucine carbon skeleton was 
detectable in strain Biscogniauxia cylinderispora.  
2.2.2 Lactones 
 
Figure 28 Lactones (169-172). 
Fungi can produce a variety of lactones as the 3-hydroxylation of fatty 
acids and even 4- or 5-hydroxylations.
[363]
 Trichoderma viride produces 
the well-known coconut odor lactone, 6-pentyl--pyrone.[364] In our earlier 
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research to the soil fungi Trichoderma viride and Trichoderma 
asperellum, several new alkyl- and alkenyl-2H-pyran-2-ones were 
examined and unambiguously synthetically varified.
[365]
 Specially, two 
lactones are widely distributed in the fungal volatile organic compounds. 
6-Methyl-5,6-dihydro-2H-pyran-2-one (169) owns the predominate peak 
in D. eschscholzii and D. concentrica, while it occurs in small amounts in 
D. clavata, D. cf. caldarium and D. novae-zelandiae. It was firstly 
discovered in 1859 from steam distillation of European mountain ash 
berries, Sorbus aucuparia (Rosaceae).
[366] 
6-Heptyl-2H-pyran-2-one 
(170) could be only observed in D. clavata and D. childiae, while its 
longer alkyl chain derivative, 6-pentyl--pyrone derivative (171) is 
extremely abundant in D. clavata, D. childiae and D. australis and 
detectable in D. novae-zelandiae and Hypoxylon sp. nov. JF 11167.  
This fungal family is also producing other lactones as minor products. 
Benzofuran (172) was generated only in the fungal strain H. 
macrocaipum. It also constitutes one of the two major components from 
the essential oil of Viola odorata Linn (Violaceae) leaves.
[367]
 This 
medicinal plant is able to cure bronchitis, digestive disorders, 
postoperative tumor metastasis, diabetes and cancer.
[367]  
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2.2.2.1 Structural elucidation of two lactones 169 and 171 
  
Figure 29 Mass spectra of two Lactones 169 and 171 and the authentic synthetic samples.  
The mass spectra of the two lactones 169 and 171 give some clue in 
their structural elucidation (Figure 29). The molecular ion of compound 
169 occurs at m/z = 112. The loss of the methyl branch shows fragment 
ion at m/z = 97. The base peak at m/z = 68 can be explained either by 
cleavage of carbon dioxide or by loss of acetaldehyde. From the former 
ion, the methyl group is cleavaged and results in the fragment ion at m/z 
= 53. The singal at m/z = 39 arises from the latter ion through the 
cleavage of carbon monoxide. This suggested the structure of 6-methyl-
5,6-dihydro-2H-pyran-2-one as natural product 169.  
The similar mass fragment mechanism can be applied in the explanation 
of compound 171. Fragment ion at m/z = 95 appears as the base peak. 
The peaks at m/z = 110, 123, 137 and 165 are all derived from the 
cleavage of the alkyl branch chain at different points. The singal at m/z = 
222 stands for the molecular ion, from which the loss of carbon dioxide 
explains the fragment ion at m/z = 177, followed by elimination of C2H to 
obtain the ion at m/z = 153. On the other hand, after cleavage of the alkyl 
39
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chain, fragment ion at m/z = 95 can be decreased into m/z = 82 via loss 
of CH
+
 or splits into two fragment ions at m/z = 39 and 57. It can also 
produce fragment ion at m/z = 68 by the loss of CO, further releasing 
CH
+
 group to have ion at m/z = 55. Therefore, the structure of the volatile 
171 was suggested as 6-nonyl-2H-pyran-2-one.  
 
Scheme 15 Synthesis of 6-methyl-5,6-dihydro-2H-pyran-2-one (169)  and 6-nonyl-2H-pyran-
2-one (171).  
The reference compounds of 169 and 171 were obtained via synthesis 
(Scheme 15). Compound 169 was produced by esterification from 4-
penten-2-ol (173) and acryloyl chloride (174) via nucleophilic addition,
[368]
 
followed by an olefin metathesis with Hoveyda-Grubbs II catalyst.
[369]
 For 
the production of compound 171, gold complex (PPh3)AuCl was used to 
catalyse the reaction between 1-undecene (176) and propiolic acid 
(177).
[370]
 The synthetic substances, 6-methyl-5,6-dihydro-2H-pyran-2-
one and 6-nonyl-2H-pyran-2-one, were proved to be identical to the 
volatile organic compounds (169 and 171), respectively, in comparison of 
their mass spetra and retention indices.    
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2.2.3 Furans 
 
Figure 30 Furans (178-181). 
Furan derivatives were also observed in the investigated fungal strains 
(Figure 30). 1-(2-Furanyl)-ethanone (178) appeared in five fungal strains, 
D. clavata, D. childiae, D. hawksworthii, D. concentrica and H. 
macrocaipum. Its methylated derivative 179 was produced by fungi B. 
cylinderispora. Four strains emitted 2-nonylfuran (180). Among them, D. 
childiae released this furan in predominate large amount. Its analogue 
181 was yet only detectable in D. childiae. 
2.2.3.1 Structural assignment of furan 180 
2-Nonylfuran was obtained by the treatment of furan (182) with 1-
bromononane (183) under deprotonation of n-butyllithium with 53% yield 
(Scheme 16). Synthetic 180 and natural product from fungal species 
showed the same mass spectrum and retention time, conforming their 
identity (Figure 31).  
 
Scheme 16 Synthesis of 2-nonylfuran (180).  
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Figure 31 Mass spectra of natural product 180 (left) and 2-nonylfuran (right). 
2.2.4 Nitrogen and sulfur compounds 
 
Figure 32 Nitrogen and sulfur compounds (184-189). 
Several simple nitrogen and sulfur compounds were also detected in the 
headspace analysis (Figure 32). Pyrazine class can be easily traced in 
the Daldinia fungus. Pyrazine (184) was detected in D. clavata and B. 
cylindrispora, whereas methyl pyrazine (185) was found in five and 2,5-
dimethylpyrazine (186) was produced by seven strains of 14 investigated 
fungus seperately. They were also previously discovered in fungistatic 
soils.
[371]
 Unfortunately, trimethylpyrzine (187) was exclusively detectable 
in H. macrocaipum. They display the inhibitory activity against some 
fungal species, like Paecilomyces lilacinus, Pochonia chlamydosporia 
and Clonostachys rosa.
[347]
 In previous study, the biosynthesis of the 
alkylated pyrazine via acetoin building blocks in Corynebacterium 
glutamicum was suggested.
[347]
 In D. concentrica, 2,6-dimethylpyridine 
(188) was observed at low concentration. Finally, a thiazol derivative 2-
acetylthiazole (189) occurred in most of all fungus.  
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2.2.5 Aromatic Compounds 
 
Figure 33 Aromatic compounds (190-218).  
The class of aromatic compounds represents the most diverse class of 
secondary metabolites in the investigated fungi strains. Twenty-nine 
aromatic compounds were identified (Figure 33). Acetophenone (210) 
and phenylethyl alcohol (191) were present almost in every strain. They 
are very common in diverse bacteria.
[279]
 There are two possible 
biosynthetic pathways to obtain 210. On one hand, it cam start from L-
phenylalanine, being transferred via cinnamoyl-CoA, attacked by water, 
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subsequent oxidised by a dehydrogenase and final decarboxylated.
[279]
 
On the other hand, it can begin from benzoyl-CoA, a two-carbon 
elongation and at last a decarboxylation.
[279]
 As a side product in 
manufacturing 210, compound 211 can be also detected in H. 
macrocaipum. Phenylethyl alcohol (191) is derived from a different 
biosynthetic pathway, arising from the same precursor, L-phenylalanine, 
through transamination, oxidative decarboxylation and reduction.
[279]
 
Furthermore, -methyl benzenemethanol (190) was produced as a minor 
product in seven fungal strains. 2-(4-Methoxyphenyl)ethanol (192) 
counld be found only in the strain Hypoxylon sp. nov. STMA 11183. It 
was reported in the extract of wood-rotting funguns Gloeophyllum 
odoratum and might be biogenetically obtained from the ligin of the host 
tree.
[372]
 3-Methylphenol (193) was collected from H. macrocaipum and 
was previously reported as defensive volatile in the forked fungus beetle, 
Bolitotherus cornutus.
[373]
 However, 2,5-dimethylphenol (194) was 
present large in amount in Hypoxylon sp. nov. JF 11167 and H. 
macrocaipum. Its structure was also determined by direct comparison of 
the mass spectra and retention indices of all six dimethylphenol 
regiosmers obtained from commercial suppliers, thus established the 
identity (Table 4).   
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Structure Compound name I (HP-5) MS matcha 
 
2,6-Dimethylphenol 1108 862 
 
2,4-Dimethylphenol 1147 879 
 
2,5-Dimethylphenol (194) 1152 913 
 
3,5-Dimethylphenol 1164 903 
 
2,3-Dimethylphenol 1177 901 
 
3,4-Dimethylphenol 1191 892 
Table 4 Retention indices of all regiosmers of dimethylphenol. aMS match of the mass 
spectrum of the natural product from fungal strain Hypoxylon sp. nov. JF 11167 in 
comparison to the mass spectrum of the tabulated compound (a value of 1000 would indicate 
identical mass spectra, positive compound identification can usually be assumed for a 
value >900).[374] 
A group of benzaldehydes were also present in this fungal family. 
Benzaldeyde (195) was produced by D. australis and D. concentrica, 
whereas, 2-hydroxybenzaldehyde (196) and its ester (212) can be 
observed from D. eschscholzii. They are derivatives from salicylic acid 
which generates from chorismic acid via the shikimate pathway.
[375]
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Hydroxybenzaldehyde is able to improve the antifungal and anti-
mycotoxigenic ability against Aspergillus flavus and A. parasiticus 
incorporation of other existing antifungal agents.
[376]
  
Afterwards, hydroxy-methylbenzaldehyde compound 197 and its 
methoxylated derivative 198 were detected in strains Hypoxylon sp. nov. 
JF 11167 and H. macrocaipum. For compound 197, all ten constitional 
isomers of hydroxyl-methylbenzaldehydes were pursued from chemical 
suppliers. A comparsion of the headspace extract from Hypoxylon sp. 
nov. JF 11167 to all these compounds by GC-MS identified 197 as 2-
hydroxy-4-methylbenzaldehyde (Table 5). This compound was also 
isolated from Mondia whytei Skeels (Asclepidiaceae), which is capable of 
modifying taste and in charge of sweet aromatic fragrance arising from 
M. whytei root-bark.
[377]
 On the other hand, all ten methoxy-
methylbenzaldehydes were afforded by methylation of hydroxyl-
methylaldehydes with the treatment of potassium carbonate and methyl 
iodide. The GC-MS analysis of all these compounds indicated that 
natural product 198 was assigned as 2-methoxy-4-methylbenzaldehyde 
with the same retention index and best matching mass spectrum (Table 
6).  
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Structure Compound name I (HP-5) MS matcha 
 
2-Hydroxy-3-methylbenzaldehyde 1139 902 
 
2-Hydroxy-5-methylbenzaldehyde 1160 893 
 
2-Hydroxy-4-methylbenzaldehyde (197) 1165 902 
 
2-Hydroxy-6-methylbenzaldehyde 1202 904 
 
3-Hydroxy-2-methylbenzaldehyde 1374 878 
 
3-Hydroxy-4-methylbenzaldehyde 1396 874 
 
3-Hydroxy-5-methylbenzaldehyde 1399 857 
 
3-Hydroxy-6-methylbenzaldehyde 1408 785 
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4-Hydroxy-3-methylbenzaldehyde 1427 857 
 
4-Hydroxy-2-methylbenzaldehyde 1452 857 
Table 5 Retention indices of all regioisomers of hydroxy-methylbenzaldehyde.
 aMS match of 
the mass spectrum of the natural product from fungal strain Hypoxylon sp. nov. JF 
11167 in comparison to the mass spectrum of the tabulated compound (a value of 
1000 would indicate identical mass spectra, positive compound identification can 
usually be assumed for a value >900).[374] 
 
Structure Compound name I (HP-5) MS matcha 
 
2-Methoxy-3-methylbenzaldehyde 1265 894 
 
3-Methoxy-4-methylbenzaldehyde 1307 697 
 
3-Methoxy-5-methylbenzaldehyde 1313 670 
 
3-Methoxy-6-methylbenzaldehyde 1323 650 
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2-Methoxy-6-methylbenzaldehyde 1335 890 
 
3-Methoxy-2-methylbenzaldehyde 1335 741 
 
2-Methoxy-5-methylbenzaldehyde 1352 884 
 
2-Methoxy-4-methylbenzaldehyde (198) 1364 934 
 
4-Methoxy-3-methylbenzaldehyde 1366 660 
 
4-Methoxy-2-methylbenzaldehyde 1368 628 
Table 6 Retention indices of all regioisomers of methoxy-methylbenzaldehyde.
 aMS match 
of the mass spectrum of the natural product from fungal strain Hypoxylon sp. nov. JF 
11167 in comparison to the mass spectrum of the tabulated compound (a value of 
1000 would indicate identical mass spectra, positive compound identification can 
usually be assumed for a value >900).[374] 
Besides, D. novae-zelandiae emitted another salicylic acid derivative, 4-
methoxybenzaldehyde (199) in trace amount. The bastidiomycete 
Polyporus sapidus can generate and degrade this benzaldehyde 
quantitatively and simultaneously in terms of fast oxidation from distinct 
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fungal enzyme systems.
[378]
 Three constitutional isomers of dimethoxy 
benzaldehydes (200, 201, 202) were present in the strains Hypoxylon sp. 
nov. STMA 11183, H. macrocaipum and H. rubiginosum, respectively. 
Compound 200 and 201 are likely derived from isovanillin and vanillin.
[379] 
2-Methoxy-5-methylphenol (203) was identified from Hypoxylon sp. nov. 
JF 11167, while its methylated product 205 was found in several strains, 
D. novae-zelandiae, D. hawksworthii, Hypoxylon sp. nov. JF 11167, H. 
macrocaipum and H. rubiginosum, which was also detected in Truffle 
Tuber melanosporum (Soria).
[380]
 For unambiguous structural elucidation 
of 205 as a dimethoxytoluene, all six constitutional isomers were 
purchased from commericial suppliers and examined via GC-MS. The 
result showed that 3,4-dimethoxytoluene was identical for compound 205 
in terms of close retention indices and the best MS match (Table 7).  
Structure Compound name I (HP-5) MS matcha 
 
2,3-Dimethoxytoluene 1176 905 
 
3,4-Dimethoxytoluene (205) 1240 937 
 
2,5-Dimethoxytoluene 1252 772 
 
2,4-Dimethoxytoluene 1257 742 
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2,6-Dimethoxytoluene 1259 779 
 
3,5-Dimethoxytoluene 1271 716 
Table 7 Retention indices of all regiosmers of dimethoxytoluene. aMS match of the mass 
spectrum of the natural product from fungal strain Hypoxylon sp. nov. JF 11167 in 
comparison to the mass spectrum of the tabulated compound (a value of 1000 would indicate 
identical mass spectra, positive compound identification can usually be assumed for a 
value >900).[374] 
 
Scheme 17 Proposed biosynthesis of volatile aromatic compounds (194, 197, 198, 203 and 
205).[374]   
To some structurally related aromatic compounds (194, 197, 198, 203 
and 205) released by Xylariaceae, a common biosynthesis pathway can 
be assumed and summarized in Scheme 17. It begins with 194, which is 
either oxidised at the 2-methyl group (red) to afford the corresponding 
aldehyde 197, subsequently O-methylated (green) with S-
adenosylmethionine (SAM) to produce 198, or in which a C-C bond is 
replaced by oxygen (blue) to result in the hypothetical intermediate 203 
that is further methylated into 205 (green). This proposal could also 
contribute to the structural assignment of volatile compounds. For 
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example, compound 203 could be determined as 2-methoxy-5-
methylphenol by comparsion with a commercially available standard. 
However, not all the regisomers with different ring substitution patterns 
were obtainable from chemical suppliers and other possibilities of the 
contitutinoal isomers cannot fully be excluded for the structural 
elucidation of 203. The biosynthetic assumption described above can 
establish the identification of 203 as 2-methoxy-5-methylphenol from 
another perspective.   
Deliberately, 1,2-dimethoxybenzene (204) occurred in H. rubiginosum 
and can be formed by the enzyme guaiacol O-methyltransferase, which 
methylates guaiacol.
[381]
 2,5-Dimethoxytoluene (206) and 1,2-dimethoxy-
4-(methoxymethyl)benzene (207) were only observed in H. rubiginosum. 
Two trimethoxy-substituted components 208 and 209 were created by 
fungal strains Hypoxylon sp. nov. STMA 11183, H. rubiginosum and H. 
macrocaipum. Metabolite 213 was present in D. concentrica. 
In addition, a few characteristic chromanes and naphthalene derivatives 
enriched the variety of this fungal family. Compound 214 is often 
detected in this class, for instance, D. childiae, D. hawksworthii and 
Hypoxylon sp. nov. JF 11167. Its reference compound was generated 
from 1-(2,6-dihydroxyphenyl)ethanone (219) by the treatment with acetyl 
chloride and potassium carbonate in acetone under reflux as a minor 
product (Scheme 18). In comparison of mass spectrum and retention 
index, the synthetic 5-hydroxy-2-methyl-4H-chromen-4-one proved to be 
the natural product 214 (Figure 34).  
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Scheme 18 Synthesis of 5-hydroxy-2-methyl-4H-chromen-4-one (214). 
 
 
Figure 34 Mass spetra of natural product 214 (left) and 5-hydroxy-2-methyl-4H-chromen-4-
one (right). 
After that, mellein (217) was also found in the strain Hypoxylon sp. nov. 
STMA 11183 in small amount, which is a typical fungal metabolite initially 
detected in Aspergillus melleus
[382]
 and also isolated from the ant Lasius 
fuliginosus as a trail pheromone.
[383]
 Its fungicidal, antibacterial and HCV 
(Hepatitis-C-Virus) protease-inhibitory properties have been investigated 
subsequently.
[384],[385]
 The biosynthetic gene clusters from bacteria 
Saccharopolyspora erythraea for establishing the polyketide origin of 
mellein has been identified.
[386] 
The biosynthesis to this compound can 
be explained via a polyketide synthase, usage of acetyl-CoA as a start 
unit, chain extension with four malonyl-CoA units, followed by aromatic 
cyclization.
[387]
  
The precursor of compound 218, 8-methoxy-1-naphthol, has been 
discovered in 1960 by Allport & Bu’Lock from D. concentrica[388] and 
owns the nematicidal and antifungal activities.
[389]
 It can be assumed that  
1,8-dimethoxynaphthalene (218) is more likely to be derived from 8-
39 51 63 80 91
108
136
148
176
30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180
39 52 63 80 92
108 136 148
176
30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180
O
OH O
m/z m/z
 
 
109 
 
methyl-1-naphthol via methylation, which can be only traced in D. 
childiae. 8-Methyl-1-naphthol and 1,1’-binaphthalene-4,4’-5,5’-tetrol 
(BNT) are responsible for the purple dark stromatal surface of Daldinia 
species
[390]
 and originated from pentaketide of melanin biosynthesis as 
side metabolic intermediates.
[391]
  
At last, the two coumarins 215 and 216 are the main products existing in 
many of the analyzed fungal strains. Its reference compound, 2-methyl-
4-chromanone was obtained by methylation of deprotonated chroman-4-
one (221) with a moderate yield (31%) represented in Scheme 19. 2-
Methyl-4-chromanone was conducted as natural product 215 in terms of 
its gas chromatographic behaviour and mass spectrum (Figure 35). 
 
Scheme 19 Synthesis of 2-methyl-4-chromanone (215). 
 
Figure 35 Mass spetra of natural product 215 (left) and 2-methyl-4-chromanone (right). 
Coumarin biosynthesis has not been completely elucidated yet, although 
it has been an extraordinary popular target for phytochemical and 
pharmacological research due to its numerous bioactivities, for instance, 
antibacterial,
[392]-[394]
 antioxidant,
[395]
 anti-inflammatory,
[396]
 rodenticidal,
[397]
  
termiticidal
[398],[399]
 and other biological effects.
[400]-[403]
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pathway to simple coumarins starts from phenylpropanoid pathway via 
ortho-hydroxylation (red arrows) of cinnamate (223) and p-coumarate 
(226), caffeate (230) and ferulate (233), respectively. Followed by 
isomerization, final lactonization can reach coumarin (225) and 
umbelliferone (229), esculetin (232) and scopoletin (236) (in Figure 
36).
[404]
 To understand the mechanism of simple coumarin formation, the 
irreversible step ortho-hydroxylation is extremely crucial. The identified 
compound 216 might be obtained via further hydroxylation in blue arrow.  
 
Figure 36 Coumarin biosynthetic pathway in plants. Red arrows stands for the ortho-
positions, where oxygen atoms are introducted by ortho-hydroxylation. This action is 
performed under catalysis of the ortho-hydroxylases from Arabidopsis (AtF6’H1), Ruta 
graveolens (RgC2’H), and Ipomoea batatas (Ib1 and lb2).[404]  Hydroxylation in blue arrow 
might achieve compound 216.  
 
 
 
111 
 
2.2.6 Terpenoids 
Terpenoids constitute another prosperous class with various secondary 
metabolites although most of them were found in trace amounts in the 
investigation. Terpenoids are a rich family of natural products which can 
be assembled with the two building blocks dimethylallyl pyrophosphate 
(DMAPP) and isopentenyl pyrophosphate (IPP). The linear precusors 
can be generated by either mevalonate pathway or deoxyxylulose 
phosphate pathway.
[405]
 Mevalonate pathway takes place in 
archaebacteria and most eukaryotes, including all metazoans and fungi. 
On the other hand, most of eubacteria, such as all Gram-negative 
bacteria and mycobacteria utilize deoxyxylulose phosphate pathway for 
the production of diverse classes of terpenoids.
[406]
  
 
Figure 37 Monoterpenes.   
There were five monoterpenes (C10), fifteen sesquiterpenes (C15) and 
two diterpenes (C20) identified in the investigated fungal strains (Figures 
37 and 38). The furanoid form of cis-linalool oxide (237) and trans-
linalool oxide (238) were detected in small amounts in several 
investigated fungal strains. For instance, in D. clavata, D. childiae, D. 
novae-zelandiae, H. rubiginosum and B. cylinderispora. Both compounds 
were isolated as major aglycone moieties in fresh tea leaves and 
exhibited considerable antifungal activities against Colletotrichum 
camelliae Massea.
[407]
 The pyranoid form of cis-linalool oxide (239) was 
demonstrated in the headspace extracts of D. clavata, D. childiae and B. 
cylinderispora.  
 
 
112 
 
Another two monoterpenes, 2-hydroxy-1,8-cineole (240) and 1,3,3-
trimethyl-2-oxabicyclo[2.2.2]octan-6-one (241), showed very high 
amounts in the extracted volatile mixture of H. griseobrunneum. In 
Omarini’s work, both substrates were considered as the oxygenated 
outcomes by transformation of 1,8-cineole through solid-state 
fermentation (SSF) with two mushrooms Pleurotus ostreatus and 
Favolus tenuiculus.
[408]
 1,8-Cineole was reported as eucalyptol after 
discovered by Cloez in 1870 as major product in Eucalyptus globulus 
plant oil.
[409]
 Recently, a series of VOCs from three endophytic fungi 
species of the family Xylariaceae, Hypoxylon sp. and related anamorph 
Nodulisporium sp. were able to generate 1,8-cineole.
[410]-[412]
 Meanwhile 
the identification of the hyp3 gene expressed in Escherichia coli, the first 
monoterpene synthase set the milestone for fully understanding the 1,8-
cineole biosynthesis, thereby supplied us with a new perspective of 
differing terpene synthases in fungi in comparison to those in plants and 
bacteria.
[405]
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Figure 38 Sesquiterpenes and diterpenes.  
For the sesquiterpenes, most of them were present in specific fungal 
strains, beside pogostol (34) and -bulnesene (252). Pogostol (34) is a 
major product in D. australis, D. cf. caldarium and D. concentrica. But it 
is present in a small scale in D. clavata, D. eschscholzii, D. hawksworthii 
and B. cylinderispora. It is one of the extracts in musky oil from the 
patchouli plant and has been utilized in traditional Chinese medicine due 
to its antiemetic properties.
[413]
 Weyerstahl completed the full structural 
assignment of pogostol by NMR.
[414]
 In previous study, the pogostol 
biosynthesis was suggested by initial feeding experiments with six 
13
C-
labelled isotopomers of mevalonalactone in fungus Genuculosporium 
and subsequent analysis of its secondary metabolites with CLSA-
NMR.
[284]
 D. australis, D. cf. caldarium and D. concentrica emitted -
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bulnesene (252) in trace amount. It was also extracted from Pogostemon 
cablin and can restrain platelet-activating factor (PAF) and arachidonic 
acid (AA) in order to reduce rabbit platelet aggregation.
[415]
  
Besides that, the rest thirteen sesquiterpenes were located differentially 
in certain fungal species. D. clavata emitted -curcumene (243), which is 
furnished from (2E,6E)-farnesyl diphosphate under the catalysis of -
curcumene synthase.
[416]
 trans--Bergamotene (244), described as the 
first male pheromone in the parasitic Hymenoptera.
[417]
 The gene cluster 
of fumagillin biosynthesis in Aspergillus fumigatus was responsible for 
the production of this terpene.
[418]
 trans--Bergamotene (244) can only be 
found in D. childiae,  where nerolidol (242) was also detected.   
In D. concentrica, dihydro--ionone (245) and its analogue trans--
ionone (246) were detected. They are widely present in different flowers 
and fruits, for instance, blackberries, peaches and apricots,
[419]
 and used 
extensively in the flavoring industry due to their characteristic aromatic 
scent.
[420]
 Terpinene-4-ol (247) was generated by fungal species 
Hypoxylon sp. nov. JF 11167. Its antifungal activity in vivo was tested 
against mycotoxigenic plant pathogens.
[421]
 D. australis provided T-
muurolol (249), which was previously isolated from Calocedrus 
macrolepis var. formosana Florin leaf and showed strongly inhibition 
against the growth of Rhizoctonia solani and Fusarium oxysporum.
[422]-
Bisabolol (248) and -acorenol (251)  were found in H. rubiginosum.  
Biscogniauxia cylinderispora was enabled to create δ-cadinene (250). -
Barbatene (253) was released by D. australis and its biosynthesis is fully 
understood by using 
13
C- and 
2
H-labelled acetate, mevalonate and 
glycerol.
[423]
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In addition, two isomers, -cedrene (254) and -cedrene (255) were 
released by H. macrocaipum. The biosynthesis of these two 
sesquiterpenes were elucidated and determined by analysis of volatile 
compounds from the fungus Fusarium verticillioides.
[424]  
Ultimately, two diterpenes were also identified in different strains. 
8(14),15-Pimaradiene (256) was found in D. hawksworthii, and 
abietatriene (257) was detected in the volatiles of and B. cylinderispora 
respectively. 
The results of this project lead to conclude that 88 diverse fungal 
volatiles from 14 fungal strains of the fungal Xylariaceae family were 
discovered, including fatty acids derivatives, lactones, furans, nitrogen 
and sulfur compounds, aromatic compounds, and terpenes. The 
structures for these metabolites have been suggested based on their 
mass spectra and on a retention index increment system. Several certain 
volatiles were approached and verified by the synthesis of key reference 
compounds or commercial suppliers.  
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2.3 Oxazolidinone derivatives 
2.3.1 Synthesis of linezolid derivatives 
As described in the introduction chapter, linezolid derivative 92 was 
considered as a potential antimicrobial agent owing to its low enthalpic 
energy in binding affinity to the ribosomel model. Therefore, the  
stereoselective total synthesis to the targe molecule was performed and 
its isomer 258 was yielded through the similar strategy as well.   
 
Figure 39 Linezolid derivatives 92 and 258.  
2.3.1.1 Retrosynthesis of (4S,5'R)-3'-(3-fluoro-4-morpholinophenyl)-
[4,5'-bioxazolidine]-2,2'-dione (92) 
 
Scheme 20 Retrosynthetic analysis to oxazolidinone 92.  
As shown in Scheme 20, target compound can be reached by 
nucleophilic attack from amine 72 at the epoxide 259. This amide can be 
derived from morpholine 262 and 3,4-difluoronitrobenzene (67). 
Meanwhile, the epoxide can be obtained from Garners’ aldehyde 260. In 
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literatures, several protocols have described the stereoselective 
conversion from L-serine 261 to this aldehyde.
[425]
  
2.3.1.2 Synthesis of the epoxide 270 
 
Scheme 21 Synthetic Pathway to epoxide 270.  
The total synthesis of molecule 92 can be divided into two parts. For the 
synthesis of epoxide 270, it initially began with L-serine (261) by 
protection of di-tert-butyl dicarbonate under basic condition in 1,4-
dioxane to reach the Boc-protected amide 263.
[426]
 Subsequently, 
methylation in carboxylic group with usage of methyl iodide and 
potassium carbonate in dimethylformamide generated compound 
264.
[426]
 The moderate yield over two steps was 25%. It was then treated 
with 2,2-dimethoxypropane and para-toluenesulfonic acid in hot benzene 
resulting in the acetonide protected serine ester 265 efficiently with 86% 
conversion.
[426]
 Reduction with lithium aluminium hydride was carried out 
to introduce alcohol 266 in a reasonable yield of 81%.
[427]
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Entry Reagents Solvents Reaction 
Condition 
Yield (%) Optical Activity 
([] 20/D) 
1 DMP DCM r.t. 72 -70.88° 
2 (COCl)2, 
DMSO, DIEPA 
DCM -78 °C 92 -77.30° 
3 TEMPO, 
NaOCl, NaBr, 
NaHCO3 
toluene/EtOAc/H2O 
(6:6:1) 
0 °C 65 -87.28° 
     -90° (Lit.) 
Table 8 Different oxidation methods in the production of aldehyde 260.  
For having Garner’s aldehyde 260, three distinct oxidation approaches 
were implemented (detailed in Table 8). Among them, Dess-Martin 
periodinane (DMP) oxidation demands the most simple reaction 
condition
[428]
 but preparation of DMP reagent in traditional routine can be 
toxic and dangerous owing to its byproduct, iodine.
[429]
 Optical activity of 
the product also has the largest difference compared to value in 
literature.
[426]
 It can be resulted from the inpurity or further oxidation into 
the corresponding carboxylic acid. Swern oxidation with oxalyl chloride, 
DMSO and N,N-diisopropylethylamine at -78 °C led to Garner’s aldehyde 
(260) with an excellent yield (92%).
[430]
 TEMPO oxidation with sodium 
hypochlorite, sodium bromide and sodium bicarbonate in cold solvent 
mixture of toluene, ethyl acetate and distilled water (6:6:1) generated 260 
with the least epimerization of -center in an acceptable yield (65%).[431]   
Afterwards, olefination with the zinc/methylene iodide/trimethylaluminum 
reagent gave optical pure material in an acceptable yield (43%).
[432]
 
Optimal method under salt-free Wittig conditions using 
methyltriphenylphosphonium bromide (Ph3PCH3Br) and potassium 
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bis(trimethylsilyl)amide (KHMDS) as base produced 267 in excellent 
yield and high optical purity (85%).
[433]
  
Later, the acetonide protecting group was cleavaged by para-
toluenesulfonic acid in cold methanol and resulted in 268 in a good yield 
(82%).
[434]
 First oxazolidinone ring was cyclized by the addition of thionyl 
chloride in cold tetrahydrofuran yielding olefine 269 (82%).
[435]
 Two 
possible mechanisms of this process were depicted in Scheme 22. 
Initially, the hydroxyl group in thionyl chloride attacks upon thionyl 
chloride and loses hydrochloride. Subsequently, nucleophilic attack from 
the carbonyl group in carbamate moiety to -carbon generates the 
oxazolidinone ring 274. This produces an amine cation and cleavages 
sulfur dioxide. Due to the deprotonation of the tert-butyl group, 
compound 269 can be achieved (in red arrows). Another possibility is 
that the electron moves into the oxygen atom so that tert-butyl group is 
cleavaged and carboxyl acid is formed, which allows a SN 1 reaction at  
-carbon to obtain the oxazolidinone ring and split sulfur dioxide (in blue 
arrows).  
 
Scheme 22 Two possible mechanisms (red and blue arrows) of formation of oxazolidinone 
269.  
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Last step was the epoxidation of olefin 269 with meta-
chloroperoxybenzoic acid, which produced a mixture of diastereomers,  
270 (dr 6:4) with an acceptable yield (59%).  
2.3.1.3 Synthesis of 3-fluoro-4-morpholinoaniline (72) 
 
Scheme 23 Synthesis of 3-fluoro-4-morpholinoaniline 72. 
On the other hand, morpholine derivative 72 was synthesized from 3,4-
difluoronitrobenzene (67) and excess morpholine (262), via a nuclephilic 
aromatic displacement to selectively obtain the p-substituted 
nitrobenzene 275 in an excellent conversion (92%).
[319]
 This was later 
reduced by excess sodium borohydride and cobaltous chloride in warm 
methanol with a moderate yield (72%).
[435]
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2.3.1.4 Nucleophilic attack from amine 72 to epoxide 270 
 
Entry Catalysts Solvents Reaction conditions Yield (%) 
1 LiOTf MeCN 60 °C 0 
2 LiBr THF r.t. 0 
3 SnCl4
.5H2O THF 50 °C 0 
4 NiCl2
.6H2O THF 50 °C 0 
5 ZnCl2 THF 50 °C 0 
6 CuI THF 50 °C 0 
7 ZrCl4 THF r.t. 0 
8 CoCl2 MeCN r.t. 0 
9  DMF 70-80 °C 0 
10  EtOH/H2O (9:1)  0 
Table 9 Testing reaction conditions for epoxide ring opening with amines.  
The following key step was the opening of the epoxide ring with a 
nucleophilic attack from amine 72. Therefore, a variety of distinct 
reagents, catalysts, reaction solvents, and reaction conditions have been 
evaluated in Table 9. For instance, amine 72 was tried to open the 
terminal epoxide in warmed acetonitrile solution of lithium 
trifluoromethanesulfonate by internal SN2 reaction.
[436]
 However, no 
conversion was observed. Thus, the activation of the epoxide was further 
investigated. For Li
+
 owns a strong oxophilicity, which enables to activate 
oxygen-containing electrophiles for nucleophilic attack,
[437],[438]
 thence 
lithium bromide was used to catalyse the opening of epoxide rings by 
amines.
[439]
 Besides, a group of transition metal-based lewis acids were 
also evaluated, including tin(IV) chloride, nickel chloride, zinc chloride, 
copper(I) iodide.
[440]
 Due to the efficient catalytic performance in 
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nucleophilic epoxide ring opening by amines, zirconium(IV) chloride
[441]
 
and  cobalt(II) chloride
[442]
 were attempted as well. Further trials with 
different solvents, for example dimethylformamide
[443]
 or mixture of 
ethanol and distilled water (9:1),
[444]
 were additionally investigated. 
Unfortunately, neither of them was succeeded in the combination of the 
two fragments.  
2.3.1.5 Adjusted retrosynthetic analysis to oxazolidinone 92 
In consequence, the retrosynthetic plan was changed (Scheme 24). 
Through a Buchwald-Hartwig amination,
[445]
 molecule 92 can be derived 
from coupling of 278 and 279. 
 
Scheme 24 Adjusted retrosynthetic analysis to oxazolidinone 92. 
2.3.1.6 Synthesis of oxazolidinone 278 
 
Scheme 25 Synthesis of oxazolidinone 278. 
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As shown in Scheme 25, slight alterations in synthetic approach took 
place in order to afford target molecule. Vinyl oxazolidine 267 was 
converted into epoxide with meta-chloroperoxybenzoic acid in an 
acceptable yield (79%). With repeated column chromatography 
purifications, the epoxides 280 and 281 were separated from each other 
in a ratio of 2.2:1. The crystal structure of 281 was determined by X-ray 
crystallography (Figure 40). Then, the desired major compound 280 was 
treated with aqueous ammonia and converted into the corresponding 
amino alcohol 282 efficiently (77%).
[446]
  
 
Figure 40 The ORTEP crystal structure of epoxide 281. Grey colour stands for carbon, white 
represents hydrogen atoms, oxygen atoms are painted in red and blue depicts nitrogen.  
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Entry Reagents Solvents  Reaction Conditions  Yield (%) 
1 N,N’-carbonyldiimidazole THF r.t., 20 hrs 0 
2 N,N’-carbonyldiimidazole, 
TEA 
DCM r.t., 20 hrs 0 
3 diethyl carbonate, K2CO3  under reflux 0  
4 triphosgene, TEA DCM 0 °C 42 
5 triphosgene, DIEPA DCM 0 °C 31 
6 triphosgene THF under reflux 14 
Table 10 Testing reaction conditions for formation of compound 278.   
Several reaction conditions were considered in the purpose of the 
construction of 1,3-oxazolidin-2-one 278 (described in Table 10).-
Amino alcohol 282 was treated with N,N’-carbonyldiimidazole either in 
anhydrous tetrahydrofuran
[447]
 or under triethylamine basic condition in 
dry dichloromethane
[436]
 through an intramolecular attack of the primary 
amine function at the carbonyl group of the carbamate moiety in order to 
afford compound 278. The reactions were stirred at room temperature 
over 20 hours, however, starting material was entirely recovered and no 
product was observed. In another case, diethyl carbonate and potassium 
carbonate as base were added and stirred under reflux,
[448]
 but no 
product was found. Besides, alternative solutions with employment of 
triphosgene was added into the reaction mixture with triethylamine
[449]
 or 
Hünig’s base[450] in cold dichloromethane, or to THF and heated under 
reflux for 1 hour.
[451]
 All of them succeeded in introducing the 
oxazolidinone auxiliary 278. The mechanism is depicted in Scheme 26. 
Nucleophilic attack of the amine group in 282 to triphosgene brings 
isocyanate 286 via 284 or 285, followed by cyclization and protonation of 
anion 287 to afford 278.  
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Scheme 26 Proposed mechanism in the production of 278 with triphosgene.  
 
 
 
Entry Reagents Solvents  Reaction Conditions  Yield (%) 
1 thionyl chloride THF 0 °C 0  
2 DAST THF 0 °C 0  
3 Ph3P-CCl4-Et3N MeCN r.t. 0  
4 Ph3PCl2 DCM 0 °C 0  
5 MsCl, DIPEA THF 0 °C 0  
6 TsCl pyridine  60 °C 0 
7 tBuOK THF 0 °C 0  
8 NaH THF under reflux 81 
Table 11 Synthesis of oxazolidinone 278 via intermediate 283.  
In addition, Boc-protection under basic condition in 1,4-dioxane was 
carried out and produced compound 283 quantitatively (95%). The ring 
closure was performed with several reagents (Table 11). Thionyl chloride 
in cold tetrahydrofuran was tried again but failed.
[434]
 Theoretically, 
treatment with N,N-diethylaminosulfur trifluoride (DAST) under mild 
condition can lead to compound 283 via an intramolecular cyclization.
[452]
 
As stated in Scheme 27, Boc-protected amino alcohol 283 reacts with 
DAST to afford the intermediate 288, then either via a regular fluorinating 
 
 
126 
 
mechanism further developing the fluorinated compound 291 (Route 1) 
or forming a more stable five member cationic intermediate 289 by an 
intramolecular SN2 mechanism, subsequently to lose the tert-butyl group 
and yield the heterocycle 278 (Route 2).
[452]
 Unfortunately, this approach 
did not work out either.  
 
Scheme 27 Proposed mechanism of cyclisation of 283 with DAST.[452]   
Another possibility is the usage of triphenylphosphine-carbon 
tetrachloride-triethylamine (PPh3-CCl4-Et3N) system, via an SN2 process, 
nucleophilic attack of the carbonate on the activated hydroxyl bearing 
center. This shoud lead to cyclization and formation of the desired 
product (Scheme 28).
[453]
 However, this reagent failed and no product 
was examined. The alternative reagent, dichlorotriphenylphosphorane 
was also attempted but no product was detected.
[432]
   
 
Scheme 28 Proposed mechanism of cyclisation of 283 with Ph3P-CCl4-Et3N system.  
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Furthermore, mesylation and tosylation were taken in consideration as 
well. Thereby, a nucleophilic displacement of the mesyloxy and tosyloxy 
leaving group by the carbamate moiety drives the formation of 
oxazolidinone ring.
[454]
 The former method exploited methanesulfonyl 
chloride and N, N-diisopropylethylamine (DIPEA) in cold 
dichloromethane
[454]
 and the inferior implanted para-toluenesulfonyl 
chloride in warm pyridine. Unfortunately, neither of them completed the 
cyclisation.  
Base catalysed cyclisation with potassium t-butoxide in anhydrous 
tetrahydronfuran via an alkoxide species as intermediate was likewise 
performed in this study.
[455],[456]
 Finally, compound 283 was treated with 
sodium hydride in hot tetrahydrofuran to form first oxazolidinone auxiliary 
278 in a good yield (81%).
[457]
  
2.3.1.7 Formation of oxazolidinone 92 
 
Scheme 29 Synthesis of oxazolidinone 92.  
Furthermore, diazotization of amine 72 with sodium nitrite and para-
toluenesulfonic acid, followed by iodination with potassium iodide 
resulted in iodo compound 279 with 90% conversion.
[445],[458]
 The 
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significant transformation in this entire synthesis was the transition metal 
catalysed C-N bonding-forming processes. Herein, according to 
Buchwald protocol,
[459],[460] 
copper iodide was employed as catalyst, 
caesium carbonate as base and N,N’-dimethylethylenediamine as 
ligands so that the coupling between oxazolidinone 278 and iodo 
component 279 was made to afford compound 293 in excellent yield 
(95%).
[445] 
The last step was the cleavage of both protecting groups, 
under strong acidic condition (4N hydrochloric acid) and the treatment 
with excess N,N-diisopropylethylamine and triphosgene in cold 
tetrahydrofuran to introduce the second oxazolidinone ring 92 (87% over 
two steps).
[461]
 The overall yield of the longest linear sequence was 5% in 
13 steps. 
2.3.1.8 Synthesis of oxazolidinone 258 
 
Scheme 30 Synthesis of oxazolidinone 258.  
The same strategy was applied for the production of another 
oxazolidinone derivative 258. Epoxide 281 was attacked by ammonia 
and converted into the corresponding amino alcohol 295 (72%),
[446]
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followed by ring closure by treatment with triphosgene and N,N-
diisopropylethylamine to achieve oxazolidinone 296 in moderate yield 
(30%).
[461]
 Cross coupling reaction under Buchwald conditions generated 
297 efficiently (98%).
[445]
 Under strong acidic condition, the protecting 
groups were cleavaged and the treatment with triphosgene and excess 
N,N-diisopropylethylamine introduced another oxazolidinone ring in 258 
(66% yield over two steps).
[461]
 The overall yield of the longest linear 
sequence was 1.6% in 12 steps. The crystal structures of both linezolid 
derivatives 92 and 258 were show in Figure 41. These also confirmed 
the stereochemical question in the production of both compounds 
containing two distinct stereocenters. Their biological evaluation will be 
discussed in the following chapter.  
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Figure 41 The ORTEP crystal structures of linezolid derivatives 92 (top) and 258 (down). 
Grey colour stands for carbon, white represents hydrogen atoms, oxygen atoms are painted 
in red, blue depicts nitrogen and fluoride is coloured in bright green.  
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2.3.2 Tedizolid derivatives  
2.3.2.1 Restrosynthetic analysis of tedizolid derivatives  
 
Scheme 31 Restrosynthetic analysis of tedizolid derivative 102.  
A restrosynthesis plan of compound 102 is present in Scheme 31. 
Compound 102 can be assembled with iodo compound 299 and borane 
ester 300 via a Suzuki cross coupling reaction. The tetrazolyl pyridine 
borane ester can be derived from 2-aminopyridine (303). On the other 
hand, a Buchwald-Hartwig amination combines intermediate 278 and 1-
fluoro-3-iodobenzene (301) to produce 299.  
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2.3.2.2 Synthesis of iodo compound 299 
 
Scheme 32 Synthesis of iodo compound 299. 
The approach to molecule 299 started from diazotization of 3-fluroaniline 
(303) with sodium nitrite and para-toluenesulfonic acid, followed by 
iodination with potassium iodide leading to 1-fluoro-3-iodobenzene 
(301).
[445]
 Due to its volatility and instability in air, most of the product was 
vanished via rotary evaporator and only 21% could be obtained. Cross 
coupling reaction between 301 and 278 under Buchwald conditions 
resulted in 304 efficiently (98%).
[445]
 Deprotection under strong acidic 
condition and cyclization with triphosgene and excess N,N-
diisopropylethylamine afforded compound 306 containing two 
oxazolidinone rings (75% yield over two steps).
[461]
 Then, it was treated 
with N-iodosuccinimide in the presence of trifluoroacetic acid (TFA) to 
give iodo compound 300 with 43% yield within 3 hours.
[462]
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2.3.2.3 Synthesis of pyridines 311, 312 and 313
 
Scheme 33 Synthesis of brominated pyridines 311, 312 and 313.  
For the pyridine compounds, they were manufactured from commercially 
available and cheap material, 2-aminopyridine (302), via two times 
brominations, initially para-substitution with bromide in cold ethanol to 
afford 2-amino-5-bromopyridine (307) in a moderate yield (51%), 
followed by substitution of the amino group with bromine atom via 
diazotization to have 2,5-dibromopyridine (308) with 47% yield.
[463]
 
Afterwards, the 2-bromo atom was replaced by a cyanide ion using 
copper cyanide and sodium cyanide as co-reagent under 
dimethylformamide (DMF) reflux condition for 7 hours
[464]
 and 
consequently generated 5-bromopicolinonitrile (309) in an acceptable 
yield (57%). The tetrazole ring of 2-(tetrazol-5-yl)-5-bromopyridine 310 
was prepared with sodium azide under high temperature reaction 
condition.
[464]
 Unfortunately, this compound was unstable in column 
chromatography, thereby crude product was used for next step without 
further purification.  Addition of iodomethane to solution of 310 in cold 
dimethylformamide produced a mixture of 2-methyltetrazolyl pyridine 
(311) and 1-methyltetrazolyl pyridine (312), which was separated by 
silica-gel column chromatography to yield 17% of each.
[464]
 Oxadiazolyl 
pyridine 313 was made by rearrangement reaction of 310 with acetic 
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anhydride under dimethylformamide in reflux condition.
[464]
 The yield over 
two steps was 35%.   
2.3.2.4 Miyaura Borylation   
 
Scheme 34 Borane esterification of 311, 312 and 313.  
As planned (Scheme 34), organoborane ester 300, 314 and 315 were 
obtained by treatment with bis(pinacolato)diboron and potassium acetate 
under catalysis of Pd(dppf)Cl2 in warm 1,4-dioxane, respectively.
[462]
 
Owing to their instability on silica-gel column chromatography, none of 
them was purified and directly used in the next step. 
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2.3.2.5 Synthesis of tedizolid 104 via Suzuki Cross Coupling  
 
Scheme 35 Mechanism of Suzuki-Miyaura Cross-coupling Reaction.[465]  
 
Entr
y 
Catalysts Reagents Solvents Reaction 
conditions 
Yiel
d 
(%) 
1 Pd(ddf)Cl2 K2CO3 1,4-dioxane/H2O (7:1) 80 °C, 16 hrs 0 
2 Pd(ddf)Cl2 K2CO3 1,4-dioxane/EtOH/H2O 
(3:1:1) 
40-50 °C, 3 hrs 0 
3 Pd(ddf)Cl2 K2CO3 1,4-dioxane/EtOH/H2O 
(3:1:1) 
under reflux, 3 hrs 0 
4 Pd(OAc)2 K2CO3 DMF/H2O (1:1) 90
 °C, 6 hrs 0 
5 Pd(OAc)2/SPhos 
(1:2) 
K3PO4 n-butanol 100 °C 0 
6 Pd(PPh3)4 Ag2O THF/H2O (10:1) r.t., 12 hrs 0 
7 Pd(PPh3)4 Na2CO3 DMF/H2O (10:1) 75 °C 0 
Table 12 Testing Suzuki reaction conditions for molecule 104. SPhos: 2-
Dicyclohexylphosphino-2′,6′-dimethoxybiphenyl. 
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The construction of the pivotal C-C bond between the pyridyl and phenyl 
groups was carried out with a variety of palladium catalyzed Suzuki 
cross-coupling reaction conditions (Table 12). In first trial, using 
Pd(ddf)Cl2 as catalyst and potassium carbonate as base, borane ester 
315 and aryl iodide 299 were stirred in a degassed solvent mixture of 
1,4-dixaone and distilled water in a volume ratio of 7:1 at 80 °C for 16 
hours.
[466]
 However, both starting materials were recovered and no 
reaction was observed. One main reason is the low solubility of the iodo 
compound. Therefore, ethanol was added into the solvent mixture for 
improving the solubility and reaction mixture was stirred at around 40-50 
°C. GC-MS analysis of reaction residue observed that the borane ester 
was cleavaged from pyridine ring to reach compound 316. The reason 
could be the instability of compound 315 in the GC-MS chamer with high 
temperatures. Afterwards, harsh condition was applied and the reaction 
was run under reflux for 3 hours. Apart from 316, 3-fluoro-4-iodo 
benzenamine (317) was also detected by GC-MS, which was probably 
derived from completely cleavage of both oxazolidinone rings from 
molecule 299.  
 
Changing the catalyst into palladium acetate, two differents reaction 
conditions were tested. One used a solvent mixture of  
dimethylformamide and distilled water in a volume ratio of 1:1. Indeed, 
the starting material 299 was better soluble than the previous trials and 
the reaction was run at 90 °C for 6 hours. However, in this case, no 
product was achieved either.
[462]
 On the other hand, a combination of 
palladium and diakylbiphenylphosphino ligands (SPhos) was reported 
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with highly catalytic activity to proceed these coupling reactions.
[467]
 It 
was also performed in practical trial but failed.  
In addition, two cases with tetrakis(triphenylphosphine)palladium(0) were 
introduced into the tests. One was treated with Pd(PPh3)4 and silver(I) 
oxide in solvent mixture of tetrahydrofuran and distilled water (10:1) and 
stirred at room temperature for 20 hours.
[468]
 Compound 316 was 
identified from the reaction residue by GC-MS and no more products 
could be isolated. In another case, Pd(PPh3)4 and sodium carbonate 
were employed and reaction mixture was stirred in dimethylformamid 
and distilled water (10:1) at 70 °C overnight.
[469]
 Still, no reaction took 
place.  
The reasons for the failure of the Suzuki cross coupling could be various. 
For instance, the insolubility of the iodo compound 299 in most common 
organic solvents, in which the two oxazolidinone rings might deactive the 
molecule reactivity, thereby  the reaction couldnot be proceeded as 
expected. The incompletely degassed solvents could be another impact 
on this, because Suzuki coupling reaction has to be done in an extremely 
anaerobic environment.  
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2.3.2.6 Alternative solution to oxazolidinone 104 
 
Scheme 36 Alternative solution to afford oxazolidinone 104.  
Since the Suzuki coupling reaction between 299 and 315 did not give a 
satisfied result, the alternative solution was concerned that iodo 
compound 299 was initially borylated into 318 and further performed the 
Suzuki cross coupling reaction with 313 (Scheme 36). Several conditions 
were conducted (Table 13). 
 
Entry Catalysts Reagents Solvents Reaction 
conditions 
Yield 
(%) 
1 CuI NaH, pinacolborane THF r.t. 0 
2 Pd(ddf)Cl2 TEA, 
bis(pinacolato)diboron 
1,4-dioxane under reflux, 7 hrs 0 
3 Pd(ddf)Cl2 CH3COOK, 
bis(pinacolato)diboron 
1,4-dioxane 80 °C, 3 hrs 0 
4 Pd(ddf)Cl2 CH3COOK, 
bis(pinacolato)diboron 
DMSO 80 °C, 3 hrs 75 
Table 13 Formation of boronate ester 318 via Miyuara borylation. 
 
 
139 
 
In the first entry, formation of arylboronate 318 was made by a CuI-
catalyzed coupling reaction of pinacolborane under the protonation of 
sodium hydride at room temperature.
[470]
 After stirring several days, 
around 74% of the starting material was recovered and no desired 
product was provided. Two more common borylation reactions with 
bis(pinacolato)diboron, Pd(ddf)Cl2 and different bases (triethylamine or 
potassium acetate)
[471]
 were performed. The prior was heated under 
reflux for 7 hours and the latter one was run at 80 °C for 3 hour. 
However, no product was found. It was noticed that in each case, iodo 
compound 299 exhibited extremely poor solubility in common organic 
solvents, for example, tetrahydrofuran, 1,4-dioxane and 
dichloromethane, further influenced the molecule reactivity. Thus, 
dimethylsulfoxid was utilized in the reaction.
[472]
 NMR analysis indicated 
that 318 was generated and contained 75% proportion of the entire 
reaction residue. Due to the possible instability in column 
chromatography on silica gel, boronate ester 318 was used for Suzuki 
cross coupling reaction without purification. It was stirred with brominated 
pyridine 313 by treatment with Pd(PPh3)4 as catalyst and sodium 
carbonate as base in the degassed solvent mixture of 1,4-dioxane and 
distilled water (3:1) and heated for 1 hour.
[473] 
It existed only compound 
317 after purification by column chromatography.  
 
  
Scheme 37 Suzuki cross coupling between 318 and 313. 
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2.3.2.7 Synthesis of tedizolid derivatives via Stille reaction  
 
Scheme 38 Mechanism of Stille cross coupling reaction.[465]   
Rhee and Im disclosed the first route to gain tedizolid by employment of 
Stille cross coupling reaction.
[465],[474] 
However, a poor yield and the 
residual tin impurity contained in the active pharmaceutical ingredient 
(API) drove the research into a facile, economical and environmentally 
benign approach.
[464],[474] 
Therefore, Suzuki coupling was introduced by 
Huang as an alternative improved methodology.
[462] 
Since it did not 
accomplish the expectation in the constitution of target compounds 102-
104 and has become problematic to some extent, Stille coupling was 
reconsidered into the entry.   
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Scheme 39 Formation of tedizolid derivative 104 via Stille coupling.  
As illustrated in Scheme 39, two possible routes can afford 104. Iodo 
compound 299 was converted into organostannane 319 in an acceptable 
yield (53%) by treatment with hexabutylditin and 
bis(triphenylphosphine)palladium (II) dichloride as catalyst in hot 1,4-
dioxane for 2 hours. After that, Stille coupling of organostannane 319 
and brominated pyridine 313 with bis(triphenylphosphine)palladium (II) 
dichloride and lithium chloride in hot N-methy-2-pyrrolidone for 4 hours 
resulted final product 104 with a poor yield (30%). It also can attach 
tributyltin group firstly to 313, in return organotin 320 was afforded in a 
better yield (77%), further coupled with iodo compound 299 via a Stille 
reaction to reach 104 in a low yield (26%). 
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Scheme 40 Formation of tedizolid derivatives 102 and 103 via Stille coupling.  
The similar strategy can be implemented to generate the other two 
tedizolid derivatives. 5-Bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine (311) 
and 5-bromo-2-(1-methyl-1H-tetrazol-5-yl)pyridine (312) were treated 
with organostannane 320 under the Stille reaction condition, respectively. 
After 4 hours reaction time, compounds 102 and 103 were all yielded 
(32% and 38%, separately). The results of Stille coupling were still 
imperfect, including low conversion with poor yield, complicated and toxic 
operation, and difficult purification containing tin residues. Therefore, 
either the reaction condition is necessary to be optimized or other cross 
coupling reaction for construction of carbon-carbon bond should be 
concerned, such as Negishi coupling between an organohalide and an 
organozinc compound, and Hiyama coupling between organohalides and 
organosilicon compound, thereby the coupling fragments have to be 
modified accordingly. 
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Scheme 41 Formation of isomers 325, 326, and 327. 
Isomers of tedizolid derivatives can also be obtained via this synthetic 
pathway (in Scheme 41). Buchwald cross coupling of fragments 301 and 
296 gave the compound 321 in an excellent yield (97%),
[445]
 followed by 
deprotection under acidic condition and cyclization with triphosgene to 
afford oxazolidinone 322 in a moderate yield (78% over two steps).
[461] 
Iodination of 323 with N-iodosuccinimide in the presence of trifluoroacetic 
acid (TFA) at room temperature converted into corresponding iodo 
compound 324 efficiently (78%).
[462]
 Afterwards, the future synthetic plan 
is to transform 324 into tin substitutes, followed by Stille coupling 
reaction with brominated pyridines 311-313 can deliver substances 325, 
326 and 327.  
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2.4 Bioactivity Test  
 
Figure 42 The fungal metabolites and their related compounds, of which biological 
antibacterial and antifungal activity tests in vitro were performed.   
The determination of minimum inhibitory concentration (MIC) value is the 
priority biological data in a program aiming at discovering novel 
antibacterial agents. The in vitro antibacterial and antifungal activity of 43 
authentic synthetic samples and natural products obtained from three 
different projects, comprised of 17 chlorinated aromatic compounds, 2 
lactones, 1 pyran, 10 oxazolidinones, 3 morpholin aromatic substances, 
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2 chromanes, and 8 ketones (seen in Figures 42 and 43), against a 
panel of common fungal and bacterial microorganisms was evaluated 
and presented in Tables 14-17. The involved fungal strains embrace 
Schizosaccharomyces pombe, Pichia anomal, Mucor hiemalis, Candida 
albicans, and Rhodotorula glutinis. Gram-positive strains tested included 
Micrococcus luteus, Bacillus subtillis, Staphylococcus aureus, S. aureus 
MRSA, Mycobacterium sp., and Mycobacterium smegmatis, while the 
selected Gram-negative organisms were limited to Escherichia coli, 
Chromobacterium violaceum and Pseudomonas aeruginosa. Five control 
drugs were used as references, such as Oxytetracyclin hydrochlorid, 
Gentamycin, Nystatin, Kanamycin, and Linezolid.  
The result indicated that among the chlorinated aromatic compounds, 
several species exhibited potency in particular against fungal organisms 
(Tables 14 and 15).  For instance, the MIC value of 2,5-dichloro-1,3-
dimethoxybenzene (106f), 1,5-dichloro-2,4-dimethoybenzene (106h) and 
1,4.dichloro-2,5-dimethoybenzene (106j) for fungal strain Pichia anomala 
was at 33.3 g/mL, which shared the same value as the antifungal 
medication, Nystatin. 2-Chloro-1,3-dimethoxybenzene (105c) and 1,2-
dichloro-3,5-dimethoxybenzene (106g) however against the same fungal 
species with less activity than the formers. For Mucor hiemalis, majority 
of chlorinated molecules displayed inhibition activity, such as 1,3- 
dichloro-2,4-dimethoxybenzene (106e), 1,2-dichloro-3,5-
dimethoxybenzene (106g) and 1,3-dichloro-2,5-dimethoybenzene (106k) 
owned the MIC value at 33.3 g/mL, while 2-chloro-1,3-
dimethoxybenzene (105c), 1,2-dichloro-3,4-dimethoxybenzene (106a), 
1,2-dichloro-4,5-dimethoxybene (106d) and 2,5-dichloro-1,3-
dimethoxybenzene (106f) only reached 67.0 g/mL. Nevertheless, all of 
the values were still higher than control pills Nystatin in the aspect of 
antifungal activity. Besides, 1,2-dichloro-3,4-dimethoxybenzene (106a) 
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and 1,3-dichloro-2,5-dimethoybenzene (106k) exhibited antifungal 
character against Candida albicans, whilst they also showed antibacterial 
function to Gram-negative bacteria Chromobacterium violaceum. 
Additionally, 106e behaved weak antibacterial activity against 
Chromobacterium violaceum. But these numbers were not so attractive 
for emerging a new generation of remedies either. Unfortunately, the 
identified natural products, 4-chloro-1,2-dimethoxybenzene (105b) and 
1,5-dichloro-2,3-dimethoxybenzene (106b) emitted by the fungus 
Geniculosporium did not restrain the growth of any tested strains and no 
inhibition was observed.  
The natural products released and identified from Xylariaceae family 
brought out interesting achievements as well (Tables 15 and 17). Two 
lactones 169 and 171 were examined and delivered with total different 
outcome. It contained no activity against the selected microorganisms in 
the former lactone. In contrast, 6-nonyl-2H-pyran-2-one (171) is more 
active in this field. It exhibited potent antifungal activity against fungal 
species Schizosaccharomyces prombe, Mucor hiemalis, Candida 
albicans and Rohodotorula glutinis, whose value is equal or even much 
better than reference compound Nystain, displayed moderate antifungal 
activity against Pichia anomala and weak antibacterial property against 
Gram-positive bacteria Bacillus subtilis and Staphylococcus aureus. 2-
Nonylfuran (180) has moderate antifungal activity against Mucor 
hiemalis. Afterwards, the moderate antifungal activity belongs to two 
chromanes 214 and 215 against fungal organisms Mucor hiemalis and 
Rhodotorula glutinis. It did not detect any antifungal or antibacterial 
activity of Ant alarm pheromones, manicone (133) against the chosen 
microorganisms. This also happened in natural product 137 ((4R,5R,6S)-
137d) as well as their synthesized isomers.  
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Figure 43 The synthetic oxazolidinone substances and intermediates envolved in the 
production were evaluated for antimicrobial and cytotoxic activities.  
In addition, a series of the synthetic oxazolidinone analogs and 
intermediates with potential antibiotic ability were tested for their 
antifungal and antibacterial activity (Tables 16 and 17). To be surprised 
and frustrated, the linezolid derivative 92 with the most promising 
theoretical calculation result yet failed the activity tests and no inhibition 
towards the selected fungal strains, Gram-positive and Gram-negative 
pathogens was discovered. The same problem occurred in its precursor 
293. On the contrary, their isomers 297 and 258 revealed weak 
antifungal activity towards Mucor hiemalis and Rhodotorula glutinis. 
These results were completely beyond the expectation. In the following 
screening tests, compound 304 was found out to own the weak 
antifungal activity against Mucor hiemalis. Dioxazolidinone ring 
substance 306 showed no inhibition in searching the biological activity. 
Its iodo substitutes 299, however, displayed moderate antifungal activity 
towards all chosen fungal microorganisms, among which had strongest 
effected on the growth of Mucor hiemali, mildly against Candida albicans, 
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and gently treated Schizosaccharomyces prombe, Pichia anomala and 
Rhodotorula glutinis. It also displayed antibacterial activity against Gram-
positive bacteria Staphylococcus aureus, Bacillus subtilis, S. aureus 
MRSA, Micrococcus luteus and Gram-negative bacteria 
Chromobacterium violaceum. The oxazolidinone analogues with different 
stereochemical center, such as 321, 323 and 324, however were not 
able to develop any bioactivity against the screened microorganisms.  
Apart from that, the morpholine aromatic compounds were also 
assessed. Only 4-(2-fluoro-4-nitrophenyl)morpholine (275) and 4-(2-
fluoro-4-iodophenyl)morpholine (279) exhibited weak antifungal activity 
towards Mucor hiemalis and Rhodotorula glutinis. No inhibition was 
investigated from 3-fluoro-4-morpholinoaniline (72).  
To sum up briefly, a total of 43 chemicals, either volatile natural products 
or authentic synthetic substances obtained from 3 different projects were 
screened in evaluating their activity in effecting the growth of 14 distinct 
organisms, including 5 fungal strains, 6 Gram-positive bacteria and 3 
Gram-negative bacteria. In general, the chlorinated aromatic compounds 
perform better antifungal ability and three of them (106f, 106h and 106j) 
own the same minimum inhibitory concentration by treatment with Pichia 
anomala as the control drugs, Nystatin. In contrast, the identified natural 
products (105b and 106b) from the fungus Geniculosporium did not 
show any inhibitory effects. The volatiles from headspace analysis of 
fungal Xylariaceae family behave mostly against fungal expansion, 
especially 6-nonyl-2H-pyran-2-one (171) manifested antifungal activity 
towards certain fungal species. It was more disappointing that except 
chemical intermediate 299 with moderate property in those biotests, 
nearly none of oxazolidinone derivatives obtained via synthesis delivered 
interesting results. 
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Test organism (g /mL) DSM 105a 105b 105c 105d 105e 105f 106a 106b 106c 106d Reference 
Schizosaccharomyces prombe 70572 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 42.0 – 67.0 [c] 
Pichia anomala 70572 n.i. n.i. 67.0 n.i. n.i. n.i. n.i. n.i. n.i. n.i. 33.3 [c] 
Mucor hiemalis 2656 n.i. n.i. 67.0 n.i. n.i. n.i. 67.0 n.i. n.i. 67.0 5.26 – 16.6 [c] 
Candida albicans 1665 n.i. n.i. n.i. n.i. n.i. n.i. 67.0 n.i. n.i. n.i. 33.3 [c] 
Rhodotorula glutinis 10134 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. ≤ 0.52 – 16.7 
[c] 
Micrococcus luteus 20030 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 0.42 [a] 
Bacillus subtilis 10 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 6.7 – 8.3 [a] 
Escherichia coli 1116 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 0.83 [a] 
Staphylococcus aureus  346 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 0.1 – 0.21 [a] 
Mycobacterium sp.  43270 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 2.1 [a] 
Chromobacterium violaceum  30191 n.i. n.i. n.i. n.i. n.i. n.i. 33.3 n.i. n.i. n.i. 0.83 – 8.3 [a] 
Pseudomonas aeruginosa  50071 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 16.6 – 21.0 [b] 
cell line L929 IC50  >10 >10 >10 >10 >10 >10 >10 >10 >10 >10  
Table 14 In vitro antibacterial and antifungal activity. n.i.: no inhibition. MIC: Minimum inhibitory concentration; [a]Oxytetracyclin hydrochloride; 
[b]Gentamycin; [c]Nystatin; DMSZ: German Collection of Microogranisms and Cell Cultures Braunchweig. 
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Test organism (g /mL) DSM 106e 106f 106g 106h 106i 106j 106k 169 171 180 Reference 
Schizosaccharomyces prombe 70572 n.i. n.i. n.i. n.i. n.i. n.i. 67.0 n.i. 16.6 n.i. 42.0 – 67.0 [c] 
Pichia anomala 70572 n.i. 33.3 67.0 33.3 n.i. 33.3 n.i. n.i. 33.3 n.i. 33.3 [c] 
Mucor hiemalis 2656 33.3 67.0 33.3 n.i. n.i. n.i. 33.3 n.i. 16.6 16.6 5.26 – 16.6 [c] 
Candida albicans 1665 n.i. n.i. n.i. n.i. n.i. n.i. 67.0 n.i. 16.6 n.i. 33.3 [c] 
Rhodotorula glutinis 10134 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 16.6 n.i. ≤ 0.52 – 16.7 
[c] 
Micrococcus luteus 20030 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 0.42 [a] 
Bacillus subtilis 10 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 67.0 n.i. 6.7 – 8.3 [a] 
Escherichia coli 1116 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 0.83 [a] 
Staphylococcus aureus  346 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 67.0 n.i. 0.1 – 0.21 [a] 
Mycobacterium sp.  43270 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 2.1 [a] 
Chromobacterium violaceum  30191 67.0 n.i. n.i. n.i. n.i. n.i. 67.0 n.i. n.i. n.i. 0.83 – 8.3 [a] 
Pseudomonas aeruginosa  50071 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 16.6 – 21.0 [b] 
cell line L929 IC50 1000 g/ml  >10 >10 >10 >10 >10 >10 >10 6 >10 >10  
cell line L929 IC50 10000g/ml*         3.1 30   
Table 15 In vitro antibacterial and antifungal activity. n.i.: no inhibition. MIC: Minimum inhibitory concentration; [a]Oxytetracyclin hydrochloride; 
[b]Gentamycin; [c]Nystatin; DMSZ: German Collection of Microogranisms and Cell Cultures Braunchweig ; * this test was only repeated with 169 and 
171.  
 
 
 
151 
 
Test organism (g /mL) DSM 293 92 297 258 304 306 299 321 323 324 Refenrence 
Staphylococcus aureus 346 n.i. n.i. n.i. n.i. n.i. n.i. 33.3 n.i. n.i. n.i. 0.21; 2.1 [a],[e] 
S. aureus MRSA 11822 n.i. n.i. n.i. n.i. n.i. n.i. 67.0 n.i. n.i. n.i. 4.2; 2.1 [f],[e] 
Mycobacterium smegmatis ATCC 
70084 
n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 8.3; 2.1 [d],[e] 
Bacillus subtilis 10 n.i. n.i. n.i. n.i. n.i. n.i. 33.3 n.i. n.i. n.i. 4.2; 0.42 [a],[e] 
Micrococcus luteus 1790 n.i. n.i. n.i. n.i. n.i. n.i. 67.0 n.i. n.i. n.i. 0.83; 2.1 [a],[e] 
Escherichia coli 1116 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 1.7; / [a],[e] 
Chromobacterium violaceum  30191 n.i. n.i. n.i. n.i. n.i. n.i. 67.0 n.i. n.i. n.i. 0.42; 67.0 [a],[e] 
Pseudomonas aeruginosa PA14 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 0.42; / [b],[e] 
Schizosaccharomyces pombe 70572 n.i. n.i. n.i. n.i. n.i. n.i. 67.0 n.i. n.i. n.i. 16.6; / [c],[e] 
Pichia anomala 6766 n.i. n.i. n.i. n.i. n.i. n.i. 67.0 n.i. n.i. n.i. 8.3; / [c],[e] 
Mucor hiemalis 2656 n.i. n.i. 67.0 67.0 67.0 n.i. 16.6 n.i. n.i. n.i. 8.3; / [c],[e] 
Candida ablbicans 1665 n.i. n.i. n.i. n.i. n.i. n.i. 33.3 n.i. n.i. n.i. 16.6; / [c],[e] 
Rhodotorula glutinis 10134 n.i. n.i. 67.0 n.i. n.i. n.i. 67.0 n.i. n.i. n.i. 16.6; / [c],[e] 
Table 16 In vitro antibacterial and antifungal activity. n.i.: no inhibition. MIC: Minimum inhibitory concentration; [a]Oxytetracyclin hydrochloride; 
[b]Gentamycin; [c]Nystatin; [d]Kanamycin; [e]Linezolid. DMSZ: German Collection of Microogranisms and Cell Cultures Braunchweig. 
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Test organism (g /mL) DSM 275 72 279 214 215 133 a b b’ c c’ d d’ Acetone 
20 l 
Acetone/10% 
DMSO 20 l 
Staphylococcus aureus 346 n.i. n.i. n.i. 67.0 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
S. aureus MRSA 11822 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
Mycobacterium 
smegmatis 
ATCC 
70084 
n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
Bacillus subtilis 10 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
Micrococcus luteus 1790 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
Escherichia coli 1116 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
Chromobacterium 
violaceum  
30191 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
Pseudomonas 
aeruginosa 
PA14 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
Schizosaccharomyces 
pombe 
70572 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
Pichia anomala 6766 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
Mucor hiemalis 2656 67.0 n.i. 67.0 33.3 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
Candida ablbicans 1665 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
Rhodotorula glutinis 10134 67.0 n.i. 67.0 33.3 67.0 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
Table 17 In vitro antibacterial and antifungal activity. n.i.: no inhibition. MIC: Minimum inhibitory concentration; [a]Oxytetracyclin hydrochloride; 
[b]Gentamycin; [c]Nystatin; [d]Kanamycin; [e]Linezolid. DMSZ: German Collection of Microogranisms and Cell Cultures Braunchweig. 
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3. Conclusion  
In this thesis, three different projects were conducted individually. First 
project described the elucidation of the structures of two suspected 
volatile substances released by the endophytic fungus Geniculosporium 
sp. 9910. They were chlorinated dimethoxybenzenes according to the 
suggestions of the mass spectral libraries. Therefore, the constitutional 
isomers of both volatiles (Figure 19) were obtained via synthesis 
(Scheme 8 and 9) or acquired from commercial suppliers. The 
unambiguous structures of the natural products 105 and 106 were 
clarified as 4-chloro-1,2-dimethoxybenzene (105b) and 1,5-dichloro-2,3-
dimethoxybenzene (106b) by the judgement of their mass spectra and 
retention indices.  
In the second case, a panel of volatile organic compounds were emitted 
from 14 xylariaceous fungal microorganisms and analyzed by GC-MS. A 
collection of 88 substances from multiple categories was ultimately 
determined, including fatty acid derivatives (alcohols, aldehydes and 
ketones, esters), lactones, furans, nitrogen and sulfur compounds, 
aromatic compounds and terpenoids. For certain species, synthetic 
approaches and purchased chemicals were utilized to prove the 
predictions by mass spectral libraries. For instance, manicone 133 was 
reached by five-step synthesis (Scheme 10) from commercial available 
2-methylbutanal (140). However, the process of identification of two 
alcoholic ketone 137 was severely complicated and bumpy. Initially, all 
eight stereoisomers of 137 were achieved from an aldol addition and 
separately by GC on a homochiral stationary phase. One of them was 
considered as natural product accordling to its GC retention time. Later, 
two isomers ((4R,5S,6S)-137a and (4S,5R,6S)-137b) were afforded 
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through stereoselective synthesis (Scheme 12), yet the result of chiral 
GC excluded the possibility due to different retention time compared to 
natural products. The task was subsequently accomplished by extensive 
chromatographic purification of racemic mixture of eight stereoisomers.  
Afterwards, (4R,5R,6S)-5-hydroxy-4,6-dimethyloctan-3-one ((4R,5R,6S)-
137d) was matched to natural product 137 based on the retention time in 
chiral GC spectra (Figure 26). The structures of other organic volatile 
compounds were elucidated much more easily. 6-Methyl-5,6-dihydro-2H-
pyran-2-one (169), 6-nonyl-2H-pyran-2-one (171) and 2-nonylfuran (180) 
were produced in either one- or two-step synthesis (Scheme 15 and 16) 
and determined by their mass spectra and retention indices. For 
aromatic compounds, structurally related compounds 194, 197, 198, 203 
and 205 were identified as volatile organic compounds by commercial 
available authentic samples while 5-hydroxy-2-methyl-4H-chromen-4-
one (214) and 2-methyl-4-chromanone (215) were generated by one-
step synthesis (Scheme 18 and 19) and also showed up in the 
headspace analysis.  
In the last programm, the synthesis of linezolid derivative 92 predicted in 
silico was performed. The key steps were the introduction of the 
oxazolidinone ring and the formation of C-N bonding. First entry was to 
have the 2-oxazolidone initially, further epoxidation followed by 
nucleophilic attack from 3-fluoro-4-morpholinoaniline (72). A variety of 
reaction conditions were performed but yet resulted in no desired 
product. The route was therefore modified to yield epoxides 280 and 281 
with the oxazolidine ring at the first place, subsequently attacked by 
aqueous ammonia to reach the amino alcohol 282, then cyclization into 
the first oxazolidinone ring 278. Buchwald cross coupling under the 
catalysis of copper iodide joined the two fragments 278 and 279. Strong 
acid opened the oxazolidine ring and built the second oxazolidinone ring 
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by usage of triphosgene in excess Hünig’s base. In the consequence, 
compound 92 was generated in 13 steps as the longest linear sequence. 
Similar synthetic method was applied in the production of its isomer 258. 
The crystal structures of both molecules were obtained and determined 
to confirm the stereochemical issues.  
The construction of tedizolid derivatives 102, 103 and 104 was primarily 
planned to combine iodo compound 299 and pyridine borante ester 300 
via Suzuki-Miyaura cross coupling reaction. Substance 304 was reached 
by Buchwald cross coupling between 1-fluoro-3-iodobenzene (301) and 
oxazolidinone 278, followed by deprotection, cyclization and iodination. 
In the other hand, commercially available and cheap chemical, 2-
aminopyridine (302) was processed via bromination, cyanation, and later 
was treated with sodium azide to afford the tetrazole ring compound 310. 
It was treated with either iodomethane or acetic anhydride to yield 2-
methyltetrazolyl pyridine (311) and 1-methyltetrazolyl pyridine (312) or 
oxadiazolyl pyridine 313, respectively. Afterwards, Miyaura borylation of 
those pyridines yielded the corresponding organoborane ester 300, 314 
and 315. The next step with palladium catalyzed Suzuki-Miyaura cross-
coupling reaction failed. The reason could be the insolubility  iodo 
compound 299 owing to the two oxazolidinone rings and the 
incompletely degassed solvents. The borylation of 299 was also made 
only in DMSO solvent and the conversion was around 75%. 
Unfortunately, the following Suzuki reaction didnot take place as 
expected. Intentionally, Stille coupling was executed instead, including 
transformation of iodo compound 299 or brominated pyridine 313 into 
corresponding organostannane 318 or 315, followed by C-C bond 
coupling with bis(triphenylphosphine)palladium (II) dichloride and lithium 
chloride to afford target molecule 104 in poor yield. This was also utilized 
in terms of other tedizolid derivatives 102 and 103. The purification of the 
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products was not performed very successfully. Therefore, none of them 
was pure and clean enough in pursuit of their specific bioactivity in 
biotests. The optimization of the Stille reaction condition, improvement of 
purification methods for the products or even other C-C bond coupling 
attempts are demanded to complete the route.  
Afterwards, the bioassays of the volatile organic compounds from fungi 
and the synthetic products or intermediates involved into the total 
synthesis of oxazolidinone derivatives were made. Mainly, the antifungal 
and antibacterial activity of these compounds against selected common 
fungal organisms, Gram-positive and Gram-negative pathogens was 
evaluated. The reports demonstrated that 6-nonyl-2H-pyran-2-one (171) 
identified from xylariaceous fungi behaved the moderate bioactivity 
against most fungal microorganisms and weak antibacterial effect 
towards Gram-positive bacteria. The lactone 169 was moderately 
cytotoxic, but devoid of significant antimicrobial activity. The chlorinated 
dimethoxybenzenes (106f, 106h and 106j) showed antifungal property to 
some extents. The most astonished and discouraged result was obtained 
by screening the oxazolidinone derivatives. The most promising drug 
candidate (4S,5'R)-3'-(3-fluoro-4-morpholinophenyl)-[4,5'-bioxazolidine]-
2,2'-dione (92) did not exhibited bioactivity against any chosen 
organisms. Its isomer 258 demonstrated only very week antifungal 
activity. This also happened in the intermediates afforded during the 
synthesis, beside 299 with moderate antifungal and antibacterial activity, 
none of them reached the original expectation. The reasons could be 
that the chosen bacteria are able to transport these compounds out of 
the cell via efflux pumps or even these molecules could not reach inside 
the bacteria in case to inhibit their growth.  
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4. Experimental Part 
4.1 General 
4.1.1 Chemicals  
All commercial available chemicals were purchased and delivered from 
the chemical suppliers, for instance, Sigma Aldrich Chemie GmbH 
(Steinheim, Germany), Acros Organics (Geel, Belgium), Fluka Chemie 
GmbH (Buchs, Switzerland), abcr GmbH (Karlsruhe, Germany), TCI 
Deutschland GmbH (Eschborn, Germany), Merck KGaA (Darmstadt, 
Germany) and Carl Roth GmbH and Co. KG (Karlsruhe, Germany). They 
were used without any further purification. Technical grade solvents were 
distilled with standard method prior to usage. 
4.1.2 Reaction conditions 
All the flasks involved in the reactions were clean and dried over 400 oC 
by heating gun. All anaerobic reactions were carried out under nitrogen 
or argon atmosphere.  
4.1.3 Thin layer chromatography  
To monitor the reactions and column chromatography, analytical thin 
layer chromatography was used during and after the reactions. The 0.2 
mm thickness and precoated silica gel TLC plates (Polygram Sil G/UV254) 
were purchased from the manufacture, Macherey-Nagel, Düren, 
Germany. The plates were either verified under UV-light (λ = 254 nm) or 
colored by distinct reagents to visualize the spots (staining), including 
molybdophosphoric acid reagent (10 g molybdophosphoric acid and 100 
mL ethanol), potassium permanganate reagent (5 g potassium 
permanganate, 20 g potassium carbonate, 1N sodium hydroxide and 300 
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mL distilled water), and ninhydrin reagent (1.5 g ninhydrin, 100 mL n-
butanol and 3.0 mL acetic acid). After staining, the plates were warmed 
by heating gun for visualization.  
4.1.4 Column chromatography 
Silica gel 60 (0.04-0.063 mm, 230-400 mesh ASTM) was purchased by 
Macherey-Nagel and used for the flash column chromatography. The 
column was eluted with mixture of different organic solvents, such as 
hexane, cyclohexane, ethyl acetate, chloroform, methanol and so on, or 
inorganic solvent, like ammonia, as mobile phase.  
4.1.5 Gas chromatography-mass spectrometry (GC-MS) 
GC-MS analyses were carried out on an Agilent 7890A connected with 
an Agilent 5975C inert mass detector (Hewlett-Packard Company, 
Wilmington, USA) fitted with non polar BPX-5 (25 m, 0.22 mm i. d., 0.25 
m film, SGE Inc., Melbourne, Australia) and HP5-MS fused silica 
capillary column (30 m, 0.25 mm i. d., 0.25 μm film, Agilent). GC 
conditions were as follows: inlet pressure 77.1 kPa, He 23.3 mL min
−1
, 
injection volume 1.5 μL, transfer line 300 °C, electron energy 70 eV. The 
operation mode was splitless (60 s valve time) and the carrier gas was 
He at 1.2 mL min
−1
. The GC was programmed as follows: 5 min at 50 °C 
increasing with 5 °C min
−1
 to 320 °C. Retention indices (I) were 
determined from a homologous series of n-alkanes (C8–C38). 
4.1.6 Chiral gas chromatography 
Chiral gas chromatography was performed on an Agilent 7820 A fitted 
with CP-ChiraSil-Dex CB capillary column (25 m, 0.25 mm i. d., 0.36 m 
film, Agilent) with following temperature program: 100 °C, 150 °C (1 
°C/min), 245 °C (20 °C/min). The operation mode was splitless 50:1. 
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4.1.7 High-performance liquid chromatography (HPLC) 
The separation of enantiomers 137a, 137b, 137c and 137d was done by 
analytical high-performance liquid chromatography using the following 
conditions: system: Fa. Knauer GmbH (Berlin, Germany), 2 pumps P-1 
HPLC plus (max. 750 bar), oven T-1 with 2 integrated 6-Port valves, 
photodiode array detector PDA-1 (190-1000 nm); column: KNAUER 
Europher II 100-5 C18, 3μm, 16.0 mm × 250 mm; solvent: 
acetonitrile/water (35/65); flow rate:16.0 mL min
−1
; pressure: 242 bar, 
temperature: 25 °C. 
Enantiomers 137a, 137c, 137d were separated by HPLC on a 
homochiral stationary phase using the following conditions: system: Fa. 
Knauer GmbH (Berlin, Germany), 2 pumps P-1 HPLC plus (max. 750 
bar), oven T-1 with 2 integrated 6-Port valves, photodiode array detector 
PDA-1 (190-1000 nm); column: DAICEL Chiralpak IA, 5μm, 4.6 mm × 
250 mm; solvent: n-hexane/2-propanol (98/02); flow rate:1.0 mL min
−1
; 
pressure: 34 bar, temperature: 25 °C. 
4.1.8 Strains and culture conditions 
Geniculosporium sp. 9910 was obtained from Barbara Schulz 
(Braunschweig) and grown on potato–carrot medium[475] on petri dishes 
and incubated for 21 d at 28 °C prior to analysis. Daldinia clavata STMA 
06094, Daldinia childiae MUCL 53761, Daldinia australis CBS 119013, 
Daldinia cf. caldarium CBS 113045, Daldinia eschscholzii STMA 11017, 
Daldinia novae-zelandiae STMA 05243, Daldinia hawksworthii STMA 
13010, Daldinia concertrica STMA 05061, Hypoxylon sp.nov. JF 11167, 
Hypoxylon sp.nov. STMA 11183, Hypoxylon macrocaipum STMA 05121, 
Hypoxylon griseobrunneum STMA 10235, Hypoxylon rubiginosum STMA 
03027, and Biscogniauxia cylinderispora STMA 12118 were  acquired 
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from Marc Stadler (Braunschweig) and grown on YMG medium (Yeast 
and Malt Extract with Glucose) on petri dishes and incubated for 7 d at 
28 
o
C prior to analysis.  
4.1.9 CLSA sampling  
The volatiles emitted by agar plate cultures with growing fungi were 
trapped on charcoal filters through the closed-loop stripping apparatus 
(CLSA) headspace technique. After 16 to 24 hours of collection at room 
temperature (20 
o
C) and under natural day and night light conditions, a 
solvent extract with dichloromethane (50 mL) of the adsorbed filter was 
directly analyzed by GC-MS. All headspace sampling were carried out in 
duplicates.  
4.1.10 Spectroscopic methods 
4.1.10.1 Nuclear magnetic resonance (NMR) 
NMR spectra were recorded on Bruker AV I (400 MHz), AV III HD 
Prodigy (500 MHz) and AV III HD Cryo (700 MHz) spectrometers, and 
were referenced against CDCl3 (δ = 7.26 ppm), C6D6 (δ = 7.16 ppm), 
CD3OD (δ = 3.31 ppm) and DMSO-D6 (δ = 2.50 ppm) for 
1
H-NMR, and 
CDCl3 (δ = 77.16 ppm), C6D6 (δ = 128.06 ppm), CD3OD (δ = 49.00 ppm), 
DMSO-D6 (δ = 39.52 ppm)  for 
13
C-NMR. The multiplicities are specified 
as follows: singlet (s), doublet (d), triplet (t), quartet (q), quintet (quin), 
sextet (sex), septet (sept). 
4.1.10.2 Infrared spectroscopy (IR spectroscopy)  
IR Spectra were measured with the method Diamant-ATR by use of 
Bruker Tensor 27 and an Alpha FT-IR spectrometer from Bruker. The 
intensities of the peaks were described as s (strong), m (medium), and w 
(weak). 
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4.1.10.3 UV-Vis 
UV/Vis spectra were recorded on a Cary 100 UV/Vis spectrometer 
(Agilent). The wavelength of the maximal absorption was described in 
nm and the absorbance was described as cm
-2
mmol
-1
. 
4.1.10.4 Optical rotatory power  
They were recorded on a P8000 Polarimeter (Krüss). 
4.1.11 X-ray crystallography 
All the X-ray crystallography data were obtained from slow evaporation 
of a concentrated solution in C6D6. The data collections were performed 
on Bruker D8-Venture and X8-KappaApexII diffractometers ((Bruker 
CMOS-Photon100 detector)) equipped with a low temperature device 
(Oxford ryostream 800er series, Oxford Cryosystems, 100K) using CuKα 
radiation (λ = 1.54178 Å, monochromated by a HELIOS multilayer 
optics). Intensities were measured by fine-slicing ω-and φ-scans and 
corrected for background, polarization and Lorentz effects. A semi-
empirical (mulabs) absorption correction
[476] 
was carried out on both data 
sets. The structures were solved by a dual-space method (SHELXT-
2014)
[477]
 and refined by full-matrix least squares on F
[477]
 (SHELXL-
2014).
[478]
 All non-hydrogen atoms were refined anisotropically. Hydrogen 
atoms at carbon were placed in calculated positions and refined 
isotropically using a riding model.  
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4.2. Synthesis  
4.2.1 1-Chloro-2,3-dimethoxybenzene (105a) 
 
To a solution of veratrole 107 (1.38 g, 1.0 mmol) in anhydrous ether (2.0 
mL), 1.6 M n-butyllithium in hexane (1.25 mL) was added slowly and the 
mixture was stirred at room temperature for 48 hours. The resulting 
solution of (2,3-dimethoxyphenyl)lithium was diluted with dry ether (12 
mL), triethylamine (101 mg, 1.0 mmol) was added to the solution and 
stirred for 10 minutes. Trifluoromethanesulfonyl chloride (169 mg, 1.0 
mmol) was added dropwise to the mixture. After stirring at room 
temperature for 1 hour, the reaction was quenched by the addition of 
water. The aqueous phase was extracted three times with diethyl ether. 
The combined extracts were dried over MgSO4, concentrated in vacuo 
and purified by flash column chromatography on silica gel  to afford 105a 
(80 mg, 0.47 mmol, 47%) as pale yellow oil.  
TLC (hexane/ethyl acetate = 10:1) Rf = 0.40. IR (ATR) 𝑣 = 3003 (w), 
2936 (w), 2835 (w), 1582 (w), 1481 (m), 1460 (m), 1427 (m), 1295 (w), 
1263 (m), 1237 (m), 1173 (w), 2253 (w), 1079 (w), 1041 (s), 1001 (s), 
855 (m), 799 (w), 771 (m), 736 (m), 654 (w), 556 (w) cm
-1
. UV-Vis 
(CH2Cl2) max (log ) 280 (3.15), 273 (3.17), 231 (3.55) nm. MS (EI, 70 
eV) m/z (%) 172 (100) [M]+, 174 (33), 159 (21), 157 (65), 129 (27), 94 
(22), 79 (21), 65 (30), 51 (24), 44 (21), 40 (40). GC (HP5-MS): I = 1278. 
1
H NMR (400 MHz, CDCl3, TMS): δ = 6.96 (m, 2H, 2 x CH), 6.81 (m, 1H, 
CH), 3.87 (s, 3H, OCH3), 3.86 (s, 3H, OCH3) ppm. 
13
C NMR (100 MHz, 
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CDCl3, TMS): δ = 154.0 (C), 145.5 (C), 128.4 (C), 124.3 (CH), 122.0 
(CH), 110.9 (CH), 60.6 (OCH3), 56.1 (OCH3) ppm.  
4.2.2 4-Chloro-1,2-dimethoxybenzene (105b) 
 
To a cooled solution (0 °C) of 3,4-dimethoxyaniline 108 (3.1 g, 20.0 
mmol) in 6 M HCl (30 mL) was added a 2.5 M solution of NaNO2 (1.40 g, 
20.0 mmol) in H2O (8 mL), resulting in solution A. In a separate flask 
CuSO4 (5.8 g, 26.7 mmol) was dissolved in H2O (25 mL) and NaCl (2.3 
g, 40.0 mmol) was added. To this solution was added Na2SO3 (1.70 g, 
13.4 mmol) in H2O (6 mL). It was decanted from the precipitate and 
washed with H2O. The precipitate was dissolved in concentrated HCl (11 
mL) and cooled to 0 °C. Solution A was added dropwise and stirred for 1 
h at room temperature, followed by 30 min at 100 °C. After cooling to 
room temperature it was extracted three times with EtOAc. The collected 
extracts were dried over MgSO4 and concentrated under reduced 
pressure. The residue was purified by flash column chromatography on 
silica gel affording 105b (2.1 g, 12.2 mmol, 61%) as colourless oil. 
TLC (hexane/ethyl acetate = 10:1) Rf = 0.22. IR (ATR) 𝑣 = 3003 (w), 
2956 (w), 2908 (w), 1591 (m), 1500 (s), 1441 (m), 1402 (w), 1252 (s), 
1226 (s), 1177 (m), 1131 (m), 1022 (s), 873 (m), 838 (m), 797 (m), 763 
(m), 643 (m) cm
-1
. UV-Vis (CH2Cl2) max (log ) 283 (3.47), 235 (3.91) 
nm. MS (EI, 70 eV) m/z (%) 172 (100) [M]
+
, 157 (64), 129 (39), 111 (15), 
93 (37), 86 (8), 79 (27), 65 (35), 51 (17). GC (HP5-MS): I = 1332. 
1
H 
NMR (400 MHz, CDCl3, TMS): δ = 6.87 (dd, 1H, 
4
JH,H = 2.4 Hz, 
3
JH,H = 
8.5 Hz, CH), 6.84 (d, 1H, 
4
JH,H = 2.4 Hz, CH), 6.76 (d, 1H, 
3
JH,H = 8.5 Hz, 
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CH), 3.85 (s, 3H, OCH3), 3.84 (s, 3H, OCH3) ppm. 
13
C NMR (100 MHz, 
CDCl3, TMS): δ = 149.5 (C), 147.8 (C), 125.6 (C), 120.2 (CH), 112.0 
(CH), 111.9 (CH), 56.02 (OCH3), 55.98 (OCH3) ppm.  
4.2.3 2-Chloro-1,3-dimethoxybenzene (105c) 
 
To a solution of 2-chlorobenzene-1,3-diol 110 (72 mg, 0.5 mmol) in 
acetone (4 mL), potassium carbonate (346 mg, 2.5 mmol) was added 
and stirred 10 minutes. Then methyl iodide (184 mg, 1.3 mmol) was 
added to the reaction mixture. The reaction was stirred under reflux 16 
hours. It was cooled to room temperature and extracted three times with 
ether. The organic phases were collected, dried over MgSO4, 
concentrated in vacuo and purified by column chromatography on silica 
gel to obtain 105c (76 mg, 0.44 mmol, 88%) as yellow solid. 
TLC (hexane/ethyl acetate = 10:1) Rf = 0.38. IR (ATR): 𝑣 = 3011 cm
-1 
(w), 2966 (w), 2947 (w), 2840 (w), 1594 (m), 1472 (m), 1435 (m), 1299 
(m), 1253 (m), 1191 (w), 1174 (w), 1099 (m), 1053 (m), 1025 (m), 849 
(w), 764 (m), 709 (m), 654 (m), 597 (m). UV/Vis λmax (log ε) 280 (3.08), 
274 (3.10), 230 (3.79) nm. MS (EI, 70 eV) m/z (%) 172 (100) [M]+, 173 
(33), 143 (14), 142 (11), 131 (16), 129 (54), 127 (16), 114 (18), 107 (15), 
79 (17), 77 (10), 65 (16), 63 (19), 51 (16). GC (HP5-MS): I = 1404. 1H 
NMR (400 MHz, CDCl3, TMS): δ = 7.17 (t, 1H, 
3
JH,H = 8.7 Hz, CH), 6.60 
(d, 2H, 
3
JH,H = 8.4 Hz, 2 x CH), 3.90 (s, 6H, 2 x OCH3) ppm. 
13
C NMR 
(100 MHz, CDCl3, TMS): δ = 156.2 (2 x C), 127.1(CH), 110.6 (C), 104.7 
(2 x CH), 56.3 (2 x OCH3) ppm.  
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4.2.4 2-Chloro-1,4-dimethoxybenzene (105f) 
 
A solution of 1,4-dimethoxybenzene 111 (414 mg, 3.0 mmol) in CH2Cl2 
was treated with Bn(Me)3N
+
ICl4
-
 (1.30 g, 3.0 mmol) and stirred over night 
at room temperature. The reaction mixture was diluted with H2O and 
extracted three times with EtOAc. The combined organic layers were 
dried over MgSO4 and concentrated under reduced pressure. The 
residue was purified by flash column chromatography on silica gel 
yielding 105f (174 mg, 1.0 mmol, 34%) as red oil.  
TLC (hexane/ethyl acetate = 20:1) Rf = 0.31. IR (ATR) 𝑣 = 3003 (w), 
2948 (w), 2836 (w), 1581 (w), 1496 (s), 1461 (m), 1438 (m), 1271 (m), 
1213 (s), 1180 (m), 1039 (s), 882 (m), 797 (m), 735 (s) cm
-1
. UV-Vis 
(CH2Cl2) max (log ) 294 (3.56), 230 (3.78) nm. MS (EI, 70 eV) m/z (%) 
172 (58) [M]
+
, 157 (100), 129 (22), 107 (12), 79 (17), 63 (14), 53 (8). GC 
(HP5-MS): I = 1292. 
1
H NMR (400 MHz, CDCl3, TMS): δ = 6.95 (d, 1H, 
4
JH,H = 3.0 Hz, CH), 6.86 (d, 1H, 
4
JH,H = 3.0 Hz, 
3
JH,H = 9.0 Hz, CH), 6.76 
(dd, 1H, 
4
JH,H = 3.0 Hz, 
3
JH,H = 9.0 Hz, CH), 3.84 (s, 3H, OCH3), 3.75 (s, 
3H, OCH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 153.8 (C), 149.4 
(C), 123.0 (C), 116.1 (CH), 113.2 (CH), 112.8 (CH), 56.7 (OCH3), 55.8 
(OCH3) ppm.  
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4.2.5 1,2-Dichloro-3,4-dimethoxybenzene (106a), 1,4-dichloro-2,3-
dimethoxybenzene (106c), and 1,3-dichloro-2,4-dimethoxybenzene 
(106e) 
Sodium methoxide (1.08 g, 20.0 mmol) was added to a stirred solution of 
1,2,3,4-tetrachlorobenzene 112 (1.08 g, 5.0 mol) in 
hexamethylphosphoramide (15 mL). The reaction mixture was stirred at 
120 °C for 3 hours and cooled to room temperature. Then methyl iodide 
(1.06 g, 7.5 mmol) was added to the reaction flask and the mixture was 
stirred for another hour at room temperature. The mixture was poured 
into 2N HCl and extracted three times with diethyl ether. The organic 
layers were dried over MgSO4 and concentrated in vacuo. From the 
crude product that mainly contained monosubstitution products small 
amounts of disubstitution products could be isolated by rigorous 
purification via column chromatography on silica gel. Three target 
compounds were obtained: 106a (40 mg, 0.19 mmol, 4%, pale yellow 
oil), 106c (100 mg, 0.48 mmol, 10%, colourless solid), and 106e (40 mg, 
0.19 mmol, 4%, colourless oil).  
 
TLC (hexane/ethyl acetate = 5:1) Rf = 0.25. IR (ATR): 𝑣 = 3005 (w), 2939 
(w), 2840 (w), 1579 (w), 1474 (m), 1431 (m), 1400 (m), 1291 (m), 1262 
(m), 1169 (w), 1140 (w), 1043 (m), 1007 (m), 889 (w), 834 (m), 796 (m), 
752 (w), 672 (m), 644 (w), 598 (w) cm-1. UV-Vis (CH2Cl2) max (log ) 288 
(3.23), 283 (3.22), 230 (3.84). MS (EI, 70 eV): m/z (%) 206 (100) [M]+, 
208 (68), 193 (50), 191 (77), 165 (22), 163 (33), 150 (22), 148 (36), 128 
(58), 127 (41), 141 (23), 115 (21), 113 (62), 99 (55), 97 (28), 85 (36), 50 
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(26). GC (HP5-MS): I = 1466. 1H NMR (400 MHz, CDCl3, TMS): δ = 7.15 
(d, 1H, 
3
JH,H = 9.0 Hz, CH), 6.76 (d, 1H, 
3
JH,H = 9.0 Hz, CH), 3.86 (s, 3H, 
OCH3), 3.85 (s, 3H, OCH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 
152.4 (C), 146.7 (C), 127.5 (C), 124.7 (CH), 124.5 (C), 111.0 (CH), 60.6 
(OCH3), 56.2 (OCH3) ppm.  
 
TLC (hexane/ethyl acetate = 5:1) Rf = 0.47. IR (ATR): 𝑣 = 3003 (w), 2973 
(w), 2941 (w), 2876 (w), 1579 (w), 1459 (m), 1430 (m), 1403 (m), 1239 
(m), 1152 (w), 1128 (m), 1004 (s), 865 (m), 797 (m), 645 (m), 627 (m) 
cm-1. UV-Vis (CH2Cl2) max (log ) 274 (2.60), 231 (3.87) nm.  MS (EI, 70 
eV): m/z (%) 206 (100) [M]+, 208 (74), 193 (57), 191 (82), 163 (28), 150 
(39), 148 (58), 130 (24), 129 (23), 128 (63), 127 (49), 120 (25), 113 (35), 
99 (48), 97 (28), 85 (38), 62 (21), 53 (31), 50 (27). GC (HP5-MS): I = 
1339. 1H NMR (400 MHz, CDCl3, TMS): δ = 7.07 (s, 2H, 2 x CH), 3.92 (s, 
6H, 2 x OCH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 150.7 (2 x C), 
127.1 (2 x C), 125.1 (2 x CH), 61.1 (2 x OCH3) ppm.  
 
TLC (hexane/ethyl acetate = 5:1) Rf = 0.56. IR (ATR): 𝑣 = 3007 (w), 2968 
(w), 2941 (w), 2873 (w), 2840 (w), 1579 (w), 1466 (m), 1433 (m), 1402 
(m), 1294 (m), 1270 (w), 1227 (m), 1151 (w), 1081 (s), 1008 (m), 914 
(m), 794 (s), 750 (m), 686 (m), 644 (w), 576 (w) cm-1. UV-Vis (CH2Cl2) 
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max (log ) 288 (3.22), 283 (3.21), 230 (3.84). MS (EI, 70 eV): m/z (%) 
206 (100) [M]+, 208 (67), 193 (25), 191 (38), 165 (46), 163 (74), 150 (23), 
148 (36), 113 (33), 99 (25), 97 (28), 85 (21). GC (HP5-MS): I = 1487. 1H 
NMR (400 MHz, CDCl3, TMS): δ = 7.23 (d, 1H, 
3
JH,H = 9.0 Hz, CH), 6.66 
(d, 1H, 
3
JH,H = 9.0 Hz, CH), 3.90 (s, 3H, OCH3), 3.89 (s, 3H, OCH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 155.1 (C), 153.2 (C), 127.7 (CH), 
120.7 (C), 118.2 (C), 107.9 (CH), 60.6 (OCH3), 56.5 (OCH3) ppm.  
4.2.6 2,5-Dichloro-1,3-dimethoxybenzene (106f) and 1,2-dichloro-3,5-
dimethoxybenzene (106g)  
Sodium methoxide (432 mg, 8.0 mmol) was added to a stirred solution of 
1,2,3,5-tetrachlorobenzene 113 (432 mg, 2.0 mmol) in 
hexamethylphosphoramid (15 mL) at 120 °C under the protection of 
nitrogen. The reaction mixture was stirred at 120 °C for 3 hours and 
cooled to room temperature. Then methyl iodide (426 mg, 3.0 mmol) was 
added to the reaction flask and stirred for another hour at room 
temperature. The mixture was poured into the diluted hydrochloride acid 
and extracted with diethyl ether. The organic layers were dried over 
magnesium sulfate, concentrated in vacuo and purified by flash column 
chromatography on silica gel to give 106f (120 mg, 0.58 mmol, 29%, 
colourless solid) and 106g (72 mg, 0.35 mmol, 18%, colourless solid).  
 
TLC (hexane/ethyl acetate = 10:1) Rf = 0.27. IR (ATR): 𝑣 = 3092 (w), 
3032 (w), 2976 (w), 2942 (w), 2909 (w), 2839 (w), 1590 (m), 1567 (m), 
1459 (m), 1439 (m), 1404 (m), 1315 (m), 1296 (m), 1230 (m), 1119 (m), 
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1061 (m), 914 (m), 869 (m), 820 (m), 669 (s), 633 (m), 582 (m) cm-1. UV-
Vis (CH2Cl2) max (log ) 276 (3.01), 231 (3.90) nm. MS (EI, 70 eV): m/z 
(%) = 206 (100) [M]+, 208 (62), 177 (15), 165 (38), 163 (65), 113 (33), 99 
(32), 97 (30), 85 (15), 63 (16), 62 (22). GC (HP5-MS): I = 1556. 1H NMR 
(400 MHz, CDCl3, TMS): δ = 6.60 (s, 2H, 2 x CH), 3.89 (s, 6H, 2 x OCH3) 
ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 156.4 (2 x C), 133.0 (C), 
109.3 (C), 105.5 (2 x C), 56.5 (2 x OCH3) ppm.  
 
TLC (hexane/ethyl acetate = 10:1) Rf = 0.45. IR (ATR): 𝑣 = 3092 cm
-1 
(w), 2983 (w), 2954 (w), 2939 (w), 2837 (w), 1594 (m), 1569 (m), 1463 
(m), 1429 (m), 1410 (m), 1323 (m), 1274 (m), 1214 (m), 1185 (m), 1159 
(m), 1095 (m), 1030 (m), 933 (m), 857 (m), 825 (m), 782 (m), 697 (s), 
658 (m), 639 (m), 621 (m). UV-Vis (CH2Cl2) max (log ) 289 (3.42), 229 
(3.91) nm. MS (EI, 70 eV): m/z (%) = 206 (100) [M]+, 208 (68), 177 (21), 
165 (69), 163 (69), 148 (24), 141 (23), 113 (34), 99 (30), 97 (31), 85 (24), 
62 (23). GC (HP5-MS): I = 1565. 1H NMR (400 MHz, CDCl3, TMS): δ = 
6.62 (d, 1H, 
4
JH,H = 2.7 Hz, CH), 6.42 (d, 1H, 
4
JH,H = 2.7 Hz, CH), 3.87 (s, 
3H, OCH3), 3.79 (s, 3H, OCH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): 
δ = 158.7 (C), 156.7 (C), 133.8 (C), 113.5 (C), 106.4 (CH), 98.6 (CH), 
56.4 (OCH3), 55.7 (OCH3) ppm.  
4.2.7 1,5-Dichloro-2,3-dimethoxybenzene (106b) 
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To a solution of 3,5-dichlorobenzene-1,2-diol 114 (54 mg, 0.3 mmol) in 
acetone (2.4 mL), potassium carbonate (208 mg, 1.5 mmol) was added 
and stirred 10 minutes. Then methyl iodide (111 mg, 0.78 mmol) was 
added to the reaction mixture. The reaction was stirred under reflux 16 
hours. It was cooled to room temperature and extracted with ether. The 
organic phases were collected, dried over MgSO4, concentrated in vacuo 
and purified by flash column chromatography on silica gel to afford 106b 
(50 mg, 0.24 mmol, 80%) as colourless solid.  
TLC (hexane/ethyl acetate = 10:1) Rf = 0.55. IR (ATR) 𝑣 = 3089 cm
-1 (w), 
3005 (w), 2967 (w), 2939 (w), 2831 (w), 1572 (m), 1480 (m), 1425 (m), 
1399 (m), 1292 (m), 1263 (m), 1229 (m), 1171 (m), 1102 (m), 1043 (m), 
999 (m), 895 (m), 830 (m), 760 (m), 718 (m), 589 (m). UV-Vis (CH2Cl2) 
max (log ) 286 (3.22), 280 (3.20), 231 (3.83) nm. MS (EI, 70 eV) m/z (%) 
206 (84) [M]+, 208 (56), 193 (65), 191 (100), 165 (27), 163 (43), 148 (23), 
128 (53), 127 (53), 113 (34), 99 (46), 97 (27), 85 (31), 62 (20), 50 (28). 
GC (HP5-MS): I = 1426. 1H NMR (400 MHz, CDCl3, TMS): δ = 6.98 (d, 
1H, 
4
JH,H = 2.5 Hz, CH), 6.80 (d, 1H, 
4
JH,H = 2.5 Hz, CH), 3.86 (s, 3H, 
OCH3), 3.84 (s, 3H, OCH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 
154.1 (C), 144.4 (C), 129.1 (C), 128.9 (C), 121.6 (CH), 111.7 (CH), 60.8 
(OCH3), 56.3 (OCH3) ppm.  
4.2.8 1,2-Dichloro-4,5-dimethoxybenzene (106d) 
 
A solution of 1,2-dimethoxybenzene 107 (690 mg, 5.0 mmol) in acetic 
acid (15 mL) was treated with Bn(Me)3N
+
ICl4
-
 (4.20 g, 10.0 mmol,). It was 
stirred for 1 h at room temperature and then diluted with H2O. The 
 
 
171 
 
mixture was extracted three times with EtOAc, dried over MgSO4 and 
concentrated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel yielding 106d (466 mg, 2.25 mmol, 
45%) as pale yellow oil. 
TLC (hexane/ethyl acetate = 10:1) Rf = 0.39. IR (ATR) 𝑣 = 3004 (w), 
2966 (w), 2906 (w), 2839 (w), 1594 (m), 1503 (s), 1432 (s), 1362 (m), 
1337 (m), 1253 (s), 1210 (s), 1178 (s), 1131 (s), 1025 (s), 919 (s), 838 
(s), 793 (s), 676 (s) cm
-1
. UV-Vis (CH2Cl2) max (log ) 290 (3.51), 235 
(3.91) nm. MS (EI, 70 eV) m/z (%) 206 (100) [M]
+
, 191 (62), 163 (28), 
145 (15), 128 (46), 113 (33), 99 (41), 85 (12), 63 (9), 50 (12). GC (HP5-
MS): I = 1505. 
1
H NMR (400 MHz, CDCl3, TMS): δ = 6.90 (s, 2H, 2 x 
CH), 3.86 (s, 6H, 2 x OCH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 
148.3 (2 x C), 123.4 (2 x C), 112.9 (2 x CH), 56.2 (2 x OCH3) ppm.  
4.2.9 1,5-Dichloro-2,4-dimethoxybenzene (106h) 
 
To a solution of 4,6-dichlorobenzene-1,3-diol 115 (54 mg, 0.3 mmol) in 
acetone (4 mL), potassium carbonate (208 mg, 1.5 mmol) was added 
and stirred 10 minutes. Then methyl iodine (111 mg, 0.78 mmol) was 
added to the reaction mixture. The reaction was stirred under reflux 16 
hours. It was cooled to room temperature and extracted three times with 
ether. The organic phases were collected, dried over MgSO4, 
concentrated in vacuo and purified by flash column chromatography on 
silica gel to afford 1,5-dichloro-2,4-dimethoxybenzene 106h (49 mg, 0.24 
mmol, 80%) as yellow solid.  
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TLC (hexane/ethyl acetate = 10:1) Rf = 0.37. IR (ATR) 𝑣 = 2976 cm
-1 (w), 
2946 (w), 2879 (w), 2847 (w), 1575 (m), 1494 (m), 1470 (m), 1455 (m), 
1428 (m), 1373 (m), 1294 (m), 1231 (m), 1207 (m), 1172 (m), 1087 (m), 
1055 (m), 1020 (m), 860 (m), 803 (m), 741 (m), 579 (m) cm-1. UV-Vis 
(CH2Cl2) max (log ) 292 (3.59), 233 (3.89) nm. MS (EI, 70 eV) m/z (%) 
206 (84) [M]+, 208 (56), 191 (23), 165 (63), 163 (100), 148 (23), 113 (23), 
99 (33), 97 (29), 85 (22), 63 (15), 62 (20), 61 (17). GC (HP5-MS): I = 
1545. 1H NMR (400 MHz, CDCl3, TMS): δ = 7.34 (s, 1H, CH), 6.53 (s, 
1H, CH), 3.90 (s, 6H, 2 x OCH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): 
δ = 156.4 (2 x C), 130.5 (CH), 114.0 (2 x C), 97.8 (CH), 56.5 (2 x OCH3) 
ppm.  
4.2.10 1,4-Dichloro-2,5-dimethoxybenzene (106j)  
 
A solution of 1,4-dimethoxybenzene 111 (207 mg, 1.5 mmol) in acetic 
acid (6 mL) was treated with Bn(Me)3N
+
ICl4
-
 (1.30 g, 3.0 mmol) and 
stirred for 2 h at room temperature. It was diluted with water and 
extracted three times with EtOAc. The combined organic layers were 
dried over MgSO4 and concentrated under reduced pressure. The 
residue was purified by flash column chromatography on silica gel 
yielding 106j (118 mg, 0.57 mmol, 38%) as colourless oil.  
TLC (hexane/ethyl acetate = 20:1) Rf = 0.30. IR (ATR) 𝑣 = 3029 (w), 
2909 (w), 1501 (s), 1481 (m), 1439 (s), 1367 (m), 1279 (m), 1213 (s), 
1187 (m), 1079 (s), 1025 (s), 858 (s), 775 (s) cm
-1
. UV-Vis (CH2Cl2) max 
(log ) 299 (3.69), 230 (3.90) nm. MS (EI, 70 eV) m/z (%) 206 (58) [M]
+
, 
191 (100), 163 (14), 141 (31), 113 (8), 97 (15), 85 (10), 53 (19). GC 
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(HP5-MS): I = 1448. 
1
H NMR (400 MHz, CDCl3, TMS): δ = 6.97 (s, 2H, 2 
x CH), 3.85 (s, 6H, 2 x OCH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ 
= 149.2 (2 x C), 120.9 (2 x C), 114.5 (2 x CH), 56.8 (2 x OCH3) ppm.  
4.2.11 2,3-Dichloro-1,4-dimethoxybenzene (106i) 
 
To a solution of 1,4-benzoquinone 116 (4.32 g, 40.0 mmol) in dry ether 
(35 mL), sulfuryl chloride (6.5 mL, 80.0 mmol) was added and stirred for 
16 hours at room temperature. The mixture was cooled in an iced bath 
and filtered. The black solid was washed with cold ether (10 mL) and 
dried in high vacuo. A suspension of the solid was treated with AcOH (20 
mL) and concentrated H2SO4 (2 mL), stirred for 24 hours at 60 
o
C and 
poured into ice. The reaction mixture was extracted three times with 
diethyl ether. The collected organic layers were washed with brine, dried 
over MgSO4 and evaporated the solvents to produce brown solid (3.1 g). 
To this brown solid (3.1 g, 17.3 mmol) in acetone (69.2 mL), potassium 
carbonate (11.93 g, 86.5 mmol) was added and stirred 10 minutes. Then 
methyl iodide (6.39 g, 45.0 mmol) was added to the reaction mixture. 
The reaction was stirred under reflux 16 hours. It was cooled to room 
temperature and extracted three times with diethyl ether. The organic 
phases were collected, dried over MgSO4, concentrated in vacuo and 
purified by flash column chromatography on silica gel to afford 106i (1.03 
g, 5.01 mmol, 13 %) as yellow solid. 
TLC (hexane/ethyl acetate = 10:1) Rf = 0.42. IR (ATR) 𝑣 = 3094 (w), 
2967 (w), 2946 (w), 2914 (w), 2873 (w), 2840 (w), 1591 (w), 1570 (w), 
1479 (m), 1457 (m), 1406 (w), 1303 (w),1262 (m), 1192 (w), 1116 (w), 
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1038 (s), 900 (w), 790 (s), 711 (w), 608 (m) cm
-1
. UV-Vis (CH2Cl2) max 
(log ) 296 (3.59), 229 (3.76) nm. MS (EI, 70 eV) m/z (%) 206 (77) [M]+, 
208 (59), 195 (22), 193 (83), 192 (17), 148 (18), 143 (34), 141 (74), 115 
(36), 113 (80), 99 (24), 97 (40), 87 (40), 85 (32), 63 (17), 62 (21), 61 (18). 
GC (HP5-MS): I = 1574. 1H NMR (400 MHz, CDCl3, TMS): δ = 6.81 (s, 
2H, 2 x CH), 3.86 (s, 6H, 2 x OCH3) ppm. 
13
C NMR (100 MHz, CDCl3, 
TMS): δ = 150.3 (2 x C), 123.1 (2 x C), 110.0 (2 x CH), 56.8 (2 x OCH3) 
ppm.  
4.2.12 2,6-Dichlorobenzene-1,4-diol (119) 
 
To a solution of 2,6-dichloro-p-hydroquinone 118 (1.0 g, 5.7 mmol) in 20 
mL of ethyl acetate, 10 mL of phosphate buffer  (10 mmol, Na2HPO4, 10 
mmol KH2PO4, PH = 7.0) with L-ascorbic acid (4.0 g) was added. The 
mixture was shaken in a separated funnel for 5 mins. The mixture was 
extracted three times with ethyl acetate, the combined extracts were 
dried over MgSO4 and concentrated in vacuo to afford 119 (1.0 g, 5.6 
mmol, 99%) as colourless solid. 
TLC (hexane/ethyl acetate = 10:1) Rf = 0.56. IR (ATR) 𝑣 = 3384 cm
-1 (w), 
3075 (w), 2900 (w), 2517 (m), 2415 (m), 2077(w), 1791 (m), 1746 (w), 
1687 (w), 1614 (w), 1577 (m), 1477 (s), 1430 (m), 1344 (m), 1275 (w), 
1213 (m), 1112 (m), 1095 (m), 971 (s), 947 (s), 844 (m), 803 (s), 700 (w), 
599 (w) cm-1. UV-Vis (CH2Cl2) max (log ) 351(1.38), 296 (3.58), 229 
(3.49) nm. MS (EI, 70 eV) m/z (%) 180 (63) [M+1H]+, 178 (92), 114 (18), 
113 (21), 88 (34), 87 (41), 86 (47), 85 (31), 79 (53), 62 (30), 61 (29), 60 
(68), 63 (16), 53 (100), 51 (54), 50 (43), 49 (22). 1H NMR (400 MHz, 
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CDCl3, TMS): δ = 6.72 (s, 2H, 2 x CH), 4.86 (s, 2H, 2 x OH) ppm. 
13
C 
NMR (100 MHz, CDCl3, TMS): δ = 151.9 (C), 143.5 (C), 123.9 (2 x C), 
116.4 (2 x CH) ppm.  
4.2.13 1,3-Dichloro-2,5-dimethoxybenzene (106k) 
 
To a solution of 2,6-dichlorobenzene-1,4-diol 118 (90 mg, 0.5 mmol,) in 
acetone (4 mL), potassium carbonate (691 mg, 5.0 mmol) was added 
and stirred 10 minutes. Then methyl iodine (185 mg, 1.3 mmol) was 
added to the reaction mixture. The reaction was stirred under reflux 16 
hours. It was cooled to room temperature and extracted three times with 
diethyl ether. The organic phases were collected, dried over MgSO4, 
concentrated in vacuo and purified by flash column chromatography on 
silica gel to afford 1,3-dichloro-2,5-dimethoxybenzene 106k  (49 mg, 0.24 
mmol, 48%) as colourless solid.  
TLC (hexane/ethyl acetate = 10:1) Rf = 0.56. IR (ATR) 𝑣 = 3087 cm
-1 (w), 
2992 (w), 2949 (w), 2903 (w), 2835 (w), 1704 (w), 1663(w), 1610 (m), 
1594 (m), 1559 (m), 1480 (s), 1420 (m), 1403 (m), 1306 (m), 1257 (m), 
1222 (s), 1175 (m), 1074 (m), 1042 (s), 984 (s), 909 (w), 909 (m), 850 
(m), 831 (m), 804 (s), 761 (s), 717 (m), 606 (m) cm-1. UV-Vis (CH2Cl2) 
max (log ) 292 (3.56), 287 (3.45), 230 (3.78) nm. MS (EI, 70 eV) m/z (%) 
206 (56) [M]+, 208 (39), 195 (18), 193 (78), 192 (16), 191 (100), 165 (22), 
163 (32), 163 (32), 113 (25), 99 (32), 97 (24), 63 (16), 62 (22), 62 (22), 
53 (26). GC (HP5-MS): I = 1443. 1H NMR (400 MHz, CDCl3, TMS): δ = 
6.84 (s, 2H, 2 x CH), 3.84 (s, 3H, OCH3), 3.76 (s, 3H, OCH3) ppm. 
13
C 
NMR (100 MHz, CDCl3, TMS): δ = 155.7 (C), 146.2 (C), 129.5 (2 x C), 
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114.5 (2 x CH), 60.8 (OCH3), 55.9 (OCH3) ppm.  
4.2.14 (E)-Ethyl 2,4-dimethylhex-2-enoate (142) 
 
To a solution of LiCl (1.02 g, 24.0 mmol), DBU (3.04 g, 20.0 mmol) and 
ethyl 2-(diethoxyphosphoryl)propanoate (5.72 g, 24 mmol) in acetonitrile 
(240 mL), 2-methylbutanal (1.72 g, 20.0 mmol) was added and stirred at 
room temperature for one hour. Then, it was quenched with distilled 
water, extracted with ether. The collected organic phases were dried 
over MgSO4, concentrated in vacuo and purified by flash column 
chromatography on silica gel to afford (E)-ethyl 2,4-dimethylhex-2-enoate 
142 (1.3 g, 7.67 mmol, 38%) and ethyl (Z)-2,4-dimethylhex-2-enoate (15 
mg, 0.088 mmol, 1%) as colourless oil.  
Analytical data for  (E)-142: TLC (hexane/ethyl acetate = 20:1) Rf = 0.31. 
IR (ATR) ?̃? = 2962 (m), 2930 (m), 2874 (m), 1709 (w), 1650 (m), 1458 
(m), 1367 (m), 1316 (m), 1269 (w), 1235 (w), 1152 (w), 1033 (m), 995 
(m), 924 (m), 871 (m), 776 (s), 748 (w), 532 (s) cm
-1
. UV-Vis (CH2Cl2) 
max (log ) 231 (4.71) nm. MS (EI, 70 eV): m/z (%) = 170 (60) [M]
+
, 125 
(70), 123 (21), 113 (87), 109 (57), 102 (28), 97 (41), 96 (70), 95 (89), 87 
(30), 85 (28), 81 (43), 73 (20), 69 (44), 67 (89), 56 (33), 55 (100), 53 
(44), 43 (72), 41 (97), 39 (55). GC (BPX-5): I = 1152. 
1
H NMR (400 MHz, 
CDCl3, TMS): δ = 6.53 (dq, 
4
JH,H = 1.4 Hz,
3
JH,H = 10.0 Hz, 1H, CH), 4.19 
(q, 
3
JH,H = 7.1 Hz, 2H, CH2), 2.48-2.32 (m, 1H, CH), 1.84 (d, 
4
JH,H = 1.4 
Hz, 3H, CH3), 1.50-1.34 (m, 2H, CH2), 1.30 (t, 
3
JH,H = 7.1 Hz, 3H, CH3), 
1.00 (d, 
3
JH,H = 6.7 Hz, 3H, CH3), 0.86 (t, 
3
JH,H = 7.4 Hz, 3H, CH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 168.5 (C), 147.8 (CH), 126.5 (C), 
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60.4 (CH2), 34.9 (CH), 29.6 (CH2), 19.6 (CH3), 14.3 (CH3), 12.5 (CH3), 
11.9 (CH3) ppm.  
Analytical data for  (Z)-142: TLC (hexane/ethyl acetate = 20:1) Rf = 0.29. 
IR (ATR) ?̃? = 2962 (m), 2930 (m), 2873 (m), 1715 (w), 1646 (m), 1456 
(m), 1372 (m), 1326 (m), 1262 (w), 1221 (w), 1171 (w), 1096 (m), 1044 
(m), 1023 (m), 971 (m), 889 (s), 771 (m), 594 (s) cm
-1
. UV-Vis (CH2Cl2) 
max (log ) 229 (4.71) nm. MS (EI, 70 eV): m/z (%) = 170 (56) [M]
+
, 125 
(72), 123 (21), 113 (69), 109 (61), 102 (25), 97 (34), 96 (59), 87 (25), 81 
(40), 69 (39), 67 (81), 56 (32), 55 (79), 53 (41), 43 (71), 41 (87), 39 (50). 
GC (BPX-5): I = 1081. 
1
H NMR (400 MHz, CDCl3, TMS): δ = 6.53 (dq, 
4
JH,H = 1.5 Hz,
3
JH,H = 10.1 Hz, 1H, CH), 4.18 (q, 
3
JH,H = 7.1 Hz, 2H, CH2), 
3.04-2.93 (m, 1H, CH), 1.88 (d, 
4
JH,H = 1.5 Hz, 3H, CH3), 1.38-1.21 (m, 
2H, CH2), 1.29 (t, 
3
JH,H = 7.1 Hz, 3H, CH3), 0.96 (d, 
3
JH,H = 6.6 Hz, 3H, 
CH3), 0.84 (t, 
3
JH,H = 7.5 Hz, 3H, CH3) ppm. 
13
C NMR (100 MHz, CDCl3, 
TMS): δ = 168.5 (C), 148.3 (CH), 126.1 (C), 60.0 (CH2), 35.0 (CH), 30.1 
(CH2), 20.8 (CH3), 20.2 (CH3), 14.2 (CH3), 11.8 (CH3), ppm. 
4.2.15 (E)-2,4-Dimethylhex-2-en-1-ol (143) 
 
To a solution of (E)-ethyl 2,4-dimethylhex-2-enoate 142 (1.16 g, 6.8 
mmol) in anhydrous dichloromethane (27.2 mL), DIBAL-H (13.6 mL, 13.6 
mmol, 1M in Hexane) was added dropwise at -78 °C and stirred at - 78 
°C overnight. Then, saturated NH4Cl aqueous solution was added and 
allowed to warm to room temperature. The reaction mixture was filtered 
through Celite®, extracted with dichloromethane, dried over MgSO4, 
concentrated in vacuo and purified by flash column chromatography on 
silica gel to produce 143 (481 mg, 3.75 mmol, 55%) as colourless oil.  
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TLC (hexane/ethyl acetate = 5:1) Rf = 0.32. IR (ATR) 𝑣 = 3321 (m), 2960 
(m), 2922 (m), 2872 (m), 1454 (m), 1377 (m), 1260 (m), 1237 (w), 1091 
(w), 1003 (s), 949 (m), 863 (m), 808 (m), 771 (w), 602 (w) cm
-1
. UV-Vis 
(CH2Cl2) max (log ) 231 (3.24) nm. MS (EI, 70 eV): m/z (%) = 128 (7) 
[M]
+
, 97 (53), 95 (23), 83 (7), 81 (13), 79 (7), 73 (77), 71 (32), 69 (18), 67 
(13), 58 (10), 57 (17), 56 (10), 55 (52), 44 (10), 43 (100), 41 (25), 40 
(13), 39 (11). GC (HP-5MS): I = 996. 
1
H NMR (400 MHz, CDCl3, TMS): δ 
= 5.17 (ddq, 
4
JH,H = 1.3 Hz, 
3
JH,H = 9.5, 2.7 Hz, 1H, CH), 4.00 (d, 
4
JH,H = 
1.2 Hz, 2H, CH2), 2.37-2.21 (m, 1H, CH), 1.67 (d, 
4
JH,H = 1.4 Hz, 3H, 
CH3), 1.46 (s, 1H, OH), 1.42-1.15 (m, 2H, CH2), 0.93 (d, 
3
JH,H = 6.7 Hz, 
3H, CH3), 0.84 (t, 
3
JH,H = 7.4 Hz, 3H, CH3) ppm. 
13
C NMR (100 MHz, 
CDCl3, TMS): δ = 133.4 (CH), 132.7 (C), 69.0 (CH2), 33.7 (CH), 30.9 
(CH2), 30.2 (CH3), 13.8 (CH3), 11.9 (CH3) ppm. 
4.2.16 (E)-4,6-Dimethyloct-4-en-3-ol (144) 
 
To a solution of (E)-2,4-dimethylhex-2-en-1-ol 143 (481 mg, 3.75 mmol) 
in anhydrous dichloromethane (7.5 mL), pyridium chlorochromate (968 
mg, 4.5 mmol) was added at room temperature and stirred overnight at 
this temperature. The reaction mixture was filtered through silica gel, 
concentrated in vacuo and used for next step without purification.  
To a solution of allylic aldehyde (3.75 mmol) in anhydrous diethyl ether 
(7.5 mL), prepared EtMgBr (7.5 mL, 7.50 mmol, 1M in Et2O) was added 
dropwise at 0 °C and stirred at 0 °C for two hours. Then, distilled water 
was put into the reaction mixture slowly, extracted with Et2O, dried over 
MgSO4, concentrated in vacuo and purified by flash column 
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chromatography on silica gel to obtain 144 (328 mg, 2.10 mmol, 56%, dr 
1:1) as colourless oil. 
Analytical data for mixture of diastereomers: TLC (hexane/ethyl acetate 
= 10:1) Rf = 0.38. IR (ATR) 𝑣 = 3359 (m), 2960 (s), 2930 (m), 2873 (m), 
1457 (m), 1376 (m), 1315 (w), 1261 (w), 1237 (w), 1093 (m), 1050 (m), 
991 (s), 964 (m), 890 (m), 866 (m), 830 (w), 776 (m), 620 (w), 546 (m) 
cm
-1
. UV-Vis (CH2Cl2) max (log ) 230 (3.19) nm. MS (EI, 70 eV): A: m/z 
(%) = 156 (3) [M]
+
, 128 (43), 111 (10), 110 (95), 100 (100), 98 (14), 96 
(13), 92 (8), 86 (29), 84 (32), 82 (17), 78 (13), 77 (11), 73 (14), 72 (82), 
70 (45), 68 (28), 58 (91), 56 (41), 44 (90), 42 (29), 41 (30). B: m/z (%) = 
156 (2) [M]
+
, 128 (45), 110 (11), 109 (96), 99 (100), 97 (12), 85 (20), 83 
(34), 81 (20), 73 (11), 71 (76), 69 (40), 67 (27), 57 (80), 55 (35), 44 (34), 
43 (47), 41 (28), 40 (26). GC (HP-5MS): I = 1111 (A) and 1115 (B). 
1
H 
NMR (500 MHz, CDCl3, TMS): δ = A: 5.15-5.09 (m, 1H, CH), 3.89 (t, 
3
JH,H = 6.8 Hz, 1H, CH), 2.32-2.22 (m, 1H, CH), 1.58 (d, 
4
JH,H = 1.4 Hz, 
3H, CH3), 1.57-1.47 (m, 2H, CH2), 1.39-1.14 (m, 2H, CH2), 0.92 (dd, 
3
JH,H 
= 12.0, 6.7 Hz, 3H, CH3), 0.86-0.79 (m, 6H, 2 x CH3) ppm. B: 5.15-5.09 
(m, 1H, CH), 3.89 (t,
 3
JH,H = 6.8 Hz, 1H, CH), 2.32-2.22 (m, 1H, CH), 1.58 
(d, 
4
JH,H = 1.4 Hz, 3H, CH3), 1.57-1.47 (m, 2H, CH2), 1.39-1.14 (m, 2H, 
CH2), 0.92 (dd, 
3
JH,H = 12.0, 6.7 Hz, 3H, CH3), 0.86-0.79 (m, 6H, 2 x CH3) 
ppm. 
13
C NMR (125 MHz, CDCl3, TMS): δ = A: 135.6 (C), 133.3 (CH), 
79.5 (CH), 33.8 (CH), 30.4 (CH2), 27.8 (CH2), 20.9 (CH3), 12.1 (CH3), 
11.6 (CH3), 10.1 (CH3) ppm. B: 135.5 (C), 133.9 (CH), 80.0 (CH), 33.9 
(CH), 30.5 (CH2), 27.7 (CH2), 20.8 (CH3), 12.1 (CH3), 11.4 (CH3), 10.2 
(CH3) ppm.  
4.2.17 (E)-4,6-Dimethyl-4octen-3-one (133) 
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To a solution of 144 (312 mg, 2.0 mmol) in anhydrous dichloromethane 
(4.0 mL), pyridinium chlorochromate (520 mg, 2.4 mmol) was added and 
stirred overnight at room temperature. The reaction mixture was filtered 
over silica gel, concentrated in vacuo and purified by flash column 
chromatography on silica gel to afford (E)-4,6-dimethyl-4octen-3-one 133 
(114 mg, 0.74 mmol, 37%) as colourless oil.  
TLC (hexane/ethyl acetate = 10:1) Rf = 0.53. IR (ATR) 𝑣 = 2962 (m), 
2931 (m), 2875 (m), 1670 (s), 1458 (m), 1375 (m), 1341 (m), 1262 (m), 
1227 (m), 1132 (m), 1085 (m), 1051 (m), 1015 (m), 991 (m), 896 (m), 
800 (m), 581 (w) cm
-1
. UV-Vis (CH2Cl2) max (log ) 308 (2.79), 233 (5.05) 
nm. MS (EI, 70 eV): A: m/z (%) = 154 (33) [M]
+
, 155 (4), 126 (9), 125 
(100), 106 (8), 97 (11), 96 (4), 84 (6), 81 (4), 69 (17), 67 (5), 57 (11), 56 
(3), 55 (43), 53 (3), 43 (13), 41 (9), 40 (5). GC (HP-5MS): I = 1140.  
1
H 
NMR (400 MHz, CDCl3, TMS): δ = 6.37 (dq, 
3
JH,H = 9.7 Hz, 
4
JH,H = 1.4 
Hz, 1H, CH), 2.69 (q, 
3
JH,H = 7.3 Hz, 2H, CH2), 2.56-2.40 (m, 1H, CH), 
1.79 (d, 
4
JH,H = 1.3 Hz, 3H, CH3), 1.53-1.24 (m, 2H, CH2), 1.16-0.96 (m, 
6H, 2 x CH3), 0.87 (t, 
3
JH,H = 7.4 Hz, 3H, CH3) ppm. 
13
C NMR (100 MHz, 
CDCl3, TMS): δ = 202.9 (C), 47.7 (CH), 135.6 (C), 35.1 (CH), 30.4 (CH2), 
29.7 (CH2), 19.69 (CH3), 11.89 (CH3), 11.6 (CH3), 8.9 (CH3) ppm.  
4.2.18 Preparation of stereoisomers of 137  
To a solution of diisopropylamine (2.02 g, 20.0 mmol) in anhydrous THF 
(50 mL) was added  n-butyllithium (12.5 mL, 1.6 M  in hexane, 20.0 
mmol) at 0 °C. The mixture was stirred at 0 
o
C  for 1 hour and 
subsequently cooled to  -78 °C. Pentan-3-one (1.72 g, 20.0 mmol) in 
anhydrous THF (10 mL) was added  slowly at  -78 °C  and the mixture 
was stirred at this temperature for another hour, followed by the addition 
of 2-methylbutanal (1.72 g, 20.0 mmol) in anhydrous THF (10 mL). 
Stirring at  -78 °C  was continued for one more hour. The mixture was 
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warmed to room temperature, hydrolysed with saturated ammonium 
chloride solution and extracted three times with diethyl ether. The 
collected organic phases were dried over MgSO4  and concentrated 
under reduced pressure to yield  5-hydroxy-4,6-dimethyloctan-3-one 
(2.34 g, 13.6 mmol, 68%) as a mixture  of eight stereoisomers. 
Spectroscopic data are given below for the enantioselectively 
synthesised or chromatographically purified stereoisomers. 
4.2.19 (2E,4Z)-Ethyl 2,4-dimethylhex-2-enoate (148) 
 
To a solution of oxalyl chloride (3.81 g, 30.0 mmol) in anhydrous 
dichloromethane (16.6 mL), dimethyl sulfoxide (4.88 g, 62.5 mmol) was 
added dropwise at -78 °C. After stirring 5 minutes, (S)-(-)-2-
methylbutanol (2.20 g, 25.0 mmol) in anhydrous dichloromethane (6.9 
mL) was added to the reaction mixture and stirred for another 30 minutes 
at -78 °C. Then, triethylamine (12.65 g, 150 mmol) was added to the 
solution and it was warmed to room temperature, 
(ethoxycarbonylethylidiene) triphenyl phosphorane (10.85 g, 30 mmol) 
was put into the flask and stirred under reflux for 24 hours. The reaction 
mixture was washed with distilled water, extracted with dichloromethane, 
dried over MgSO4, concentrated in vacuo and purified by flash column 
chromatography on silica gel to afford ethyl  (2E,4S)-2,4-dimethylhex-2-
enoate 148 as colourless oil (2.27 g, 13.34 mmol, 53%) and small 
amount of ethyl  (2Z,4S)-2,4-dimethylhex-2-enoate (0.13 g, 0.76 mmol, 
3%) as colourless oils.  
TLC (hexane/ethyl acetate = 10:1) Rf = 0.44. IR (ATR) 𝑣 =  2962 (w), 
2930 (w), 2874 (w), 1709 (s), 1650 (w), 1458 (w), 1367 (w), 1316 (w), 
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1269 (m), 1235 (s), 1152 (m), 1095 (m), 1033 (w), 995 (w), 924 (w), 871 
(w), 776 (w), 748 (s), 533 (w) cm
-1
. UV-Vis (CH2Cl2) max (log ) 231 
(4.80) nm. MS (EI, 70 eV): m/z (%) = 170 (34) [M]
+
, 125 (39), 123 (37), 
113 (48), 109 (31), 96 (46), 95 (51), 81 (23), 69 (24), 68 (21), 67 (90), 65 
(24), 55 (62), 53 (58), 43 (64), 42 (23), 41 (100), 40 (20), 39 (83). GC 
(BPX-5): I = 1156. 
1
H NMR (400 MHz, CDCl3, TMS): δ = 5.57 (dq, 
4
JH,H = 
1.4 Hz, 
3
JH,H = 10.0 Hz, 1H, CH), 4.12 (q, 
3
JH,H = 7.1 Hz, 2H, CH2), 2.96-
2.87 (m, 1H, CH), 1.82 (d,
 4
JH,H = 1.4 Hz, 3H, CH3), 1.27-1.20 (m, 2H, 
CH2), 1.23 (t, 
3
JH,H = 7.1 Hz, 3H, CH3), 0.89 (d, 
3
JH,H = 6.6 Hz, 3H, CH3), 
0.78 (t, 
3
JH,H = 7.4 Hz, 3H, CH3) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 
168.4 (C), 148.3 (CH), 126.0 (C), 60.0 (CH2), 35.0 (CH), 30.2 (CH2), 20.8 
(CH3), 20.2 (CH3), 14.2 (CH3), 11.8 (CH3) ppm. Optical rotation: []D
20
= 
+28.4 (c 0.1, ethanol). 
4.2.20 (2E,4S)-2,4-Dimethylhex-2-en-1-ol (149) 
 
To a solution of (2E,4S)-ethyl 2,4-dimethylhex-2-enoate (6.91 g, 40.7 
mmol) in anhydrous dichloromethane (397.2 mL), diisobutylammonium 
hydrid (1.2 M in toluene, 165.5 mL, 198.6 mmol) was added dropwise at 
-78 °C and stirred at this temperature overnight. A solution of saturated 
NH4Cl was added and the solution was warmed to room temperature. 
The white sediment was filtered and the reaction mixture was extracted 
with dichloromethane. The collected organic layers were dried over 
MgSO4, concentrated in vacuo and purified by flash column 
chromatography on silica gel to achieve 149 as colourless oil (4.04 g, 
31.5 mmol, 77%). 
TLC (hexane/ethyl acetate = 5:1) Rf = 0.31. IR (ATR) 𝑣 = 3319 (w), 2960 
(m), 2922 (m) 2872 (m), 1454 (m), 1376 (w), 1236 (w), 1115 (w), 1003 
 
 
183 
 
(s), 949 (w), 863 (w), 811 (w), 711 (w), 601 (w) cm
-1
. UV-Vis (CH2Cl2) 
max (log ) 227 (2.81), 221 (2.31) nm. MS (EI, 70 eV): m/z (%) = 110 (1) 
[M-H2O]
+
, 87 (7), 71 (6), 70 (6), 69 (22), 67 (7), 59 (7), 58 (29), 57 (67), 
56 (10), 55 (51), 53 (15), 51 (10), 45 (39), 43 (74), 42 (25), 41 (67), 40 
(12), 39 (100), 38 (7). GC (BPX-5): I = 1068. 
1
H NMR (400 MHz, CDCl3, 
TMS): δ = 4.98 (dt, 4JH,H = 0.5 Hz, 
3
JH,H = 9.9 Hz, 1H, CH), 4.09-4.01 (m, 
2H, CH2), 2.30-2.19 (m, 1H, CH), 1.73 (d,
 4
JH,H = 1.5 Hz, 3H, CH3), 1.99-
2.04 (m, 1H, OH), 1.31-1.06 (m, 2H, CH2), 0.86 (d, 
3
JH,H = 6.6 Hz, 3H, 
CH3), 0.75 (t, 
3
JH,H = 7.4 Hz, 3H, CH3) ppm. 
13
C NMR (100 MHz, CDCl3): 
δ = 135.0 (C), 132.9 (CH), 61.9 (CH2), 33.8 (CH), 30.4 (CH2), 21.3 (CH3), 
21.2 (CH3), 11.9 (CH3) ppm. Optical rotation: []D
20
 = +10.4 (c 0.1, 
ethanol). 
4.2.21 (2S,3S,4S)-2,3-Epoxy-2,4-dimethylhexan-1-ol (150a) 
 
In a round-bottom flask, molecular sieves (2.34 g, 4Ǻ, 1.0 g/10 mmol) 
and dry dichloromethane (117 mL) were settled and cooled to -10 °C. 
Then, (+)-diethyl L-tartrate (579 mg, 2.81 mmol), titanium isopropoxide 
(665 mg, 2.34 mmol) and cumene hydroperoxide (4.45, 80% in cumene, 
23.4 mmol) were added and stirred for 10 minutes at -10 °C. The 
reaction mixture was subsequently cooled to -23 °C, alcohol 149 (3.00 g, 
23.4 mmol) in anhydrous dichloromethane (8.30 mL, 2M) was added 
dropwise and stirred overnight at -23 °C. Distilled water was added to the 
solution and stirred for another 30 minutes. It was filtered over Celite®, 
dried over MgSO4, concentrated in vacuo and purified by flash column 
chromatography on silica gel to achieve 150a as colourless oil (2.71 g, 
18.8 mmol, 80%, dr > 10:1 by GC/MS analysis). 
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TLC (hexane/ethyl acetate = 1:1) Rf = 0.47. IR (ATR) 𝑣 = 2960 (m), 2932 
(m), 2881 (w), 2859 (w), 1708 (m), 1462 (w), 1383 (w), 1254 (w), 1182 
(w), 1057 (m), 1022 (m), 962 (w), 940 (m), 835 (s), 810 (m), 773 (s), 674 
(m) cm
-1
. UV-Vis (CH2Cl2) max (log ) 231 (2.04) nm. MS (EI, 70 eV): m/z 
(%) = 126 (0.5) [M-H2O]
+
, 111 (1), 97 (4), 87 (11),  75 (13), 74 (9), 71 
(10), 70 (16), 69 (33), 67 (5), 59 (22), 58 (58), 57 (58), 56 (7), 55 (74), 53 
(10), 51 (6), 45 (46), 43 (100), 42 (20), 41 (68), 40 (8), 39 (52), 38 (5). 
GC (BPX-5): I = 1106. 
1
H NMR (400 MHz, CDCl3, TMS): δ = 3.68 (dd, 
4
JH,H = 4.7 Hz, 
3
JH,H = 12.2 Hz, 1H, CH2), 3.57 (dd, 
3
JH,H = 8.2, 12.2 Hz, 
1H, CH2), 2.77 (d, 
3
JH,H = 8.9 Hz, 1H, CH), 2.05-1.99 (m, 1H, OH), 1.67-
1.55 (m,
 
1H, CH), 1.40-1.31 (m, 2H, CH2), 1.30 (s, 3H, CH3), 0.97 (t, 
3
JH,H 
= 7.3 Hz, 3H, CH3), 0.9 (d, 
3
JH,H = 6.6 Hz, 3H, CH3) ppm. 
13
C NMR (100 
MHz, CDCl3, TMS): δ = 65.6 (CH2), 64.9 (CH), 60.3 (C), 34.1 (CH), 27.9 
(CH2), 15.6 (CH3), 14.2 (CH3), 11.3 (CH3) ppm. Optical rotation: []D
20
 = 
+12.9 (c 0.1, ethanol). 
4.2.22 (4S,5S,6S)-5-((tert-Butyldimethylsilyl)oxy)-4,6-dimethyloctan-
3-ol (152a) 
 
To a solution of epoxyl alcohol 150a (2.11 g, 14.6 mmol), 2.92 g of 4Å 
molecular sieves and diisopropylethylamine (2.54 g, 19.7 mmol) in 
anhydrous dichloromethane (43.8 mL), tert-butyldimethylsilyl 
trifluoromethanesulfonate (5.02 g, 19.0 mmol) was added dropwise at -
42 °C and stirred for 2 hours at this temperature. It was poured on diethyl 
ether and 100 mL of PH 5.5 phosphate buffer was added to the reaction 
mixture. The aqueous phase was extracted with ether. The collected 
organic layers were washed with distilled water, 5% NaHCO3 and birne, 
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dried over MgSO4 and concentrated in vacuo to generate colourless oil 
and used without further purification.  
To the reaction mixture in anhydrous diethyl ether (38.2 mL), prepared 
EtMgBr (38.2 mL, 38.2 mmol, 1.0 mol/L) was added dropwise at 0 °C 
and stirred for 2 hours at this temperature. Then, it was washed with 
distilled water, extracted with ether, dried over MgSO4, concentrated in 
vacuo and purified by flash column chromatography on silica gel to 
obtain 152a (2.03 g, 7.0 mmol, 48%, colourless oil) as a mixture of 
diastereomers (dr = 55:45).  
TLC (hexane/ethyl acetate = 20:1) Rf = 0.21. IR (ATR) 𝑣  = 3462 (w), 
2959 (m), 2932 (m), 2880 (w), 2858 (w), 1463 (w), 1382 (w), 1253 (m), 
1109 (w), 1045 (m), 1002 (m), 971 (m), 833 (s), 772 (s), 675 (m) cm
-1
. 
UV-Vis (CH2Cl2) max (log ) 286 (2.54), 232 (4.35) nm. MS (EI, 70  eV, 
major diastereomer):  m/z  (%) = 231 (17) [M-C(CH3)3]
+
, 230 (7), 213 (6), 
202 (12), 201 (57), 175 (8), 174 (15), 173 (100), 162 (5), 161 (42), 147 
(20), 145 (11), 143 (11), 133 (13), 119 (9), 115 (32), 105 (18), 83 (10), 77 
(6), 76 (7), 75 (91), 74 (6),  73 (58), 69 (14), 59 (8), 57 (10), 55 (8), 43 
(10), 41 (9). GC (HP-5): I = 1615 (major diastereomer) and I = 1594 
(minor diastereomer). 
1
H NMR (400 MHz, CDCl3, TMS): δ = 3.73 (dd, 
4
JH,H = 3.0 Hz, 
3
JH,H = 4.7 Hz, 1H, CH), 3.53 (ddd, 
4
JH,H = 3.3 Hz, 
3
JH,H = 
6.4 Hz, 1H, CH), 2.01 (br s, 1H, OH), 1.71-1.53 and 1.18-1.04 (m, 6H, 
2xCH, 2xCH2), 0.11-0.05 (n, 6H, 2xCH3)  ppm. 
13
C NMR (100 MHz, 
CDCl3, TMS, major diastereomer): δ = 79.0 (CH), 76.3 (CH), 40.1 (CH), 
39.7 (CH), 28.1 (CH2), 26.1 (3xCH3), 25.8 (CH2), 18.4 (C), 14.8 (CH3), 
12.5 (CH3), 10.5 (CH3), 8.7 (CH3), -3.4 (CH3), -4.2 (CH3) ppm. Optical 
rotation:  []D
20
=  +12.9 (c  0.1,  ethanol). 
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4.2.23 (4R,5S,6S)-5-((tert-Butyldimethylsilyl)oxy)-4,6-dimethyloctan-
3-one (153a) 
 
To a solution of alcohol 152a (1.32 g, 4.56 mmol) in anhydrous 
dichloromethane (9.0 mL), pyridinium chlorochromate (1.32 g, 9.12 
mmol) was added and stirred overnight at room temperature. The 
reaction mixture was filtered over silica gel, concentrated in vacuo and 
purified by flash column chromatography on silica gel to produce 153a as 
colourless oils (1.16 g, 4.03 mmol, 88%). 
TLC (hexane/ethyl acetate = 10:1) Rf = 0.55. IR (ATR) 𝑣 = 2959 (m), 
2933 (m), 2880 (w), 2858 (w), 1713 (m), 1674 (w), 1461 (m), 1380 (w), 
1254 (m), 1099 (m), 1051 (m), 1006 (m), 973 (m), 866 (m), 834 (s), 803 
(m), 773 (s), 773 (m) cm
-1
. UV-Vis (CH2Cl2) max (log ) 237 (2.40) nm. 
MS (EI, 70 eV): m/z (%) = 286 (1) [M]
+
, 230 (18), 229 (100), 206 (16), 
201 (13), 173 (10), 145 (26), 143 (76), 115 (16), 75 (65), 73 (24), 56 (24), 
44 (16), 40 (13). GC (HP-5MS): I = 1581. 
1
H NMR (400 MHz, CDCl3, 
TMS): δ = 3.89 (dd, 4JH,H = 3.9 Hz, 
3
JH,H = 5.8 Hz, 1H, CH), 2.70 (m, 1H, 
CH), 2.61-2.43 (m, 2H, CH2), 1.43-1.38 (m, 2H, CH2), 1.07 (dd,
 4
JH,H = 
2.6 Hz, 
3
JH,H = 7.0 Hz, 3H, CH3), 1.04 (t, 
3
JH,H = 7.3 Hz, 3H, CH3), 1.09-
1.02 (m, 1H, CH), 0.89 (s, 12H, 4 x CH3), 0.90-0.87 (m, 3H, CH3), 0.04 (d,
 
3
JH,H =  16.9 Hz, 6H, 2 x CH3)  ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ 
= 214.5 (C), 76.7 (CH), 49.5 (CH), 41.0 (CH), 35.6 (CH2), 26.3 (3 x CH3), 
25.2 (CH2), 18.7 (C), 15.9 (CH3), 13.9 (CH3), 12.5 (CH3), 8.0 (CH3), -3.8 
(CH3), -3.9 (CH3) ppm.  Optical rotation: []D
20
 =  –10.8 (c 0.37, ethanol). 
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4.2.24 (4R,5S,6S)-5-Hydroxy-4,6-dimethyloctan-3-one (137a) 
 
To a solution of 153a (178 mg, 0.62 mmol) in anhydrous THF (5 mL), 
hydrogen fluoride pyridine (5.2 mL, 70% HF) was added carefully at 0 °C 
and stirred at this temperature for 1 hour. It was quenched with aqueous 
NaHCO3 solution until no further effervescence and neutral PH. The 
reaction mixture was extracted with diethyl ether, dried over MgSO4, 
concentrated in vacuo and purified by column chromatography on silica 
gel to yield 137a as colourless oils (48 mg, 0.31 mmol, 50%).  
TLC (hexane/ethyl acetate = 5:1) Rf = 0.33. IR (ATR) 𝑣 = 3490 (w), 2996 
(m), 2937 (m), 2878 (m), 1701 (s), 1459 (m), 1410 (w), 1379 (m), 1299 
(w), 1237 (w), 1149 (w), 1105 (w), 967 (m), 846 (w), 8023 (w), 775 (w) 
cm
-1
. UV-Vis (CH2Cl2) max (log ) 229 (3.26), 201 (3.74) nm. MS (EI, 70 
eV): m/z (%) = 154 (6) [M-H2O]
+
, 125 (9), 115 (28), 98 (4), 97 (23), 87 
(14), 86 (68), 85 (5), 83 (4), 71 (5), 70 (6), 69 (29), 58 (11), 57 (100), 56 
(5), 55 (9), 45 (13), 43 (7), 41 (15), 39 (3). GC (HP-5MS): I = 1240. 
1
H 
NMR (400 MHz, CDCl3, TMS): δ = 3.62 (dt, 
4
JH,H =  2.6 Hz, 
3
JH,H = 8.9 Hz, 
1H, CH), 2.88 (d, 
4
JH,H = 3.0 Hz, 1H, OH), 2.74 (dq, 
4
JH,H =  2.5 Hz, 
3
JH,H 
= 7.2 Hz, 1H, CH), 2.63-2.44 (m, 2H, CH2), 1.84-1.3 (m, 2H, CH2), 1.20-
1.14 (m, 1H, CH), 1.11 (d, 
3
JH,H = 7.2 Hz, 3H, CH3), 1.07 (t, 
3
JH,H = 7.2 Hz, 
3H, CH3), 0.91(t,
 3
JH,H =  7.4 Hz, 3H, CH3), 0.81 (d, 
3
JH,H = 6.8 Hz, 3H, 
CH3)   ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 217.1 (C), 74.4 (CH), 
47.0 (CH), 36.8 (CH), 34.8 (CH2), 25.0 (CH2), 14.8 (CH3), 10.8 (CH3), 9.1 
(CH3), 7.7 (CH3) ppm. Optical rotation: []
20
D =  –3.3 (c 0.3, ethanol). 
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4.2.25 (2R,3R,4S)-2,3-Epoxy-2,4-dimethylhexan-1-ol (150b) 
 
This compound was prepared via the same procedure as described 
above for 150a, only (–)-diethyl D-tartrate was used instead of (+)-diethyl 
L-tartrate. Starting from 149 (2.0 g, 16.6 mmol), the final purification by 
flash column chromatography on silica gel  yielded  150b  (2.11 g, 14.6 
mmol, 88%, dr > 95:5 by GC/MS analysis) as colourless oil.  
TLC (hexane/ethyl acetate = 1:1) Rf = 0.47. IR (ATR) 𝑣 = 2960 (m), 2932 
(m), 2881 (w), 2859 (w), 1708 (m), 1462 (w), 1383 (w), 1254 (w), 1182 
(w), 1057 (m), 1022 (m), 962 (w), 940 (m), 835 (s), 810 (m), 773 (s), 674 
(m) cm
-1
. UV-Vis (CH2Cl2) max (log ) 230 (2.27), 222 (2.10) nm. MS (EI, 
70 eV): m/z (%) = 126 (0.5) [M-H2O]
+
, 111 (1), 97 (4), 87 (11),  75 (13), 
74 (9), 71 (10), 70 (16), 69 (33), 67 (5), 59 (22), 58 (58), 57 (58), 56 (7), 
55 (74), 53 (10), 51 (6), 45 (46), 43 (100), 42 (20), 41 (68), 40 (8), 39 
(52), 38 (5). GC (BPX-5): I = 1106. 
1
H NMR (400 MHz, CDCl3, TMS): δ = 
3.68 (dd, 
4
JH,H = 4.7 Hz, 
3
JH,H = 12.2 Hz, 1H, CH2), 3.57 (dd, 
3
JH,H = 8.2, 
12.2 Hz, 1H, CH2), 2.77 (d, 
3
JH,H = 8.9 Hz, 1H, CH), 2.05-2.02 (dd, 
4
JH,H = 
4.7 Hz, 
3
JH,H = 8.1 Hz, 1H, OH), 1.63 (p,
 3
JH,H = 7.6 Hz, 1H, CH), 1.40-
1.31 (m, 2H, CH2), 1.30 (s, 3H, CH3), 0.97 (t, 
3
JH,H = 7.3 Hz, 3H, CH3), 
0.9 (d, 
3
JH,H = 6.6 Hz, 3H, CH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): 
δ = 65.6 (CH2), 64.9 (CH), 60.3 (C), 34.1 (CH), 27.9 (CH2), 15.6 (CH3), 
14.2 (CH3), 11.3 (CH3) ppm. Optical rotation: []D
20
 = +20.0 (c 0.1, 
ethanol). 
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4.2.26 (4R,5R,6S)-5-((tert-Butyldimethylsilyl)oxy)-4,6-dimethyloctan-
3-ol (152b) 
 
The same two-step procedure as for the preparation of  152a  was used. 
The starting material  150b  (1.31 g, 9.1  mmol) was converted into the 
target compound  152b (0.7 g, 2.43 mmol, 27%) as a mixture of 
diastereomers (dr = 2:1) that was obtained as a colourless oil. 
TLC (hexane/ethyl acetate = 10:1) Rf = 0.35. IR (ATR) 𝑣  = 3450 (w), 
2959 (m), 2932 (m), 2880 (w), 2859 (w), 1463 (m), 1383 (w), 1253 (m), 
1047 (m), 1002 (m), 968 (m), 833 (s), 772 (s), 674 (m) cm
-1
.UV-Vis 
(CH2Cl2) max (log ) 242 (2.95) nm. 
1
H NMR (400 MHz, CDCl3, TMS): δ = 
3.66 (t, 
4
JH,H = 3.9 Hz, 1H, CH), 3.54 (m, 1H, CH), 1.79 (s, 1H, OH), 1.67-
1.64 (m, 1H, CH), 1.60-1.52 (m, 2H, CH2), 1.49-1.45 (m, 2H, CH2), 1.12-
1.09 (m, 1H, CH), 0.91 (s, 15H, 5 x CH3), 0.92-0.87 (m, 6H, 2 x CH3), 
0.08 (d,
 3
JH,H =  5.0 Hz, 6H, 2 x CH3)  ppm. 
13
C NMR (100 MHz, CDCl3, 
TMS): δ = 79.0 (CH), 76.3 (CH), 40.1 (CH), 39.6 (CH), 28.1 (CH2), 26.1 
(3 x CH3), 25.8 (CH2), 18.4 (C), 14.8 (CH3), 12.5 (CH3), 10.5 (CH3), 8.7 
(CH3), -3.4 (CH3), -4.2 (CH3) ppm. Optical rotation: []D
20
 = +2.5 (c 0.1, 
ethanol). 
4.2.27 (4S,5R,6S)-5-((tert-Butyldimethylsilyl)oxy)-4,6-dimethyloctan-
3-one (153b) 
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The same procedure as for  153a  was used.  The starting material  152b 
(381 mg, 1.32 mmol) was converted into 153b (328 mg, 1.14 mmol, 
86%) that was obtained as colourless oil. 
TLC (hexane/ethyl acetate = 10:1) Rf = 0.55. IR (ATR) 𝑣 = 2960 (m), 
2932 (m), 2881 (w), 2858 (w), 1712 (m), 1674 (w), 1461 (m), 1381 (w), 
1253 (m), 1099 (m), 1051 (m), 1007 (m), 973 (m), 834 (s), 803 (m), 772 
(s), 673 (m) cm
-1
. UV-Vis (CH2Cl2) max (log ) 287 (2.56), 232 (4.29) nm. 
MS (EI, 70 eV): m/z (%) = 271 (1) [M-CH3]
+
, 230 (17), 229 (100), 201 
(12), 173 (10), 145 (14), 143 (76), 115 (13), 75 (52), 73 (21), 57 (21). GC 
(HP-5MS): I = 1591. 
1
H NMR (400 MHz, CDCl3, TMS): δ = 3.85 (dd, 
4
JH,H 
= 2.9 Hz, 
3
JH,H = 6.7 Hz, 1H, CH), 2.73 (p, 
3
JH,H = 7.0 Hz, 1H, CH), 2.56-
2.42 (m, 2H, CH2), 1.47-1.26 (m, 1H, CH2), 1.17-1.09 (m, 1H, CH2), 1.08-
1.02 (m, 1H, CH), 0.90 (s, 15H, 5 x CH3), 0.87 (t, 
3
JH,H = 7.4 Hz, 3H, CH3), 
0.80 (d, 
3
JH,H = 6.8 Hz, 3H, CH3), 0.05 (d,
 3
JH,H =  6.3 Hz, 6H, 2 x CH3)  
ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 214.0 (C), 76.0 (CH), 49.8 
(CH), 39.5 (CH), 35.4 (CH2), 26.5 (CH2), 25.8 (3 x CH3), 18.1 (C), 13.9 
(CH3), 13.6 (CH3), 11.9 (CH3), 7.3 (CH3), -4.2 (CH3), -4.4 (CH3) ppm. 
Optical rotation: []D
20
 = +13.2 (c 0.36, ethanol). 
4.2.28 (4S,5R,6S)-5-Hydroxy-4,6-dimethyloctan-3-one (137b) 
 
The same procedure as for 137a  was used. The  ketone  153b  (162 mg, 
0.57 mmol)  was converted into  137b  (71 mg, 0.41 mmol, 72%)  that 
was obtained as a colourless oil. 
TLC (hexane/ethyl acetate = 5:1) Rf = 0.33. IR (ATR) 𝑣 = 3483 (w), 2966 
(w), 2936 (w), 2878 (w), 1702 (s), 1459 (m), 1410 (w), 1378 (m), 1237 
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(w), 1148 (w), 1103 (m), 974 (m), 805 (w), 773 (w), 540 (m) cm
-1
. UV-Vis 
(CH2Cl2) max (log ) 224 (3.68), 202 (4.06) nm. MS (EI, 70 eV): m/z (%) = 
154 (6) [M-H2O]
+
, 125 (8), 115 (22), 98 (3), 97 (20), 87 (11), 86 (56), 85 
(4), 83 (3), 71 (5), 70 (4), 69 (22), 58 (9), 57 (100), 56 (4), 55 (7), 45 (11), 
43 (6), 41 (12). GC (HP-5MS): I = 1242. 
1
H NMR (500 MHz, C6D6): δ = 
3.58 (dd, 
4
JH,H = 4.7 Hz, 
3
JH,H = 6.5 Hz, 1H, CH), 2.40 (dq, 
4
JH,H =  4.7 Hz, 
3
JH,H = 7.1 Hz,
 
1H, CH), 2.24 (s, 1H, OH), 2.07-1.92 (m, 2H, CH2), 0.97 
(dd, 
4
JH,H = 4.2 Hz, 
3
JH,H = 6.9 Hz, 6H, 2 x CH3), 0.91 (t, 
3
JH,H = 7.2 Hz, 
3H, CH3), 0.8 (t, 
3
JH,H = 7.4 Hz, 3H, CH3) ppm. 
13
C NMR (125 MHz, 
C6D6): δ = 214.5 (C), 74.7 (CH), 48.2 (CH), 37.5 (CH), 34.9 (CH2), 26.1 
(CH2), 14.5 (CH3), 11.4 (CH3), 11.1 (CH3), 7.8 (CH3) ppm. Optical 
rotation: []20D = +1.8 (c 0.7, Ethanol). 
4.2.29 Epimerisation of (4R,5S,6S)-137a and (4S,5R,6S)-137b 
To a solution of the ketone (4R,5S,6S)-137a or (4S,5R,6S)-137b (10 mg, 
0.058 mmol) in methanol (0.6 mL), potassium carbonate (17 mg, 0.12 
mmol) was added and the mixture was stirred at room temperature 
overnight. Distilled water (10 mL) was added and the aqueous phase 
was extracted extracted three times with ethyl acetate. The combined 
organic layers were dried over MgSO4 and concentrated in vacuo. A 
small sample of the epimerisation product was added to the mixture of 
eight stereoisomers of 137 in a ca. 1:5 ratio, followed by GC-MS analysis. 
4.2.30 Chromatographic separation of stereoisomers of 137 
A portion of the mixture of stereoisomers (100 mg) was subjected to 
purification. The racemate of 137b was separated from the other six 
stereoisomers by column chromatography on silica gel, yielding (rac)-
137b (30 mg). Subsequently, a sample of (rac)-137b (6.0 mg) was 
subjected to separation of the enantiomers by HPLC on a chiral 
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stationary phase  (DAICEL Chiralpak IA)  to give  (4S,5R,6S)-137b  (3.0 
mg) and (4R,5S,6R)-137b (3.0 mg).  
The mixture of stereoisomers 137a, 137c and 137d (70 mg) was 
separated by reversed phase HPLC using a  KNAUER Europher II 100-5 
C18 column to yield (rac)-137d (12 mg), (rac)-137c (15 mg) and (rac)-
137a (20 mg). Separation of the racemates of 137c and 137d on a chiral 
stationary phase (DAICEL Chiralpak IA) finally gave pure (4S,5S,6S)-
137c (7 mg) and (4R,5R,6R)-137c (7 mg), and (4R,5R,6S)-137d  (6 mg) 
and (4S,5S,6R)-137d (6 mg). A separation of the enantiomers of 137a  
via HPLC on a chiral column was not successful. 
(4R,5R,6S)-5-Hydroxy-4,6-dimethyloctan-3-one (137d) 
 
IR (ATR) 𝑣 = 3479 (w), 2963 (w), 2934 (w), 2877 (w), 1739 (w), 1702 (s), 
1458 (m), 1409 (w), 1376 (m), 1299 (w), 1259 (w), 1233 (w), 1136 (w), 
1106 (w), 1085 (w), 1021 (m), 972 (m), 956 (m), 867 (m), 799 (m), 736 
(m), 702 (w), 516 (w), 446 (w), 409 (w) cm
-1
. UV-Vis (CH2Cl2) max (log ) 
231 (2.99) nm. MS (EI, 70 eV): m/z (%) = 154 (4) [M-H2O]
+
, 125 (9), 116 
(4), 115 (57), 113 (5), 98 (6), 97 (24), 87 (9), 86 (46), 85 (4), 83 (6), 71 
(4), 70 (8), 69 (35), 58 (8), 57 (100), 56 (5), 55 (8), 45 (7), 43 (5), 41 (11). 
GC (HP-5MS): I = 1281.
1
H NMR (500 MHz, C6D6): δ = 3.63 (dd, 
4
JH,H = 
3.7 Hz, 
3
JH,H = 7.5 Hz, 1H, CH), 2.47 (dq, 
3
JH,H = 7.2, 8.4 Hz, 1H, CH), 
2.12 (dd, 
4
JH,H = 2.4 Hz, 
3
JH,H = 7.2 Hz, 2H, CH2), 1.4-1.23 (m, 5H, CH2, 
CH3), 1.22-1.13 (m, 1H, CH), 0.97 (t, 
3
JH,H = 7.2 Hz, 3H, CH3), 0.83 (dd, 
4
JH,H = 3.0 Hz,
3
JH,H = 6.9 Hz, 3H, CH3), 0.81 (s, 1H, OH), 0.76 (d, 
3
JH,H = 
7.2 Hz, 3H, CH3) ppm. 
13
C NMR (125 MHz, C6D6): δ = 215.0 (C), 75.8 
(CH), 48.8 (CH), 37.0 (CH), 36.1 (CH2), 27.1 (CH2), 14.0 (CH3), 12.5 
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(CH3), 12.0 (CH3), 7.8 (CH3) ppm. Optical rotation: []
20
D = - 2.4 (c 0.3, 
ethanol). 
(4S,5S,6R)-5-Hydroxy-4,6-dimethyloctan-3-one (137d) 
 
Analytical data were identical to those of  (4S,5R,6S)-137d. Optical 
rotation: []D
20
 = +1.3 (c 0.3, ethanol). 
(4S,5S,6S)-5-Hydroxy-4,6-dimethyloctan-3-one (137c) 
 
IR (ATR) 𝑣 = 3459 (w), 2962 (w), 2935 (w), 2877 (w), 1710 (m), 1458 (m), 
1411 (w), 1377 (m), 1258 (s), 1082 (m), 1010 (s), 864 (m), 790 (s), 734 
(w), 700 (w), 661 (w), 407 (w) cm
-1
. UV-Vis (CH2Cl2) max (log ) 229 
(3.39) nm. MS (EI, 70 eV): m/z (%) = 154 (4) [M-H2O]
+
, 125 (9), 116 (4), 
115 (62), 114 (5), 98 (5), 97 (22), 87 (8), 86 (34), 85 (4), 83 (5), 71 (4), 
70 (6), 69 (31), 58 (8), 57 (100), 56 (4), 55 (8), 45 (6), 43 (4), 41 (10). GC 
(HP-5MS): I = 1277. 
1
H NMR (500 MHz, C6D6): δ = 3.35 (q, 
3
JH,H = 5.6 
Hz, 1H, CH), 2.48 (dq, 
3
JH,H = 6.3, 7.2 Hz, 1H, CH), 2.16-2.0 (m, 2H, 
CH2), 1.65-1.43 (m, 5H, CH2, CH3), 1.25-1.15 (m, 1H, CH), 0.93 (t, 
3
JH,H 
= 7.2 Hz, 3H, CH3), 0.86 (dd, 
4
JH,H = 2.4 Hz, 
3
JH,H = 7.2 Hz, 3H, CH3), 
0.83 (s, 1H, OH), 0.77 (d, 
3
JH,H =  6.8 Hz, 3H, CH3) ppm. 
13
C NMR (125 
MHz, C6D6): δ = 215.7 (C), 78.5 (CH), 47.7 (CH), 38.1 (CH), 36.2 (CH2), 
23.6 (CH2), 16.3 (CH3), 14.8 (CH3), 11.8 (CH3), 7.7 (CH3) ppm. Optical 
rotation: []20D = +0.9 (c 0.2, ethanol). 
(4R,5R,6R)-5-Hydroxy-4,6-dimethyloctan-3-one (137c) 
 
 
194 
 
 
Analytical data were identical to those of (4R,5S,6S)-137c. Optical 
rotation: []D
20
= –1.3 (c 0.3, ethanol). 
(4S,5R,6R)-5-Hydroxy-4,6-dimethyloctan-3-one (137a) 
 
Analytical data  of (rac)-137a were identical  to those of (4R,5S,6S)-137a 
obtained by enantioselective synthesis. 
(4S,5R,6S)-5-Hydroxy-4,6-dimethyloctan-3-one (137b) 
 
Analytical data were identical to those of  (4S,5R,6S)-137b obtained by 
enantioselective synthesis. 
(4R,5S,6R)-5-Hydroxy-4,6-dimethyloctan-3-one (137b) 
 
Analytical data were identical to those of  (4S,5R,6S)-137b. Optical 
rotation: []D
20 
= –1.7 (c 0.7, ethanol). 
4.2.31 Pent-4-en-2-yl acrylate (175) 
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To a solution of pent-4-en-2-ol (345 mg, 4.0 mmol) and triethylamine 
(559 mg, 5.52 mmol) in anhydrous dichloromethane (13.3 mL), acryloyl 
chloride (362 mg, 4.0 mmol) was added dropwise at 0 °C and stirred at 
this temperature for 1 hour. Then, it was warmed to room temperature 
and stirred overnight. The reaction mixture was quenched with 1N HCl 
and extracted with dichloromethane. The collected organic phases were 
washed with saturated aqueous NaHCO3 and birne, dried over MgSO4 
and concentrated in vacuo to afford 175 as pale yellow oil (367 mg, 2.62 
mmol, 66%). 
TLC (hexane/ethyl acetate = 40:1) Rf = 0.2. IR (ATR) 𝑣 = 3079 (w), 2978 
(w), 2930 (w), 2854 (w), 1713 (s), 2637 (w), 1506 (w), 1451 (w), 1406 (w), 
1381 (w), 1251 (m), 1192 (m), 1121 (m), 1051 (m), 991 (m), 920 (m), 801 
(m), 587 (w) cm
-1
. UV-Vis (CH2Cl2) max (log ) 251 (4.25), 226 (4.22), 
222 (4.17) nm. MS (EI, 70 eV): m/z (%) = 140 (0.2) [M]
+
, 100 (1), 99 (24), 
96 (2), 69 (4), 68 (8), 67 (6), 56 (4), 55 (100), 53 (5), 45 (3), 43 (7), 41 
(20), 39 (18). GC (BPX-5): I = 922. 
1
H NMR (400 MHz, CDCl3, TMS): δ = 
(dd, 
4
JH,H = 1.5 Hz, 
3
JH,H = 17.3 Hz, 1H, CH2), 6.10 (dd, 
3
JH,H = 10.4, 17.0 
Hz, 1H, CH), 5.80 (dd, 
4
JH,H = 1.5 Hz, 
3
JH,H = 10.4 Hz, 1H, CH2), 5.81-
5.72 (m, 1H, CH), 5.04 (d, 
3
JH,H = 6.3 Hz, 1H, CH2), 5.01 (d, 
3
JH,H = 6.3 
Hz, 1H, CH2), 5.11-5.06 (m, 1H, CH), 2.39-2.28 (m, 2H, CH2), 1.28 (d, 
3
JH,H = 6.3 Hz, 3H, CH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 167 
(C), 133.6 (CH), 130.3 (CH2), 128.9 (CH), 117.7 (CH2), 70.3 (CH), 40.2 
(CH2), 19.4 (CH3) ppm.  
4.2.32 6-Methyl-5,6-dihydro-2H-pyran-2-one (169) 
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To a solution of pent-4-en-2-ylacrylate (290 mg, 2.07 mmol) in anhydrous 
dichloromethane (41.4 mL), Hoveyda-Grubbs II catalyst (13 mg, 0.021 
mmol) was added and stirred under reflux for 4 hours. Then, it was 
cooled to room temperature and concentrated in vacuo. The residue was 
purified by flash column chromatography on silica gel to achieve 169 as 
pale yellow oil (60 mg, 0.54 mmol, 26%).   
TLC (hexane/ethyl acetate = 1:1) Rf = 0.2. IR (ATR) 𝑣 = 2981 (w), 2937 
(w), 2906 (w), 1715 (s), 1389 (m), 1245 (s), 1167 (w), 1107 (m), 1051 (s), 
995 (w), 925 (m), 886 (w), 848 (m), 813 (s), 700 (w), 662 (m) cm
-1
. UV-
Vis (CH2Cl2) max (log ) 228 (4.08) nm. MS (EI, 70 eV): m/z (%) = 112 
(3) [M]
+
, 97 (13), 69 (19), 68 (100), 53 (5), 43 (16), 42 (15), 41 (20), 40 
(32), 39 (45), 38 (9), 38 (4). GC (HP-5): I = 1074. (BPX-5): I = 1100. 
1
H 
NMR (400 MHz, CDCl3, TMS): δ = 6.84-6.79 (m, 1H, CH), 5.97-5.94 (m, 
1H, CH), 4.53-4.49 (m, 1H, CH), 2.31-2.24 (m, 2H, CH2), 1.38 (d, 
3
JH,H = 
6.3 Hz, 3H, CH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 164.5 (C), 
144.9 (CH), 121.2 (CH), 74.3 (CH), 30.9 (CH2), 20.7 (CH3) ppm. HRMS-
ESI: calcd. for C6H8O2 112.0524; found 112.0524 [M]
+
.  
4.2.33 6-Nonyl-2H-pyran-2-one (171) 
 
Propiolic acid (49 mg, 0.7 mmol) was added to a solution of 1-Undecyne 
(106 mg, 0.7 mmol) and chloro(triphenylphosphine)gold (I) catalyst (4 mg, 
0.01 mmol) in anhydrous dichloromethane (4 mL) in a sealed tube. Then, 
silver trifluoromethanesulfonate (2 mg, 0.01 mmol) was added and the 
tube was closed instantly. After that, it was heated to 50 °C for 15 hours. 
The solvent was evaporated and the residue was purified over column 
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chromatography on silica gel to obtain 6-nonyl-2H-pyran-2-one 171 (46 
mg, 0.12 mmol, 30%) as colourless oil. 
TLC (hexane/ethyl acetate = 15:1) Rf = 0.12. IR (ATR) 𝑣 = 2923 (s), 2853 
(m), 1726 (s), 1633 (m), 1557 (s), 1464 (m), 1397 (w), 1377 (w), 1354 
(w), 1266 (w), 1172 (w), 1085 (m), 979 (w), 892 (w), 852 (w), 796 (s), 
722 (m), 548 (w), 491 (w) cm
-1
. UV-Vis (CH2Cl2) max (log ) 300 (4.65), 
217 (4.39) nm. MS (EI, 70 eV): m/z (%) = 222 (14) [M]
+
, 137 (20), 123 
(37), 110 (47), 96 (13), 95 (100), 94 (17), 82 (49), 81 (45), 69 (11), 67 
(16), 55 (23), 53 (18), 43 (32), 41 (52), 39 (67). GC (HP-5): I = 1889. 
(BPX-5): I = 1905. 
1
H NMR (400 MHz, CDCl3, TMS): δ = 7.21-7.17 (m, 
1H, CH), 6.09-6.07 (dd, 
4
JH,H = 0.5 Hz, 
3
JH,H = 9.3 Hz, 1H, CH), 5.91-5.89 
(dd, 
4
JH,H = 0.8 Hz, 
3
JH,H = 6.6 Hz, 1H, CH), 2.40 (t,
 3
JH,H = 7.6 Hz, 2H, 
CH2), 1.59 (dt, 
3
JH,H = 7.5, 15 Hz, 2H, CH2), 1.28-1.19 (m, 12H, 6 x CH2), 
0.81 (t, 
3
JH,H = 6.9 Hz, 3H, CH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): 
δ = 166.8 (C), 162.9 (C), 143.7 (CH), 113.0 (CH), 102.6 (CH), 33.8 (CH2), 
31.8 (CH2), 29.4 (CH2), 29.2 (2x CH2), 28.9 (CH2), 26.9 (CH2), 22.6 (CH2), 
14.1 (CH3) ppm. HRMS-ESI: calcd. for C14H22O2 222.1620; found 
222.1620 [M]
+
.  
4.2.34 2-Nonylfuran (180) 
 
To a solution of furan (500 mg, 7.3 mmol) in anhydrous THF (25 mL), a 
solution of n-BuLi (1.6 M in hexane, 4.6 mL, 7.30 mmol) was added 
dropwise at -78 °C and stirred for 30 minutes. Then, a solution of 1-
bromo nonane (1.54 g, 7.03 mmol) in dry THF (2 mL) was added. It was 
stirred at room temperature for another 3 hours. Distilled water (4 mL) 
was added and the reaction mixture was extracted with diethyl ether. The 
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collected organic layers were dried over MgSO4, concentrated in vacuo 
and purified by flash column chromatography on silica gel to yield 2-
nonylfuran 180 (757 mg, 3.90 mmol, 53%) as colourless oil.  
TLC (hexane) Rf = 0.51. IR (ATR) 𝑣 = 2924 (m), 2854 (m), 1597 (w), 
1507 (w), 1464 (w), 1379 (w), 1146 (w), 1077 (w), 1006 (w), 924 (w), 885 
(w), 794 (w), 723 (s), 599 (w) cm
-1
. UV-Vis (CH2Cl2) max (log ) 277 
(2.85), 229 (4.56) nm. MS (EI, 70 eV): m/z (%) = 194 (13) [M]
+
, 151 (6), 
137 (6), 123 (8), 96 (7), 95 (7), 94 (8), 82 (35), 81 (100), 67 (6), 55 (5), 
53 (12), 43 (8), 41 (12), 39 (5). GC (HP-5): I = 1397. (BPX-5): I = 1399. 
1
H NMR (400 MHz, CDCl3, TMS): δ = 7,29 (dd, 
3
JH,H = 0.9 Hz, 1.9 Hz, 1H, 
CH), 6.27 (dd, 
3
JH,H = 1.9, 3.1 Hz, 1H, CH), 5.97-5.96 (m, 1H, CH), 2.61 
(t, 
3
JH,H = 7.6 Hz, 2H, CH2), 1.66-1.59 (m, 2H, CH2), 1.35-1.24 (m, 12H, 6 
x CH2), 0.89-0.86 (m, 3H, CH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): 
δ = 156.7 (CH), 140.6 (C), 110.0 (CH), 104.5 (CH), 31.9 (CH2), 29.5 
(CH2), 29.4 (CH2), 29.3 (CH2), 29.2 (CH2), 28.1 (CH2), 28.0 (CH2), 22.7 
(CH2), 14.1 (CH3) ppm. HRMS-ESI: calcd. for C13H22O 194.1671; found 
194.1667 [M]
+
.  
4.2.35 5-Hydroxy-2-methyl-4H-chromen-4-one (214) and 3-acetyl-5-
hydroxy-2-methyl-4H-chromen-4-one (220) 
To a solution of 1-(2,6-dihydroxyphenyl)ethanone (304 mg, 2.0 mmol) in 
acetone (10 mL), potassium carbonate (1.38 g, 10.0 mmol) was added 
and stirred at room temperature for 15 minutes. Then, acetyl chloride 
(157 mg, 2.0 mmol) was added and stirred under reflux for 24 hours. It 
was cooled to room temperature, washed with distilled water, extracted 
with diethyl ether. The collected organic phases were dried over MgSO4, 
concentrated in vacuo and purified by flash column chromatography over 
silica gel to afford 5-hydroxy-2-methyl-4H-chromen-4-one 214 (37 mg, 
0.21 mmol, 11%) as yellow solid and side product 3-acetyl-5-hydroxy-2-
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methyl-4H-chromen-4-one 220 (154 mg, 0.71 mmol, 35%) as yellow 
solid.  
 
TLC (hexane/ethyl acetate/toluene = 3:1:1) Rf = 0.36. IR (ATR) ?̃? = 3075 
(w), 2970 (w), 2930 (w), 2850 (w), 2781 (w), 1664 (s), 1622 (s), 1596 (s), 
1465 (m), 1404 (s), 1377 (s), 1305 (s), 1250 (s), 1228 (s), 1183 (m), 
1158 (m), 1110 (m), 1061 (m), 1002 (m), 953 (s), 867 (m), 838 (m), 799 
(s), 745 (s),  741 (m), 681 (m), 617 (m), 587 (s) cm
-1
. UV-Vis (CH2Cl2) 
max (log ) 325 (4.64), 253 (5.08), 230 (5.30) nm. MS (EI, 70 eV): m/z 
(%) = 177 (12) [M+H]
+
, 176 (100), 148 (32), 147 (26), 136 (22), 108 (37), 
91 (10), 39 (12). GC (HP-5): I = 1640. (BPX-5): I = 1592. 
1
H NMR (400 
MHz, CDCl3, TMS): δ = 12.54 (s, 1H, OH), 7.48 (t, 
3
JH,H = 8.3 Hz, 1H, 
CH), 6.84 (dd, 
4
JH,H = 0.9 Hz, 
3
JH,H = 8.5 Hz, 1H, CH), 6.76 (dd, 
4
JH,H = 
0.9 Hz, 
3
JH,H = 8.3 Hz, 1H, CH), 6.09 (s, 1H, CH), 2.38 (s, 3H, CH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 183.6 (C), 167.7 (C), 160.9 (C), 
156.9 (C), 135.2 (CH), 111.3 (CH), 110.6 (C), 109.3 (CH), 106.9 (CH), 
20.8 (CH3) ppm. HRMS-ESI: calcd. for C10H8O3 176.0473; found 
176.0472 [M]
+
.  
 
TLC (hexane/ethyl acetate/toluene = 3:1:1) Rf = 0.33. IR (ATR) ?̃? = 3073 
(w), 2965 (w), 2925 (w), 2851 (w), 1692 (s), 1642 (s), 1601 (s), 1503 (m), 
1469 (s), 1409 (s), 1376 (m), 1348 (m), 1296 (s), 1213 (s), 1164 (m), 
1129 (m), 1078 (m), 1057 (m), 1036 (m), 994 (m), 953 (m), 881 (m), 861 
(m), 812 (s), 756 (s),  707 (s), 650 (m), 634 (m), 593 (m), 531 (m) cm
-1
. 
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UV-Vis (CH2Cl2) max (log ) 328 (4.65), 241 (5.17), 228 (5.19) nm. MS 
(EI, 70 eV): m/z (%) = 219 (11) [M+H]
+
, 218 (88), 204 (13), 203 (100), 
137 (53), 136 (17), 108 (21), 67 (26), 43 (23), 39 (13). GC (HP-5): I = 
1800. (BPX-5): I = 1839. 
1
H NMR (400 MHz, CDCl3, TMS): δ = 12.42 (s, 
1H, OH), 7.52 (t, 
3
JH,H = 8.4 Hz, 1H, CH), 6.86 (dd, 
4
JH,H = 0.9 Hz, 
3
JH,H = 
8.4 Hz, 1H, CH), 6.80 (d, 
4
JH,H = 0.9 Hz, 
3
JH,H = 8.3 Hz, 1H, CH), 6.09 (s, 
1H, CH), 2.62 (s, 3H, CH3), 2.52 (s, 3H, CH3) ppm. 
13
C NMR (100 MHz, 
CDCl3, TMS): δ = 199.3 (C), 181.5 (C), 170.4 (C), 161.1 (C), 155.7 (C), 
135.9 (CH), 122.3 (C), 112.2 (CH), 110.5 (CH), 106.9 (CH), 32.4 (CH3), 
20.2 (CH3) ppm. HRMS-ESI: calcd. for C12H10O4 218.0579; found 
218.0579 [M]
+
.  
4.2.36 3-Methylchroman-4-one (215)  
To a solution of diisopropylamine (202 mg, 2.0 mmol) in anhydrous THF 
(5.0 mL), n-BuLi (1.25 mL, 2.0 mmol, 1.6 M in Hexane) was added at 0 
°C and stirred at this temperature for 1 hour, then cooled to - 78 °C. 4-
Chromanone (296 mg, 2.0 mmol) in anhydrous THF (1.0 mL) was put in 
and maintained this temperature for 1 hour. After that, methyl iodide (284 
mg, 2.0 mmol) was added to the reaction mixture and stirred at -78 °C for 
1 hour and maintained at 0 °C overnight. It was washed with saturated 
NH4Cl aqueous solution, extracted with ethyl acetate, dried over MgSO4, 
concentrated in vacuo and purified by flash column chromatography on 
silica gel to provide 3-methylchroman-4-one 215 as colourless oil (100 
mg, 0.62 mmol, 31%) and 3,3-dimethylchroman-4-one (81 mg, 0.46 
mmol, 23 %) as colourless oil as well.  
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TLC (cyclohexane/ethyl acetate = 5:1) Rf = 0.4. IR (ATR) 𝑣 = 2971 (w), 
2932 (w), 2875 (w), 1687 (m), 1604 (m), 1579 (w), 1477 (m), 1467 (m), 
1454 (m), 1386 (w), 1386 (m), 1323 (m), 1294 (m), 1247 (m), 1209 (m), 
1147 (m), 1128 (w), 1104 (w), 1071 (m), 1037 (m), 1013 (m), 970 (m), 
960 (m), 940 (w), 895 (w), 825 (m), 772 (m), 753 (s), 691 (m), 676 (w), 
650 (w), 576 (w), 533 (m), 518 (w), 436 (w) cm
-1
. UV-Vis (CH2Cl2) max 
(log ) 320 (3.70), 251 (4.09), 214 (4.27) nm. MS (EI, 70 eV): m/z (%) = 
163 (10) [M+H]
+
, 162 (94), 121 (18), 120 (100), 93 (7), 92 (90), 77 (4), 76 
(4), 65 (7), 64 (18), 63 (16), 50 (4), 39 (9). GC (HP-5MS): I = 1367. 
1
H 
NMR (500 MHz, CDCl3): δ = 7.89 (dd, 
4
JH,H = 1.8 Hz, 
3
JH,H = 7.8 Hz, 1H, 
CH), 7.45 (ddd, 
4
JH,H = 1.8 Hz, 
3
JH,H = 8.3, 7.2 Hz, 1H, CH), 7.00 (ddd, 
4
JH,H = 1.1 Hz, 
3
JH,H = 8.0, 7.2 Hz, 1H, CH), 6.95 (dd,
 4
JH,H = 1.0 Hz, 
3
JH,H 
= 8.4 Hz, 1H, CH2), 4.49 (dd, 
3
JH,H = 11.3, 5.1 Hz, 1H, CH2), 4.14 (t, 
3
JH,H 
= 11.1 Hz, 1H), 2.85 (m, 1H, CH), 1.21 (d, 
3
JH,H = 7.0 Hz, 3H, CH3) ppm. 
13
C NMR (125 MHz, CDCl3): δ = 194.9 (C), 161.8 (C), 136.9 (CH), 127.5 
(CH), 121.5 (CH), 120.7 (C), 117.8 (CH), 72.3 (CH2), 40.8 (CH), 10.8 
(CH3) ppm. HRMS-ESI: calcd. for C10H10O2 162.0681; found 162.0681 
[M]
+
.  
 
TLC (cyclohexane/ethyl acetate = 5:1) Rf = 0.49. IR (ATR) ?̃? = 3069 (w), 
2966 (w), 2929 (w), 2869 (w), 1687 (m), 1605 (m), 1580 (w), 1476 (m), 
1464 (m), 1453 (m), 1392 (w), 1362 (w), 1314 (m), 1277 (m), 1256 (w), 
1240 (w), 1209 (m), 1182 (w), 1146 (m), 1105 (m), 1035 (m), 992 (w), 
950 (m), 931 (w), 865 (w), 818 (w), 789 (w), 757 (m), 699 (m), 658 (w), 
574 (w), 525 (m), 473 (w), 451 (w), 431 (w) cm
-1
. UV-Vis (CH2Cl2) max 
(log ) 318 (2.68), 251 (3.08), 214 (3.48) nm. MS (EI, 70 eV): m/z (%) = 
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177 (4) [M+H]
+
, 176 (37), 161 (7), 121 (19), 120 (100), 92 (33), 65 (4), 64 
(6), 63 (5), 39 (4). GC (HP-5MS): I = 1365. 
1
H NMR (500 MHz, CDCl3): δ 
=  7.90 (dd, 
4
JH,H = 1.8 Hz, 
3
JH,H = 7.8 Hz, 1H, CH), 7.46 (ddd, 
4
JH,H = 1.8 
Hz, 
3
JH,H = 8.4, 7.1 Hz, 1H, CH), 7.01 (ddd,
 4
JH,H =  1.1 Hz, 
3
JH,H = 8.1, 7.2 
Hz, 1H, CH), 6.95 (dd, 
4
JH,H = 1.0 Hz, 
3
JH,H = 8.4 Hz, 1H, CH), 4.14 (s, 2H, 
CH2), 1.20 (s, 6H, 2 x CH3) ppm. 
13
C NMR (125 MHz, CDCl3): δ = 197.4 
(C), 161.3 (C), 135.7 (CH), 127.9 (CH), 121.6 (CH), 119.7 (C), 117.8 
(CH), 76.8 (CH2), 41.8 (C), 20.6 (2 x CH3) ppm. HRMS-ESI: calcd. for 
C11H12O2 176.0837; found 176.0838 [M]
+
.  
4.2.37 Preparation of methoxy-methyl-benzaldehydes 
To a solution of  the  hydroxy-methyl-benzaldehyde (34 mg, 0.25 mmol) 
in anhydrous DMF (6.0 mL), K2CO3 (35 mg, 0.25 mmol) was added and  
the mixture was  stirred at room temperature for 30 minutes. Then, 
methyl iodide (30 L, 68 mg, 0.5 mmol) was added and  the  reaction 
was stirred  at room temperature overnight.  The reaction  was quenched  
by the addition of  distilled water,  and the aqueous phase was  extracted 
three times  with ethyl acetate. The combined organic phases were dried 
with MgSO4 and concentrated in vacuo. The residue was purified by  
column chromatography on silica gel. 
2-Methoxy-3-methylbenzaldehyde 
 
Yield: 26 mg (0.17 mmol, 69%), colourless  oil.  
TLC (cyclohexane/ethyl acetate = 10:1) Rf = 0.18. (UV) MS (EI, 70 eV) 
m/z (%) 150 (100) [M]+, 149 (31), 135 (29), 134 (10), 133 (49), 132 (52), 
121 (10), 119 (12), 118 (10), 105 (26), 104 (18), 91 (47), 90 (26), 89 (18), 
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78 (13), 77 (26). GC (HP-5MS): I = 1265. 1H NMR (400 MHz, CDCl3, 
TMS): δ = 10.38 (d, 4JH,H = 0.8 Hz, 1H, CHO), 7.68 (dd, 
3
JH,H = 7.7 Hz, 
4
JH,H = 1.7 Hz, 1H, CH), 7.51-7.40 (m, 1H, CH), 7.13 (t, 
3
JH,H = 7.6 Hz, 
1H, CH), 3.88 (s, 3H, OCH3), 2.34 (s, 3H, CH3) ppm. 
13
C NMR (100 MHz, 
CDCl3, TMS): δ = 190.4 (CHO), 161.9 (C), 137.7 (CH), 132.4 (C), 129.3 
(C), 126.6 (CH), 124.5 (CH), 63.2 (OCH3), 15.6 (CH3) ppm.  
2-Methoxy-5-methylbenzaldehyde 
 
Yield: 33 mg (0.22 mmol, 89%), colourless oil. 
TLC (cyclohexane/ethyl acetate = 10:1) Rf = 0.15. (UV) MS (EI, 70 eV) 
m/z (%) 150 (100) [M]+, 149 (38), 135 (14), 133 (26), 132 (20), 121 (10), 
118 (10), 105 (18), 104 (17), 91 (33), 90 (13), 89 (13), 77 (19). GC (HP-
5MS): I = 1352. 1H NMR (400 MHz, CDCl3, TMS): δ = 10.43 (d, 
4
JH,H = 
0.7 Hz, 1H, CHO), 7.61 (d, 
4
JH,H = 2.4 Hz, 1H, CH), 7.34 (dd, 
3
JH,H = 8.5 
Hz, 
4
JH,H = 2.4 Hz, 1H, CH), 6.88 (t, 
3
JH,H = 8.5 Hz, 1H, CH), 3.89 (s, 3H, 
OCH3), 2.30 (s, 3H, CH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 
190.1 (CHO), 160.1 (C), 136.7 (CH), 130.1 (C), 128.7 (CH), 124.6 (C), 
111.7 (CH), 55.8 (OCH3), 20.3 (CH3) ppm.  
2-Methoxy-4-methylbenzaldehyde (198) 
 
Yield: 35 mg (0.23 mmol, 91%), white solid. 
 
 
204 
 
TLC (cyclohexane/ethyl acetate = 10:1) Rf = 0.18. (UV) MS (EI, 70 eV) 
m/z (%) 150 (100) [M]+, 149 (60), 135 (11), 133 (39), 132 (26), 118 (28), 
105 (21), 104 (15), 91 (37), 90 (15), 89 (13), 77 (15). GC (HP-5MS): I = 
1372. 1H NMR (400 MHz, CDCl3, TMS): δ = 10.38 (s, 1H, CHO), 7.71 (d, 
3
JH,H = 7.8 Hz, 1H, CH), 6.84-6.80 (m, 1H, CH), 6.77 (s, 1H, CH), 3.90 (s, 
3H, OCH3), 2.40 (s, 3H, CH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ 
= 189.6 (CHO), 162.0 (C), 147.5 (C), 128.7 (CH), 122.8 (C), 121.8 (CH), 
112.3 (CH), 55.7 (OCH3), 22.4 (CH3) ppm.  
4-Methoxy-3-methylbenzaldehyde 
 
Yield: 32 mg (0.21 mmol, 84%), white solid. 
TLC (cyclohexane/ethyl acetate = 10:1) Rf = 0.15. (UV) MS (EI, 70 eV) 
m/z (%) 150 (69) [M]+, 151 (6), 149 (100), 121 (7), 106 (3), 91 (17), 89 
(2), 78 (3), 77 (8), 65 (2). GC (HP-5MS): I = 1366. 1H NMR (400 MHz, 
CDCl3, TMS): δ = 9.84 (s, 1H, CHO), 7.70 (dd, 
3
JH,H = 8.4 Hz, 
4
JH,H = 2.2 
Hz, 1H, CH), 7.67 (dd, 
4
JH,H = 2.2, 1.0 Hz, 1H, CH), 6.91 (d, 
3
JH,H = 8.4 
Hz, 1H, CH), 3.90 (s, 3H, OCH3), 2.25 (s, 3H, CH3) ppm. 
13
C NMR (100 
MHz, CDCl3, TMS): δ = 191.3 (CHO), 163.0 (C), 131.6 (CH), 130.8(CH), 
129.6 (C), 127.8 (C), 109.8 (CH), 55.8 (OCH3), 16.3 (CH3) ppm.  
4-Methoxy-2-methylbenzaldehyde 
 
Yield: 32 mg (0.21 mmol, 84%), yellow oil. 
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TLC (cyclohexane/ethyl acetate = 10:1) Rf = 0.18. (UV) MS (EI, 70 eV) 
m/z (%) 150 (65) [M]+, 151 (6), 149 (100), 122 (3), 121 (17), 106 (2), 91 
(12), 89 (2), 78 (4), 77 (9), 63 (2), 51 (3). GC (HP-5MS): I = 1368. 1H 
NMR (400 MHz, CDCl3, TMS): δ = 10.38 (s, 1H, CHO), 7.75 (d, 
3
JH,H = 
8.5 Hz, 1H, CH), 6.84 (dd, 
3
JH,H = 8.5 Hz, 
4
JH,H = 2.5 Hz 1H, CH), 6.76-
6.73 (m, 1H, CH), 3.86 (s, 3H, OCH3), 2.65 (s, 3H, CH3) ppm. 
13
C NMR 
(100 MHz, CDCl3, TMS): δ = 191.3 (CHO), 163.8 (C), 143.4 (C), 134.9 
(CH), 128.1 (C), 117.1 (CH), 111.6 (CH), 55.6 (OCH3), 20.0 (CH3) ppm.  
3-Methoxy-4-methylbenzaldehyde 
 
Yield: 35 mmol (0.23 mmol, 91%), white solid. 
TLC (cyclohexane/ethyl acetate = 10:1) Rf = 0.18. (UV) MS (EI, 70 eV) 
m/z (%) 150 (100) [M]+, 151 (9), 149 (89), 135 (4), 122 (4), 121 (22), 106 
(4), 91 (25), 89 (3), 79 (3), 78 (5), 77 (13), 65 (4), 51 (3), 44 (3). GC (HP-
5MS): I = 1307. 1H NMR (400 MHz, CDCl3, TMS): δ = 9.92 (s, 1H, CHO), 
7.36 (dd, 
3
JH,H = 7.5 Hz, 
4
JH,H = 1.5 Hz, 1H, CH), 7.33 (d, 
4
JH,H = 1.4 Hz, 
1H, CH), 7.29 (dd, 
3
JH,H = 7.3 Hz, 
4
JH,H = 1.0 Hz, 1H, CH), 3.89 (s, 3H, 
OCH3), 2.29 (s, 3H, CH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 
192.1 (CHO), 158.5 (C), 136.0 (C), 135.0 (C), 131.0 (CH), 124.6 (CH), 
108.0 (CH), 55.6 (OCH3), 17.0 (CH3) ppm.  
3-Methoxy-2-methylbenzaldehyde 
 
Yield: 27 mg (0.18 mmol, 72%), yellow oil.  
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TLC (cyclohexane/ethyl acetate = 10:1) Rf = 0.24. (UV) MS (EI, 70 eV) 
m/z (%) 150 (100) [M]+, 151 (9), 149 (40), 135 (5), 121 (15), 120 (12), 
119 (10), 107 (8), 105 (8), 91 (39), 79 (7), 78 (7), 77 (20), 51 (5). GC 
(HP-5MS): I = 1335. 1H NMR (400 MHz, CDCl3, TMS): δ = 10.64 (d, 
4
JH,H 
= 0.6 Hz, 1H, CHO), 7.37 (dd, 
3
JH,H = 8.4, 7.6 Hz, 1H, CH), 6.83 (d, 
3
JH,H 
= 8.4 Hz, 1H, CH), 6.79 (dq, 
3
JH,H = 7.6 Hz, 
4
JH,H = 0.8 Hz, 1H, CH), 3.89 
(s, 3H, OCH3), 2.56 (s, 3H, CH3) ppm. 
13
C NMR (100 MHz, CDCl3, TMS): 
δ = 192.4 (CHO), 163.4 (C), 142.1 (C), 134.6 (CH), 124.2 (CH), 123.5 
(C), 109.2 (CH), 55.9 (OCH3), 21.6 (CH3) ppm.  
3-Methoxy-5-methylbenzaldehyde 
 
Yield: 28 mg (0.19 mmol, 75%), yellow oil. 
TLC (cyclohexane/ethyl acetate = 10:1) Rf = 0.23. (UV) MS (EI, 70 eV) 
m/z (%) 150 (100) [M]+, 151 (9), 149 (85), 122 (5), 121 (33), 119 (3), 106 
(3), 105 (2), 92 (2), 91 (16), 89 (2), 79 (3), 78 (4), 77 (10), 65 (3), 63 (2), 
51 (2). GC (HP-5MS): I = 1313. 1H NMR (400 MHz, CDCl3, TMS): δ = 
9.95 (s, 1H, CHO), 7.29 (tt, 
4
JH,H = 1.7, 0.7 Hz, 1H, CH), 7.22 (dd, 
4
JH,H = 
2.6, 1.3 Hz, 1H, CH), 7.01 (ddd, 
4
JH,H = 2.4, 1.5, 0.8 Hz, 1H, CH), 3.86 (s, 
3H, OCH3), 2.42 (d, 
4
JH,H = 0.9 Hz, 3H, CH3) ppm. 
13
C NMR (100 MHz, 
CDCl3, TMS): δ = 192.5 (CHO), 160.3 (C), 140.5 (C), 137.9 (C), 124.5 
(CH), 122.3 (CH), 109.6 (CH), 55.6 (OCH3), 21.3 (CH3) ppm.  
5-Methoxy-2-methylbenzaldehyde 
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Yield: 21 mg (0.14 mmol, 56%), colourless oil. 
TLC (cyclohexane/ethyl acetate = 10:1) Rf = 0.19. (UV) MS (EI, 70 eV) 
m/z (%) 150 (100) [M]+, 151 (9), 149 (45), 135 (4), 122 (9), 121 (68), 119 
(2), 107 (7), 106 (2), 92 (2), 91 (13), 89 (3), 79 (4), 78 (6), 77 (14), 65 (3), 
63 (2), 51 (3). GC (HP-5MS): I = 1323. 1H NMR (400 MHz, CDCl3, TMS): 
δ = 10.27 (s, 1H, CHO), 7.32 (d, 4JH,H = 2.9 Hz, 1H, CH), 7.16 (d, 
3
JH,H = 
8.2 Hz, 
4
JH,H = 0.9 Hz, 1H, CH), 7.04 (dd, 
3
JH,H = 8.4 Hz, 
4
JH,H = 2.9 Hz, 
1H, CH), 3.88 (s, 3H, OCH3), 2.60 (s, 3H, CH3) ppm. 
13
C NMR (100 MHz, 
CDCl3, TMS): δ = 192.2 (CHO), 158.2 (C), 134.8 (C), 133.1 (C), 132.9 
(CH), 120.9 (CH), 114.2 (CH), 55.6 (OCH3), 18.2 (CH3) ppm.  
2-Methoxy-6-methylbenzaldehyde 
 
Yield: 27 mg (0.18 mmol, 72%), white solid.   
TLC (cyclohexane/ethyl acetate = 10:1) Rf = 0.29. (UV) MS (EI, 70 eV) 
m/z (%) 150 (100) [M]+, 151 (10), 149 (47), 135 (16), 134 (6), 133 (27), 
132 (13), 119 (5), 118 (15), 105 (13), 104 (7), 91 (30), 90 (19), 89 (12), 
79 (6), 78 (9), 77 (14). GC (HP-5MS): I = 1335. 1H NMR (400 MHz, 
CDCl3, TMS): δ = 10.64 (d, 
4
JH,H = 0.6 Hz, 1H, CHO), 7.37 (dd, 
3
JH,H = 
8.4, 7.6 Hz, 1H, CH), 6.83 (d, 
3
JH,H = 8.4 Hz, 1H, CH), 6.79 (dq, 
3
JH,H = 
7.6 Hz, 
4
JH,H = 0.8 Hz, 1H, CH), 3.89 (s, 3H, OCH3), 2.56 (s, 3H, CH3) 
ppm. 
13
C NMR (100 MHz, CDCl3, TMS): δ = 192.4 (CHO), 163.3 (C), 
142.1 (C), 134.6 (CH), 124.2 (CH), 123.5 (C), 109.2 (CH), 55.9 (OCH3), 
21.6 (CH3) ppm.  
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4.2.38 (S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-
hydroxypropanoate (264) 
 
To a solution of L-serine (15.85 g, 0.15 mol) in 1N sodium hydroxide 
aqueous solution (320 mL), a solution of di-tert-butyl dicarbonate (39.2 g, 
0.18 mol) in 1,4-dioxane (140 mL) was added at 0 °C and stirred 30 
minutes at this temperature. Then, it was warmed to room temperature 
and stirred for another 3.5 hours. The reaction mixture was cooled in an 
ice bath, acidified to pH 2-3 by addition of 1N potassium bisulfate. The 
aqueous phase was extracted with ethyl acetate. The combined organic 
phases were dried over MgSO4, concentrated under reduced pressure 
using a rotary evaporator and used for next step without purification.  
To a solution of N-Boc-L-serine (0.15 mol) in dimethylformamide (140 
mL), potassium carbonate (22.78 g, 0.165 mol) was added at 0 °C and 
stirred for 10 minutes. Then, methyl iodide (18.68 mL, 42.6 g, 0.3 mol) 
was added dropwise at 0 °C and stirred another 30 minutes at this 
temperature. The reaction was allowed to warm to room temperature and 
stirred overnight.The reaction mixture was filtered and washed with ethyl 
acetate and distilled water. The collected organic layers were washed 
with brine, dried over MgSO4, concentrated under reduced pressure 
using a rotary evaporator and purified by flash column chromatography 
on silica gel to afford 264 (28.87 g. 0.13 mol, 90% over two steps) as 
pale oil.  
TLC (cyclohexane/ethyl acetate = 1:1) Rf =0.38. UV-Vis (EtOH) max (log 
) 201 (3.13) nm. IR (ATR) ?̃? = 3390 (m), 2977 (w), 1688 (s), 1506 (m), 
1456 (m), 1438 (w), 1392 (w), 1366 (m), 1349 (w), 1284 (m), 1209 (m), 
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1158 (s), 1058 (m), 1029 (m), 921 (w), 872 (w), 851 (w), 810 (w), 779 
(w), 759 (w), 528 (w), 461 (w) cm
-1
. 
1
H NMR (400 MHz, CDCl3): δ = 5.60-
5.45 (m, 1H, NH), 4.35 (s, 1H, CH2), 3.90 (qd, 
3
JH,H = 11.2, 3.8 Hz, 2H, 
CH, CH2), 3.76 (s, 3H, CH3), 2.61 (s, 1H, OH), 1.43 (s, 9H, 3 x CH3) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 171.5(C), 155.9 (C), 80.4 (C), 63.5 
(CH2), 55.8 (CH), 52.7 (CH), 28.4 (3 x CH3) ppm. Optical rotation: []D
20
 
= -2.3 (c 0.5, ethanol). HRMS-ESI: calcd. for C9H17NNaO5
+
 242.0999; 
found 242.0999. 
4.2.39 (S)-3-tert-Butyl 4-methyl 2,2-dimethyloxazolidine-3,4-
dicarboxylate (265) 
 
In a 1 L three-necks round flask with reflux condenser, N-Boc-L-serine 
methyl ester 264 (28.87 g, 0.13 mol), 2,2-dimethoxypropane (34.32 g, 
0.33 mol) and p-toluenesulfonic acid monohydrate (380 mg, 2.0 mmol) in 
benzene (438 mL, 0.3 mol/L) were put in and heated at 110 °C for 4 
hours. The reaction was monitored by TLC. Then, it was cooled down, 
quenched with saturated NaHCO3 aqueous solution, extracted with 
diethyl ether. The collected organic phases were washed with birne, 
dried over MgSO4, concentrated under reduced pressure using a rotary 
evaporator and purified by flash column chromatography on silica gel to 
yield 265 (30.3 g, 0.117 mol, 89%, dr 62:38) as pale oil. 
TLC (cyclohexane/ethyl acetate = 5:1) Rf =0.3. IR (ATR) 𝑣 = 2978 (w), 
1757 (m), 1699 (s), 1479 (w), 1456 (w), 1437 (w), 1377 (s), 1364 (s), 
1250 (m), 1202 (m), 1163 (s), 1091 (s), 1066 (m), 1053 (m), 1000 (w), 
945 (w), 846 (m), 807 (w), 769 (m), 659 (w), 639 (w), 553 (w), 515 (w), 
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463 (w), 419 (w) cm
-1
. UV-Vis (EtOH) max (log ) 201 (3.17) nm. MS (EI, 
70 eV): m/z (%) = 244 (18) [M-CH3]
+
, 188 (8), 186 (13), 146 (4), 144 
(100), 128 (18), 99 (22), 86 (6), 84 (17), 83 (5), 59 (6), 58 (7), 57 (91), 56 
(10), 55 (3), 43 (6), 42 (4), 41 (16), 39 (3). GC (HP-5MS): I = 1443. 
1
H 
NMR (400 MHz, CDCl3): δ = A: 4.47 (dd, 
3
JH,H = 6.7, 2.7 Hz, 1H, CH), 
4.12 (dt, 
3
JH,H = 6.6 Hz, 
2
JH,H = 9.2 Hz, 2H, CH2), 3.74 (s, 3H, CH3), 1.65 
(s, 3H, CH3), 1.62 (s, 3H, CH3), 1.39 (s, 9H, 3 x CH3) ppm.; B: 4.36 (dd, 
3
JH,H = 7.0, 3.1 Hz, 1H, CH), 4.07-3.96 (m, 2H, CH2), 3.74 (s, 3H, CH3), 
1.62 (s, 3H, CH3), 1.51 (s, 3H, CH3), 1.48 (s, 9H, 3 x CH3) ppm. 
13
C NMR 
(100 MHz, CDCl3): δ = A: 171.8 (C), 151.3 (C), 95.2 (C), 80.4 (C), 66.4 
(CH2), 59.4 (CH), 52.4 (CH3), 28.4 (3 x CH3), 25.3 (CH3), 24.5 (CH3) 
ppm.; B: 171.39 (C), 152.2 (C), 94.5 (C), 81.0 (C), 66.1 (CH2), 59.3 (CH), 
52.5 (CH3), 28.5 (3 x CH3), 26.1 (CH3), 25.1 (CH3) ppm. Optical 
rotation: []D
20
 = -4.3 (c 0.5, ethanol). HRMS-ESI: calcd. for C11H18NO5
+
 
244.1185; found 244.1186. 
4.2.40 (R)-tert-Butyl 4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-
carboxylate (266) 
 
To a suspension of LiAlH4 (2.11 g, 56.0 mmol) in anhydrous diethyl ether 
(140 mL), methyl ester 265 (7.23 g, 28.0 mmol) in anhydrous diethyl 
ether (140 mL) was added slowly portion by portion and stirred at room 
temperature overnight. The reaction was monitored by TLC. It was 
cooled to 0 °C and quenched by slow addition of 1.5 mL distilled water, 
1.5 mL of 15% NaOH aqueous solution and  then 6 mL distilled water. 
The reaction mixture was stirred at room temperature for 1 hour, filtered 
and washed with generous diethyl ether. The collected organic phases 
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were dried over MgSO4, concentrated under reduced pressure using a 
rotary evaporator and purified by flash column chromatography on silica 
gel to afford 266 (5.25 g, 22.8 mmol, 81%) as yellow pale oil.  
TLC (cyclohexane/ethyl acetate = 3:2) Rf =0.35 (Ninhydrin Stain). IR 
(ATR) 𝑣 = 3432 (w), 2978 (w), 2936 (w), 2879 (w), 1694 (m), 1671 (m), 
1477 (w), 1457 (w), 1387 (s), 1365 (s), 1297 (w), 1257 (m), 1207 (w), 
1170 (m), 1154 (m), 1105 (m), 1086 (m), 1071 (w), 1046 (m), 957 (w), 
847 (m), 807 (w), 770 (w), 730 (m), 671 (w), 562 (w), 519 (w), 460 (w) 
cm
-1
. UV-Vis (EtOH) max (log ) 201 (2.93) nm. MS (EI, 70 eV): m/z (%) 
= 216 (24) [M-CH3]
+
, 200 (22), 160 (25), 158 (9), 144 (24), 117 (5), 116 
(78), 101 (6), 100 (85), 83 (15), 59 (16), 58 (16), 57 (100), 56 (16), 43 
(10), 42 (8), 41 (27), 39 (5). GC (HP-5MS): I = 1436. 
1
H NMR (400 MHz, 
CDCl3): δ = 4.16-3.62 (m, 5H, CH, 2 x CH2), 3.53 (s, 1H, OH), 1.5 (s, 6H, 
2 x CH3), 1.44 (s, 9H, 3 x CH3) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 
154.0 (C), 94.1 (C), 81.2 (C), 65.3 (CH2), 64.7 (CH2), 59.5 (CH), 28.5 (3 x 
CH3), 27.2 (CH3), 24.6 (CH3) ppm. Optical rotation: []D
20
 = -1.8 (c 0.9, 
ethanol). HRMS-ESI: calcd. for C10H18NO4
+
 216.1236; found 216.1238. 
4.2.41 (S)-tert-Butyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate 
(260) 
 
To a solution of oxalyl chloride (3.53 g, 28.0 mmol) in anhydrous 
dichloromethane (43 mL), dimethyl sulfoxide (4.39 g, 56.0 mmol) in 
anhydrous dichloromethane (5.4 mL) was added dropwise at -78 °C and 
stirred at this temperature for 30 minutes. Afterwards, 266 (4.31 g, 18.7 
mmol) in anhydrous dichloromethane (32 mL) was added dropwise at - 
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78 °C and stirred at this temperature for another 30 minutes. After that, 
N,N-diisopropylethylamine (14.0 g, 108.2 mmol) was added and warmed 
slowly to 0 °C. 1M HCl (70 mL) ice-cold solution was used to quench the 
reaction mixture. The aqueous phase was extracted with 
dichloromethane. The combined organic layers were washed with pH 7.7 
phosphate buffer, dried over MgSO4, concentrated under reduced 
pressure using a rotary evaporator and purified by flash column 
chromatography on silica gel to obtain 260 (3.94 g, 17.2 mmol, 92%, dr 
63:17) as colourless bright oil.  
TLC (cyclohexane/ethyl acetate = 4:1) Rf = 0.25 (Ninhydrin Stain). IR 
(ATR) 𝑣 = 2979 (w), 2936 (w), 2280 (w), 1704 (s), 1478 (w), 1457 (w), 
1365 (s), 1297 (w), 1258 (w), 1233 (w), 1165 (m), 1090 (m), 1059 (m), 
1018 (w), 950 (w), 923 (w), 847 (m), 810 (m), 771 (w), 700 (w), 562 (w), 
517 (w), 498 (s), 462 (w) cm
-1
. UV-Vis (EtOH) max (log ) 201 (3.34) nm. 
MS (EI, 70 eV): m/z (%) = 200 (8) [M-CO]
+
, 156 (7), 144 (10), 114 (9), 
101 (3), 100 (39), 98 (3), 86 (2), 84 (5), 83 (9), 70 (3), 59 (8), 58 (11), 57 
(100), 56 (8), 55 (3), 44 (3), 43 (7), 42 (5), 41 (22), 39 (5). GC (HP-5MS): 
I = 1337. 
1
H NMR (400 MHz, CDCl3): δ = A: 9.53 (d, 
3
JH,H = 2.6 Hz, 1H, 
CH), 4.41-4.14 (m, 1H, CH), 4.06 (d, 
3
JH,H = 5.2 Hz, 2H, CH2), 1.66-1.52 
(m, 6H, 2 x CH3), 1.52-1.38 (m, 12H, 3 x CH3) ppm.; B: 9.59 (d, 
3
JH,H = 
1.9 Hz, 1H, CH), 4.41-4.14 (m, 1H, CH), 4.06 (d, 
3
JH,H = 5.2 Hz, 2H, 
CH2), 1.66-1.52 (m, 6H, 2 x CH3), 1.52-1.38 (m, 9H, 3 x CH3) ppm. 
13
C 
NMR (100 MHz, CDCl3): δ = A: 199.6 (CH), 111.5 (C), 95.2(C), 81.2 (C), 
64.8 (CH), 64.1(CH2), 28.4 (3 x CH3), 25.9 (CH3), 23.9 (CH3) ppm.; B: 
199.6 (CH), 11.4 (C), 94.5 (C), 81.5 (C), 64.9 (CH), 63.5 (CH2), 28.4 (3 x 
CH3), 26.6 (CH3), 24.8 (CH3) ppm. Optical rotation: []D
20
 = -4.3 (c 0.4, 
ethanol). 
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4.2.42 (R)-tert-Butyl 2,2-dimethyl-4-vinyloxazolidine-3-carboxylate 
(267) 
 
To a suspension of methyltriphenylphosphonium bromide (24.21 g, 67.91 
mmol) in THF (590 mL), potassium bis(trimethylsilyl)amide (92.8 mL, 
65.0 mmol, 0.7 M in toluene) was added and stirred at room temperature 
for 1 hour, subsequently cooled to -78 °C and a solution of Garner’s 
aldehyde 260 (8.86 g, 38.7 mmol) in THF (118 mL) was put into the 
reaction mixture dropwise. It was warmed to room temperature slowly 
over 2 hours, then quenched with methanol (59 mL) and poured directly 
into a mixture of saturated potassium sodium tartrate and distilled water 
(1:1, 1180 mL). The aqueous phase was extracted with ethyl acetate, 
while the collected organic layers were dried over MgSO4, concentrated 
under reduced pressure using a rotary evaporator and purified by flash 
column chromatography on silica gel to generate 267 (7.46 g, 32.9 
mmol, 85%) as yellow bright oil.  
TLC (cyclohexane/ethyl acetate = 10:1) Rf = 0.32 (Ninhydrin Stain). IR 
(ATR) 𝑣 = 2979 (w), 2935 (w), 2872 (w), 1693 (s), 1478 (w), 1456 (w), 
1375 (s), 1364 (s), 1253 (m), 1206 (w), 1173 (m), 1141 (w), 1087 (s), 
1059 (m), 983 (w), 919 (w), 860 (w), 840 (w), 806 (w), 768 (w), 743 (w), 
718 (w), 670 (w), 515 (w), 462 (w) cm
-1
. UV-Vis (EtOH) max (log ) 201 
(3.10) nm. MS (EI, 70 eV): m/z (%) = 212 (18) [M-CH3]
+
, 157 (6), 156 
(78), 154 (4), 112 (36), 96 (8), 70 (15), 69 (4), 59 (8), 58 (5), 57 (100), 56 
(11), 55 (4), 53 (3), 44 (5), 43 (5), 42 (7), 41 (26), 39 (7). GC (HP-5MS): I 
= 1276. 
1
H NMR (400 MHz, CDCl3): δ = 5.91-5-59 (m, 1H, CH), 5.36-
5.01 (m, 2H, CH2), 4.49-4.20 (m, 1H, CH), 4.02 (dd, 
3
JH,H = 8.9, 6.2 Hz, 
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1H, CH2), 3.72 (dd, 
4
JH,H = 2.3 Hz, 
3
JH,H = 8.9 Hz, 1H, CH2), 1.58 (s, 6H, 2 
x CH3), 1.51-1.38 (m, 9H, 3 x CH3) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 
152.1 (C), 137.5 (CH), 115.9 (CH2), 68.2 (CH2), 59.8 (CH), 28.5 (5 x 
CH3) ppm. Optical rotation: []D
20
 = +0.9 (c 0.7, ethanol). 
4.2.43 (R)-tert-Butyl (1-hydroxybut-3-en-2-yl)carbamate (268) 
 
To a solution of vinyl oxazolidinone 267 (100 mg, 0.44 mmol) in 
methanol (4.4 mL), p-toluenesulfonic acid (42 mg, 0.22 mmol) was 
added at 0 °C, warmed to room temperature slowly and stirred overnight. 
Then, it was washed with saturated NaHCO3 aqueous solution, extracted 
with diethyl ether, dried over MgSO4, concentrated under reduced 
pressure using a rotary evaporator and purified by flash column 
chromatography on silica gel to afford 268 (62 mg, 0.36 mmol, 82%) as 
colourless oil.  
TLC (cyclohexane/ethyl acetate = 1:1) Rf = 0.35 (Ninhydrin Stain). IR 
(ATR) 𝑣 = 3334 (w), 3085 (w), 2978 (w), 2932 (w), 1683 (s), 1504 (m), 
1456 (w), 1391 (m), 1366 (m), 1248 (m), 1162 (s), 1048 (m), 990 (m), 
920 (m), 878 (m), 850 (w), 781 (w), 597 (w), 461 (w) cm
-1
. UV-Vis (EtOH) 
max (log ) 201 (2.70) nm. MS (EI, 70 eV): m/z (%) = 156 (8) [M-H2O]
+
, 
114 (8), 101 (18), 100 (46), 59 (25), 58 (5), 57 (100), 56 (90), 55 (13), 54 
(4), 44 (15), 43 (8), 42 (5), 41 (59), 40 (6), 39 (19). GC (HP-5MS): I = 
1319. 
1
H NMR (400 MHz, CDCl3): δ = 5.79 (ddd, 
3
JH,H = 17.5, 10.5, 5.3 
Hz,1H, CH), 5.32-5.16 (m, 2H, CH2), 5.01 (d, 
3
JH,H = 8.8 Hz, 1H, CH), 
4.22 (d, 
3
JH,H = 8.7 Hz, 1H, CH), 3.73-3.55 (m, 2H, CH2), 2.58 (s, 1H, 
OH), 1.43 (s, 9H, 3 x CH3) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 156.2 
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(C), 135.6 (CH), 116.6 (CH2), 80.0 (C), 65.2 (CH2), 54.8 (CH), 28.5 (3 x 
CH3) ppm. Optical rotation: []D
20
 = +1.2 (c 1.1, ethanol). 
4.2.44 (R)-4-Vinyloxazolidin-2-one (269) 
 
To a solution of 268 (0.65 g, 3.78 mmo) in anhydrous THF (75.6 mL, 
0.05 mol/L), thionyl chloride (3.6 g, 30.24 mmol) was added dropwise at 
0 °C, warmed to room temperature slowly and stirred at room 
temperature overnight. Then, the reaction mixture was concentrated 
under reduced pressure using a rotary evaporator and purified by flash 
column chromatography on silica gel to obtain 269 (350 mg, 3.1 mmol, 
82%) as colourless oil.  
TLC (cyclohexane/ethyl acetate = 1:1) Rf = 0.17 (KMnO4). IR (ATR) 𝑣 = 
3279 (m), 2987 (w), 2913 (w), 1726 (s), 1647 (w), 1542 (w), 1479 (w), 
1396 (m), 1349 (w), 1319 (w), 1228 (m), 1127 (w), 1092 (w), 1047 (m), 
1021 (m), 989 (m), 928 (m), 768 (m), 719 (m), 614 (m), 513 (m), 424 (w) 
cm
-1
. UV-Vis (EtOH) max (log ) 201 (2.89) nm. MS (EI, 70 eV): m/z (%) 
= 114 (34) [M]
+
, 87 (20), 84 (38), 70 (14), 69 (100), 59 (8), 57 (12), 56 
(74), 55 (78), 45 (16), 44 (10), 43 (66), 42 (41), 41 (11), 40 (31). GC (HP-
5MS): I = 1214. 
1
H NMR (400 MHz, CDCl3): δ = 6.23 (s, 1H, NH), 5.81 
(ddd, 
3
JH,H = 15.5, 10.1, 7.3 Hz, 1H, CH), 5.34-5.22 (m, 2H, CH2), 4.53 
(td, 
3
JH,H = 8.5, 1.9 Hz, 1H, CH), 4.44-4.43 (m, 1H, CH2), 4.05 (ddd, 
3
JH,H 
= 8.7, 6.6, 2.0 Hz, 1H, CH2) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 
160.0(C), 135.8 (CH), 118.7 (CH2), 70.1 (CH2), 55.4 (CH) ppm. Optical 
rotation: []D
20
 = +2.0 (c 0.5, ethanol). HRMS-ESI: calcd. for C5H7NO2
+
 
113.0477; found 113.0476. 
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4.2.45 4-(Oxiran-2-yl)oxazolidin-2-one (270) 
 
To a solution of olefine 269 (57 mg, 0.5 mmol) in dichloromethane (8.30 
mL), meta-chloroperoxybenzoic acid (138 mg, 0.8 mmol) was added was 
added at 0 °C and stirred at room temperature for one week and washed 
with saturated NaHCO3 aqueous solution untill mCPBA was consumed 
completely. It was extracted with diethyl ether, dried over MgSO4, 
concentrated under reduced pressure using a rotary evaporator and 
purified by flash column chromatography on silica gel to afford 270 (38 
mg, 0.3 mmol, 59%, dr 6:4) as colourless oil.  
TLC (cyclohexane/ethyl acetate = 1:2) Rf = 0.1 (KMnO4). 
1
H NMR (400 
MHz, CDCl3): δ = A: 6.76 (s, 1H, NH), 4.5 (td, 
2
JH,H = 8.9 Hz, 
3
JH,H = 2.9 
Hz, 1H, CH2), 4.28 (ddd, 
2
JH,H = 8.9 Hz, 
3
JH,H = 5.3, 3.7 Hz, 1H, CH), 3.83 
(ddt, 
3
JH,H = 10.8, 8.9, 5.3 Hz, 1H, CH), 3.87-3.75 (m, 1H, CH), 2.82 (td, 
2
JH,H = 4.3 Hz, 
3
JH,H =  1.1 Hz, 1H, CH2), 2.67 (td, 
2
JH,H = 4.6 Hz, 
3
JH,H = 
2.6 Hz, 1H, CH2) ppm.; B: 6.58 (s, 1H, NH), 4.5 (td, 
2
JH,H = 8.9 Hz, 
3
JH,H = 
2.9 Hz, 1H, CH2), 4.28 (ddd, 
2
JH,H = 8.9 Hz, 
3
JH,H = 5.3, 3.7 Hz, 1H, CH), 
3.83 (ddt, 
3
JH,H = 10.8, 8.9, 5.3 Hz, 1H, CH), 3.87-3.75 (m, 1H, CH), 2.82 
(td, 
2
JH,H = 4.3 Hz, 
3
JH,H =  1.1 Hz, 1H, CH2), 2.67 (td, 
2
JH,H = 4.6 Hz, 
3
JH,H 
= 2.6 Hz, 1H, CH2) ppm. 
13
C NMR (100 MHz, CDCl3): δ = A: 160.0 (C), 
67.3 (CH), 53.8 (CH2), 52.7 (CH2), 44.6 (CH) ppm.; B: 160.0 (C), 66.7 
(CH), 53.1 (CH2), 52.3 (CH2), 44.5 (CH) ppm. HRMS-ESI: calcd. for 
C5H7NO3
+
 129.0426; found 129.0425. 
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4.2.46 Epoxidation of Compound 267 
To a solution of olefin 267 (6.17 g, 27.19 mmol) in dichloromethane (453 
mL, 0.06 mol/L), meta-chloroperoxybenzoic acid (13.41 g, 54.38 mmol, 
70-75%) was added at 0 °C and stirred at room temperature for one 
week and washed with saturated NaHCO3 aqueous solution untill 
mCPBA was consumed completely. It was extracted with diethyl ether, 
dried over MgSO4, concentrated under reduced pressure using a rotary 
evaporator and purified by flash column chromatography on silica gel to 
afford 280 (3.48 g, 14.34 mmol, 53%) as white solid and 281 (1.74 g, 
7.16 mmol, 26%) as white solid as well.  
 
TLC (cyclohexane/ethyl acetate = 5:1) Rf = 0.29 (Ninhydrin Stain). IR 
(ATR) 𝑣 =  2979 (w), 2934 (w), 2878 (w), 1693 (s), 1478 (w), 1457 (w), 
1375 (s), 1364 (s), 1320 (w), 1298 (w), 1246 (m), 1208 (w), 1166 (m), 
1100 (w), 1083 (m), 1057 (m), 1012 (w), 968 )w), 947 (w), 906 (m), 850 
(m), 828 (m), 769 (m), 730 (w), 677 (w), 660 (w), 566 (w), 519 (w), 493 
(w), 462 (w)  cm
-1
. MS (EI, 70 eV): m/z (%) = 228 (9) [M-CH3]
+
, 208 (5), 
207 (24), 172 (11), 156 (5), 128 (57), 112 (7), 84 (7), 69 (6), 58 (6), 57 
(100), 56 (38), 55 (13), 44 (44), 43 (18), 42 (11), 41 (64), 40 (40), 39 
(21). GC (HP-5MS): I = 1462. UV-Vis (EtOH) max (log ) 201 (3.35) nm. 
1
H NMR (400 MHz, CDCl3): δ = A: 4.09-3.93 (m, 2H, CH2), 3.60-3.35 (m, 
1H, CH), 5.34-5.22 (m, 2H, CH2), 3.05-2.85 (m, 2H, CH2), 2.85-2.75 (m, 
1H, CH), 1.61 (s, 6H, 2 x CH3), 1.47 (s, 9H, 3 x CH3) ppm. B: 4.09-3.93 
(m, 2H, CH2), 3.60-3.35 (m, 1H, CH), 5.34-5.22 (m, 2H, CH2), 3.05-2.85 
(m, 2H, CH2), 2.85-2.75 (m, 1H, CH), 1.58 (s, 6H, 2 x CH3), 1.45 (s, 9H, 3 
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x CH3) ppm. 
13
C NMR (100 MHz, CDCl3): δ = A: 152.5 (C), 94.6 (C), 80.3 
(C), 66.3 (CH2), 59.2 (CH), 52.6 (CH), 48.6 (CH2), 28.6 (3 x CH3), 26.8 
(CH3), 23.3 (CH3) ppm.; B: 152.0 (C), 94.0 (C), 80.6 (C), 65.7 (CH2), 59.5 
(CH), 52.2 (CH), 48.4 (CH2), 28.5 (3 x CH3), 27.6 (CH3), 24.5 (CH3) ppm. 
Optical rotation: []D
20
 = +1.3 (c 0.3, ethanol). HRMS-ESI: calcd. for 
C11H18NO4
+
 228.1237; found 228.1237. 
  
TLC (Cyclohexane: Ethyl acetate = 5:1) Rf = 0.23 (Ninhydrin Stain). IR 
(ATR) 𝑣 = 2987 (w), 2935 (w), 2884 (w),  2884 (w), 1696 (s), 1478 (w), 
1459 (w), 1410 (w), 1376 (m), 1362 (m), 1293 (w), 1251 (w), 1230 (w), 
1211 (w), 1162 (w), 1137 (w), 1101 (w), 1084 (m), 1056 (w), 1023 (w), 
992 (w), 970 (w), 946 (w), 897 (w), 861 (w), 848 ()w), 827 (w), 806 (w), 
791 (w), 768 (m), 739 (w), 680 (w), 567 (w), 517 (w), 463 (w), 446 (w) 
cm
-1
. UV-Vis (EtOH) max (log ) 201 (3.92) nm. MS (EI, 70 eV): m/z (%) 
= 228 (14) [M-CH3]
+
, 172 (13), 170 (6), 129 (6), 128(77), 112 (8), 84 (5), 
69 (6), 59 (5), 57 (100), 56 (28), 55 (9), 44 (13), 43 (10), 42 (9), 41 (48), 
40 (5), 39 (14). GC (HP-5MS): I = 1469.
1
H NMR (400 MHz, CDCl3): δ = 
4.38-4.07 (m, 1H, CH), 3.96-3.62 (m, 2H, CH2), 3.18 (dd, 
3
JH,H = 14.1 Hz, 
2
JH,H = 8.4 Hz, 1H, CH2), 2.72 (t, 
3
JH,H = 4.4 Hz, 1H, CH), 2.62 (d, 
2
JH,H = 
8.5 Hz, 1H, CH2), 1.60-1.50 (m, 6H, 2 x CH3), 1.47 (s, 9H, 3 x CH3) ppm. 
13
C NMR (100 MHz, CDCl3): δ = A: 151.7 (C), 94.3 (C), 80.7 (C), 63.1 
(CH2), 56.5 (CH), 51.2 (CH), 44.3 (CH2), 28.5 (3 x CH3), 26.6 (CH3), 23.3 
(CH3) ppm.; B: 152.0 (C), 93.8 (C), 80.3 (C), 63.2 (CH2), 56.5 (CH), 51.2 
(CH), 44.3 (CH2), 28.5 (3 x CH3), 27.2 (CH3), 24.4 (CH3) ppm. Optical 
rotation: []D
20 
= 0.0 (c 0.1, ethanol). HRMS-ESI: calcd. for C11H18NO4
+
 
228.1237; found 228.1234. 
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4.2.47 (S)-tert-Butyl 4-((R)-2-amino-1-hydroxyethyl)-2,2-
dimethyloxazolidine-3-carboxylate (282) 
 
To 25% aqueous ammonia (107 mL), a solution of epoxide 280 (1.3 g, 
5.35 mmol) in ethanol (11 mL) was added rapidly and stirred at room 
temperature overnight. Then, a solution of aqueous 1N NaOH (214 mL) 
was put into the reaction mixture and extracted with dichloromethane. 
The collected organic phases were dried over MgSO4, concentrated 
under reduced pressure using a rotary evaporator and purified by flash 
column chromatography on silica gel to afford 282 (1.34 g, 5.14 mmol, 
96%) as white solid.  
TLC (chloroform/methanol/ammonia = 80:10:1) Rf = 0.24 (Ninhydrin 
Stain). IR (ATR) 𝑣 = 3373 (w), 3297 (w), 2979 (w), 2937 (w), 2875 (w), 
2737 (w), 1683 (s), 1588 (w), 1478 (w), 1460 (w), 1362 (s), 1311 (w), 
1284 (w), 1254 (w), 1206 (m), 1167 (w), 1146 (w), 1116 (w), 1088 (w), 
1074 (w), 1045 (w), 1035 (w), 994 (w), 978 (w), 943 (w), 920 (w), 849 
(w), 807 (w), 763 (w), 728 (w), 728 (w), 681 (w), 663 (w), 640 (w), 564 
(w), 528 (w), 483 (w), 461 (w) cm
-1
. UV-Vis (EtOH) max (log ) 201 (3.52) 
nm. 
1
H NMR (400 MHz, CDCl3): δ = 4.22-3.99 (m, 1H, CH), 3.96-3.85 
(m, 2H, CH2), 3.60-3.45 (m, 1H, CH), 2.85-2.65 (m, 4H, CH2, NH2), 1.51 
(s, 3H, CH3), 1.47 (s, 12H, 4 x CH3) ppm. 
13
C NMR (100 MHz, CDCl3): δ 
= 154.0 (C), 94.1 (C), 81.0 (C), 71.9 (CH), 65.5 (CH2), 59.5 (CH), 43.1 
(CH2), 28.5 (3 x CH3), 27.4 (CH3), 24.3 (CH3) ppm. Optical rotation: 
[]D
20
 = +0.5 (c 0.2, ethanol). 
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4.2.48 (S)-tert-Butyl 4-((R)-2-((tert-butoxycarbonyl)amino)-1-
hydroxyethyl)-2,2-dimethyloxazolidine-3-carboxylate (283) 
 
To a solution of amino alcohol 282 (2.43 g, 9.36 mmol) in 1N NaOH 
aqueous solution, a solution of di-tert-butyl dicarbonate (2.45 g, 11.23 
mmol) in 1,4-dioxane (8.8 mL) was added at 0 °C and stirred at this 
temperature for 30 minutes. Then, it was warmed to room temperature 
and stirred at room temperature overnight. It was acidified to pH 2-3 by 
addition of 1N potassium bisulfate aqueous solution, extracted with ethyl 
acetate. The combined organic phases were dried over MgSO4, 
concentrated under reduced pressure using a rotary evaporator and 
purified by flash column chromatography on silica gel to produce 283 
(3.3 g, 9.17 mmol, 95%) as white solid.  
TLC (cyclohexane/ethyl acetate = 3:1) Rf = 0.26 (Ninhydrin Stain). IR 
(ATR): 3321 (w), 3231 (w), 2974 (w), 2915 (w), 2884 (w), 1691 (m), 1666 
(m), 1552 (m), 1457 (w), 1422 (w), 1377 (m), 1362 (m), 1349 (w), 1302 
(m), 1273 (w), 1252 (m), 1170 (w), 1150 (m), 1114 (w), 1093 (w), 1080 
(m), 1066 (m), 1042 (w), 979 (w), 951 (w), 924 (w), 881 (m), 846 (w), 846 
(w), 806 (w), 789 (w), 763 (w), 726 (w), 656 (w), 578 (w), 561 (w), 525 
(w), 510 (w), 482 (w), 463 (w), 445 (w), 422 (w) cm
-1
. UV-Vis (EtOH) max 
(log ) 201 (3.62) nm. 1H NMR (400 MHz, CDCl3): δ = 5.73 (s, 1H, NH), 
4.15 (s, 1H, OH), 4.13-3.09 (m, 1H, CH), 4.03-3.89 (m, 2H, CH2), 3.69-
3.46 (m, 2H, CH2), 2.97-2.81 (m, 1H, CH), 1.51 (s, 3H, CH3), 1.48 (s, 
12H, 4 x CH3), 1.43 (s, 9H, 3 x CH3) ppm. 
13
C NMR (100 MHz, CDCl3): δ 
= 158.4 (C), 154.3 (C), 94.2 (C), 81.2 (C), 79.8 (C), 72.5 (CH), 65.1 
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(CH2), 59.1 (CH), 43.1 (CH2), 28.5 (3 x CH3), 28.4 (3 x CH3), 27.5 (CH3), 
24.3 (CH3) ppm. Optical rotation: []D
20
 = -7.1 (c 0.1, ethanol). 
4.2.49 (4S,5'R)-tert-Butyl 2,2-dimethyl-2'-oxo-[4,5'-bioxazolidine]-3-
carboxylate (278) 
 
To a solution of N-Boc amino alcohol 283 (1.26 g, 3.51 mmol) in 
anhydrous THF (35 mL), sodium hydride (168 mg, 4.21 mmol, 60% in 
mineral oil) was added and stirred under reflux for 3 hours. Then, it was 
cooled to room temperature, washed with saturated ammonium chloride 
aqueous solution, extracted with dichloromethane, dried over MgSO4, 
concentrated under reduced pressure using a rotary evaporator and 
purified by flash column chromatography on silica gel to generate 278 
(0.87 g, 3.02 mmol, 86%) as white solid.  
TLC (cyclohexane/ethyl acetate = 1:2) Rf = 0.32 (Ninhydrin Stain). IR 
(ATR) 𝑣 = 3315 (w), 3008 (w), 2972 (w), 2905 (w), 1752 (w), 1715 (m), 
1694 (m), 1477 (w), 1456 (w), 1440 (w), 1392 (w), 1362 (m), 1339 (m), 
1301 (w), 1287 (w), 1249 (w), 1233 (w), 1209 (w), 1170 (w), 1155 (w), 
1097 (w), 1052 (w), 1028 (w), 987 (w), 967 (w), 947 (w), 921 (w), 874 
(w), 784 (w), 765 (w), 748 (w), 701 (w), 653 (w), 615 (w), 566 (w), 544 
(w), 516 (w), 465 (w) cm
-1
. UV-Vis (EtOH) max (log ) 201 (3.91) nm. MS 
(EI, 70 eV): m/z (%) = 213 (8) [M-OCH3]
+
, 207 (11), 200 (28), 171 (47), 
155 (11), 144 (20), 101 (7), 100 (66), 98 (6), 87 (41), 84 (6), 83 (10), 68 
(9), 59 (7), 58 (10), 57 (100), 56 (21), 55 (7), 44 (10), 43 (8), 42 (9), 41 
(31), 39 (11). GC (HP-5MS): I = 2124. 
1
H NMR (400 MHz, CDCl3): δ = 
5.94 (s, 1H, NH), 4.80-4.55 (m, 1H, CH), 4.30-4.01 (m, 2H, CH2), 3.95 
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(dd, 
3
JH,H = 9.5, 5.5 Hz, 1H, CH), 3.80-3.49 (m, 2H, CH2), 1.54 (s, 3H, 
CH3), 1.50 (s, 3H, CH3), 1.46 (s, 9H, 3 x CH3) ppm. 
13
C NMR (100 MHz, 
CDCl3): δ = 159.7 (C), 153.4 (C), 94.4 (C), 81.2 (C), 76.3 (CH), 64.5 
(CH2), 59.0 (CH), 43.6 (CH2), 28.4 (3 x CH3), 27.7 (CH3), 24.5 (CH3) 
ppm. Optical rotation: []D
20
 = -8.8 (c 0.1, ethanol). 
4.2.50 4-(2-Fluoro-4-nitrophenyl)morpholine (275) 
 
To a solution of morpholine (21.57 g, 247.6 mmol) and N,N-
diisopropylethylamine (32 g, 247.6 mmol) in ethyl acetate (130 mL), 3.4-
difluoronitrobenzene (35.92 g, 225.8 mmol) was added slowly via an 
additional funnel.  After adding two-thirds, the reaction was warmed 
higher than 35 °C. Subsequently, it was cooled in an ice bath. The rest of 
3,4-difluoronitrobenzene was added over 30 minutes. The reaction 
mixture was warmed to room temperature and stirred at this temperature 
overnight. Then, dichloromethane (100 mL), ethyl acetate (400  mL) and 
distilled water (100 mL) were added to the reaction, in which yellow solid 
was produced. The aqueous phase was extracted with ethyl acetate. The 
collected organic layers were dried over MgSO4, concentrated under 
reduced pressure using a rotary evaporator and recrystallized from 
acetone and water to affford 4-(2-fluoro-4-nitrophenyl)morpholine 275 
(45.85 g, 202.88 mmol, 90%) as  yellow crystals. 
IR (ATR) 𝑣 = 3050 (w), 2962 (w), 2906 (w), 2878 (w), 2851 (w), 1601 (m), 
1514 (m), 1492 (m), 1466 (w), 1444 (w), 1383 (w), 1361 (w), 1324 (m), 
1272 (m), 1261 (m), 1222 (m), 1213 (m), 1122 (m), 1089 (m), 1072 (m), 
1048 (m), 1027 (m), 947 (m), 915 (m), 858 (w), 848 (w), 815 (w), 802 
(m), 745 (m), 711 (m), 653 (m), 601 (w), 575 (w), 557 (w), 534 (w), 475 
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(w), 419 (w) cm
-1
. UV-Vis (EtOH)max (log ) 354 (3.12), 201 (3.47) nm. 
MS (EI, 70 eV): m/z (%) = 227 (9) [M+H]
+
, 226 (80), 225 (11), 210 (5), 
196 (5), 169 (9), 168 (100), 167 (5), 138 (22), 122 (13), 121 (8), 102 (7), 
95 (13), 94 (7), 75 (6). GC (HP-5MS): I = 1916. 
1
H NMR (400 MHz, 
CDCl3): δ = 7.97 (ddd, 
4
JH,H = 2.6, 1.1Hz, 
3
JH,H = 9.0 Hz, 1H, CH), 7.88 
(dd, 
4
JH,H = 2.6 Hz, 
3
JH,H = 13.1 Hz, 1H, CH),  6.91 (t, 
3
JH,H = 8.8 Hz, 1H, 
CH), 3.89-3.83 (m, 4H, 2 x CH2), 3.30-3.25 (m, 4H, 2 x CH2) ppm. 
13
C 
NMR (100 MHz, CDCl3): δ = 153.2 (d, 
1
JC,F = 249.5 Hz, C), 145.6 (d, 
2
JC,F 
= 7.7 Hz, C), 131.4 (d, 
3
JC,F = 8.1 Hz, CH), 121.1 (d, 
4
JC,F = 3.0 Hz, CH), 
117.0 (d, 
3
JC,F = 3.9 Hz, CH), 112.7 (d, 
2
JC,F = 26.4 Hz, C), 66.7 (2 x CH2), 
50.0 (d, 
4
JC,F = 5.0 Hz, 2 x CH2) ppm. 
19
F NMR (400 MHz, CDCl3): δ = -
119.0 ppm.  
4.2.51 3-Fluoro-4-morpholinoaniline (72) 
 
To a solution of 4-(2-fluoro-4-nitrophenyl)morpholine (7.79 g, 34.5 mmol) 
and cobalt(II) chloride hexahydrate (16.42 g, 69.0 mmol) in methanol 
(206 mL), sodium borohydride (13.04 g, 345 mmol) was added in 
portions with stirring at 60 °C overnight. Then, 3N hydrochloric acid was 
added and extracted with diethyl ether. The combined organic layers 
were dried over MgSO4, concentrated under reduced pressure using a 
rotary evaporator and purified by flash column chromatography on silica 
gel to produce 3-fluoro-4-morpholinoaniline 72 (4.85 g, 24.7 mmol, 72%) 
as brown solid.  
TLC (cyclohexane/ethyl acetate = 1:1) Rf = 0.35 (UV). IR (ATR) 𝑣 = 3415 
(w), 3333 (w), 3229 (w), 2971 (w), 2938 (w), 2897 (w), 2864 (w), 2822 
(w), 1638 (w), 1577 (w), 1511 (m), 1478 (w), 1448 (w), 1375 (w), 1335 
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(w), 1316 (w), 1300 (w), 1271 (w), 1248 (w), 1220 (w), 1205 (w), 1160 
(w), 1108 (m), 1043 (w), 1026 (w), 961 (w), 926 (w), 915 (w), 843 (w), 
814 (w), 741 (w), 725 (w), 711 (w), 653 (w), 626 (w), 613 (w), 580 (w), 
516 (w), 495 (w), 464 (w), 431 (w) cm
-1
. UV-Vis (EtOH) max (log ) 301 
(2.79), 247 (3.57), 203 (3.74) nm. MS (EI, 70 eV): m/z (%) = 197 (61) 
[M+H]
+
, 196 (100), 195 (41), 151 (13), 139 (40), 138 (100), 137 (88), 136 
(6), 124 (25), 117 (23), 111 (6), 110 (16), 109 (11), 90 (12), 83 (33), 68 
(12), 57 (10). GC (HP-5MS): I = 1721. 
1
H NMR (400 MHz, CDCl3): δ = 
6.85-6.71 (m, 1H, CH), 6.48-6.35 (m, 2H, 2 x CH), 4.05-3.71 (m, 4H, 2 x 
CH2), 3.73-3-33 (m, 2H, NH2), 3.05-2.86 (m, 4H, 2 x CH2) ppm. 
13
C NMR 
(100 MHz, CDCl3): δ = 156.8 (d, 
1
JC,F = 245.2 Hz, C), 143.0 (d, 
2
JC,F = 
10.5 Hz, C), 131.8 (d, 
3
JC,F = 9.6 Hz, CH), 120.4 (d, 
4
JC,F = 4.4 Hz, CH), 
110.7 (d, 
3
JC,F = 3.0 Hz, CH), 104.0 (d, 
2
JC,F = 23.7 Hz, C), 67.2 (2 x CH2), 
51.8 (d, 
4
JC,F = 2.4 Hz, 2 x CH2) ppm. 
19
F NMR (400 MHz, CDCl3): δ = -
123.1 ppm.  
4.2.52 4-(2-Fluoro-4-iodophenyl)morpholine (279) 
 
To a solution of p-toluenesulfonic acid monohydrate (571 mg, 3.0 mmol) 
in acetonitrile (2.0 mL), 3-fluoro-4-morpholinoaniline (196 mg, 1.0 mmol) 
was added. Then, it was cooled to 10-15 °C, a solution of sodium nitrite 
(138 mg, 2.0 mmol) and potassium iodide (415 mg, 2.5 mmol) in distilled 
water (0.5 mL) was added slowly to the suspension and stirred for 10 
minutes. It was warmed to room temperature and stirred at room 
temperature till the starting material was completely consumed. To the 
reaction mixture, distilled water, sodium bicarbonate and sodium 
thiosulfate were added, extracted with ethyl acetate. The collected 
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organic phases were washed with distilled water and birne, dried over 
MgSO4, concentrated under reduced pressure using a rotary evaporator 
and purified by flash column chromatography on silica gel to create 4-(2-
fluoro-4-iodophenyl)morpholine 279 (297 mg, 0.97 mmol, 97%) as yellow 
solid.  
TLC (cyclohexane/ethyl acetate = 5:1) Rf = 0.39 (UV). IR (ATR) 𝑣 = 3004 
(w), 2961 (w), 2892 (w), 2851 (w), 1719 (w), 1679 (w), 1597 (w), 1558 
(w), 1487 (m), 1450 (w), 1401 (w), 1372 (w), 1333 (w), 1295 (w), 1251 
(w), 1234 (w), 1201 (w), 1165 (w), 1111 (m), 1071 (w), 1045 (w), 1030 
(w), 919 (w), 859 (w), 852 (w), 842 (w), 802 (m), 725 (w), 646 (w), 572 
(w), 496 (w), 470 (w), 422 (w) cm
-1
. MS (EI, 70 eV): m/z (%) = 309 (46) 
[M+2H]
+
, 308 (76), 307 (73), 306 (16), 250 (54), 249 (100), 248 (99), 235 
(18), 221 (14), 136 (10), 125 (25), 124 (23), 123 (50), 122 (52), 110 (13), 
109 (19), 108 (12), 103 (30), 97 (19), 96 (65), 95 (79), 94 (10), 82 (11), 
77 (15), 76 (42), 75 (11), 69 (11), 58 (28), 52 (11), 51 (13), 43 (22). GC 
(HP-5MS): I = 1819. UV-Vis (EtOH) max (log ) 255 (3.79), 201 (3.95) 
nm. 
1
H NMR (400 MHz, CDCl3): δ = 7.40-7.30 (m, 2H, 2 x CH), 6.66 (d, 
3
JH,H = 8.9 Hz, 1H, CH), 4.35-3.63 (m, 4H, 2 x CH2), 3.22-2.90 (m, 4H, 2 
x CH2) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 156.8 (d, 
1
JC,F = 251.7 Hz, 
C), 140.1 (d, 
2
JC,F = 10.5 Hz, C), 133.7 (d, 
3
JC,F = 3.7 Hz, CH), 125.3 (d, 
2
JC,F = 23.4 Hz, CH), 120.4 (d, 
3
JC,F = 3.5 Hz, CH), 83.3 (d, 
3
JC,F = 8.3 Hz, 
C), 67.0 (2 x CH2), 50.8 (d, 
4
JC,F = 3.5 Hz, 2 x CH2) ppm. 
19
F NMR (400 
MHz, CDCl3): δ = -120.3 ppm.  
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4.2.53 (4S,5'R)-tert-Butyl 3'-(3-fluoro-4-morpholinophenyl)-2,2-
dimethyl-2'-oxo-[4,5'-bioxazolidine]-3-carboxylate (293) 
 
To a solution of oxazolidinone 278 (112 mg, 0.39 mmol) in 1,4-dioxane 
(3.9 mL), 4-(2-fluoro-4-iodophenyl)morpholine (120 mg, 0.39 mmol), 
copper iodide (4 mg, 0.02 mmol), caesium carbonate (254 mg, 0.78 
mmol) were added, evacuated and backfilled with argon three times. 
Then, N,N’-dimethylethylenediamine (3 mg, 0.039 mmol, 10 mol%) was 
added, evacuated and backfilled with argon again. The reaction mixture 
was stirred at 110 °C for three hours and cooled to room temperature. It 
was diluted with ethyl acetate, filtered through Celite® and concentrated 
under reduced pressure using a rotary evaporator. The residue was 
purified by flash column chromatography on silica gel to generate 293 
(178 mg, 0.38 mmol, 97%) as white solid.  
TLC (cyclohexane/ethyl acetate = 2:1) Rf = 0.39 (UV). IR (ATR)  𝑣  =  
2974 (w), 2932 (w), 2829 (w), 1738 (m), 1690 (m), 1630 (w), 1573 (w), 
1486 (w), 1451 (w), 1423 (w), 1410 (w), 1387 (w), 1361 (m), 1348 (m), 
1328 (w), 1287 (w), 1271 (w), 1234 (w), 1194 (w), 1168 (m), 1137 (w),   
1114 (m), 1097 (w), 1080 (m), 1046 (m), 1021 (m), 935 (m), 921 (w), 882 
(w), 863 (w), 843 (w), 824 (w), 803 (w), 765 (w), 751 (w), 736 (w), 659 
(w), 614 (w), 580 (w), 567 (w), 541 (w), 515 (w), 468 (w), 449 (w), 427 
(w) cm
-1
. UV-Vis (EtOH) max (log ) 258 (3.97), 201 (4.05) nm. 
1
H NMR 
(500 MHz, CDCl3): δ = 7.40 (dd, 
4
JH,H = 2.5 Hz, 
3
JH,F = 14.3 Hz, 1H, CH), 
7.10 (d, 
3
JH,H = 8.9 Hz, 1H, CH), 6.91 (t, 
3
JH,H = 9.1 Hz, 1H, CH), 4.59 (q, 
3
JH,H = 7.8 Hz, 1H, CH), 4.30-4.01 (m, 3H, CH, CH2), 4.04-3.93 (m, 2H, 
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CH2), 3.85 (dd, 
4
JH,H = 3.5 Hz, 
3
JH,H = 5.8 Hz, 4H, 2 x CH2), 3.03 (dd, 
3
JH,H 
= 5.8 Hz, 
4
JH,H = 3.5 Hz, 4H, 2 x CH2), 1.64-1.32 (m, 15H, 5 x CH3) ppm. 
13
C NMR (125 MHz, CDCl3): δ = 155.6 (d, 
1
JC,F = 246.3 Hz, C), 154.3 (C), 
153.6 (C), 136.5 (d, 
3
JC,F = 9.0 Hz, C), 133.4 (d, 
2
JC,F = 10.5 Hz, C), 118.9 
(d, 
4
JC,F = 4.1 Hz, CH), 114.4 (CH), 107.9 (d, 
3
JC,F = 25.8 Hz, CH), 94.6 
(C), 81.4 (C), 72.8 (CH), 67.1 (2 x CH2), 64.5 (CH2), 59.2 (CH), 51.1 (d, 
4
JC,F = 2.9 Hz, 2 x CH2), 48.6 (CH2), 27.8 (3 x CH3), 27.8 (CH3), 24.5 
(CH3) ppm. 
19
F NMR (400 MHz, CDCl3): δ = -120.1, -120.6 ppm. Optical 
rotation: []D
20
 = -9.4 (c 0.2, ethanol). HRMS-ESI: calcd. for 
C23H32FN3O6
+
 465.2275; found 465.2271. 
4.2.54 (4S,5'R)-3'-(3-Fluoro-4-morpholinophenyl)-[4,5'-
bioxazolidine]-2,2'-dione (92) 
 
To a solution of oxazolidinone 293 (622 mg, 1.34 mmol) in 
dichloromethane (13 mL), 4N HCl in 1,4-dioxane (3.4 mL, 13.4 mmol) 
was added and stirred at room temperature overnight. It was 
concentrated under reduced pressure using a rotary evaporator and 
used for the next step without purification. 
To a suspension of amino salts (1.34 mmol) in anhydrous THF (13 mL), 
N,N-diisopropylethylamine (434 mg, 3.35 mmol) was added till the salts 
were completely dissolved into the organic solvent. Then, triphosgene 
(400 mg, 1.34 mmol) in anhydrous THF was added at 0 °C over 1 hour 
and stirred at 0 °C for 2-3 hours. After that, it was warmed to room 
temperature and stirred overnight. The reaction mixture was washed with 
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distilled water, extracted with ethyl acetate, dried over MgSO4, 
concentrated under reduced pressure using a rotary evaporator and 
purified by flash column chromatography on silica gel to yield 92 (409 
mg, 1.17 mmol, 87% over two steps) as white solid.  
TLC (ethyl acetate) Rf = 0.18 (UV). IR (ATR) 𝑣 =  3367 (w), 2976 (w), 
2959 (w), 2942 (w), 2914 (w), 2853 (w), 2820 (w), 1750 (m), 1723 (m), 
1625 (w), 1572 (w), 1514 (m), 1472 (w), 1446 (w), 1399 (w), 1376 (w), 
1346 (w), 1325 (w), 1300 (w), 1272 (w), 1225 (m), 1166 (w), 1138 (w), 
1120 (m), 1076 (w), 1050 (m), 1024 (w), 997 (w), 958 (w), 940 (w), 919 
(w), 871 (m), 846 (w), 816 (m), 751 (m), 732 (m), 719 (w), 657 (w), 633 
(w), 605 (w), 577 (w), 528 (w), 503 (w), 494 (w), 467 (w), 424 (w), 410 
(w) cm
-1
. UV-Vis (EtOH) max (log ) 258 (3.50), 201 (3.92) nm. 
1
H NMR 
(500 MHz, DMSO-D6): δ = 8.12 (s, 1H, NH), 7.48 (dd, 
4
JH,H = 2.5 Hz, 
3
JH,F 
= 15.0 Hz, 1H, CH), 7.17 (dd, 
4
JH,H  = 2.5 Hz, 
3
JH,H = 8.8 Hz, 1H, CH), 
7.07 (t, 
3
JH,H = 9.3 Hz, 1H, CH), 4.72 (ddd, 
3
JH,H = 8.8, 6.2, 4.3 Hz, 1H, 
CH), 4.53-4.27 (m, 1H, CH), 4.24-3.98 (m, 2H, CH2), 3.79-3.74 (m, 2H, 
CH2), 3.73 (dt, 
3
JH,H = 4.8, 3.0 Hz, 4H, 2 x CH2), 3.02-2.86 (m, 4H, 2 x 
CH2) ppm.  
13
C NMR (125 MHz, DMSO-D6): δ = 157.6 (d, 
1
JC,F = 406.3 
Hz, C), 154.1 (C), 154.0 (C), 136.2 (d, 
3
JC,F = 8.8 Hz, C), 133.7 (d, 
2
JC,F = 
10.6 Hz, C), 119.8 (d, 
4
JC,F = 4.1 Hz, CH), 114.6 (d, 
4
JC,F = 3.1 Hz, CH), 
107.2 (d, 
3
JC,F = 26.2 Hz, CH), 73.2 (CH), 66.6 (2 x CH2), 65.3 (CH2), 
53.7 (CH), 51.2 (d, 
4
JC,F = 2.9 Hz, 2 x CH2), 46.2 (CH2) ppm. 
19
F NMR 
(500 MHz, DMSO-D6): δ = -121.4 ppm. Optical rotation: []D
20
 = -2.0 (c 
0.2, ethanol). HRMS-ESI: calcd. for C16H19FN3O5
+
 352.1303; found 
352.1303. 
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4.2.55 (S)-tert-Butyl 4-((S)-2-amino-1-hydroxyethyl)-2,2-
dimethyloxazolidine-3-carboxylate (295) 
 
To 25% aqueous ammonia (140 mL), a solution of epoxide 281 (1.7 g, 
7.0 mmol) in ethanol (14 mL) was added rapidly and stirred at room 
temperature overnight. Then, a solution of aqueous 1N NaOH (280 mL) 
was put into the reaction mixture and extracted with dichloromethane. 
The collected organic phases were dried over MgSO4, concentrated 
under reduced pressure using a rotary evaporator and purified by flash 
column chromatography on silica gel to afford 295 (1.31 g, 5.05 mmol, 
72%) as white solid.  
TLC (chloroform/methanol/ammonia = 80:10:1) Rf = 0.06 (Ninhydrin 
Stain). IR (ATR) 𝑣 =  3356 (w), 3287 (w), 3183 (w), 2980 (w), 2935 (w), 
2877 (w), 1699 (m), 1685 (m), 1599 (w), 1476 (w), 1456 (w), 1386 (m) 
1363 (m), 1348 (m), 1329 (m), 1308 (w), 1254 (w), 1230 (w), 1203 (w), 
1170 (w), 1150 (w), 1111 (w), 1087 (w), 1066 (m), 1029 (m), 982 (w), 
949 (w), 887 (w), 865 (w), 807 (w), 789 (w), 766 (w), 747 (w), 721 (w), 
690 (w), 667 (w), 586 (w), 548 (w), 520 (w), 502 (w), 480 (w), 463 (w) cm
-
1
. UV-Vis (EtOH) max (log ) 201 (3.02) nm. 
1
H NMR (400 MHz, CDCl3): 
δ = 4.25-3.62 (m, 2H, CH2), 2.99-2.53 (m, 1H, CH), 2.49-2.19 (m, 3H, 
CH, CH2), 1.56 (s, 3H, CH3), 1.47 (s, 12H, 4 x CH3) ppm. 
13
C NMR (100 
MHz, CDCl3): δ = 154.7 (C), 94.2 (C), 81.3 (C), 74.2 (CH), 64.6 (CH2), 
60.6 (CH), 44.7 (CH2), 28.5 (3 x CH3), 27.1 (CH3), 24.3 (CH3) ppm. 
Optical rotation: []D
20 
= -5.7 (c 0.2, ethanol). HRMS-ESI: calcd. for 
C12H24N2O4Na
+
 283.1628; found 283.1628. 
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4.2.56 (4S,5'S)-tert-Butyl 2,2-dimethyl-2'-oxo-[4,5'-bioxazolidine]-3-
carboxylate (296) 
 
To a solution of amino alcohol 295 (809 mg, 3.11 mmol) and N,N-
diisopropylethylamine (804 mg, 6.22 mmol) in anhydrous THF (31 mL), 
triphosgene (0.93 g, 3.11 mmol) in anhydrous THF (31 mL) was added at 
0 °C over 1 hour and stirred at 0 °C for 2-3 hours. Then, it was stirred at 
room temperature overnight, washed with distilled water, extracted with 
ethyl acetate, dried over MgSO4, concentrated under reduced pressure 
using a rotary evaporator and purified by flash column chromatography 
on silica gel to create 296 (653 mg, 2.29 mmol, 74%) as white solid.  
TLC (cyclohexane/ethyl acetate = 1:2) Rf = 0.32 (Ninhydrin stain). IR 
(ATR) 𝑣 =  3269 (w), 2776 (w), 2932 (w), 1749 (w), 1707 (w), 1681 (m), 
1499 (w), 1476 (w), 1437 (w), 1388 (m), 1363 (m), 1349 (w), 1315 (w), 
1287 (m), 1258 (m), 1214 (w), 1169 (w), 1155 (w), 1087 (m), 1054 (m), 
1012 (w), 968 (w), 951 (w), 936 (w), 880 (w), 859 (w), 843 (w), 806 (w), 
770 (w), 743 (w), 719 (w), 666 (w), 565 (w), 533 (w), 521 (w), 459 (w), 
424 (w) cm
-1
. UV-Vis (EtOH) max (log ) 201 (3.40) nm. MS (EI, 70 eV): 
m/z (%) = 213 (6) [M-OCH3]
+
, 207 (42), 200 (16), 171 (40), 144 (13), 100 
(55), 98 (6), 87 (38), 86 (8), 83 (10), 58 (10), 57 (100), 56 (32), 44 (54), 
41 (41), 39 (14). GC (HP-5MS): I = 2124. 
1
H NMR (500 MHz, CDCl3): δ = 
4.71-4.55 (m, 1H, CH), 4.40-3.99 (m, 2H CH2), 3.96 (dd, 
3
JH,H = 9.5, 5.5 
Hz, 1H, CH), 3.80-3.50 (m, 2H, CH2), 1.64-1.40 (m, 24H, 8 x CH3) ppm. 
13
C NMR (125 MHz, CDCl3): δ = 159.5 (C), 153.5 (C), 94.4 (C), 81.2 (C), 
76.4 (CH), 64.5 (CH2), 59.0 (CH), 43.6 (CH2), 28.4 (3 x CH3), 27.7 (CH3), 
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24.5 (CH3) ppm. Optical rotation: []D
20
 = +1.6 (c 0.2, ethanol). HRMS-
ESI: calcd. for C13H22N2O5Na
+
 309.1421; found 309.1421. 
4.2.57 (4S,5'S)-tert-Butyl 3'-(3-fluoro-4-morpholinophenyl)-2,2-
dimethyl-2'-oxo-[4,5'-bioxazolidine]-3-carboxylate (297) 
 
To a solution of oxazolidinone 296 (143 mg, 0.5 mmol) in 1,4-dioxane 
(5.0 mL), 4-(2-fluoro-4-iodophenyl)morpholine (154 mg, 0.5 mmol), 
copper iodide (5 mg, 0.025 mmol), caesium carbonate (326 mg, 1.0 
mmol) were added, evacuated and backfilled with argon three times. 
Then, N,N’-dimethylethylenediamine (4 mg, 0.05 mmol, 10 mol%) was 
added, evacuated and backfilled with argon again. The reaction mixture 
was stirred at 110 °C for three hours and cooled to room temperature. It 
was diluted with ethyl acetate, filtered through Celite® and concentrated 
under reduced pressure using a rotary evaporator. The residue was 
purified over column chromatography on silica gel to generate 297 (229 
mg, 0.49 mmol, 98%, dr 53:47) as white solid.  
TLC (cyclohexane/ethyl acetate = 5:1) Rf = 0.31 (UV). IR (ATR) 𝑣 = 3071 
(w), 3004 (w), 2961 (w), 2920 (w), 2892 (w), 2852 (w), 2689 (w), 1733 
(w), 1597 (w), 1558 (w), 1487 (m), 1450 (w), 1401 (w), 1372 (w), 1334 
(w), 1296 (w), 1259 (w), 1251 (w), 1233 (w), 1201 (m), 1165 (w), 1112 
(m), 1072 (w), 1045 (w), 1031 (w), 919 (m), 859 (m), 842 (m), 802 (m), 
726 (w), 647 (w), 572 (m), 496 (w), 470 (w), 424 (w) cm
-1
. UV-Vis (EtOH) 
max (log ) 255 (3.62), 206 (3.26) nm. 
1
H NMR (500 MHz, CDCl3): δ = 
7.45 (dd, 
4
JH,H = 2.6 Hz, 
3
JH,F = 14.4 Hz, 1H, CH), 7.10 (dd, 
4
JH,H = 2.8 Hz, 
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3
JH,H = 8.9 Hz, 1H, CH), 6.98 (m, 1H, CH), 5.15-4.73(m, 1H, CH), 4.43-
4.20 (m, 1H, CH), 4.21-3.96 (m, 4H, 2 x CH2), 3.88 (q, 
4
JH,H = 4.6 Hz, 
3
JH,H = 6.0 Hz, 4H, 2 x CH2), 3.11-3.00 (m, 4H, 2 x CH2) 1.68-1.40 (m, 
15H, 5 x CH3) ppm. 
13
C NMR (125 MHz, CDCl3): δ = A: 155.7 (d, 
1
JC,F = 
246.6 Hz, C), 154.5 (C), 153.3 (C), 136.3 (C), 133.5 (C), 119.2 (CH), 
114.1 (d, 
4
JC,F = 3.3 Hz, CH), 114.4 (CH), 107.7 (d, 
3
JC,F = 26.3 Hz, CH), 
94.8 (C), 81.5 (C), 71.3 (CH), 67.0 (2 x CH2), 63.5 (CH2), 57.9 (CH), 51.1 
(2 x CH2), 46.4 (CH2), 28.5 (3 x CH3), 27.3 (CH3), 23.9 (CH3) ppm.; B: 
155.7 (d, 
1
JC,F = 246.6 Hz, C), 154.4 (C), 152.0 (C), 136.3 (C), 133.5 (C), 
119.2 (CH), 114.1 (d, 
4
JC,F = 3.3 Hz, CH), 114.4 (CH), 107.7 (d, 
3
JC,F = 
26.3 Hz, CH), 95.1 (C), 81.3 (C), 71.3 (CH), 67.0 (2 x CH2), 63.3 (CH2), 
57.6 (CH), 51.1 (2 x CH2), 46.4 (CH2), 28.4 (3 x CH3), 26.8 (CH3), 22.5 
(CH3) ppm. 
19
F NMR (500 MHz, CDCl3): δ = -120.2, -120.3 ppm. Optical 
rotation: []D
20
 = +1.6 (c 0.3, ethanol). 
4.2.58 (4S,5'S)-3'-(3-Fluoro-4-morpholinophenyl)-[4,5'-bioxazolidine]-
2,2'-dione (258) 
 
To a solution of oxazolidinone 297 (46 mg, 0.1 mmol) in dichloromethane 
(1.0 mL), 4N HCl in 1,4-dioxane (0.25 mL, 1.0 mmol) was added and 
stirred at room temperature overnight. It was concentrated under 
reduced pressure using a rotary evaporator and used for the next step 
without purification. 
To a suspension of amino salts (0.1 mmol) in anhydrous THF (1.0 mL), 
N,N-diisopropylethylamine (33 mg, 0.25 mmol) was added till the salts 
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were completely dissolved into the organic solvent. Then, triphosgene 
(30 mg, 0.1 mmol) in anhydrous THF was added at 0 °C over 1 hour and 
stirred at 0 °C for 2-3 hours. After that, it was warmed to room 
temperature and stirred overnight. The reaction mixture was washed with 
distilled water, extracted with ethyl acetate, dried over MgSO4, 
concentrated under reduced pressure using a rotary evaporator and 
purified by flash column chromatography on silica gel to yield 258 (23 
mg, 0.066 mmol, 66% over two steps) as white solid.  
TLC (Ethyl acetate) Rf = 0.18 (UV). IR (ATR) 𝑣 = 3303 (w), 2969 (w), 
2946 (w), 2899 (w), 2868 (w), 2818 (w), 1767 (w), 1735 (m), 1628 (w), 
1571 (w), 1469 (w), 1449 (w), 1416 (w), 1389 (w),1352 (w), 1329 (w), 
1310 (w), 1272 (w), 1257 (m), 1226 (w), 1170 (w), 1140 (w), 1120 (w), 
1098 (w), 1072 (w), 1055 (w), 1022 (w), 937 (w), 924 (w), 879 (w), 851 
(w), 817 (w), 751 (w), 728 (w), 658 (w), 637 (w), 607 (w), 582 (w), 526 
(w), 506 (w), 472 (w), 445 (w), 413 (w) cm
-1
. UV-Vis (EtOH) max (log ) 
258 (3.21), 204 (3.10) nm. 
1
H NMR (500 MHz, DMSO-D6): δ = 8.17 (s, 
1H, NH), 7.50 (dd, 
4
JH,H = 2.6 Hz, 
3
JH,F = 15.0 Hz, 1H, CH), 7.33-7.16 (m, 
1H, CH), 7.13-6-98 (m, 1H, CH), 4.73 (ddd, 
3
JH,H = 9.6, 6.2, 3.6 Hz, 1H, 
CH), 4.44 (t, 
3
JH,H = 9.1 Hz, 1H, CH), 4.20 (dd, 
3
JH,H = 8.9, 4.7 Hz, 1H, 
CH2), 4.15-4.03 (m, 2H, CH2), 3,79 (dd, 
3
JH,H = 9.3, 6.2 Hz, 1H, CH2), 
3.76-3.72 (m, 4H, 2 x CH2), 3.03-2.93 (m, 4H, 2 x CH2) ppm. 
13
C NMR 
(125 MHz, DMSO-D6): δ = 156.4 (d, 
1
JC,F = 627.9 Hz, C), 155.5 (C), 
153.6 (C), 135.6 (d, 
3
JC,F = 8.8 Hz, C), 133.7 (d, 
2
JC,F = 10.6 Hz, C), 119.2 
(d, 
4
JC,F = 4.1 Hz, CH), 114.2 (d, 
4
JC,F = 3.1 Hz, CH), 106.7 (d, 
3
JC,F = 26.2 
Hz, CH), 72.7 (CH), 66.1 (2 x CH2), 65.4 (CH2), 53.8 (CH), 50.7 (d, 
4
JC,F = 
2.8 Hz, 2 x CH2), 46.5 (CH2) ppm. 
19
F NMR (500 MHz, DMSO-D6): δ = -
121.4 ppm. Optical rotation: []D
20
 = +5.5 (c 0.1, ethanol). HRMS-ESI: 
calcd. for C16H19FN3O5
+
 352.1303; found 352.1303. 
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4.2.59 5-Bromopyridin-2-amine (307) 
 
To a solution of 2-aminopyridine (56.4 g, 0.6 mol) in ethanol (600 mL), 
bromide (34.8 mL, 0.66 mol) was added dropwise at 0 °C and stirred at 
low temperature for 1hour. The solution was concentrated and a solution 
of sodium hydroxide (30 g, 0.78 mol) in distilled water (500 mL) was 
added at 0 °C. Then, it was filtered, the solid was washed with cold water 
(60 mL) and boiling heptane (2 x 120 mL) to remove 3,5-dibromopyridin-
2-amine and the rest was purified by flash column chromatography on 
silica gel to afford 5-bromopyridin-2-amine 307 (52.46 g, 0.3 mol, 51%) 
as yellow brown solid.  
TLC (cyclohexane/ethyl acetate = 3:1) Rf = 0.34 (UV). IR (ATR)  𝑣  =  
3452 (w), 3281 (w), 1624 (w), 1586 (w), 1562 (w), 1549 (w), 1512 (w), 
1473 (w), 1386 (w), 1310 (w), 1287 (w), 1260 (w), 1140 (w), 1088 (w), 
999 (w), 961 (w), 927 (w), 820 (m), 745 (w), 667 (w), 642 (w), 630 (w), 
512 (m), 441 (w), 411 (w) cm
-1
. UV-Vis (EtOH) max (log ) 313 (3.04), 
243 (3.69) nm. MS (EI, 70 eV): m/z (%) = 174 (96) [M+H]
+
, 173 (7), 172 
(100), 156 (6), 147 (47), 145 (31), 135 (6), 119 (7), 93 (9), 91 (8), 79 
(14), 73 (24), 66 (20), 51 (6), 44 (34), 41 (8), 40 (12), 39 (11), 38 (5). GC 
(HP-5MS): I = 1302. 
1
H NMR (500 MHz, MeOD): δ = 9.47 (d, 4JH,H = 2.4 
Hz, 1H, CH), 9.08 (dd, 
4
JH,H = 2.5 Hz, 
3
JH,H = 8.9 Hz, 1H, CH),  8.08 (d, 
3
JH,H = 8.9 Hz, 1H, CH), 6.20 (s, 2H, NH2) ppm. 
13
C NMR (125 MHz, 
MeOD): δ = 159.7 (C), 148.5 (CH), 141.5 (CH), 111.8 (CH), 107.4 (C) 
ppm.  
 
 
235 
 
4.2.60 2,5-Dibromopyridine (308) 
 
To a cold aqueous 48% hydrogen bromide solution (37 mL, 0.33 mol), 5-
bromopyridin-2-amine (13.0 g, 75.2 mmol) was added over 10 minutes. 
After that, bromide (11 mL, 0.21 mol) was put into the reaction mixture at 
0 °C. Then, a solution of sodium nitrite (16.1 g, 0.19 mol) in distilled 
water (19 mL) was added dropwise at 0 °C and stirred for 30 minutes, 
subsequently another solution of sodium hydroxide (28.0 g, 0.7 mol) in 
distilled water (30 mL) was added below room temperature and extracted 
with ethyl acetate. The collected organic phases were dried over MgSO4, 
concentrated under reduced pressure using a rotary evaporator, filtered 
and purified over column chromatography to afford 2,5-dibromopyridine 
308 (8.43 g, 35.6 mmol, 47%) as white crystals.  
TLC (cyclohexane/ethyl acetate = 20:1) Rf = 0.26 (UV). IR (ATR) 𝑣 = 
3204 (w), 3099 (w), 1545 (m), 1505 (w), 1470 (w), 1435 (m), 1393 (w), 
1355 (w), 1276 (w), 1261 (w), 1158 (w), 1139 (w), 1113 (m), 1089 (m), 
1076 (m), 996 (m), 913 (w), 829 (m), 734 (w), 715 (w), 624 (w), 481 (w), 
421 (w), 406 (w) cm
-1
. UV-Vis (EtOH) max (lg ) 277 (3.13), 228 (3.70) 
nm. MS (EI, 70 eV): m/z (%) = 238.8 (52) [M+2H]
+
, 237.8 (6), 236.8 
(100), 234.8 (54), 158.8 (7), 157.8 (83), 156.8 (7), 155.8 (84), 130.8 (5), 
128.8 (7), 76.8 (10), 75.8 (36), 74.8 (8), 50.8 (6), 49.8 (16). GC (HP-
5MS): I = 1261. 
1
H NMR (500 MHz, CDCl3): δ = 8.43 (dd, 
5
JH,H = 0.7 Hz, 
4
JH,H = 2.5 Hz, 1H, CH), 7.65 (dd, 
4
JH,H = 2.6 Hz, 
3
JH,H = 8.4 Hz, 1H, CH), 
7.37 (dd, 
5
JH,H = 0.7 Hz, 
3
JH,H = 8.4 Hz, 1H, CH) ppm. 
13
C NMR (125 
MHz, CDCl3): δ = 151.3 (CH), 141.1 (CH), 140.5 (C), 130.0 (CH), 120.0 
(C) ppm. HRMS-ESI: calcd. for C5H3BrN2
+
 234.8632; found 234.8633. 
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4.2.61 5-Bromopicolinonitrile (309) 
To a solution of 2,5-dibromopyridine 308 (8.29 g, 35 mmol) in 
dimethylformamide (80 mL), copper cyanide (3.47 g, 39 mmol) and 
sodium cyanide (1.93 g, 39 mmol) were added and stirred at 150 °C for 7 
hours. After cooling to room temperature, it was poured into distilled 
water, extracted with ethyl acetate. The collected organic phases were 
washed with brine, dried over MgSO4, concentrated under reduced 
pressure using a rotary evaporator, filtered and purified by flash column 
chromatography on silica gel to afford 5-bromopicolinonitrile 309 (3.67 g, 
20.1 mmol, 57%)  as yellow solid and side product pyridine-2,5-
dicarbonitrile (0.39 g, 3.0 mmol, 17%) as yellow solid.  
 
TLC (cyclohexane/ethyl acetate = 3:1) Rf = 0.31 (UV). IR (ATR) 𝑣 = 3107 
(w), 3075 (w), 3050 (w), 2991 (w), 2905 (w), 2233 (w), 1561 (w), 1551 
(w), 1481 (w), 1451 (w), 1357 (w), 1282 (w), 1248 (w), 1195 (w), 1125 
(w), 1087 (w), 1006 (w), 936 (w), 843 (m), 796 (w), 781 (w), 740 (w), 646 
(w), 559 (w), 541 (m), 427 (w) cm
-1
. UV-Vis (EtOH) max (log ) 275 
(3.26), 239 (3.72), 202 (3.71) nm. MS (EI, 70 eV): m/z (%) = 185 (7) 
[M+2H]
+
, 183 (100), 181 (92), 105 (4), 103 (85), 77 (28), 75 (13), 52 (9), 
50 (9), 48 (3), 39 (2). GC (HP-5MS): I = 1291. 
1
H NMR (500 MHz, 
CDCl3): δ = 8.78 (dd, 
5
 JH,H = 0.8 Hz, 
4
JH,H = 2.3 Hz, 1H, CH), 8.00 (dd, 
4
JH,H = 2.3 Hz, 
3
JH,H = 8.3 Hz, 1H, CH), 7.60 (dd, 
5
JH,H = 0.8 Hz, 
3
JH,H = 
8.3 Hz, 1H, CH) ppm. 
13
C NMR (125 MHz, CDCl3): δ = 152.7 (CH), 139.9 
(CH), 132.2 (C), 129.4 (CH), 125.2 (C), 116.7 (CN) ppm. HRMS-ESI: 
calcd. for C6H3BrN2
+
 181.9480; found 181.9480. 
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TLC (cyclohexane/ethyl acetate = 3:1) Rf = 0.12 (UV). IR (ATR) 𝑣 = 3092 
(w), 3069 (w), 3029 (w), 2948 (w), 2241 (w), 1505 (w), 1582 (w), 1556 
(w), 1542 (w), 1486 (w), 1462 (m), 1372 (w), 1292 (w), 1250 (w), 1213 
(w), 1178 (w), 1129 (w), 1021 (m), 947 (w), 856 (m), 825 (w), 751 (w), 
664 (w), 640 (w), 565 (m), 519 (w) cm
-1
. UV-Vis (EtOH) max (log ) 273 
(3.09), 230 (3.60) nm. MS (EI, 70 eV): m/z (%) = 132 (12) [M+2H]
+
, 129 
(100), 102 (39), 100 (9), 78 (2), 76 (22), 74 (2), 52 (15), 50 (4). GC (HP-
5MS): I = 1288. 
1
H NMR (500 MHz, CDCl3): δ = 8.98 (dd, 
5
JH,H = 0.9 Hz, 
4
JH,H = 2.1 Hz, 1H, CH), 8.17 (dd, 
4
JH,H = 2.1 Hz,  
3
JH,H = 8.1 Hz, 1H, CH), 
7.86 (dd, 
5
 JH,H = 1.0 Hz, 
3
JH,H = 8.1 Hz, 1H, CH) ppm. 
13
C NMR (125 
MHz, CDCl3): δ = 153.3 (CH), 140.8 (CH), 136.7 (C), 128.3 (CH), 115.9 
(C), 115.1 (CN), 113.2 (CN) ppm. HRMS-ESI: calcd. for C7H3N3
+
 
129.0327; found 129.0328. 
4.2.62 5-Bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine (311) and 5-
bromo-2-(1-methyl-1H-tetrazol-5-yl)pyridine (312) 
To a solution of 5-bromopicolinonitrile 309 (0.37 g, 2.0 mmol) in 
anhydrous dimethylformamide (4.0 mL), sodium azide (0.16 g, 2.4 mmol) 
and ammonium chloride (0.11 g, 2.0 mmol) was added and heated at 
120 °C for 1 hour. Then, it was diluted with ethyl acetate (20.0 mL) and 
cooled to room temperature. It was filtered, washed with ethyl acetate, 
fried in vacuo to obtain white solid. This crude product was used for next 
step without purification. A mixture of 5-bromo-2-(1H-tetrazol-5-
yl)pyridine 310 (2.0 mmol) and sodium hydroxide (0.36 g, 9.0 mmol) in 
anhydrous dimethylformamide (4.0 mL) were stirred at room temperature 
for 3 hours. It was concentrated under reduced pressure using a rotary 
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evaporator and re-dissolved in anhydrous dimethylformamide (3.0 mL). 
Methyl iodide (0.21 mL, 3.4 mmol) was added dropwise at 0 °C and 
stirred at room temperature for 2 hours. It was then partitioned between 
water and ethyl acetate. The organic phases were washed with distilled 
water, dried MgSO4, concentrated under reduced pressure using a rotary 
evaporator, filtered and purified by flash column chromatography to 
generate 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine 311 (125 mg, 
0.52 mmol, 17%) as white solid and byproduct 5-bromo-2-(1-methyl-1H-
tetrazol-5-yl)pyridine 312 (120 mg, 0.5 mmol, 17%) as yellow solid.  
 
TLC (cyclohexane/ethyl acetate = 3:1) Rf = 0.18 (UV). IR (ATR) 𝑣 = 3087 
(w), 3046 (w), 2954 (w), 2345 (w), 2109 (w), 1988 (w), 1738 (w), 1579 
(w), 1557 (w), 1513 (w), 1443 (w), 1415 (w), 1400 (w), 1377 (w), 1363 
(w), 1289 (w), 1235 (w), 1210 (w), 1152 (w), 1131 (w), 1087 (w), 1050 
(w), 1016 (w), 1001 (w), 936 (w), 914 (w), 857 (w), 771 (w), 760 (w), 728 
(w), 702 (w), 684 (w), 629 (w), 512 (w), 496 (w), 441 (w), 409 (w) cm
-1
. 
UV-Vis (EtOH) max (log ) 283 (3.30), 245 (3.63), 201 (3.70) nm. MS (EI, 
70 eV): m/z (%) = 240 (15) [M]
+
, 239 (7), 214 (7), 213 (96), 212 (34), 211 
(100), 210 (35), 208 (19), 207 (66), 191 (5), 185 (35), 184 (19), 183 (34), 
182 (17), 158 (29), 156 (31), 135 (5), 133 (9), 105 (6), 104 (10), 103 (28), 
77 (12), 76 (37), 75 (7), 62 (5), 51 (9), 50 (9), 43 (33), 40 (19), 38 (5). GC 
(HP-5MS): I = 1871. 
1
H NMR (500 MHz, CDCl3): δ = 8.80 (d, 
4
JH,H = 2.3 
Hz, 1H, CH), 8.11 (dd, 
5
JH,H = 0.8 Hz, 
3
JH,H = 8.4 Hz, 1H, CH), 7.97 (dd, 
4
JH,H = 2.3 Hz, 
3
JH,H = 8.4 Hz, 1H, CH), 4.43 (s, 3H, CH3) ppm. 
13
C NMR 
(125 MHz, CDCl3): δ = 164.3 (C), 151.5 (CH), 145.2 (C), 140.0 (CH), 
123.5 (CH), 122.3 (C), 40.0 (CH3) ppm. HRMS-ESI: calcd. for C7H6BrN5
+
 
238.9807; found 238.9806. 
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TLC (cyclohexane/ethyl acetate = 3:1) Rf = 0.37 (UV). IR (ATR) 𝑣 = 3154 
(w), 3092 (w), 3051 (w), 3031 (w), 2957 (w), 2921 (w), 2851 (w), 2335 
(w), 2080 (w), 1973 (w), 1843 (w), 1740 (w), 1716 (w), 1577 (w), 1556 
(w), 1532 (w), 1470 (w), 1453 (w), 1434 (w), 1421 (w), 1391 (w), 1355 
(w), 1285 (w), 1272 (w), 1253 (w), 1233 (w), 1212 (w), 1125 (w), 1092 
(w), 1062 (w), 1042 (w), 1006 (w), 993 (w), 926 (w), 857 (w), 763 (w), 
725 (w), 697 (w), 628 (w), 510 (w), 450 (w), 412 (w) cm
-1
. UV-Vis (EtOH) 
max (lg ) 246 (3.00), 201 (3.41) nm. MS (EI, 70 eV): m/z (%) = 241 (29) 
[M+H]
+
, 239 (30), 207 (6), 199 (8), 197 (8), 186 (14), 185 (99), 184 (27), 
183 (100), 182 (6), 181 (6), 171 (8), 169 (8), 159 (15), 158 (31), 157 (16), 
156 (31), 135 (5), 119 (5), 117 (6), 105 (7), 103 (15), 90 (10), 78 (13), 77 
(14), 76 (29), 75 (6), 63 (6), 62 (6), 51 (10), 50 (10), 43 (17). GC (HP-
5MS): I = 1912. 
1
H NMR (500 MHz, CDCl3): δ = 8.78 (dd, 
5
JH,H = 0.8 Hz, 
4
JH,H = 2.2 Hz, 1H, CH), 8.25 (dd, 
5
JH,H = 0.8 Hz, 
3
JH,H = 8.5 Hz, 1H, CH), 
8.04 (dd, 
4
JH,H = 2.3 Hz, 
3
JH,H = 8.5 Hz, 1H, CH), 4.47 (s, 3H, CH3) ppm. 
13
C NMR (125 MHz, CDCl3): δ = 151.6 (C), 150.8(CH), 143.4 (C), 140.4 
(CH), 125.6 (CH), 123.1 (C), 37.2 (CH3) ppm. HRMS-ESI: calcd. for 
C7H6BrN5
+
 238.9807; found 238.9807. 
4.2.63 2-(5-Bromopyridin-2-yl)-5-methyl-1,3,4-oxadiazole (313) 
 
To a solution of 5-bromopicolinonitrile 309 (0.37 g, 2.0 mmol) in 
anhydrous dimethylformamide (8.0 mL), sodium azide (0.16 g, 2.4 mmol) 
and ammonium chloride (0.11 g, 2.0 mmol) was added and heated at 
 
 
240 
 
120 °C for 1 hour. Then, it was diluted with ethyl acetate (20.0 mL) and 
cooled to room temperature. It was filtered, washed with ethyl acetate, 
concentrated under reduced pressure using a rotary evaporator to obtain 
white solid. This crude product was used for next step without 
purification. A mixture of 5-bromo-2-(1H-tetrazol-5-yl)pyridine 310 (2.0 
mmol), fresh distilled acetic anhydride (6.80 mL) and pyridine (0.8 mL, 
9.7 mmol) was heated to 150 °C and maintained this temperature for 3 
hours. It was cooled to room temperature, poured into distilled water and 
extracted with ethyl acetate. The combined organic layers were washed 
with brine, dried over MgSO4, filtered, concentrated under reduced 
pressure using a rotary evaporator and purified by flash column 
chromatography on silica gel to produce 2-(5-bromopyridin-2-yl)-5-
methyl-1,3,4-oxadiazole 313 (0.17 g, 0.69 mmol) as brown solid.   
TLC (cyclohexane/ethyl acetate = 1:1) Rf = 0.45 (UV). IR (ATR) 𝑣 = 3088 
(w), 3051 (w), 2924 (w), 2853 (w), 2324 (w), 2104 (w), 1991 (w), 1664 
(w), 1578 (w), 1477 (w), 1456 (w), 1441 (w), 1401 (w), 1381 (w), 1286 
(w), 1257 (w), 1236 (w), 1125 (w), 1099 (w), 1085 (w), 1034 (w), 1003 
(w), 972 (w), 958 (w), 944 (w), 841 (w), 758 (w), 748 (w), 703 (w), 688 
(w), 666 (w), 628 (w), 505 (w), 491 (w), 442 (w), 408 (w) cm
-1
. UV-Vis 
(EtOH) max (lOg ) 285 (3.35), 254 (3.49), 201 (3.51) nm. MS (EI, 70 
eV): m/z (%) = 224 (7) [M+2H]
+
, 221 (100), 128 (3), 111 (3), 97 (12), 94 
(51), 75 (19), 70 (4), 68 (3), 63 (2), 51 (6), 39 (1). GC (HP-5MS): I = 
1771. 
1
H NMR (500 MHz, CDCl3): δ = 8.80 (d, 
4
JH,H = 2.3 Hz, 1H, CH), 
8.25 (dd, 
3
JH,H = 8.4 Hz, 1H, CH), 8.04 (dd, 
4
JH,H = 2.2 Hz, 
3
JH,H = 8.4 Hz, 
1H, CH), 2.65 (s, 3H, CH3) ppm. 
13
C NMR (125 MHz, CDCl3): δ = 165.1 
(C), 163.7 (C), 151.5 (CH), 142.0 (C), 140.2 (CH), 124.0 (CH), 123.5 (C), 
11.3 (CH3) ppm. HRMS-ESI: calcd. for C8H6BrN3O
+
 238.9694; found 
238.9698. 
 
 
241 
 
4.2.64 1-Fluoro-3-iodobenzene (301) 
 
To a solution of 3-fluoroaniline (3.33 g, 30.0 mmol) in 95-97% sulfuric 
acid (10.9 mL, 19.13 g, 195 mmol) in distilled water (49.0 mL), a solution 
of sodium nitrite (2.13 g, 30.90 mmol) in distilled water (6.7 mL) was 
added slowly at 0 °C and stirred at this temperature for one hour. After 
that, another solution of potassium iodide (7.47 g, 45.0 mmol) in distilled 
water (10.0 mL) was also put into the reaction mixture gently at 0 °C and 
maintained this temperature for another hour. The aqueous phase was 
extracted with ethyl acetate. The collected organic layers were washed 
with distilled water, 10% sodium bicarbonate aqueous solution (3 x 66.6 
mL), dried over MgSO4, filtered, concentrated under reduced pressure 
using a rotary evaporator and purified by flash column chromatography 
on silica gel to afford 1-fluoro-3-iodobenzene 301 (1.63 g, 7.34 mmol, 
24%) as purple red oil.   
TLC (cyclohexane) Rf = 0.72 (UV). IR (ATR) 𝑣 =  3065 (w), 1736 (w), 
1582 (s), 1568 (m), 1516 (w), 1466 (s), 1420 (m), 1372 (w), 1328 (w), 
1291 (w), 1262 (m), 1241 (w), 1210 (s), 1157 (w), 1078 (w), 1049 (m), 
998 (m), 888 (w), 858 (m), 843 (s), 771 (s), 671 (s), 652 (m), 518 (m), 
436 (m) cm
-1
. UV-Vis (EtOH) max (lOg ) 267 (3.53), 230 (4.40), 202 
(4.53) nm. MS (EI, 70 eV): m/z (%) = 242 (9) [M+2H]
+
, 222 (100), 126 
(3), 111 (4), 97 (17), 95 (58), 92 (2), 75 (19), 73 (5), 71 (2), 68 (7), 63 (1), 
61 (2), 49 (6). GC (HP-5MS): I = 1027. 
1
H NMR (500 MHz, CDCl3): δ = 
7.49 (dt, 
4
JH,H = 1.6 Hz, 
3
JH,H = 7.2 Hz, 1H, CH), 7.45 (dt, 
4
JH,H = 1.9 Hz, 
3
JH,H = 8.1 Hz, 1H, CH), 7.10-7.02 (m, 2H, 2 x CH) ppm. 
13
C NMR (125 
MHz, CDCl3): δ = 162.5 (d, 
1
JC,F = 251.3 Hz, C), 133.5 (d, 
4
JC,F = 3.3 Hz, 
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CH), 131.4 (d, 
3
JC,F = 8.1 Hz, CH), 125.0 (d, 
2
JC,F = 23.5 Hz, CH), 115.1 
(d, 
2
JC,F = 20.9 Hz, CH), 93.7 (d, 
3
JC,F = 7.9 Hz, C) ppm. 
19
F NMR (500 
MHz, CDCl3): δ = -110.49, -111.50 ppm.  
4.2.65 (4S,5'R)-tert-Butyl 3'-(3-fluorophenyl)-2,2-dimethyl-2'-oxo-
[4,5'-bioxazolidine]-3-carboxylate (304) 
 
To a solution of bioxazolidine 278 (286 mg, 1.0 mmol) in 1,4-dioxane 
(2.00 mL), 1-fluoro-3-iodobenzene 301 (222 mg, 1.0 mmol), caesium 
carbonate (652 mg, 2.0 mmol) and copper iodide (10 mg, 0.05 mmol) 
were added, evacuated and backfilled with argon three times. After that, 
N,N’-dimethylethylenediamine (10 mg, 0.1 mmol) was put into the 
reaction and stirred under argon at 110 °C for 4 hours. It was cooled to 
room temperature, diluted with ethyl acetate, filtered through Celite®, 
concentrated under reduced pressure using a rotary evaporator and 
purified by flash column chromatography to generate 304 (388 mg, 0.98 
mmol, 98%, dr 55:45) as white solid.   
TLC (cyclohexane/ethyl acetate = 3:1) Rf = 0.24 (UV or Ninhydrin Stain). 
UV-Vis (EtOH) max (lg ) 270 (2.27), 238 (3.15), 203 (3.24) nm. IR 
(ATR) 𝑣 =  2980 (w), 2934 (w), 2873 (w), 1747 (m), 1700 (m), 1615 (w), 
1589 (w), 1497 (w), 1458 (w), 1412 (m), 1388 (w), 1365 (m), 1351 (w), 
1330 (w), 1299 (w), 1281 (w), 1256 (w), 1226 (w), 1199 (m), 1155 (w), 
1132 (w), 1113 (w), 1080 (m), 1046 (w), 1026 (w), 998 (w), 946 (w), 877 
(w), 851 (m), 808 (w), 769 (m), 751 (m), 679 (w), 667 (w), 616 (w), 57o 
(w), 518 (w), 456 (w), 417 (w) cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ = 7.43 
(t, 
3
JH,H = 8.7 Hz, 1H, CH), 7.32 (p, 
3
JH,H = 7.7 Hz, 1H, CH), 7.23 (t, 
4
JH,H = 
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6.4 Hz, 1H, CH), 6.84 (t, 
3
JH,H = 8.8 Hz, 1H, CH), 5.12-4.79 (m, 1H, CH), 
4.44-4.24 (m, 1H, CH2), 4.23-3.98 (m, 3H, CH, CH2), 3.94 (q, 
3
JH,H = 8.3 
Hz, 1H, CH2),  1.68-1.40 (m, 15H, 5 x CH3) ppm. 
13
C NMR (125 MHz, 
CDCl3): δ = A: 163.2 (d, 
1
JC,F = 245.1 Hz, C), 154.3 (C), 153.3 (C), 139.9-
139.6 (m, CH), 138.4 (t, 
4
JC,F = 10.5 Hz, CH), 113.6 (CH), 110.9 (d, 
3
JC,F = 
21.7 Hz, CH), 106.1 (C), 95.1 (C), 81.5 (C), 71.4 (CH), 63.5 (CH2), 57.9 
(CH), 46.3 (CH2), 28.4 (CH3), 27.2 (CH3), 23.9 (CH3) ppm.; B: 163.2 (d, 
1
JC,F = 245.1 Hz, C), 154.1 (C), 152.0 (C), 139.9-139.6 (m, C), 138.4 (t, 
4
JC,F = 10.5 Hz, CH), 113.6 (CH), 111.1 (d, 
3
JC,F = 21.9 Hz, CH), 105.9 
(C), 94.8 (C), 81.3 (C), 71.4 (CH), 63.3 (CH2), 57.5 (CH), 46.2 (CH2), 
28.5 (CH3), 26.9 (CH3), 22.5 (CH3) ppm. 
19
F NMR (500 MHz, CDCl3): δ = 
-110.8, -111.1 ppm. Optical rotation: []D
20
 = -26.5 (c 0.2, ethanol). 
HRMS-ESI: calcd. for C19H25FN2NaO5
+
 403.1640; found 403.1640 [M + 
Na]
+
.  
4.2.66 (4S,5'R)-3'-(3-Fluorophenyl)-[4,5'-bioxazolidine]-2,2'-dione 
(306) 
 
To a solution of oxazolidinone 304 (1.93 g, 5.08 mmol) in 
dichloromethane (50.8 mL), 4N HCl in 1,4-dioxane (12.7 mL, 50.8 mmol) 
was added and stirred at room temperature overnight. It was 
concentrated under reduced pressure using a rotary evaporator and 
used for next step without purification.  
To a solution of amino salts 305 (5.08 mmol) in anhydrous THF (50.8 
mL), N,N-diisopropylethylamine (1.65 g, 12.7 mmol) was added till the 
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salts were completely dissolved in solvent. Subsequently, triphosgene 
(1.52 g, 5.08 mmol) in anhydrous THF (50.8 mL) was added at 0 °C over 
1 hour and stirred at this temperature for 2-3 hours. It was poured into 
distilled water, extracted with ethyl acetate, dried over MgSO4, 
concentrated under reduced pressure using a rotary evaporator and 
purified by flash column chromatography on silica gel to afford 306 (1.18 
g, 4.43 mmol, 87%) as white solid.  
TLC (cyclohexane/ethyl acetate = 1:5) Rf = 0.24 (UV). UV-Vis (EtOH) 
max (lg ) 251 (2.46), 201 (3.02) nm. IR (ATR) 𝑣 = 2980 (w), 2934 (w), 
2871 (w), 1747 (m), 1700 (m), 1614 (w), 1590 (w), 1498 (w), 1459 (w), 
1413 (w), 1387 (m), 1366 (w), 1347 (m), 1329 (w), 1299 (w), 1282 (w), 
1256 (w), 1228 (m), 1200 (m), 1156 (m), 1131 (w), 1113 (w), 1080 (m), 
1046 (w), 1026 (w), 999 (w), 950 (w), 877 (w), 851 (m), 810 (w), 770 (m), 
752 (m), 679 (w), 668 (w), 615 (w), 571 (w), 519 (w), 456 (w), 417 (w) 
cm
-1
.
1
H NMR (500 MHz, DMSO-D6): δ = 8.18 (s, 1H, NH), 7.40 (dt, 
4
JH,H 
= 2.3 Hz, 
3
JH,H = 11.9 Hz, 1H, CH), 7.35 (td, 
3
JH,H = 8.2, 6.7 Hz, 1H, CH), 
7.23 (dd, 
4
JH,H = 2.1 Hz, 
3
JH,H = 8.3 Hz, 1H, CH), 6.88 (td, 
4
JH,H = 2.5 Hz, 
3
JH,H = 8.5 Hz, 1H, CH), 4.66 (ddd, 
3
JH,H = 9.5, 6.2, 3.4 Hz, 1H, CH), 4.34 
(t, 
3
JH,H = 9.0 Hz, 1H, CH2), 4.11 (dd, 
3
JH,H = 9.0, 4.7 Hz, 1H , CH2), 4.09-
4.00 (m, 2H, CH2), 3.78 (dd, 
3
JH,H = 9.4, 6.2 Hz, 1H, CH) ppm. 
13
C NMR 
(125 MHz, DMSO-D6): δ = 162.3 (d, 
1
JC,F = 241.8 Hz, C), 159.0 (C), 
153.9 (C), 140.0 (d, 
4
JC,F = 11.0 Hz, C), 130.6 (t, 
4
JC,F = 9.5 Hz, CH), 
113.8 (d, 
4
JC,F = 2.7 Hz), 110.1 (d, 
3
JC,F = 21.0 Hz, CH), 105.1 (d, 
3
JC,F = 
27.0 Hz, CH), 72.8 (CH), 65.5 (CH2), 53.8 (CH), 46.5 (CH2), ppm. 
19
F 
NMR (500 MHz, CDCl3): δ = -111.8 ppm. Optical rotation: []D
20
 = +3.5 
(c 0.2, ethanol). HRMS-ESI: calcd. for C12H11FN2NaO4
+
 289.0595; found 
289.0595 [M + Na]
+
.  
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4.2.67 (4S,5'R)-3'-(3-Fluoro-4-iodophenyl)-[4,5'-bioxazolidine]-2,2'-
dione (299) 
 
To a solution of bioxazolidinone 306 (184 mg, 0.69 mmol) in 
trifluoroacetic acid (0.69 mL), N-iodosuccinimide (161 mg, 0.72 mmol) 
was added at room temperature and stirred for 3 hours. Then, it was 
concentrated under reduced pressure using a rotary evaporator, washed 
with distilled water, extracted with ethyl acetate, dried over MgSO4, 
concentrated under reduced pressure using a rotary evaporator and 
purified over column chromatography on silica gel to obtain 299 (200 mg, 
0.51 mmol, 74%) as white solid.  
TLC (cyclohexane/ethyl acetate = 1:5) Rf = 0.28 (UV). IR (ATR)  𝑣  =  
3410 (w), 3098 (w), 2928 (w), 1772 (m), 1744 (m), 1597 (w), 1572 (w), 
1478 (m), 1421 (w), 1399 (m), 1333 (m), 1313 (w), 1279 (w), 1224 (m), 
1199 (m), 1161 (w), 1138 (w), 1111 (w), 1095 (w), 1070 (w), 1027 (m), 
976 (m), 921 (m), 881 (w), 868 (m), 803 (m), 747 (m), 730 (w), 714 (m), 
613 (w), 545 (w), 534 (w), 524 (w), 497 (m), 456 (w), 444 (w) cm
-1
. UV-
Vis (EtOH) max (log ) 249 (3.32), 205 (3.30) nm. 
1
H NMR (500 MHz, 
DMSO-D6): δ = 8.16 (d, 
3
JH,H = 1.4 Hz, 1H, NH), 7.84 (dd,  
3
JH,H = 8.7, 7.5 
Hz, 1H, CH), 7.54 (dd, 
4
JH,H = 2.5 Hz, 
3
JH,H = 10.9 Hz, 1H, CH), 7.20 (dd, 
4
JH,H = 2.5 Hz, 
3
JH,H = 8.7 Hz, 1H, CH), 4.75 (ddd, 
4
JH,H = 6.1 Hz, 
3
JH,H = 
9.5, 3.5 Hz, 1H, CH), 4.45 (t, 
3
JH,H = 9.1 Hz, 1H, CH), 4.19 (dd, 
3
JH,H = 
9.0, 4.7 Hz, 1H, CH2), 4.17-4.06 (m, 2H, CH2), 3.80 (dd, 
4
JH,H = 6.0 Hz, 
3
JH,H = 9.4 Hz, 1H, CH2) ppm. 
13
C NMR (125 MHz, DMSO-D6): δ = 161.2 
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(d, 
1
JC,F = 240.1 Hz, C), 160.0 (C), 153.8 (C), 140.3 (d, 
3
JC,F = 10.3 Hz, 
C), 139.1 (d, 
4
JC,F = 2.4 Hz, CH), 115.8 (d, 
4
JC,F = 2.9 Hz, CH), 105.5 (d, 
2
JC,F = 29.8 Hz, CH), 74.2 (d, 
2
JC,F = 26.0 Hz, C), 72.9 (CH), 65.6 (CH2), 
53.9 (CH), 46.4 (CH2) ppm. 
19
F NMR (500 MHz, DMSO-D6): δ = -93.9 
ppm. Optical rotation: []D
20
 = +53.7 (c 0.4, ethanol). HRMS-ESI: calcd. 
for C12H11FIN2NaO4
+
 414.9561; found 414.9561 [M + Na]
+
.  
4.2.68 (4S,5'S)-tert-Butyl 3'-(3-fluorophenyl)-2,2-dimethyl-2'-oxo-
[4,5'-bioxazolidine]-3-carboxylate (321) 
 
To a solution of bioxazolidine 296 (654 mg, 2.3 mmol) in 1,4-dioxane (5.0 
mL), 1-fluoro-3-iodobenzene (508 mg, 2.3 mmol), caesium carbonate 
(3.0 g, 9.20 mmol) and copper iodide (23 mg, 0.12 mmol) were added, 
evacuated and backfilled with argon three times. After that, N,N’-
dimethylethylenediamine (23 mg, 0.23 mmol) was put into the reaction 
and stirred under argon at 110 °C for 4 hours. It was cooled to room 
temperature, diluted with ethyl acetate, filtered through Celite®, 
concentrated under reduced pressure using a rotary evaporator and 
purified by flash column chromatography to generate 321 (840 mg, 2.2 
mmol, 97%) as white solid.   
TLC (cyclohexane/ethyl acetate = 3:1) Rf = 0.29 (UV or Ninhydrin Stain). 
UV-Vis (EtOH) max (lg ) 270 (2.26), 240 (3.05), 203 (3.26) nm. IR 
(ATR) 𝑣 =  2976 (w), 1739 (m), 1679 (w), 1615 (w), 1591 (w), 1496 (w), 
1479 (w), 1459 (w), 1410 (w), 1387 (w), 1364 (w), 1349 (w), 1322 (w), 
1298 (w), 1280 (w), 1261 (w), 1231 (w), 1217 (w), 1198 (w), 1157 (w), 
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1120 (w), 1091 (w), 1050 (w), 1032 (w), 1007 (w), 994 (w), 969 (w), 869 
(w), 842 (w), 805 (w), 770 (w), 756 (w), 744 (w), 721 (w), 677 (w), 663 
(w), 603 (w), 552 (w), 524 (w), 486 (w), 453 (w), 426 (w) cm
-1
. 
1
H NMR 
(500 MHz, CDCl3): δ = 7.42 (d, 
3
JH,H = 11.0 Hz, 1H, CH), 7.31 (q, 
3
JH,H = 
7.2 Hz, 1H, CH), 7.23 (d, 
3
JH,H = 8.9 Hz, 1H, CH), 6.83 (q, 
3
JH,H = 7.9 Hz, 
1H, CH), 5.10-4.90 (m, 1H, CH), 4.43-4.24 (m, 1H, CH2), 4.23-3.97 (m, 
3H, CH, CH2), 3.94 (q, 
3
JH,H = 8.6, 8.2 Hz, 1H, CH2), 1.72-1.42 (m, 15H, 5 
x CH3) ppm. 
13
C NMR (125 MHz, CDCl3): δ = A: 163.2 (d, 
1
JC,F = 245.2 
Hz, C), 154.3 (C), 153.3 (C), 139.7 (s, CH), 130.8 (CH), 113.5 (CH), 
112.4-110.3 (m, CH), 106.1 (C), 95.1 (C), 81.5 (C), 71.5 (CH), 63.5 
(CH2), 57.9 (CH), 46.3 (CH2), 28.5 (CH3), 27.2 (CH3), 23.9 (CH3) ppm.; 
B: 163.2 (d, 
1
JC,F = 245.1 Hz, C), 154.1 (C), 152.0 (C), 139.7 (C), 130.8 ( 
CH), 113.5 (CH), 12.4-110.3 (m, CH), 106.0 (d, 
3
JC,F = 27.0 Hz, CH), 94.8 
(C), 81.3 (C), 71.4 (CH), 63.3 (CH2), 57.6 (CH), 46.2 (CH2), 28.4 (CH3), 
26.9 (CH3), 22.5 (CH3) ppm. 
19
F NMR (500 MHz, CDCl3): δ = -110.8, -
111.1 ppm. Optical rotation: []D
20
 = -0.5 (c 0.2, ethanol). HRMS-ESI: 
calcd. for C19H25FN2NaO5
+
 403.1640; found 403.1640 [M + Na]
+
.  
4.2.69 (4S,5'S)-3'-(3-Fluorophenyl)-[4,5'-bioxazolidine]-2,2'-dione 
(323) 
 
To a solution of oxazolidinone 321 (308 mg, 1.0 mmol) in 
dichloromethane (10.0 mL), 4N HCl in 1,4-dioxane (2.5 mL, 10.0 mmol) 
was added and stirred at room temperature overnight. It was 
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concentrated under reduced pressure using a rotary evaporator and 
used for next step without purification.  
To a solution of amino salts 322 (1.0 mmol) in anhydrous THF (10.0 mL), 
N,N-diisopropylethylamine (324 g, 2.5 mmol) was added till the salts 
were completely dissolved in solvent. Subsequently, triphosgene (300 g, 
1.0 mmol) in anhydrous THF (10.0 mL) was added at 0 °C over 1 hour 
and stirred at this temperature for 2-3 hours. It was poured into distilled 
water, extracted with ethyl acetate, dried over MgSO4, concentrated 
under reduced pressure using a rotary evaporator and purified by flash 
column chromatography on silica gel to afford 323 (207 g, 0.78 mmol, 
78%) as white solid.  
TLC (cyclohexane/ethyl acetate 1:5) Rf = 0.24 (UV). UV-Vis (EtOH) max 
(lg ) 270 (3.03), 236 (3.80), 202 (4.10) nm. IR (ATR) 𝑣 =  3467 (w), 3205 
(w), 3128 (w), 2921 (w), 1747 (s), 1607 (w), 1589 (w), 1497 (m), 1472 
(w), 1454 (w), 1412 (m), 1382 (w), 1330 (w), 1254 (w), 1221 (m), 1199 
(m), 1174 (m), 1116 (m), 1075 (w), 1059 (w), 1039 (m), 1020 (m), 996 
(w), 963 (w), 934 (m), 897 (w), 871 (m), 858 (m), 796 (m), 741 (m), 720 
(w), 683 (m), 664 (m), 620 (w), 554 (w), 520 (w), 463 (w), 428 (w) cm
-1
. 
1
H NMR (500 MHz, DMSO-D6): δ = 8.13 (s, 1H, NH), 7.45 (dt, 
5
JH,H = 2.3 
Hz, 
3
JH,H = 11.9 Hz, 1H, CH), 7.39 (td, 
3
JH,H = 8.3, 6.3 Hz, 1H, CH), 7.28 
(dd, 
4
JH,H = 2.1 Hz, 
3
JH,H = 8.4 Hz, 1H, CH), 6.92 (td, 
5
JH,H = 2.6 Hz, 
3
JH,H = 
8.4 Hz, 1H, CH), 4.70 (ddd, 
4
JH,H = 6.2 Hz, 
3
JH,H = 9.5, 3.5 Hz, 1H, CH), 
4.39 (t, 
3
JH,H = 9.1 Hz, 1H, CH), 4.15 (dd, 
3
JH,H = 9.0, 4.7 Hz, 1H, CH2), 
4.12-4.03 (m, 2H, CH2), 3.77 (dd, 
4
JH,H = 6.1 Hz, 
3
JH,H = 9.4 Hz, 1H, CH2) 
ppm. 
13
C NMR (125 MHz, DMSO-D6): δ = 162.3 (d, 
1
JC,F = 241.8 Hz, C), 
159.0 (C), 153.9 (C), 140.0 (d, 
3
JC,F = 11.0 Hz, C), 130.6 (d, 
4
JC,F = 9.5 
Hz, CH), 113.7 (d, 
4
JC,F = 2.7 Hz, CH), 110.1 (d, 
2
JC,F = 21.0 Hz, CH), 
105.0 (d, 
2
JC,F = 27.0 Hz, CH), 72.8 (CH), 65.5 (CH2), 53.9 (CH), 46.5 
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(CH2) ppm. 
19
F NMR (500 MHz, DMSO-D6): δ = -111.8 ppm. Optical 
rotation: []20D = 17.1 (c 0.3, EtOH). HRMS-ESI: calcd. for 
C12H11FN2NaO4
+
 289.0595; found 289.0595 [M + Na]
+
.  
4.2.70 (4S,5'S)-3'-(3-Fluoro-4-iodophenyl)-[4,5'-bioxazolidine]-2,2'-
dione (324) 
 
To a solution of bioxazolidinone 323 (203 mg, 0.76 mmol) in 
trifluoroacetic acid (0.76 mL), N-iodosuccinimide (178 mg, 0.8 mmol) was 
added at room temperature and stirred for 3 hours. Then, it was 
concentrated under reduced pressure using a rotary evaporator, washed 
with distilled water, extracted with ethyl acetate, dried over MgSO4, 
concentrated under reduced pressure using a rotary evaporator and 
purified by flash column chromatography on silica gel to yield 324 (231 
mg, 0.59 mmol, 78%) as white solid.  
TLC (cyclohexane/ethyl acetate = 1:5) Rf = 0.28 (UV). IR (ATR)  𝑣  =  
3408 (w), 3254 (w), 2962 (w), 2918 (w), 1737 (m), 1715 (m), 1601 (w), 
1568 (w), 1479 (w), 1454 (w), 1431 (w), 1417 (w), 1398 (w), 1342 (w), 
1323 (w), 1292 (w), 1264 (w), 1234 (w), 1205 (w), 1164 (w), 1130 (w), 
1115 (w), 1074 (w), 1040 (w), 969 (w), 925 (w), 873 (w), 842 (w), 805 
(w), 779 (w), 761 (w), 746 (w), 728 (w), 688 (w), 671 (w), 603 (w), 572 
(w), 544 (w), 525 (w), 504 (w), 454 (w) cm
-1
. UV-Vis (EtOH) max (log ) 
247 (3.41), 206 (3.07) nm. 
1
H NMR (500 MHz, DMSO-D6): δ = 8.16 (d, 
3
JH,H = 1.6 Hz, 1H, NH), 7.84 (dd,  
3
JH,H = 8.7, 7.5 Hz, 1H, CH), 7.54 (dd, 
4
JH,H = 2.5 Hz, 
3
JH,H = 10.8 Hz, 1H, CH), 7.20 (dd, 
4
JH,H = 2.5 Hz, 
3
JH,H = 
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8.7 Hz, 1H, CH), 4.75 (ddd, 
4
JH,H = 6.1 Hz, 
3
JH,H = 9.5, 3.5 Hz, 1H, CH), 
4.43 (t, 
3
JH,H = 9.1 Hz, 1H, CH), 4.19 (dd, 
3
JH,H = 9.0, 4.7 Hz, 1H, CH2), 
4.17-4.06 (m, 2H, CH2), 3.80 (dd, 
4
JH,H = 6.0 Hz, 
3
JH,H = 9.4 Hz, 1H, CH2) 
ppm. 
13
C NMR (125 MHz, DMSO-D6): δ = 161.2 (d, 
1
JC,F = 240.2 Hz, C), 
158.9 (C), 153.7 (C), 140.2 (d, 
3
JC,F = 10.3 Hz, C), 139.0 (d, 
4
JC,F = 3.3 
Hz, CH), 115.7 (d, 
4
JC,F = 3.0 Hz, CH), 105.4 (d, 
2
JC,F = 29.8 Hz, CH), 
74.2 (d, 
2
JC,F = 26.1 Hz, C), 72.9 (CH), 65.4 (CH2), 53.8 (CH), 46.3 (CH2) 
ppm. 
19
F NMR (500 MHz, DMSO-D6): δ = -93.9 ppm. Optical rotation: 
[]D
20
 = +10.0 (c 0.1, ethanol). HRMS-ESI: calcd. for C12H11FIN2NaO4
+
 
414.9561; found 414.9561 [M + Na]
+
.  
4.2.71 (4S,5'R)-3'-(3-Fluoro-4-(tributylstannyl)phenyl)-[4,5'-
bioxazolidine]-2,2'-dione (319) 
 
To a solution of iodo compound 299 (24 mg, 0.061 mmol) in 1,4-dioxane 
(1 mL), hexabutyldistannane (0.02 mL, 23 mg, 0.04 mmol)  and 
bis(triphenylphosphine)palladium(II) dichloride (4 mg, 0.005 mmol) were 
added and stirred at 100 °C for 2 hours. The solution was filtered through 
Celite®, concentrated in vacuo and purified by flash column 
chromatography on silica gel with 10% potassium fluoride to afford 319 
(18 mg, 0.035 mmol, 53%) as colourless oil.   
TLC (cyclohexane/ethyl acetate = 1:2) Rf = 0.29 (UV). 
1
H NMR (500 
MHz, C6D6): δ = 8.50 (s, 1H, NH), 7.54-7.49 (m, 1H, CH), 7.49-7.42 (m, 
2H, 2 x CH), 3.79-3.69 (m, 2H, CH2), 3.64 (dd, 
3
JH,H = 9.3, 4.7 Hz, 1H, 
CH), 3.27-3.14 (m, 3H, CH, CH2), 1.75-1.54 (m, 6H, 3 x CH2), 1.45-1.35 
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(m, 6H, 3 x CH2), 1.33-1.13 (m, 6H, 3 x CH2), 0.93 (t, 
3
JH,H = 7.3 Hz, 9H, 
3 x CH3) ppm. 
13
C NMR (125 MHz, C6D6): δ = 168.3 (d, 
1
JC,F = 232.9 Hz, 
C), 160.2 (C), 153.5 (C), 140.9 (d, 
3
JC,F = 10.8 Hz, C), 138.1 (d, 
4
JC,F = 1.7 
Hz, CH), 121.6 (d, 
3
JC,F = 46.2 Hz, C), 114.2 (d, 
4
JC,F = 2.6 Hz, CH), 72.6 
(CH), 66.1 (CH2), 54.1 (CH), 46.1 (CH2), 29.5 (3 x CH2), 27.7 (3 x CH2), 
13.9 (3x CH3), 10.3 (3 x CH2) ppm. 
19
F NMR (500 MHz, C6D6): δ = -91.6 
ppm. HRMS-ESI: calcd. for C24H38FN2NaO4Sn
+
 579.2756; found 
579.1656 [M + Na]
+
.  
4.2.72 2-Methyl-5-(5-(tributylstannyl)pyridin-2-yl)-1,3,4-oxadiazole 
(320) 
 
To a solution of brominated pyridine 313 (24 mg, 0.1 mmol) in 1,4-
dioxane (1 mL), hexabutyldistannane (0.03 mL, 0.06 mmol) and 
bis(triphenylphosphine)palladium(II) dichloride (7 mg, 0.009 mmol) were 
added and stirred at 100 °C for 2 hours. The solution was filtered through 
Celite®, concentrated in vacuo and purified by flash column 
chromatography on silica gel with 10% potassium fluoride to afford 320 
(32 mg, 0.07 mmol, 70%) as colourless oil.   
TLC (cyclohexane/ethyl acetate = 5:1) Rf = 0.2 (UV). 
1
H NMR (500 MHz, 
CDCl3): δ = 8.79-8.62 (m, 1H, CH), 8.14 (dd, 
4
JH,H = 1.0 Hz, 
3
JH,H = 7.6 
Hz, 1H, CH), 8.02-7.88 (m, 1H, CH), 1.72-1.42 (m, 6H, 3 x CH2), 1.40-
1.26 (m, 6H, 3 x CH2), 1.22-1.05 (m, 6H, 3 x CH2), 0.93 (t, 
3
JH,H = 7.3 Hz, 
12H, 4 x CH3) ppm. 
13
C NMR (125 MHz, CDCl3): δ = 164.8 (C), 164.6 
(C), 156.2 (CH), 145.6 (CH), 142.8 (C), 141.8 (C), 122.5 (CH), 29.1 (3 x 
CH2), 27.4 (3 x CH2), 13.8 (3x CH3), 11.3 (CH3), 10.0 (3 x CH2) ppm.  
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4.2.73 (4S,5'R)-3'-(3-Fluoro-4-(6-(5-methyl-1,3,4-oxadiazol-2-
yl)pyridin-3-yl)phenyl)-[4,5'-bioxazolidine]-2,2'-dione (104) 
 
Method A: To a solution of organostannane 319 (36 mg, 0.069 mmol) in 
N-methyl-2-pyrrolidon (1 mL), brominated pyridine 313 (18 mg, 0.076 
mmol), lithium chloride (11 mg, 0.23 mmol), 
bis(triphenylphosphine)palladium(II) dichloride (3 mg, 0.004 mmol) were 
added and stirred at 120 °C for 4 hours. Then, it was cooled to room 
temperature, poured into distilled water, extracted three times with ethyl 
acetate. The collected organic phases were washed with birne, dried 
over MgSO4, concentrated in vacuo and purified by column 
chromatography on silica gel with 10% potassium fluoride to achieve 104 
(8.8 mg, 0.021 mmol, 30%) as white solid.  
Method B: To a solution of organostannane 320 (11 mg, 0.024 mmol) in 
N-methyl-2-pyrrolidon (1 mL), iodo compound 299 (11 mg, 0.027 mmol), 
lithium chloride (4 mg, 0.08 mmol), bis(triphenylphosphine)palladium(II) 
dichloride (1 mg, 0.001 mmol) were added and stirred at 120 °C for 4 
hours. Then, it was cooled to room temperature, poured into distilled 
water, extracted three times with ethyl acetate. The collected organic 
phases were washed with birne, dried over MgSO4, concentrated in 
vacuo and purified by column chromatography on silica gel with 10% 
potassium fluoride to achieve 104 (7.6 mg, 0.018 mmol, 26%) as white 
solid. 
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TLC (chloroform/methanol = 20:1) Rf = 0.14 (UV). 
1
H NMR (500 MHz, 
DMSO-D6): δ = 8.92 (q, 
3
JH,H = 1.6 Hz, 1H, NH), 8.21 (d, 
3
JH,H = 1.4 Hz, 
2H, 2 x CH), 8.14-8-08 (m, 1H, CH), 7.76 (t, 
3
JH,H = 8.8 Hz, CH), 7.66 (dd, 
4
JH,H = 2.3 Hz, 
3
JH,H = 13.6 Hz, 1H, CH), 7.47 (dd, 
4
JH,H = 2.3 Hz, 
3
JH,H = 
8.6 Hz, 1H, CH), 4.78 (ddd, 
4
JH,H = 4.7 Hz, 
3
JH,H = 9.0, 6.3 Hz, 1H, CH), 
4.43 (t, 
3
JH,H = 8.4 Hz, 1H, CH2), 4.26-4.11 (m, 3H, CH, CH2), 3.85 (dd, 
3
JH,H = 9.5, 6.4 Hz, 1H, CH2), 2.6 (s, 3H, CH3) ppm. 
13
C NMR (125 MHz, 
DMSO-D6): δ = 165.0 (C), 163.4 (C), 159.4 (d, 
1
JC,F = 246.1 Hz, C), 158.8 
(C), 153.6 (C), 149.5 (d, 
4
JC,F = 4.2 Hz, CH), 141.7 (C), 140.5 (d, 
3
JC,F = 
11.3 Hz, C), 137.4 (d, 
4
JC,F = 3.5 Hz, CH), 132.6 (d, 
5
JC,F = 2.2 Hz, C), 
131.2 (d, 
4
JC,F = 4.1 Hz, CH), 122.5 (CH), 118.7 (d, 
3
JC,F = 13.2 Hz, C), 
114.3 (d, 
4
JC,F = 3.0 Hz, CH), 105.7 (d, 
2
JC,F = 28.4 Hz), 73.0 (CH), 64.8 
(CH2), 53.2 (CH), 45.6 (CH2), 10.7 (CH3) ppm. 
19
F NMR (500 MHz, 
DMSO-D6): δ = -115.8 ppm.  
4.2.74 (4S,5'R)-3'-(3-Fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-
yl)phenyl)-[4,5'-bioxazolidine]-2,2'-dione (102) 
 
To a solution of organostannane 319 (18 mg, 0.035 mmol) in N-methyl-2-
pyrrolidon (1 mL), brominated pyridine 311 (9 mg, 0.038 mmol), lithium 
chloride (6 mg, 0.12 mmol), bis(triphenylphosphine)palladium(II) 
dichloride (2 mg, 0.002 mmol) were added and stirred at 120 °C for 4 
hours. Then, it was cooled to room temperature, poured into distilled 
water, extracted three times with ethyl acetate. The collected organic 
phases were washed with birne, dried over MgSO4, concentrated in 
vacuo and purified by column chromatography on silica gel with 10% 
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potassium fluoride to achieve 102 (4.7 mg, 0.011 mmol, 32%) as white 
solid. 
TLC (chloroform/methanol = 20:1) Rf = 0.06 (UV). 
1
H NMR (500 MHz, 
DMSO-D6): δ = 8.91 (s, 1H, NH), 8.22-8.14 (m, 2H, 2 x CH), 8.12 (s, 1H, 
CH), 7.74 (t, 
3
JH,H = 8.8 Hz, CH), 7.65 (dd, 
4
JH,H = 2.2 Hz, 
3
JH,H = 13.6 Hz, 
1H, CH), 7.46 (dd, 
4
JH,H = 2.3 Hz, 
3
JH,H = 8.0 Hz, 1H, CH), 4.78 (ddd, 
4
JH,H 
= 4.7 Hz, 
3
JH,H = 8.9, 6.4 Hz, 1H, CH), 4.43 (d, 
3
JH,H = 8.7 Hz, 1H, CH2), 
4.44 (s, 3H, CH3), 4.42 (d, 
3
JH,H = 8.7 Hz, 1H, CH2), 4.25-4.10 (m, 2H, 
CH2), 3.85 (dd, 
3
JH,H = 9.5, 6.3 Hz, 1H, CH) ppm. 
13
C NMR (125 MHz, 
DMSO-D6): δ = 163.9 (C), 158.8 (C), 159.3 (d, 
1
JC,F = 245.8 Hz, C), 158.8 
(C), 153.6 (C), 149.5 (d, 
4
JC,F = 4.0 Hz, CH), 145.2 (C), 140.2 (d, 
3
JC,F = 
11.2 Hz, C), 137.3 (d, 
4
JC,F = 3.4 Hz, CH), 131.6 (d, 
5
JC,F = 2.0 Hz), 131.1 
(d, 
4
JC,F = 4.3 Hz, CH), 122.2 (CH), 119.0 (d, 
3
JC,F = 13.3 Hz, C), 114.3 (d, 
4
JC,F = 3.0 Hz, CH), 105.7 (d, 
2
JC,F = 28.4 Hz, CH), 73.0 (CH), 64.8 (CH2), 
53.2 (CH), 45.6 (CH2) ppm. 
19
F NMR (500 MHz, DMSO-D6): δ = -115.8 
ppm.  
4.2.75 (4S,5'R)-3'-(3-Fluoro-4-(6-(1-methyl-1H-tetrazol-5-yl)pyridin-3-
yl)phenyl)-[4,5'-bioxazolidine]-2,2'-dione (103) 
 
To a solution of organostannane 319 (32 mg, 0.062 mmol) in N-methyl-2-
pyrrolidon (1 mL), brominated pyridine 312 (16 mg, 0.068 mmol), lithium 
chloride (10 mg, 0.2 mmol), bis(triphenylphosphine)palladium(II) 
dichloride (3.5 mg, 0.003 mmol) were added and stirred at 120 °C for 4 
hours. Then, it was cooled to room temperature, poured into distilled 
water, extracted three times with ethyl acetate. The collected organic 
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phases were washed with birne, dried over MgSO4, concentrated in 
vacuo and purified by column chromatography on silica gel with 10% 
potassium fluoride to achieve 103 (9.9 mg, 0.023 mmol, 38%) as white 
solid. 
TLC (chloroform/methanol = 20:1) Rf = 0.08 (UV). 
1
H NMR (500 MHz, 
DMSO-D6): δ = 9.08-8.98 (m, 1H, NH), 8.35 (dd, 
4
JH,H  = 0.9 Hz, 
3
JH,H = 
8.3 Hz, 2H, CH), 8.29 (ddd, 
4
JH,H  = 1.3 Hz, 
3
JH,H = 8.2, 2.4 Hz, 1H, CH), 
8.20-8.11 (m, 1H, CH), 7.81 (t, 
3
JH,H  = 8.8 Hz, 1H, CH), 7.70 (dd, 
4
JH,H  = 
2.3 Hz, 
3
JH,H  = 13.5 Hz, 1H, CH), 7.52 (dd, 
4
JH,H  = 2.3 Hz, 
3
JH,H  = 8.6 Hz, 
1H, CH), 4.83 (ddd, 
4
JH,H  = 4.4 Hz, 
3
JH,H  = 9.0, 6.3 Hz, 1H, CH), 4.46 (d, 
3
JH,H  = 4.3 Hz, 1H, CH2), 4.30-4.13 (m, 3H, CH, CH2), 3.89 (dd, 
3
JH,H  = 
9.4, 6.3 Hz, 1H, CH2) ppm. 
13
C NMR (125 MHz, DMSO-D6): δ = 159.4 (d, 
1
JC,F = 246.6 Hz, C), 158.8 (C), 153.6 (C), 151.8 (C), 149.0 (d, 
4
JC,F = 4.0 
Hz, CH), 143.1 (C), 140.5 (d, 
3
JC,F = 11.3 Hz, C), 137.6 (d, 
4
JC,F = 3.4 Hz, 
CH), 132.2 (d, 
5
JC,F = 2.1 Hz, C), 131.2 (d, 
4
JC,F = 4.2 Hz, CH), 124.0 (C), 
118.7 (d, 
3
JC,F = 13.3 Hz, CH), 114.3 (d, 
4
JC,F = 3.0 Hz, CH), 105.7 (d, 
2
JC,F = 28.4 Hz, CH), 73.0 (CH), 64.8 (CH2), 53.2 (CH), 45.6 (CH2), 36.7 
(CH3) ppm. 
19
F NMR (500 MHz, DMSO-D6): δ = -115.9 ppm.  
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4.3 Crystallographic data 
4.3.1 Crystal structure analysis of compound 281 
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Crystal habitus  clear colourless 
needle 
/mm-1 0.728 
Device type Bruker X8-
KappaApexII 
F 528.0 
Empirical formula C12H21NO4 Crystal size/mm
3 0.24 x 0.2 x 0.1 
Moiety formula C12H21NO4 Absorption correction empirical 
Formula weight 243.30 Tmin; Tmax 0.5263; 0.7536 
Temperature/K 100 Radiation CuK ( 1.54178) 
Crystal system Orthorhombic 2 range for data 
collection/o 
10.018 to 144.24o  
Space group  P212121 Completeness to theta 0.995 
a/Å 5.7773(2) Index ranges - 4 ≤ h ≤ 7, -9 ≤ h ≤ 11, -28 
≤ h ≤ 30 
b/Å 9.4348(3) Reflections collected  9624 
c/Å 25.0285(6) Independent reflections 2614 [Rint = 0.0403, Rsigma = 
0.0369] 
 90 Data/restraints/parameters 2614/0/160 
 90 Goodness-of-fit on F
2 1.036 
 90 Final R indexes [I>=2 (I)] R1 = 0.0303, wR2 = 0.0676 
Volume/Å3 1364.24(7) Final R indexes [all Data] R1 = 0.0350, wR2 = 0.0697 
 4 Largest diff. peak/hole/ e 
Å-3 
0.17/-0.12 
calcg/cm
3 1.185 Flack parameter 0.16(10) 
Table 18 Details of X-ray crystal structure determination of compound 281. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C2 1.429(2) N C4 1.357(2) 
O1 C3 1.434(2) C1 C2 1.513(3) 
O2 C4 1.349(2) C1 C9 1.514(3) 
O2 C5 1.475(2) C3 C11 1.522(3) 
O3 C4 1.214(2) C3 C12 1.508(3) 
O4 C9 1.444(2) C5 C6 1.514(2) 
O4 C10 1.443(2) C5 C7 1.520(3) 
N C1 1.467(2) C5 C8 1.515(3) 
N C3 1.485(2) C9 C10 1.462(3) 
Table 19 Details of X-ray crystal structure determination of compound 281. 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C2 O1 C3 108.17(13) C12 C3 C11 113.02(16) 
C4 O2 C5 120.56(14) O2 C4 N 109.96(15) 
C10 O4 C9 60.86(11) O3 C4 O2 125.77(16) 
C1 N C3 111.45(13) O3 C4 N 124.26(16) 
C4 N C1 125.56(15) O2 C5 C6 110.79(15) 
C4 N C3 122.77(14) O2 C5 C7 101.52(14) 
N C1 C2 99.96(14) O2 C5 C8 109.94(16) 
N C1 C9 109.73(14) C6 C5 C7 110.89(17) 
C2 C1 C9 115.99(14) C6 C5 C8 112.64(18) 
O1 C2 C1 104.69(14) C8 C5 C7 110.52(19) 
O1 C3 N 102.37(13) O4 C9 C1 116.30(15) 
O1 C3 C11 110.11(15) O4 C9 C10 59.55(11) 
O1 C3 C12 107.45(14) C10 C9 C1 123.04(17) 
N C3 C11 110.97(14) O4 C10 C9 59.59(11) 
N C3 C12 112.30(15)     
Table 20 Details of X-ray crystal structure determination of compound 281. 
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A B C D Angle/˚ A B C D Angle/˚ 
N C1 C2 O1 32.75(16) C3 N C1 C9 104.28(16) 
N C1 C9 O4 -160.17(15) C3 N C4 O2 174.30(15) 
N C1 C9 C10 -90.8(2) C3 N C4 O3 -6.3(3) 
C1 N C3 O1 -3.04(18) C4 O2 C5 C6 59.5(2) 
C1 N C3 C11 114.42(16) C4 O2 C5 C7 177.30(17) 
C1 N C3 C12 -117.99(16) C4 O2 C5 C8 -65.7(2) 
C1 N C4 O2 0.1(2) C4 N C1 C2 156.65(16) 
C1 N C4 O3 179.51(17) C4 N C1 C9 -81.0(2) 
C1 C9 C10 O4 -103.34(18) C4 N C3 O1 -177.96(15) 
C2 O1 C3 N 25.06(17) C4 N C3 C11 -60.5(2) 
C2 O1 C3 C11 -93.01(17) C4 N C3 C12 67.1(2) 
C2 O1 C3 C12 143.50(15) C5 O2 C4 O3 2.4(3) 
C2 C1 C9 O4 -47.9(2) C5 O2 C4 N -178.26(14) 
C2 C1 C9 C10 21.4(2) C9 C1 C2 O1 -85.09(17) 
C3 O1 C2 C1 -37.68(17) C10 O4 C9 C1 114.51(19) 
C3 N C1 C2 -18.10(17)      
Table 21 Details of X-ray crystal structure determination of compound 281. 
 
4.3.2 Crystal structure analysis of compound 92 
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Crystal habitus  clear colourless 
plank 
/mm-1 0.124 
Device type Bruker X8-
KappaApexII 
F 184.0 
Empirical 
formula 
C16H18FN3O5 Crystal size/mm
3 0.1 x 0.02 x 0.02 
Moiety formula C16H18FN3O5 Absorption correction Empirical 
Formula weight 351.33 Tmin; Tmax 0.6682; 0.7459 
Temperature/K 100 Radiation CuK ( 0.71073) 
Crystal system Triclinic 2 range for data 
collection/o 
7.38 to 55.998o  
Space group  P1 Completeness to theta 0.997 
a/Å 6.1801(7) Index ranges - 8 ≤ h ≤ 8, -8 ≤ h ≤ 8, -14 ≤ 
h ≤ 14 
b/Å 6.2673(7) Reflections collected  8022 
c/Å 11.0167(14) Independent reflections 3567 [Rint = 0.0461, Rsigma = 
0.0756] 
 81.777(7) Data/restraints/parameters 3567/3/227 
 85.382(7) Goodness-of-fit on F
2 1.058 
 63.329(6) Final R indexes [I>=2 (I)] R1 = 0.0649, wR2 = 0.1416 
Volume/Å3 377.32(8) Final R indexes [all Data] R1 = 0.0869, wR2 = 0.1687 
 1 Largest diff. peak/hole/ e 
Å-3 
0.29/-0.37 
calcg/cm
3 1.546 Flack parameter -2(2) 
Table 22 Details of X-ray crystal structure determination of compound 92. 
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Atom Atom Length/Å Atom Atom Length/Å 
F C6 1.353(5) N2 C13 1.355(7) 
O1 C1 1.429(7) N3 C14 1.455(6) 
O1 C4 1.424(7) N3 C15 1.352(6) 
O2 C12 1.449(6) C1 C2 1.515(7) 
O2 C13 1.353(6) C3 C4 1.504(8) 
O3 C13 1.227(6) C5 C6 1.394(7) 
O4 C15 1.351(6) C5 C10 1.397(7) 
O4 C16 1.441(6) C6 C7 1.377(7) 
O5 C15 1.215(6) C7 C8 1.394(7) 
N1 C2 1.472(7) C8 C9 1.395(7) 
N1 C3 1.467(6) C9 C10 1.393(7) 
N1 C5 1.424(6) C11 C12 1.532(7) 
N2 C8 1.415(6) C12 C14 1.516(7) 
N2 C11 1.450(6) C14 C16 1.538(8) 
Table 23 Details of X-ray crystal structure determination of compound 92. 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C4 O1 C1 109.2(4) C6 C7 C8 119.1(5) 
C13 O2 C12 109.2(4) C7 C8 N2 118.8(5) 
C15 O4 C16 110.3(4) C7 C8 C9 119.1(5) 
C3 N1 C2 109.6(4) C9 C8 N2 122.1(5) 
C5 N1 C2 113.9(4) C10 C9 C8 119.7(5) 
C5 N1 C3 115.0(4) C9 C10 C5 122.7(4) 
C8 N2 C11 123.2(4) N2 C11 C12 101.4(4) 
C13 N2 C8 125.2(4) O2 C12 C11 103.9(4) 
C13 N2 C11 110.9(4) O2 C12 C14 108.4(4) 
C15 N3 C14 111.6(4) C14 C12 C11 114.6(4) 
O1 C1 C2 111.2(5) O2 C13 N2 110.3(4) 
N1 C2 C1 110.4(4) O3 C13 O2 120.9(5) 
N1 C3 C4 109.5(5) O3 C13 N2 128.8(5) 
O1 C4 C3 111.7(4) N3 C14 C12 109.6(4) 
C6 C5 N1 121.1(4) N3 C14 C16 101.0(4) 
C6 C5 C10 115.2(4) C12 C14 C16 113.4(4) 
C10 C5 N1 123.7(4) O4 C15 N3 109.8(4) 
F C6 C5 118.9(4) O5 C15 O4 122.3(5) 
F C6 C7 116.9(4) O5 C15 N3 127.9(5) 
C7 C6 C5 124.2(5) O4 C16 C14 104.6(4) 
Table 24 Details of X-ray crystal structure determination of compound 92. 
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A B C D Angle/˚ A B C D Angle/˚ 
F C6 C7 C8 -179.2(4) C8 N2 C11 C12 171.7(4) 
O1 C1 C2 N1 57.2(6) C8 N2 C13 O2 178.1(4) 
O2 C12 C14 N3 -174.7(4) C8 N2 C13 O3 -1.5(9) 
O2 C12 C14 C16 -62.6(5) C8 C9 C10 C5 0.2(7) 
N1 C3 C4 O1 -59.7(6) C10 C5 C6 F 179.9(4) 
N1 C5 C6 F 1.5(7) C10 C5 C6 C7 0.6(7) 
N1 C5 C6 C7 -177.8(5) C11 N2 C8 C7 16.0(7) 
N1 C5 C10 C9 177.6(5) C11 N2 C8 C9 -162.2(5) 
N2 C8 C9 C10 178.7(4) C11 N2 C13 O2 7.1(6) 
N2 C11 C12 O2 20.1(5) C11 N2 C13 O3 -172.5(5) 
N2 C11 C12 C14 138.1(4) C11 C12 C14 N3 69.9(5) 
N3 C14 C16 O4 -15.3(5) C11 C12 C14 C16 -178.0(4) 
C1 O1 C4 C3 60.3(6) C12 O2 C13 O3 -173.1(5) 
C2 N1 C3 C4 56.3(5) C12 O2 C13 N2 7.3(6) 
C2 N1 C5 C6 -62.3(6) C12 C14 C16 O4 -132.5(4) 
C2 N1 C5 C10 119.5(5) C13 O2 C12 C11 -17.5(5) 
C3 N1 C2 C1 -55.5(6) C13 O2 C12 C14 -139.7(4) 
C3 N1 C5 C6 170.0(4) C13 N2 C8 C7 -154.0(5) 
C3 N1 C5 C10 -8.3(7) C13 N2 C8 C9 27.8(8) 
C4 O1 C1 C2 -58.7(6) C13 N2 C11 C12 -17.1(6) 
C5 N1 C2 C1 174.1(4) C14 N3 C15 O4 -9.9(6) 
C5 N1 C3 C4 -173.9(4) C14 N3 C15 O5 171.3(5) 
C5 C6 C7 C8 0.2(8) C15 O4 C16 C14 10.9(6) 
C6 C5 C10 C9 -0.8(7) C15 N3 C14 C12 135.6(4) 
C6 C7 C8 N2 -179.0(5) C15 N3 C14 C16 15.7(5) 
C6 C7 C8 C9 -0.8(7) C16 O4 C15 O5 177.6(5) 
C7 C8 C9 C10 0.6(7) C16 O4 C15 N3 -1.3(6) 
Table 25 Details of X-ray crystal structure determination of compound 92. 
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4.3.3 Crystal structure analysis of compound 258 
 
 
Crystal habitus  clear colourless 
needle 
/mm-1 0.993 
Device type Bruker D8-Venture F 736.0 
Empirical formula C16H18FN3O5 Crystal size/mm
3 0.14 x 0.05 x 0.04 
Moiety formula C16H18FN3O5 Absorption correction Empirical 
Formula weight 351.33 Tmin; Tmax 0.5659; 0.7536 
Temperature/K 100 Radiation CuK(1.54178) 
Crystal system Orthorhombic 2 range for data 
collection/o 
11.708 to 135.488o  
Space group  P212121 Completeness to theta 0.994 
a/Å 6.5424(8) Index ranges - 7 ≤ h ≤ 7, -9 ≤ h ≤ 9, -36 ≤ 
h ≤ 37 
b/Å 7.7850(10) Reflections collected  17286 
c/Å 31.526(5) Independent reflections 2905 [Rint = 0.1592, Rsigma = 
0.0965] 
 90 Data/restraints/parameters 2905/0/226 
 90 Goodness-of-fit on F
2 1.053 
 90 Final R indexes [I>=2 (I)] R1 = 0.0624, wR2 = 0.1383 
Volume/Å3 1605.7(4) Final R indexes [all Data] R1 = 0.0950, wR2 = 0.1572 
 1 Largest diff. peak/hole/ e Å
-
3 
0.45/-0.48 
calcg/cm
3 1.453 Flack parameter 0.3(2) 
Table 26 Details of X-ray crystal structure determination of compound 258. 
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Atom Atom Length/Å Atom Atom Atom 
F C9 1.372(6) N3 C10 F 
O1 C2 1.449(6) N3 C13 O1 
O1 C3 1.367(7) N3 C16 O1 
O2 C3 1.205(6) C1 C2 O2 
O3 C4 1.455(5) C1 C4 O3 
O3 C5 1.372(7) C4 C6 O3 
O4 C5 1.210(6) C7 C8 O4 
O5 C14 1.438(7) C7 C12 O5 
O5 C15 1.426(6) C8 C9 O5 
N1 C1 1.451(7) C9 C10 N1 
N1 C3 1.357(7) C10 C11 N1 
N2 C5 1.361(7) C11 C12 N2 
N2 C6 1.467(6) C13 C14 N2 
N2 C7 1.423(7) C15 C16 N2 
Table 27 Details of X-ray crystal structure determination of compound 258. 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C3 O1 C2 109.0(4) O4 C5 O3 121.1(5) 
C5 O3 C4 109.6(4) O4 C5 N2 129.2(6) 
C15 O5 C14 110.2(4) N2 C5 O3 109.7(4) 
C3 N1 C1 111.6(5) N2 C6 C4 101.8(4) 
C5 N2 C6 111.4(4) C8 C7 N2 120.7(5) 
C5 N2 C7 126.8(4) C12 C7 N2 119.9(5) 
C7 N2 C6 121.6(4) C12 C7 C8 119.4(5) 
C10 N3 C13 114.8(4) C9 C8 C7 118.0(5) 
C10 N3 C16 114.8(4) F C9 C10 118.5(5) 
C16 N3 C13 109.5(4) C8 C9 F 116.4(5) 
N1 C1 C2 100.4(4) C8 C9 C10 125.0(5) 
N1 C1 C4 112.4(5) C9 C10 N3 120.0(5) 
C4 C1 C2 114.9(4) C11 C10 N3 125.5(5) 
O1 C2 C1 104.9(4) C11 C10 C9 114.4(5) 
O2 C3 O1 121.3(5) C12 C11 C10 122.9(5) 
O2 C3 N1 129.3(6) C11 C12 C7 120.3(5) 
N1 C3 O1 109.4(4) N3 C13 C14 110.5(4) 
O3 C4 C1 110.2(4) O5 C14 C13 109.4(5) 
O3 C4 C6 104.9(4) O5 C15 C16 111.6(5) 
C1 C4 C6 112.2(4) N3 C16 C15 110.9(5) 
Table 28 Details of X-ray crystal structure determination of compound 258. 
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A B C D Angle/˚ A B C D Angle/˚ 
F C9 C10 N3 -0.8(7) C5 N2 C7 C8 10.5(8) 
F C9 C10 C11 175.6(5) C5 N2 C7 C12 -170.9(5) 
O3 C4 C6 N2 15.7(5) C6 N2 C5 O3 6.2(6) 
O5 C15 C16 N3 -56.5(6) C6 N2 C5 O4 -173.3(6) 
N1 C1 C2 O1 -20.4(5) C6 N2 C7 C8 -176.0(4) 
N1 C1 C4 O3 -58.4(6) C6 N2 C7 C12 2.6(7) 
N1 C1 C4 C6 58.1(5) C7 N2 C5 O3 -179.8(4) 
N2 C7 C8 C9 178.4(4) C7 N2 C5 O4 0.7(9) 
N2 C7 C12 C11 179.9(4) C7 N2 C6 C4 171.8(4) 
N3 C10 C11 C12 177.1(5) C7 C8 C9 F -176.0(4) 
N3 C13 C14 O5 59.4(6) C7 C8 C9 C10 2.3(8) 
C1 N1 C3 O1 -12.7(6) C8 C7 C12 C11 -1.5(8) 
C1 N1 C3 O2 168.0(5) C8 C9 C10 N3 -179.1(5) 
C1 C4 C6 N2 -103.9(4) C8 C9 C10 C11 -2.7(8) 
C2 O1 C3 O2 177.3(5) C9 C10 C11 C12 0.9(8) 
C2 O1 C3 N1 -2.1(6) C10 N3 C13 C14 172.8(4) 
C2 C1 C4 O3 55.5(6) C10 N3 C16 C15 -174.9(4) 
C2 C1 C4 C6 172.0(4) C10 C11 C12 C7 1.1(8) 
C3 O1 C2 C1 14.8(5) C12 C7 C8 C9 -0.1(8) 
C3 N1 C1 C2 20.6(5) C13 N3 C10 C9 -61.3(6) 
C3 N1 C1 C4 143.1(4) C13 N3 C10 C11 122.8(5) 
C4 O3 C5 O4 -175.5(5) C13 N3 C16 C15 54.3(6) 
C4 O3 C5 N2 5.0(5) C14 O5 C15 C16 59.3(6) 
C4 C1 C2 O1 -141.2(4) C15 O5 C14 C13 -60.3(6) 
C5 O3 C4 C1 107.6(5) C16 N3 C10 C9 170.5(4) 
C5 O3 C4 C6 -13.4(5) C16 N3 C10 C11 -5.5(7) 
C5 N2 C6 C4 -13.8(5) C16 N3 C13 C14 -56.3(6) 
Table 29 Details of X-ray crystal structure determination of compound 258. 
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4.4 Headspace analysis from xylariaceous fungal strains 
4.4.1 Total ion chromatograms of headspace extracts 
 
Figure 44 Total ion chromatograms of headspace extracts from fungal strain Daldinia 
childiae MUCL 53761. 
 
Figure 45 Total ion chromatograms of headspace extracts from fungal strain Daldinia 
australis CBS 119013.    
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Figure 46 Total ion chromatograms of headspace extracts from fungal strain Daldinia cf. 
caldarium CBS 113045.   
 
 
 
Figure 47 Total ion chromatograms of headspace extracts from fungal strain Daldinia 
eschscholzii STMA 11017.   
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Figure 48 Total ion chromatograms of headspace extracts from fungal strain Daldinia novae-
zelandiae STMA 05243.   
 
 
 
Figure 49 Total ion chromatograms of headspace extracts from fungal strain Daldinia 
hawksworthii STMA 13010.   
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Figure 50 Total ion chromatograms of headspace extracts from fungal strain Daldinia 
concentrica STMA 05061.   
 
 
Figure 51 Total ion chromatograms of headspace extracts from fungal strain Hypoxylon sp. 
nov. JF 11167.   
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Figure 52 Total ion chromatograms of headspace extracts from fungal strain Hypoxylon sp. 
nov. STMA 11183.   
 
 
 
 
Figure 53 Total ion chromatograms of headspace extracts from fungal strain Hypoxylon 
macrocaipum STMA 05121. 
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Figure 54 Total ion chromatograms of headspace extracts from fungal strain Hypoxylon 
griseobrunneum STMA 10235.   
 
 
 
 
Figure 55 Total ion chromatograms of headspace extracts from fungal strain Hypoxylon 
rubiginosum STMA 03027. 
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Figure 56 Total ion chromatograms of headspace extracts from fungal strain Biscogniauxia 
cylinderispora STMA 12118.   
4.4.2 Summary of volatile organic compounds  
Compound I I (Lit.) Ident. Occurrence 
in strain 
Pyrazine (184)  737[479] ms 1, 14 
Tiglic aldehyde (126)  749[480] ms 1,6 
2-Methyl-3-pentanone (127)  742[481] ms 1, 6, 7 
2,3-Butanediol (125)  795[479] ms 7 
2-Hexanol (123) 811 813[482] ms, ri 1 
Butyl acetate (166) 823 823[483] ms, ri 1 
Methylpyrazine (185) 829 827[484] ms, ri 1, 4, 7, 13, 14 
Acetyl valeryl (139) 838  ms 1, 6, 7, 8 
4-Methyl-3-hexanone (128) 845 842[485] ms, ri 1, 2, 3, 6, 7, 8 
Cyclohexanol (124) 886 880[486] ms, ri 2 
2,6-Dimethylpyridine (188) 888 887[487] ms, ri 8 
Cyclohexanone (138) 899 903[488] ms, ri 2, 14 
2-Hydroxyhexan-3-one (135) 901 896[489] ms, ri 1, 8 
2,5-Dimethyl-pyrazine (186) 913 911[490] ms, ri 1, 2, 3, 6, 11, 12 
1-(2-Furanyl)-ethanone (178) 916 915[491] ms, ri 1, 2, 7, 8, 11 
(E)-4-Methylhex-4-en-3-one (132) 936  ms, ri 1, 6, 8 
2-Hydroxy-4-methylhexan-3-one (136) 943  ms, ri 1, 5, 7, 11 
Ethyl 3-hydroxy-3-methylbutanoate (168) 960 955[492] ms, ri 14 
Benzaldehyde (196) 962 964[479] ms, ri 3,8 
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1-Octen-3-ol (120) 981 981[493] ms, ri 1, 2, 3, 5, 6, 8 
3-Octanone (129) 988 987[493] ms, ri 1, 3, 4, 5, 8 
6-Methyl-5-hepten-2-one (134)  988 988[494] ms, ri 6 
2-Acetyl-5-methylfuran (179) 993 987[495] ms, ri 14 
2-Octanone (130) 994 994[496] ms, ri 3 
Trimethylpyrazine (187) 1004 1005[491] ms, ri 11 
2-Acetylthiazole (189) 1018 1021[491] ms, ri 1, 3, 6, 7, 8, 9, 
11, 12, 13, 14 
2-Hydroxybenzaldehyde (196) 1044 1040[497] ms, ri 5 
-Methyl benzenemethanol (190) 1061 1063
[498] ms, ri 1, 2, 3, 6, 7, 11, 
12 
Acetonphenone (210) 1064 1061[499] ms, ri 1, 5, 6, 7, 8, 9, 
11, 12, 13, 14 
(E)-2-Octen-1-ol (121) 1070 1067[500] ms, ri 3, 5 
6-Methyl-5,6-dihydro-2H-pyran-2-one 
(169) 
1072 1074 ms, ri, 
std 
1, 4, 5, 6, 8 
3-Methyl-phenol (193)  1080 1075[501] ms, ri 11 
cis-Linalool oxide, furanoid (237)  1086 1067[502] ms, ri 1, 2, 6, 13, 14 
trans-Linalool oxide, furanoid (238) 1089 1089[503] ms, ri 2 
Hexyl propionate (167) 1107 1105[504] ms, ri 3 
Phenylethyl alcohol (191) 1113 1113[505] ms, ri 2, 3, 4, 7, 8, 9, 
10, 11, 14 
Manicone (133) 1136 1140 ms, ri, 
std 
1, 2 
1,2-Dimethoxybenzene (204) 1150 1150[506] ms, ri 13 
2,5-Dimethyl-phenol (194) 1155 1148[507] ms, ri 9, 11 
2-Hydroxy-4-methylbenzaldehyde (197) 1163 1170 ms, ri, 
std 
9, 11 
1-Phenyl-1,2-propanedione (211) 1170 1175[508] ms, ri 11 
Terpinene-4-ol (247) 1178 1178[509] ms, ri 9 
2-Methoxy-5-methylphenol (203) 1187 1191[510] ms, ri 9 
cis-Linalool oxide, pyranoid (239) 1187 1186[511] ms, ri 1, 2, 14 
Methyl 2-hydroxybenzoate (212) 1195 1195[503] ms, ri 5 
2-Hydroxy-1,8-cineole (240) 1210 1219[512] ms 10, 12 
1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octan-
6-one (241) 
1215 1217[503] ms, ri 12 
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(4R,5R,6S)-5-Hydroxy-4,6-dimethyloctan-
3-one (137) 
1239 1241 ms, ri, 
std 
1, 2, 3, 4, 6, 7, 
8, 10 
3,4-Dimethoxytoluene (205) 1239 1242 ms, ri, 
std 
6, 7, 9, 11, 13 
2,5-Dimethoxytoluene (206) 1251 1243[513] ms, ri 13 
4-Methoxybenzaldehyde (199) 1253 1250[514] ms, ri 6 
2-Undecanone (131) 1291 1291[514] ms, ri 6 
1,2,3-Trimethoxybenzene (208) 1315 1315[515] ms, ri 10, 13 
2-Methoxy-4-methylbenzaldehyde (198) 1364 1364 ms, ri, 
std 
9 
2-Methyl-4-chromanone (215) 1366 1367 ms, ri, 
std 
1, 6, 7, 8 
2-(4-Methoxyphenyl)ethanol (192) 1369 1374[516] ms, ri 10 
2-Nonylfuran (180) 1391 1399 ms, ri, 
std 
1, 2, 3, 9 
1-(2-Hydroxy-6-methoxyphenyl)ethanone 
(213) 
1397 1402[517] ms, ri 8 
1,2,3-Trimethoxy-5-methyl-benzene (209)  1412 1410[518] ms, ri 10, 11, 13 
-Cedrene (254) 1415 1411
[519] ms, ri 11 
-Cedrene (255) 1423 1423
[520] ms, ri 11 
Dihydro--ionone (245) 1437 1433
[521] ms, ri 8 
-Barbatene (253) 1446 1440
[522] ms, ri,  3 
1,2-Dimethoxy-4-
(methoxymethyl)benzene (207) 
1452 1452[523] ms 13 
2,5-Dimethoxy-benzaldehyde (202) 1460  ms 13 
4,7-Dihydroxy-2H-1-benzopyran-2-one 
(216)  
1469  ms 1, 2, 3, 6, 7, 8, 9 
3,4-Dimethoxy-benzaldehyde (201)  1483  ms 11 
trans--Ionone (246) 1484 1485
[524] ms, ri 8 
trans--Bergamotene (244) 1489 1480
[525] ms, ri 2 
-Curcumene (243) 1490 1485
[526] ms, ri 1 
-Bulnesene (252) 1508 1508
[527] ms, ri 3, 4, 8 
-Cadinene (250) 1529 1529
[528] ms, ri 14 
Dihydroactinidiolide (172) 1533 1531[503] ms, ri 11 
Mellein (217) 1547  ms, ri 10 
Nerolidol (242) 1565 1565[529] ms, ri 2 
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5-Hydroxy-2-methyl-4H-chromen-4-one 
(214) 
1593 1592 ms, ri, 
std 
2, 3, 7, 9, 8 
2-Undecylfuran (181) 1603  ms 2 
2,4-Dimethoxy-6-methyl-benzaldehyde 
(200) 
1613  ms 10 
-Acorenol (251) 1633 1632
[530] ms, ri 10, 13 
T-Muurolol (249) 1645 1645[531] ms, ri 3 
Pogostol (34) 1653 1656[532] ms, ri 1, 3, 4, 5, 7, 8, 
14 
6-Heptyl-2H-pyran-2-one (170) 1665  ms 1, 2 
1,8-Dimethoxynaphthalene (218) 1668  ms 2, 9 
-Bisabolol (248) 1676 1675
[533] ms, ri 13 
1-Tetradecanol (122) 1676 1676[534] ms, ri 3 
6-Nonyl-2H-pyran-2-one (171) 1880 1889 ms, ri, 
std 
1, 2, 3, 6, 9 
8(14),15-Pimaradiene (256) 1968 1942[535] ms, ri 7 
Abietatriene (257) 2060 2055[536] ms, ri 9 
Table 30 Organic volatile compounds released by the Xylariaceae family. Identification 
based on comparison of mass spectrum to a data base spectrum (ms), comparison of 
retention index of a published retention index on the same or a similar GC fused silica 
capillary column (ri), and comparison to a synthetic or commercially available referefence 
compound (std). 
ID Strain 
1 Daldinia clavata STMA 06094 
2 Daldinia childiae MUCL 53761 
3 Daldinia australis CBS 119013 
4 Daldinia cf. caldarium CBS 113045 
5 Daldinia eschscholzii STMA 11017 
6 Daldinia novae-zelandiae STMA 05243 
7 Daldinia hawksworthii STMA 13010 
8 Daldinia concentrica STMA 05061 
9 Hypoxylon sp.nov. JF 11167 
10 Hypoxylon sp.nov. STMA 11183 
11 Hypoxylon macrocaipum STMA 05121 
12 Hypoxylon griseobrunneum STMA 10235 
13 Hypoxylon rubiginosum STMA 03027 
14 Biscogniauxia cylinderispora STMA 12118 
Table 31 ID number of the investigated Xylariaceae fungal strains.  
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Appendix 
Number Compound GC-MS NMR 
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106a 
 
TW0220 
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wao120843 
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TWN0034 
wao120471 
106c 
 
TW0217 
TWN0058 
wao120827 
106e 
 
TW0157 
TWN0023 
wao120577 
106f 
 
TW0155 
TWN0021 
wao120260 
106g 
 
TW0154 
TWN0018 
wao120252 
106h 
 
TW0131 
TWN0022 
wao120023 
106i 
 
TW0351 
TWN0094 
wao121710 
106k 
 
TW0177 
TWN0021 
wao120513 
 
 
315 
 
117 
 
TW0168 wao120459 
119 
 
TW0167 wao120458 
E-142 
 
TW0553 wao121309 
Z-142 
 
TW0550 wao121290 
143 
 
TW0555 wao124345 
144 
 
TW0556 wao123760 
133 
 
TW0557 wao121972 
E-148 
 
TW0425 wao122218 
Z-148 
 
TW1403 wao122256 
149 
 
TW0444 wao122257 
150a 
 
TW0453 wao122701 
152a 
 
TW1389 wao123973 
153a 
 
TW0515 wao123985 
(4R,5S,6S)-137a 
 
TW1276 wao124019 
150b 
 
TW0430 wao122522 
152b 
 
TW0508 wao123191 
153b 
 
TW0509 wao123986 
(4S,5R,6S)-137b 
 
TW1277 48c5a044.16 
49c5a009.16 
(4R,5S,6R)-137b 
 
TW1278 48c5a043.16 
49c5a008.16 
 
 
316 
 
(4R,5R,6S)-137d 
 
TW1269 49c5a045.16 
50p5a019.16 
(4S,5S,6R)-137d 
 
TW1266 49c5a044.16 
50p5a012.16 
(4S,5S,6S)-137c 
 
TW1267 49c5a047.16 
49c5a009.16 
(4R,5R,6R)-137c 
 
TW1268 49c5a046.16 
50c5a008.16 
175 
 
TW0281 wao121278 
169 
 
TW0397 
TWN0105 
wao122136 
171 
 
TWN0682 wao121382 
180 
 
TW1404 wao120182 
 
 
TW1425  
 
 
TW1422  
 
 
TW1423  
 
 
TW1424  
 
 
TW1369  
 
 
TW1368  
197 
 
TW1379  
 
 
TW1367  
 
 
TW1416  
 
 
317 
 
 
 
TW1415  
 
 
TW1427  
 
 
TW1366  
 
 
TW1428  
 
 
TW1429  
205 
 
TW1377  
 
 
TW1364  
 
 
TW1430 46p5a057.17 
 
 
TW1431 43t4a010.17 
 
 
TW1432 43t4a012.17 
 
 
TW1433  
 
 
TW1365  
 
 
TW1434  
 
 
TW1380  
 
 
318 
 
 
 
TW1384  
198 
 
TW1382  
 
 
TW1383 43t4a011.17 
 
 
TW1435 46c5a024.17 
 
 
TW1421 46c5a001.17 
 
 
TW1438 46c5a005. 7 
 
 
TW1439 46c5a003.17 
 
 
TW1440 46c5a004.17 
 
 
TW1441 46c5a005.17 
214 
 
TW0400 
TWN0117 
 
wao122165 
220 
 
TW0402 
TWN0118 
 
wao122194 
 
 
TW1443  
 
 
TW1355  
 
 
TW1353  
 
 
319 
 
194 
 
TW1354  
 
 
TW1359  
 
 
TW1352  
 
 
TW1356  
215 
 
TW1343 10c5a034.17 
 
 
TW1342 10c5a033.17 
264 
 
 36x3a014.14 
265 
 
TW0572 
TW0573 
36x3a017.14 
266 
 
TW0579 30x3a060.15 
260 
 
TW0580 38x3a066.14 
267 
 
TW0595 02x4a108.15 
268 
 
TW0598 40x4a014.14 
269 
 
TW0603 48x4b052.14 
270 
 
TW0614 43x3a020.14 
280 
 
TW1027 36x4a049.15 
 
 
320 
 
281 
 
TW1028 36x4a050.15 
282 
 
 14x3a021.15 
283 
 
 08p5a027.16 
278 
 
TW1106 39x4a045.15 
275 
 
TW0578 36x3a010.14 
72 
 
TW720 38x3a020.14 
279 
 
TW0808 24x3b039.15 
293 
 
 19m5a018.15 
295 
 
 38x3a002.15 
296 
 
TW1093 13p5a039.16 
 
297 
 
 29c5a022.16 
14c5a016.17 
307 
 
TW1085 10p5a028.16 
308 
 
TW1086 12p5a004.16 
309 
 
TW1094 13t4a092.16 
 
 
TW1123 16p5b018.16 
 
 
321 
 
311 
 
TW1150 20c5a045.16 
312 
 
TW1149 20c5a046.16 
313 
 
TW1131 22p5a029.16 
301 
 
TW1119 17p5a054.16 
320 
 
 05p5a014.17 
92 
 
 07p5a046.16 
08p5a010.16 
07l3a027.16 
258 
 
 29c5boo4.16 
14c5a033.17 
304 
 
 16p5b020.16 
16c5a041.16 
321 
 
 07c5a011.17 
306 
 
 20c5a044.16 
323 
 
 11c5a047.17 
299 
 
 13c5a031.17 
 
 
322 
 
324 
 
 12c5a027.17 
319 
 
 13c5a007.17 
102 
 
 06p5a034.17 
14c5a007.17 
103 
 
 07s7a007.17 
12c5a010.17 
104 
 
 07p5a019.17 
12c5a011.17 
Table 32 Analytical data of synthetic samples and commercially available chemicals. 
 
 
 
 
 
 
 
 
 
